

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Klaus GIESE, et al.)	Confirmation No: 6369
Application Serial No.: 10/633,630)	Group Art Unit: 1635
Filed: August 5, 2003)	Examiner: Kimberly Chong
For: INTERFERING RNA MOLECULES)	

United States Patent and Trademark Office
Randolph Building
401 Dulany Street
Alexandria, Virginia 22314

Declaration under 37 C.F.R. § 1.132

I, Dr. Klaus Giese, declare and say:

1. I received a B.S. degree in Biochemistry in 1986 and a Ph.D. degree in 1990, both from the Free University of Berlin, Germany. From 1990 to 1991 I was a postdoctoral researcher and scientist at the Max-Planck-Institute in Berlin in the laboratory of Prof. Wittmann. From 1991 to 1994 I was a postdoctoral researcher and scientist at the University of California, San Francisco in the laboratory of Professor Grosschedl. From 1994 to 1998 I had positions of increasing responsibility (Scientist II, Principle Scientist, Senior Scientist) at Chiron Corporation. Since 1999 I have been Chief Scientific Office of Atugen AG, now known as Silence Therapeutics AG. A copy of my *Curriculum Vitae* is attached as EXHIBIT 1.

2. I am an inventor of the captioned application.

3. The claimed invention is directed to double stranded nucleic acid molecules where each strand contains a stretch of ribonucleotides that is 15-23 ribonucleotides long. Each stretch is made up of alternating unmodified ribonucleotides and 2'-O-methyl ribonucleotides, linked by natural phosphodiester bonds. The strands are "staggered" such that a 2'-O-methyl ribonucleotide on one strand base pairs with an unmodified ribonucleotide on the other strand.

MC

The double stranded RNA molecules are highly resistant to degradation in serum while maintaining potent activity in gene silencing via an RNA interference (RNAi) mechanism. The molecules may be blunt-ended or have one or two overhangs.

5. The molecules having the structure recited in the claims of the captioned application provide surprisingly good results both with respect to stability against nuclease degradation and to RNAi activity (gene silencing).

6. For example, Figure 15 of the captioned application describes molecules having the structure recited in the claims, and shows that they not only are very stable in serum but are also very active at inducing RNAi. Thus, Figure 15 shows a double stranded molecule made up of two complementary oligoribonucleotide molecules, shown as PTENA V15 and PTENB V15. The gel data in Figure 15B show that these molecules are essentially unchanged after a 2 hour incubation in serum (see lane 15) whereas the equivalent unmodified molecule was completely digested after only 15 minutes in serum (lane AB). Figure 15D is an immunoblot showing the effect on PTEN expression of the modified and unmodified molecules. At 48h, both the modified and unmodified molecules achieve complete knock-down of PTEN expression (lanes 15 and AB, respectively). However, after 96h, PTEN expression was still low with the modified molecule (lane V15) but had increased to pre-treatment levels with the unmodified molecule (lane AB). These data demonstrate that a molecule as claimed in the captioned application is both surprisingly effective at initiating RNA interference but is also surprisingly stable.

7. This ability of the claimed molecules to be both active and stable is yet more surprising in light of the experiences of others such as those described in US Application 2005/0209179 ("McSwiggen II", attached hereto as EXHIBIT 2), which is a continuation-in-part application that claims priority from 2003/0190635, cited by the Examiner. McSwiggen II cites various methods for attempting to identify modified RNA molecules that are active yet stable, including:

(a) generating a plurality of unmodified siNA molecules, (b) screening the siNA molecules of step (a) under conditions suitable for isolating siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence, and (c) introducing chemical modifications (e.g. chemical modifications as described herein or as otherwise known in the art) into the active siNA molecules of (b). In one embodiment,

the method further comprises re-screening the chemically modified siNA molecules of step (c) under conditions suitable for isolating chemically modified siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence.

See paragraph 193. Another method described by McSwiggen II involves the iterative method described in Figure 11:

Chemical modifications are introduced into the siNA construct based on educated design parameters (e.g. introducing 2'-modifications [sic], base modifications, backbone modifications, terminal cap modifications etc). The modified construct in [sic] tested in an appropriate system (e.g. human serum for nuclease resistance, shown, or an animal model for PK/delivery parameters). In parallel, the siNA construct is tested for RNAi activity, for example in a cell culture system such as a luciferase reporter assay). Lead siNA constructs are then identified which possess a particular characteristic while maintaining RNAi activity, and can be further modified and assayed once again. This same approach can be used to identify siNA-conjugate molecules with improved pharmacokinetic profiles, delivery, and RNAi activity

See paragraph 269. Both of these methods are iterative and require time-consuming trial and error preparation and testing of many modified molecules to obtain RNAi reagents that are both active and stable. McSwiggen II was filed in June 2004, which is later than the filing date of the captioned application, and shows that, even at this later date, McSwiggen required laborious trial and error methods to prepare and identify active, stable, RNAi agents.


9. In sharp contrast, we have found that molecules having the structure recited in the instant claims are reliably active and stable to such an extent that we no longer prepare unmodified molecules to test for RNAi activity prior to preparing modified molecules. Rather, we directly design, synthesize, and test molecules having the "staggered" structures recited in the claims. Indeed, we have shown that the results seen with PTENA V15 and PTENB V15 are generally applicable to siRNA by successfully silencing over 100 different target mRNAs using dsRNA with the structure recited in the claims

Serial No. 10/633,630

10. All statements made herein of my knowledge are true and all statements made on information and belief are believed to be true; and further, these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any document or any registration resulting therefrom.

Date:

Feb 10, 2008



Dr. Klaus Giese

EXHIBIT 1 of
EXHIBIT D

CURRICULUM VITAE AND BIBLIOGRAPHY

Name: Klaus Willi Giese, Ph.D.
Address: 53 Fairview Ave, Park Ridge NJ 07656
Phone: 201-746-0655 (h), 201-574-6170 (c)
E-Mail: k.giese@silence-therapeutics.com
Date of Birth: June 19, 1959
Personal info: Married
Citizenship: German

January 2008

Present Silence Therapeutics plc, London, UK and Silence Therapeutics AG, Berlin, Germany
Chief scientific officer of Silence Therapeutics plc and member of the Management Board (“Vorstand”) of Silence Therapeutics AG (a wholly-owned subsidiary of Silence Therapeutics plc).

1999/2005 Atugen AG, Berlin, Germany
Chief scientific officer, Vice President of Research and member of the Management Board (“Vorstand”).

1994/1998 Chiron Corporation, Emeryville, CA, USA
Escalating positions at Chiron Corporation (Scientist II, Principle Scientist and Senior Scientist/Group Leader).

EDUCATION

1991/1994 Howard Hughes Medical Institute, Univ. of California, San Francisco, USA
Postdoctor and Scientist (Laboratory of Prof. R. Grosschedl).

1990/1991 Max-Planck-Institute (MPI) for Molecular Genetics, Berlin, Germany
Postdoctor and Scientist (Dept. Prof. H.-G. Wittmann).

1987/1990 MPI for Molecular Genetics, Berlin, Germany
Ph.D. Student (Laboratory of Prof. A. Subramanian).

1982/1986 Free University of Berlin, Germany
Study of Biochemistry (Laboratory of Prof. A. Subramanian).

OTHER BUSINESS EXPERIENCE

1979/1982 Dresdner Bank AG, Berlin, Germany

PATENTS AND PUBLICATIONS

Issued/granted patents

1. **Giese, K.** and Escobedo, J. (1998). Method and construct for screening for inhibitors of transcriptional activation. US5,747,338.
2. **Giese, K.** (2002). Metastatic breast and colon cancer regulated genes. US6,468,790.
3. Hong, X. and **Giese, K.** (2003). Metastatic breast and colon cancer regulated genes. US6,635,748.
4. Williams et al. (2005). Human genes and gene expression products II. US6,964,868.
5. **Giese, K.**, Klippel-Giese, A. and Kaufmann, J. (2006). Further novel forms of interfering RNA. EP1,527,176.

Published patent applications

1. **Giese, K.** and Williams, L.T. (1996). Nucleic acids for treating obesity. EP0826045 and WO96/35787.
2. **Giese, K.** and Tamkun, J. (1997). Random and targeted promoter integration for gene analysis. WO001998012337.
3. **Giese, K.** (1998). Subtractive protein screening for gene identification. WO001999015897.
4. **Giese, K.** and Hong, X. (1998). Metastatic cancer regulated genes. WO001999033963.
5. Williams, L.T. et al. (1998). Human genes and gene expression products I. EP1190058 and WO001999033982.
6. Williams, L.T. et al. (1999). Human genes and gene expression products. EP1144636 and WO002000018916).
7. Williams, L.T. et al. (1999). Human genes and gene expression products II. EP1053319 and WO001999038972.
8. Williams, L.T. et al. (1999). Human genes and gene expression products V. EP1105474 and WO001999058675.
9. Williams, L.T. et al. (2001). Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells. US020020076735.
10. Klippel-Giese, A., Kaufmann, J. and **Giese, K.** (2002). Compounds and method for the identification and/or validation of a target. EP02000357 and US60/362388.
11. Klippel-Giese, A., Kaufmann, J. and **Giese, K.** (2002). Novel forms of interfering RNA molecules. EP02017601 and US60/402541.
12. **Giese, K.**, Kaufmann, J. and Klippel-Giese, A. (2003). Further novel forms of interfering RNA molecules. WO002004015107. International Preliminary Examination Report (PCT/EP03/08666).
13. **Giese, K.** and Kaufmann, J. (2005). Use of double-stranded ribonucleic acid for inducing cell lysis. US2005/0043263.A1.
14. **Giese, K.** and Kaufmann, J. (2005). Compounds for the treatment of hypoxia related diseases. EP04019405.2 and US60/601,983.

Publications (peer-reviewed)

1. Subramanian, A.R., Giese, K., Von Knoblauch, K., Markmann, U., Prombona, A., Srinivasa, B.R. and Timmler, G. (1986). Chloroplast ribosomes of higher-plants – purification of r-proteins, preparation of antisera and isolation of r-protein genes. *Federation Proceedings* 45, 1646-1646.
2. Giese, K., Subramanian, A.R., Larrinua, J.M. and Bogorad, L. (1987). Nucleotide sequence, promoter analysis, and linkage mapping of the unusually organized operon encoding ribosomal proteins S7 and S12 in maize chloroplasts. *J. Biol. Chem.* 262, 15251-15255.
3. Giese, K. and Subramanian, A.R. (1989). Chloroplast ribosomal protein L12 is encoded in the nucleus: Construction and identification of its cDNA clones and nucleotide sequence including the transit peptide. *Biochemistry* 28, 3525-3529.
4. Giese, K. and Subramanian, A.R. (1990). Enhanced translational utilization of chloroplast ribosomal protein mRNAs from two AUG codons shown by site-directed mutation. *Biochemistry* 29, 10562-10566.
5. Kavousi, M., Giese, K., Larrinua, J.M., McLaughlin, W.E. and Subramanian, A. R. (1990). Nucleotide sequence and map position of the gene for maize Chloroplast ribosomal protein L2. *Nucleic Acids Res.* 18, 4244-4244.
6. Giese, K. and Subramanian, A. R. (1991). Expression and functional assembly into bacterial ribosomes of a nuclear-coded chloroplast ribosomal protein with a long NH₂-terminal extension. *FEBS Lett.* 288, 72-76.
7. Giese, K., Amsterdam, A. and Grosschedl, R. (1991). DNA-binding properties of the HMG domain of the lymphoid-specific transcriptional regulator LEF-1. *Genes Dev.* 5, 2567-2578.
8. Giese, K., Cox, J., and Grosschedl, R. (1992). The HMG domain of lymphoid enhancer factor bends DNA and facilitates assembly of functional nucleoprotein structures. *Cell* 69, 185-195.
9. Giese, K. and Grosschedl, R. (1993). LEF-1 contains an activation domain that stimulates transcription in a specific context of factor binding sites. *EMBO J.* 12, 4667-4676.
10. Giese, K., Pagel, J. and Grosschedl, R. (1994). Distinct DNA-binding properties of the high mobility group domain of murine and human SRY sex-determining factors. *Proc. Natl. Acad. Sci. USA* 91, 3368-3372.
11. Giese, K., Kingsley, C., Kirshner, J. and Grosschedl, R. (1995). Assembly and function of a TCR α enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. *Genes Dev.* 9, 995-1008.
12. Love, J., Li, X., Case, D.A., Giese, K., Grosschedl, R. and Wright, P.E. (1995). Structural basis for DNA bending by the architectural transcription factor LEF-1. *Nature* (London) 376, 791-795.
13. Giese, K., Fantl, W.J., Vitt, C., Stephans, J.C., Cousens, L., Wachowicz, M. and Williams, L.T. (1996). Reduction of food intake and weight gain by ob protein requires a specific secondary structure and is reversible. *Molecular Medicine* 2, 50-58.
14. Del Rosario, M., Stephans, J.C., Zakel, J., Escobedo, J. and Giese, K. (1996). Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription. *Nature Biotechnology* 14, 1592-1596.

15. Giese, K., Pagel, J. and Grosschedl, R. (1997). Functional analysis of DNA bending and unwinding by the HMG domain of LEF-1. *Proc. Natl. Acad. Sci. USA* 94, 12845-12850.
16. Murphy, J.S., Zhou, S., Giese, K., Williams, L.T., Escobedo, J. and Dwarki, V.J. (1997). Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. *Proc. Natl. Acad. Sci. USA* 94, 13921-13926.
17. Xin, H., Stephans, J.C., Duan, S., Harrowe, G., Kim, E., Grieshammer, U., Kingsley, C. and Giese, K. (2000). Identification of a novel aspartic-like protease differentially expressed in human breast cancer cell lines. *Biochem. Biophys. Acta* 1501, 125-137.
18. Krappmann, D., Hatada, E.N., Tegethoff, S., Li, S., Klippel, A., Giese, K., Baeuerle, P. and Scheidereit, C. (2000). The I κ B kinase (IKK) complex is tripartite and contains IKK γ but not IKAP as a regular component. *J. Biol. Chem.* 275, 29779-29787.
19. Sternberger, M., Schmiedeknecht, A., Kretschmer, A., Gebhardt, F., Leenders, F., Czauderna, F., von Carlowitz, I., Engle, M., Giese, K., Beigelman, L. and Klippel, A. (2002). GeneBlocs are powerful tools to study and delineate signal transduction processes which regulate cell growth and transformation. *Antisense & Nucleic Acid Drug Dev.* 12, 131-144.
20. Czauderna, F., Fechtner, M., Aygün, H., Arnold, W., Klippel, A., Giese, K. and Kaufmann, J. (2003). Functional studies of the PI(3)-kinase signaling pathway employing synthetic and expressed siRNA. *Nucleic Acids Res.* 31, 670-682.
21. Czauderna, F., Fechtner, M., Dames, S., Aygün, H., Klippel, A., Pronk, G., Giese, K. and Kaufmann, J. (2003). Structural requirements and stabilizing modifications of synthetic siRNAs in mammalian cells. *Nucleic Acids Res.* 31, 2705-2716.
22. Czauderna, F., Santel, A., Hinz, M., Fechtner, M., Durieux, B., Fisch, G., Leenders, F., Arnold, W., Giese, K., Klippel, A. and Kaufmann, J. (2003). Inducible siRNA expression for application in a prostate cancer mouse model. *Nucleic Acids Res.* 31, 670-682.
23. Tondera, D., Santel, A., Schwarzer, R., Dames, S., Giese, K., Klippel, A. and Kaufmann, J. (2004). Knockdown of MTP18, a novel PI 3-kinase dependent protein, affects mitochondrial morphology and induces apoptosis. *J. Biol. Chem.* 279, 31544-31555.
24. Leenders, F., Möpert, K., Schmiedeknecht, A., Santel, A., Czauderna, F., Aleku, M., Penschuck, S., Dames, S., Sternberger, M., Röhl, T., Wellmann, A., Arnold, W., Giese, K., Kaufmann, J. and Klippel, A. (2004). PKN3 is required for malignant prostate cell growth downstream of activated phosphatidylinositol 3-kinase. *EMBO J.* 23, 3303-3313.
25. Schwarzer, R., Tondera, D., Arnold, W., Giese, K., Klippel, A. and Kaufmann, J. REDD1 is an integrator of HIF-1 signalling downstream of PI 3-kinase. (2005). *Oncogene* 10, 1138-1149.
26. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. (2006). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. *Gene Ther.* 13, 1222-34.
27. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, Löffler K, Fechtner M, Röhl T, Fisch G, Dames S, Arnold W, Giese K, Klippel A, Kaufmann J. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. *Gene Ther.* 2006 Apr 20 (2006).

Book chapters and reviews

1. Subramanian, A.R., Smooker, P.M. and Giese, K. (1990). Chloroplast ribosomal proteins and their genes. In: *The Ribosome: Structure, Function and Evolution* (Hill, W.E., Dahlberg, A. Garrett, R.A. Moore, P.B. Schlessinger, D. and Warner, J.R. Eds.) SM Publications, Washington, DC, pp, 655-663.
2. Weglöhner, W., Schmidt, J., Giese, K. and Subramanian, A. R. (1993). Expression and assembly of chloroplast ribosomal proteins in E.coli. In: *The Translational Apparatus: Structure, Function, Regulation, Evolution*, (Nierhaus, K.H., Subramanian, A.R., Franceschi, F., Erdmann, Y. and Wittmann-Liebold, B., Eds.). Plenum Press, New York, pp. 701-712.
3. Grosschedl, R., Giese, K. and Pagel, J. (1994). HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. *Trends Genet.* 3. 94-100.
4. Giese, K., Xin, H., Stephans, J.C. and Duan, S. (1998). Differential Display. In *PCR Methods Manual*. Eds., M. Innis, D. Gelfand, and J. Sninsky. Academic Press, p297-306. San Diego.
5. Giese, K. (2001). Gene discovery and validation technologies. *Innovations in Pharmaceutical Technology* Vol 10, 76-82.
6. Giese, K., Kaufmann, J., Pronk, G. and Klippel, A. (2002). Unravelling novel intracellular pathways in cell-based assays. *Drug Discovery Today* 3, 179-186.
7. Giese, K. (2004). Interfering RNA (siRNA) as new routes to cancer therapies. *Current Drug Discovery* February, 25-28.
8. Kaufmann, J, Pronk, G., Giese, K. and Klippel, A. (2004). Identification of novel effectors of invasive cell growth downstream of PI 3-kinase. *Biochemical Society Transactions* 32, 355-359.
9. Giese, K. (2005). Poised to change the health care landscape – siRNA therapeutics. *European BioPharmaceutical reviews* May 2005.

EXHIBIT 2 of
EXHIBIT D



US 20050209179A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2005/0209179 A1**
McSwiggen et al. (43) **Pub. Date: Sep. 22, 2005**(54) **RNA INTERFERENCE MEDIATED
TREATMENT OF ALZHEIMER'S DISEASE
USING SHORT INTERFERING NUCLEIC
ACID (SINA)**(75) **Inventors: James McSwiggen, Boulder, CO (US);
Leonid Belgelman, Longmont, CO
(US)****Correspondence Address:
MCDONNELL BOEHNEN HULBERT &
BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606 (US)**(73) **Assignee: Sirna Therapeutics, Inc., Boulder, CO**(21) **Appl. No.: 10/877,889**(22) **Filed: Jun. 25, 2004****Related U.S. Application Data**

(63) Continuation-in-part of application No. 10/607,933, filed on Jun. 27, 2003, which is a continuation-in-part of application No. 09/930,423, filed on Aug. 15, 2001, now abandoned, and which is a continuation-in-part of application No. PCT/US03/04710, filed on Feb. 18, 2003, which is a continuation-in-part of application No. 10/205,309, filed on Jul. 25, 2002. Continuation-in-part of application No. PCT/US04/16390, filed on May 24, 2004, which is a continuation-in-part of application No. 10/826,966, filed on Apr. 16, 2004, which is a continuation-in-part of application No. 10/757,803, filed on Jan. 14, 2004, which is a continuation-in-part of application No. 10/720,448, filed on Nov. 24, 2003, which is a continuation-in-part of application No. 10/693,059, filed on Oct. 23, 2003, which is a continuation-in-part of application No. 10/444,853, filed on May 23, 2003, which is a continuation-in-part of application No. PCT/US03/05346, filed on Feb. 20, 2003, and which is a continuation-in-part of application No. PCT/US03/05028, filed on Feb. 20, 2003.

Continuation-in-part of application No. PCT/US04/13456, filed on Apr. 30, 2004, which is a continuation-in-part of application No. 10/780,447, filed on Feb. 13, 2004, and which is a continuation-in-part of application No. 10/427,160, filed on Apr. 30, 2003, which is a continuation-in-part of application No. PCT/US02/15876, filed on May 17, 2002. Continuation-in-part of application No. 10/727,780, filed on Dec. 3, 2003.

(60) Provisional application No. 60/358,580, filed on Feb. 20, 2002. Provisional application No. 60/363,124, filed on Mar. 11, 2002. Provisional application No. 60/386,782, filed on Jun. 6, 2002. Provisional application No. 60/406,784, filed on Aug. 29, 2002. Provisional application No. 60/408,378, filed on Sep. 5, 2002. Provisional application No. 60/409,293, filed on Sep. 9, 2002. Provisional application No. 60/440,129, filed on Jan. 15, 2003. Provisional application No. 60/362,016, filed on Mar. 6, 2002. Provisional application No. 60/292,217, filed on May 18, 2001. Provisional application No. 60/306,883, filed on Jul. 20, 2001. Provisional application No. 60/311,865, filed on Aug. 13, 2001. Provisional application No. 60/543,480, filed on Feb. 10, 2004.

Publication Classification(51) **Int. Cl.⁷ A61K 48/00; C07H 21/02**(52) **U.S. Cl. 514/44; 536/23.1**(57) **ABSTRACT**

This invention relates to compounds, compositions, and methods useful for modulating beta-secretase (BACE), amyloid precursor protein (APP), PIN-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BACE, APP, PIN-1, PS-1 and/or PS-2 gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of BACE, APP, PIN-1, PS-1 and/or PS-2 genes.





Figure 1



= SOLID SUPPORT


R = TERMINAL PROTECTING GROUP

FOR EXAMPLE:


DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)

(2) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3






Figure 4



POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT
L = GLYCERYL OR B THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE THAT IS OPTIONALLY ABSENT

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro

italic lower case = 2'-deoxy-2'-fluoro

underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY


iB = INVERTED DEOXYABASIC

L = GLYCERYL MOIETY OR iB OPTIONALLY PRESENT

S = PHOSPHOROTHIOATE OR

PHOSPHORODITHIOATE OPTIONALLY PRESENT

Figure 6







Figure 10



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
 B = independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy







Figure 12: Phosphorylated siNA constructs



Phosphates can be modified
as described herein



Asymmetric duplex
siNA






Figure 13: 5'-phosphate modifications



**Figure 14A: Duplex forming oligonucleotide constructs that utilize
Palindrome or repeat sequences**






Figure 14C: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence, self assembly




Figure 14D: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence, self assembly and inhibition of Target Sequence Expression




Figure 15: Duplex forming oligonucleotide constructs that utilize artificial palindrome or repeat sequences




Figure 16: Examples of double stranded multifunctional siNA constructs with distinct complementary regions




Figure 17: Examples of hairpin multifunctional siNA constructs with distinct complementary regions




Figure 18: Examples of double stranded multifunctional siNA constructs with distinct complementary regions and a self complementary/palindrome region





Figure 19: Examples of hairpin multifunctional siNA constructs with distinct complementary regions and a self complementary/palindrome region



**Figure 20: Example of multifunctional siNA targeting two
Separate Target nucleic acid sequences**




Figure 21: Example of multifunctional siNA targeting two regions within the same target nucleic acid sequence





Figure 22: A549 24h BACE mRNA Expression



**Figure 23: A549 24h BACE mRNA Expression
using modified siNA**




FIGURE 24




FIGURE 25





FIGURE 26



RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (SINA)

[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/607,933, filed Jun. 27, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 09/930,423, filed Aug. 15, 2001 and is also a continuation-in-part of International Patent Application No. PCT/US03/04710, filed Feb. 18, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10/205,309, filed Jul. 25, 2002. This application is also a continuation-in-part of International Patent Application No. PCT/US04/16390, filed May 24, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/826,966, filed Apr. 16, 2004, which is continuation-in-part of U.S. patent application Ser. No. 10/757,803, filed Jan. 14, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/720,448, filed Nov. 24, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10/693,059, filed Oct. 23, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10/444,853, filed May 23, 2003, which is a continuation-in-part of International Patent Application No. PCT/US03/05346, filed Feb. 20, 2003, and a continuation-in-part of International Patent Application No. PCT/US03/05028, filed Feb. 20, 2003, both of which claim the benefit of U.S. Provisional Application No. 60/358,580, filed Feb. 20, 2002, U.S. Provisional Application No. 60/363,124, filed Mar. 11, 2002, U.S. Provisional Application No. 60/386,782, filed Jun. 6, 2002, U.S. Provisional Application No. 60/406,784, filed Aug. 29, 2002, U.S. Provisional Application No. 60/408,378, filed Sep. 5, 2002, U.S. Provisional Application No. 60/409,293, filed Sep. 9, 2002, and U.S. Provisional Application No. 60/440,129, filed Jan. 15, 2003. This application is also a continuation-in-part of International Patent Application No. PCT/US04/13456, filed Apr. 30, 2004, which is a continuation of patent application Ser. No. 10/780,447, filed Feb. 13, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/427,160, filed Apr. 30, 2003, which is a continuation-in-part of International Patent Application No. PCT/US02/15876, filed May 17, 2002, which claims the benefit of U.S. Provisional Application No. 60/362,016, filed Mar. 6, 2002, and U.S. Provisional Application No. 60/292,217, filed May 18, 2001. This application is also a continuation-in-part of U.S. patent application Ser. No. 10/727,780, filed Dec. 3, 2003. This application also claims the benefit of U.S. Provisional Application No. 60/543,480, filed Feb. 10, 2004. The instant application claims the benefit of all the listed applications, which are hereby incorporated by reference herein in their entireties, including the drawings.

FIELD OF THE INVENTION

[0002] The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions associated with Alzheimer's disease. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in beta-secretase (BACE), amyloid precursor protein (APP), PIN-1, presenilin 1 (PS-1) and/or presenilin 2 (PS-2) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to small

nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), PIN-1, presenilin 1 (PS-1) and/or presenilin 2 (PS-2) gene expression. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of beta-secretase (BACE), amyloid precursor protein (APP), PIN-1, presenilin 1 (PS-1) and/or presenilin 2 (PS-2) gene expression in a subject, such as Alzheimer's disease or dementia.

BACKGROUND OF THE INVENTION

[0003] The following is a discussion of relevant art pertaining to RNAi. The discussion is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.

[0004] RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Zamore et al., 2000, *Cell*, 101, 25-33; Fire et al., 1998, *Nature*, 391, 806; Hamilton et al., 1999, *Science*, 286, 950-951; Lin et al., 1999, *Nature*, 402, 128-129; Sharp, 1999, *Genes & Dev.*, 13:139-141; and Strauss, 1999, *Science*, 286, 886). The corresponding process in plants (Heifetz et al., International PCT Publication No. WO 99/61631) is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla (Fire et al., 1999, *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized. This mechanism appears to be different from other known mechanisms involving double stranded RNA-specific ribonucleases, such as the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L (see for example U.S. Pat. Nos. 6,107,094; 5,898,031; Clemens et al., 1997, *J. Interferon & Cytokine Res.*, 17, 503-524; Adah et al., 2001, *Curr. Med. Chem.*, 8, 1189).

[0005] The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer (Bass, 2000, *Cell*, 101, 235; Zamore et al., 2000, *Cell*, 101, 25-33; Hammond et al., 2000, *Nature*, 404, 293). Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Zamore et al., 2000, *Cell*, 101, 25-33; Bass, 2000, *Cell*, 101, 235; Bernstein et al., 2001, *Nature*, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes (Zamore et al., 2000, *Cell*, 101, 25-33;

Elbashir et al., 2001, *Genes Dev.*, 15, 188). Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (siRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al., 2001, *Genes Dev.*, 15, 188).

[0006] RNAi has been studied in a variety of systems. Fire et al., 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. elegans*. Bahramian and Zarbl, 1999, *Molecular and Cellular Biology*, 19, 274-283 and Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mammalian systems. Hammond et al., 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir et al., 2001, *Nature*, 411, 494 and Tuschl et al., International PCT Publication No. WO 01/75164, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates (Elbashir et al., 2001, *EMBO J.*, 20, 6877 and Tuschl et al., International PCT Publication No. WO 01/75164) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21-nucleotide siRNA duplexes are most active when containing 3'-terminal dinucleotide overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang nucleotides with 2'-deoxy nucleotides (2'-H) was shown to be tolerated. Single mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end of the guide sequence (Elbashir et al., 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen et al., 2001, *Cell*, 107, 309).

[0007] Studies have shown that replacing the 3'-terminal nucleotide overhanging segments of a 21-mer siRNA duplex having two-nucleotide 3'-overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to four nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated, whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir et al., 2001, *EMBO J.*, 20, 6877 and Tuschl et al., International PCT Publication No. WO 01/75164). In addition, Elbashir et al., supra, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li et al., International PCT Publication No. WO 00/44914, and Beach et al., International PCT Publication No. WO 01/68836 preliminarily suggest that siRNA may include modifications to either the phosphate-sugar backbone or the

nucleoside to include at least one of a nitrogen or sulfur heteroatom, however, neither application postulates to what extent such modifications would be tolerated in siRNA molecules, nor provides any further guidance or examples of such modified siRNA. Kreutzer et al., Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge. However, Kreutzer et al. similarly fails to provide examples or guidance as to what extent these modifications would be tolerated in dsRNA molecules.

[0008] Parrish et al., 2000, *Molecular Cell*, 6, 1077-1087, tested certain chemical modifications targeting the unc-22 gene in *C. elegans* using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that RNAs with two phosphorothioate modified bases also had substantial decreases in effectiveness as RNAi. Further, Parrish et al. reported that phosphorothioate modification of more than two residues greatly destabilized the RNAs in vitro such that interference activities could not be assayed. Id. at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and found that substituting deoxynucleotides for ribonucleotides produced a substantial decrease in interference activity, especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Id. In addition, the authors tested certain base modifications, including substituting, in sense and antisense strands of the siRNA, 4-thiouracil, 5-bromouracil, 5-iodouracil, and 3-(aminoallyl)uracil for uracil, and inosine for guanosine. Whereas 4-thiouracil and 5-bromouracil substitution appeared to be tolerated, Parrish reported that inosine produced a substantial decrease in interference activity when incorporated in either strand. Parrish also reported that incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in a substantial decrease in RNAi activity as well.

[0009] The use of longer dsRNA has been described. For example, Beach et al., International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously-derived dsRNA. Tuschl et al., International PCT Publication No. WO 01/75164, describe a *Drosophila* in vitro RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due to the danger of activating interferon response. Li et al., International PCT Publication No. WO 00/44914, describe the use of specific long (141 bp-488 bp) enzymatically synthesized or vector expressed dsRNAs for attenuating the expression of certain target genes. Zemicka-Goetz et al., International PCT Publication No. WO 01/36646, describe certain methods for inhibiting the expression of particular genes in mammalian cells using certain long (550 bp-714 bp), enzymatically synthesized or vector expressed dsRNA molecules. Fire et al., International PCT Publication No. WO 99/32619, describe particular methods for introducing certain long dsRNA molecules into cells for use in inhibiting gene expression in nematodes. Plautinck et al., International PCT

Publication No. WO 00/01846, describe certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific long dsRNA molecules. Mello et al., International PCT Publication No. WO 01/29058, describe the identification of specific genes involved in dsRNA-mediated RNAi. Pachuck et al., International PCT Publication No. WO 00/63364, describe certain long (at least 200 nucleotide) dsRNA constructs. Deschamps Depaillette et al., International PCT Publication No. WO 99/07409, describe specific compositions consisting of particular dsRNA molecules combined with certain antiviral agents. Waterhouse et al., International PCT Publication No. 99/53050 and 1998, *PNAS*, 95, 13959-13964, describe certain methods for decreasing the phenotypic expression of a nucleic acid in plant cells using certain dsRNAs. Driscoll et al., International PCT Publication No. WO 01/49844, describe specific DNA expression constructs for use in facilitating gene silencing in targeted organisms.

[0010] Others have reported on various RNAi and gene-silencing systems. For example, Parrish et al., 2000, *Molecular Cell*, 6, 1077-1087, describe specific chemically-modified dsRNA constructs targeting the *unc-22* gene of *C. elegans*. Grossniklaus, International PCT Publication No. WO 01/38551, describes certain methods for regulating polycomb gene expression in plants using certain dsRNAs. Churikov et al., International PCT Publication No. WO 01/42443, describe certain methods for modifying genetic characteristics of an organism using certain dsRNAs. Cogoni et al., International PCT Publication No. WO 01/53475, describe certain methods for isolating a *Neurospora* silencing gene and uses thereof. Reed et al., International PCT Publication No. WO 01/68836, describe certain methods for gene silencing in plants. Honer et al., International PCT Publication No. WO 01/70944, describe certain methods of drug screening using transgenic nematodes as Parkinson's Disease models using certain dsRNAs. Deak et al., International PCT Publication No. WO 01/72774, describe certain *Drosophila*-derived gene products that may be related to RNAi in *Drosophila*. Arndt et al., International PCT Publication No. WO 01/92513 describe certain methods for mediating gene suppression by using factors that enhance RNAi. Tuschl et al., International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs. Pachuk et al., International PCT Publication No. WO 00/63364, and Satishchandran et al., International PCT Publication No. WO 01/04313, describe certain methods and compositions for inhibiting the function of certain polynucleotide sequences using certain long (over 250 bp), vector expressed dsRNAs. Echeverri et al., International PCT Publication No. WO 02/38805, describe certain *C. elegans* genes identified via RNAi. Kreutzer et al., International PCT Publications Nos. WO 02/055692, WO 02/055693, and EP 1144623 B1 describes certain methods for inhibiting gene expression using dsRNA. Graham et al., International PCT Publications Nos. WO 99/49029 and WO 01/70949, and AU 4037501 describe certain vector expressed siRNA molecules. Fire et al., U.S. Pat. No. 6,506,559, describe certain methods for inhibiting gene expression in vitro using certain long dsRNA (299 bp-1033 bp) constructs that mediate RNAi. Martinez et al., 2002, *Cell*, 110, 563-574, describe certain single stranded siRNA constructs, including certain 5'-phosphorylated single stranded siRNAs that mediate RNA interference in Hela cells. Harborth et al., 2003, *Antisense & Nucleic Acid Drug*

Development, 13, 83-105, describe certain chemically and structurally modified siRNA molecules. Chiu and Rana, 2003, *RNA*, 9, 1034-1048, describe certain chemically and structurally modified siRNA molecules. Woolf et al., International PCT Publication Nos. WO 03/064626 and WO 03/064625 describe certain chemically modified dsRNA constructs.

[0011] McSwiggen et al., International PCT Publication No. WO 01/16312, describes nucleic acid mediated inhibition of BACE, PS-1, and PS-2 expression.

SUMMARY OF THE INVENTION

[0012] This invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with the maintenance or development of Alzheimer's disease and/or dementia, for example, beta-secretase (BACE), amyloid precursor protein (APP), PIN-1, presenilin 1 (PS-1) and/or presenilin 2 (PS-2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BACE, APP, PIN-1, PS-1 and/or PS-2 gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of BACE, APP, PIN-1, PS-1 and/or PS-2 genes or other genes associated with the maintenance or development of Alzheimer's disease and/or dementia.

[0013] A siNA of the invention can be unmodified or chemically-modified. A siNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized. The instant invention also features various chemically-modified synthetic short interfering nucleic acid (siNA) molecules capable of modulating BACE, APP, PIN-1, PS-1 and/or PS-2 gene expression or activity in cells by RNA interference (RNAi). The use of chemically-modified siNA improves various properties of native siNA molecules through increased resistance to nuclease degradation in vivo and/or through improved cellular uptake. Further, contrary to earlier published studies, siNA having multiple chemical modifications retains its RNAi activity. The siNA molecules of the instant invention provide useful reagents and methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.

[0014] In one embodiment, the invention features one or more siNA molecules and methods that independently or in combination modulate the expression of BACE, APP, PIN-1, PS-1 and/or PS-2 genes encoding proteins, such as proteins comprising BACE, APP, PIN-1, PS-1 and/or PS-2 associated with the maintenance and/or development of Alzheimer's disease and other neurodegenerative disorders or conditions such as dementia and stroke/cardiovascular accident (CVA), such as genes encoding sequences comprising those sequences referred to by GenBank Accession Nos. shown in Table I, referred to herein generally as BACE, APP, PIN-1, PS-1 and/or PS-2. The description below of the various aspects and embodiments of the invention is provided with

reference to exemplary BACE gene referred to herein as BACE. However, the various aspects and embodiments are also directed to other BACE genes, such as BACE homolog genes, transcript variants and polymorphisms (e.g., single nucleotide polymorphism, (SNPs)) associated with certain BACE genes. As such, the various aspects and embodiments are also directed to other genes which express other BACE related proteins or other proteins associated with Alzheimer's disease, such as APP, PIN-1, PS-1 and/or PS-2, including mutant genes and splice variants thereof. The various aspects and embodiments are also directed to other genes that are involved in BACE, APP, PIN-1, PS-1 and/or PS-2 mediated pathways of signal transduction or gene expression that are involved, for example, in the progression, development, or maintenance of disease (e.g., Alzheimer's disease). These additional genes can be analyzed for target sites using the methods described for BACE genes herein. Thus, the modulation of other genes and the effects of such modulation of the other genes can be performed, determined, and measured as described herein.

[0015] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene, wherein said siNA molecule comprises about 18 to about 21 base pairs.

[0016] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of BACE RNA via RNA interference (RNAi), wherein the double stranded siNA molecule comprises a first and a second strand, each strand of the siNA molecule is about 18 to about 23 nucleotides in length, the first strand of the siNA molecule comprises nucleotide sequence having sufficient complementarity to the BACE RNA for the siNA molecule to direct cleavage of the BACE RNA via RNA interference, and the second strand of said siNA molecule comprises nucleotide sequence that is complementary to the first strand.

[0017] In one embodiment, the invention features a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a BACE RNA via RNA interference (RNAi), wherein each strand of the siNA molecule is about 18 to about 23 nucleotides in length; and one strand of the siNA molecule comprises nucleotide sequence having sufficient complementarity to the BACE RNA for the siNA molecule to direct cleavage of the BACE RNA via RNA interference.

[0018] In one embodiment, the invention features a siNA molecule that down-regulates expression of a BACE gene, for example, wherein the BACE gene comprises BACE encoding sequence. In one embodiment, the invention features a siNA molecule that down-regulates expression of a BACE gene, for example, wherein the BACE gene comprises BACE non-coding sequence or regulatory elements involved in BACE gene expression.

[0019] In one embodiment, a siNA of the invention is used to inhibit the expression of BACE genes or a BACE gene family, wherein the genes or gene family sequences share sequence homology. Such homologous sequences can be identified as is known in the art, for example using sequence alignments. siNA molecules can be designed to target such homologous sequences, for example using perfectly complementary sequences or by incorporating non-canonical base

pairs, for example mismatches and/or wobble base pairs, that can provide additional target sequences. In instances where mismatches are identified, non-canonical base pairs (for example, mismatches and/or wobble bases) can be used to generate siNA molecules that target more than one gene sequence. In a non-limiting example, non-canonical base pairs such as UU and CC base pairs are used to generate siNA molecules that are capable of targeting sequences for differing BACE targets that share sequence homology. As such, one advantage of using siNAs of the invention is that a single siNA can be designed to include nucleic acid sequence that is complementary to the nucleotide sequence that is conserved between the homologous genes. In this approach, a single siNA can be used to inhibit expression of more than one gene instead of using more than one siNA molecule to target the different genes.

[0020] In one embodiment, the invention features a siNA molecule having RNAi activity against BACE RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having BACE encoding sequence, such as those sequences having GenBank Accession Nos. shown in Table I. In another embodiment, the invention features a siNA molecule having RNAi activity against BACE RNA, wherein the siNA molecule comprises a sequence complementary to an RNA having variant BACE encoding sequence, for example other mutant BACE genes not shown in Table I but known in the art to be associated with the maintenance and/or development of Alzheimer's disease and/or dementia. Chemical modifications as shown in Tables III and IV or otherwise described herein can be applied to any siNA construct of the invention. In another embodiment, a siNA molecule of the invention includes a nucleotide sequence that can interact with nucleotide sequence of a BACE gene and thereby mediate silencing of BACE gene expression, for example, wherein the siNA mediates regulation of BACE gene expression by cellular processes that modulate the chromatin structure or methylation patterns of the BACE gene and prevent transcription of the BACE gene.

[0021] In one embodiment, siNA molecules of the invention are used to down regulate or inhibit the expression of BACE proteins arising from BACE haplotype polymorphisms that are associated with a disease or condition, (e.g., Alzheimer's disease and other neurodegenerative disorders or conditions such as dementia and stroke/cardiovascular accident (CVA)). Analysis of BACE genes, or BACE protein or RNA levels can be used to identify subjects with such polymorphisms or those subjects who are at risk of developing traits, conditions, or diseases described herein. These subjects are amenable to treatment, for example, treatment with siNA molecules of the invention and any other composition useful in treating diseases related to BACE gene expression. As such, analysis of BACE protein or RNA levels can be used to determine treatment type and the course of therapy in treating a subject. Monitoring of BACE protein or RNA levels can be used to predict treatment outcome and to determine the efficacy of compounds and compositions that modulate the level and/or activity of certain BACE proteins associated with a trait, condition, or disease.

[0022] In one embodiment of the invention a siNA molecule comprises an antisense strand comprising a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof encoding a BACE protein. The siNA

further comprises a sense strand, wherein said sense strand comprises a nucleotide sequence of a BACE gene or a portion thereof.

[0023] In another embodiment, a siNA molecule comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence encoding a BACE protein or a portion thereof. The siNA molecule further comprises a sense region, wherein said sense region comprises a nucleotide sequence of a BACE gene or a portion thereof.

[0024] In another embodiment, the invention features a siNA molecule comprising a nucleotide sequence in the antisense region of the siNA molecule that is complementary to a nucleotide sequence or portion of sequence of a BACE gene. In another embodiment, the invention features a siNA molecule comprising a region, for example, the antisense region of the siNA construct, complementary to a sequence comprising a BACE gene sequence or a portion thereof.

[0025] In one embodiment, the antisense region of BACE siNA constructs comprises a sequence complementary to sequence having any of SEQ ID NOs. 399-723, 1471-1478, 1591-1598, 1607-1614, 1623-1630, 1639-1646, 1655-1662, 1687, or 1689. In one embodiment, the antisense region of BACE constructs comprises sequence having any of SEQ ID NOs. 724-1048, 1599-1606, 1615-1622, 1631-1638, 1647-1654, 1663-1686, 1688, 1690, 1884, 1886, 1888, 1891, 1893, 1895, 1897, or 1900. In another embodiment, the sense region of BACE constructs comprises sequence having any of SEQ ID NOs. 399-723, 1471-1478, 1591-1598, 1607-1614, 1623-1630, 1639-1646, 1655-1662, 1687, 1689, 1883, 1885, 1887, 1889, 1890, 1892, 1894, 1896, 1898, or 1899.

[0026] In one embodiment, the antisense region of APP siNA constructs comprises a sequence complementary to sequence having any of SEQ ID NOs. 1-199, 1463-1470, 1495-1502, 1511-1518, 1527-1534, 1543-1550, or 1559-1566. In one embodiment, the antisense region of APP constructs comprises sequence having any of SEQ ID NOs. 200-398, 1503-1510, 1519-1526, 1535-1542, 1551-1558, 1567-1590, 1884, 1886, 1888, or 1891. In another embodiment, the sense region of APP constructs comprises sequence having any of SEQ ID NOs. 1-199, 1463-1470, 1495-1502, 1511-1518, 1527-1534, 1543-1550, 1559-1566, 1883, 1885, 1887, 1889, or 1890.

[0027] In one embodiment, the antisense region of PSEN1 siNA constructs comprises a sequence complementary to sequence having any of SEQ ID NOs. 1049-1131, 1479-1486, 1691-1698, 1707-1714, 1723-1730, 1739-1746, 1755-1762. In one embodiment, the antisense region of PSEN1 constructs comprises sequence having any of SEQ ID NOs. 1132-1214, 1699-1706, 1715-1722, 1731-1738, 1747-1754, 1763-1786, 1884, 1886, 1888, or 1891. In another embodiment, the sense region of PSEN1 constructs comprises sequence having any of SEQ ID NOs. 1049-1131, 1479-1486, 1691-1698, 1707-1714, 1723-1730, 1739-1746, 1755-1762, 1883, 1885, 1887, 1889, or 1890.

[0028] In one embodiment, the antisense region of PSEN2 siNA constructs comprises a sequence complementary to sequence having any of SEQ ID NOs. 1215-1338, 1487-1494, 1787-1794, 1803-1810, 1819-1826, 1835-1842, 1851-1858. In one embodiment, the antisense region of PSEN2

constructs comprises sequence having any of SEQ ID NOs. 1339-1462, 1795-1802, 1811-1818, 1827-1834, 1843-1850, 1859-1882, 1884, 1886, 1888, or 1891. In another embodiment, the sense region of PSEN2 constructs comprises sequence having any of SEQ ID NOs. SEQ ID NOs. 1215-1338, 1487-1494, 1787-1794, 1803-1810, 1819-1826, 1835-1842, 1851-1858, 1883, 1885, 1887, 1889, or 1890.

[0029] In one embodiment, a siNA molecule of the invention comprises any of SEQ ID NOs. 1-1900. The sequences shown in SEQ ID NOs: 1-1900 are not limiting. A siNA molecule of the invention can comprise any contiguous BACE sequence (e.g., about 18 to about 25, or about 18, 19, 20, 21, 22, 23, 24, or 25 contiguous BACE nucleotides).

[0030] In yet another embodiment, the invention features a siNA molecule comprising a sequence, for example, the antisense sequence of the siNA construct, complementary to a sequence or portion of sequence comprising sequence represented by GenBank Accession Nos. shown in Table I. Chemical modifications in Tables III and IV and described herein can be applied to any siNA construct of the invention.

[0031] In one embodiment of the invention a siNA molecule comprises an antisense strand having about 18 to about 29 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein the antisense strand is complementary to a RNA sequence encoding a BACE protein, and wherein said siNA further comprises a sense strand having about 18 to about 29 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, and wherein said sense strand and said antisense strand are distinct nucleotide sequences with at least about 18 complementary nucleotides.

[0032] In another embodiment of the invention a siNA molecule of the invention comprises an antisense region having about 18 to about 29 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein the antisense region is complementary to a RNA sequence encoding a BACE protein, and wherein said siNA further comprises a sense region having about 18 to about 29 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein said sense region and said antisense region comprise a linear molecule with at least about 19 complementary nucleotides.

[0033] In one embodiment, a siNA molecule of the invention has RNAi activity that modulates expression of RNA encoded by a BACE gene. Because BACE genes can share some degree of sequence homology with each other, siNA molecules can be designed to target a class of BACE genes or alternately specific BACE genes (e.g., polymorphic variants) by selecting sequences that are either shared amongst different BACE targets or alternatively that are unique for a specific BACE target. Therefore, in one embodiment, the siNA molecule can be designed to target conserved regions of BACE RNA sequences having homology among several BACE gene variants so as to target a class of BACE genes with one siNA molecule. Accordingly, in one embodiment, the siNA molecule of the invention modulates the expression of one or both BACE alleles in a subject. In another embodiment, the siNA molecule can be designed to target a sequence that is unique to a specific BACE RNA sequence (e.g., a single BACE allele or BACE single nucleotide polymorphism (SNP)) due to the high degree of specificity that the siNA molecule requires to mediate RNAi activity.

[0034] In one embodiment, nucleic acid molecules of the invention that act as mediators of the RNA interference gene silencing response are double-stranded nucleic acid molecules. In another embodiment, the siNA molecules of the invention consist of duplex nucleic acid molecules containing about 18 base pairs between oligonucleotides comprising about 18 to about 25 (e.g., about 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides. In yet another embodiment, siNA molecules of the invention comprise duplex nucleic acid molecules with overhanging ends of about 1 to about 3 (e.g., about 1, 2, or 3) nucleotides, for example, about 21-nucleotide duplexes with about 18 base pairs and 3'-terminal mononucleotide, dinucleotide, or trinucleotide overhangs.

[0035] In one embodiment, the invention features one or more chemically-modified siNA constructs having specificity for BACE expressing nucleic acid molecules, such as RNA encoding a BACE protein. In one embodiment, the invention features a RNA based siNA molecule (e.g., a siNA comprising 2'-OH nucleotides) having specificity for BACE expressing nucleic acid molecules that includes one or more chemical modifications described herein. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2'-deoxyribonucleotides, 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, "acyclic" nucleotides, 5-C-methyl nucleotides, and terminal glyceryl and/or inverted deoxy abasic residue incorporation. These chemical modifications, when used in various siNA constructs, (e.g., RNA based siNA constructs), are shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of these compounds. Furthermore, contrary to the data published by Parrish et al., supra, applicant demonstrates that multiple (greater than one) phosphorothioate substitutions are well-tolerated and confer substantial increases in serum stability for modified siNA constructs.

[0036] In one embodiment, a siNA molecule of the invention comprises modified nucleotides while maintaining the ability to mediate RNAi. The modified nucleotides can be used to improve in vitro or in vivo characteristics such as stability, activity, and/or bioavailability. For example, a siNA molecule of the invention can comprise modified nucleotides as a percentage of the total number of nucleotides present in the siNA molecule. As such, a siNA molecule of the invention can generally comprise about 5% to about 100% modified nucleotides (e.g., about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides). The actual percentage of modified nucleotides present in a given siNA molecule will depend on the total number of nucleotides present in the siNA. If the siNA molecule is single stranded, the percent modification can be based upon the total number of nucleotides present in the single stranded siNA molecules. Likewise, if the siNA molecule is double stranded, the percent modification can be based upon the total number of nucleotides present in the sense strand, antisense strand, or both the sense and antisense strands.

[0037] One aspect of the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene. In one embodiment, the double stranded siNA molecule comprises one or

more chemical modifications and each strand of the double-stranded siNA is about 21 nucleotides long. In one embodiment, the double-stranded siNA molecule does not contain any ribonucleotides. In another embodiment, the double-stranded siNA molecule comprises one or more ribonucleotides. In one embodiment, each strand of the double-stranded siNA molecule comprises about 18 to about 29 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein each strand comprises about 18 nucleotides that are complementary to the nucleotides of the other strand. In one embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof of the BACE gene, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence of the BACE gene or a portion thereof.

[0038] In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene comprising an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of the BACE gene or a portion thereof, and a sense region, wherein the sense region comprises a nucleotide sequence substantially similar to the nucleotide sequence of the BACE gene or a portion thereof. In one embodiment, the antisense region and the sense region each comprise about 18 to about 23 (e.g. about 18, 19, 20, 21, 22, or 23) nucleotides, wherein the antisense region comprises about 18 nucleotides that are complementary to nucleotides of the sense region.

[0039] In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene comprising a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by the BACE gene or a portion thereof and the sense region comprises a nucleotide sequence that is complementary to the antisense region.

[0040] In one embodiment, a siNA molecule of the invention comprises blunt ends, i.e., ends that do not include any overhanging nucleotides. For example, a siNA molecule comprising modifications described herein (e.g., comprising nucleotides having Formulae I-VII or siNA constructs comprising "Stab 00"-"Stab 25" (Table IV) or any combination thereof (see Table IV)) and/or any length described herein can comprise blunt ends or ends with no overhanging nucleotides.

[0041] In one embodiment, any siNA molecule of the invention can comprise one or more blunt ends, i.e. where a blunt end does not have any overhanging nucleotides. In one embodiment, the blunt ended siNA molecule has a number of base pairs equal to the number of nucleotides present in each strand of the siNA molecule. In another embodiment, the siNA molecule comprises one blunt end, for example wherein the 5'-end of the antisense strand and the 3'-end of the sense strand do not have any overhanging nucleotides. In another example, the siNA molecule comprises one blunt end, for example wherein the 3'-end of the antisense strand and the 5'-end of the sense strand do not have any overhanging nucleotides. In another example, a siNA molecule

comprises two blunt ends, for example wherein the 3'-end of the antisense strand and the 5'-end of the sense strand as well as the 5'-end of the antisense strand and 3'-end of the sense strand do not have any overhanging nucleotides. A blunt ended siNA molecule can comprise, for example, from about 18 to about 30 nucleotides (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). Other nucleotides present in a blunt ended siNA molecule can comprise, for example, mismatches, bulges, loops, or wobble base pairs to modulate the activity of the siNA molecule to mediate RNA interference.

[0042] By "blunt ends" is meant symmetric termini or termini of a double stranded siNA molecule having no overhanging nucleotides. The two strands of a double stranded siNA molecule align with each other without overhanging nucleotides at the termini. For example, a blunt ended siNA construct comprises terminal nucleotides that are complementary between the sense and antisense regions of the siNA molecule.

[0043] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. The sense region can be connected to the antisense region via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker.

[0044] In one embodiment, the invention features double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene, wherein the siNA molecule comprises about 18 to about 21 base pairs, and wherein each strand of the siNA molecule comprises one or more chemical modifications. In another embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a BACE gene or a portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of the BACE gene. In another embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a BACE gene or portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or portion thereof of the BACE gene. In another embodiment, each strand of the siNA molecule comprises about 18 to about 23 nucleotides, and each strand comprises at least about 18 nucleotides that are complementary to the nucleotides of the other strand. The BACE gene can comprise, for example, sequences referred to in Table I.

[0045] In one embodiment, a siNA molecule of the invention comprises no ribonucleotides. In another embodiment, a siNA molecule of the invention comprises ribonucleotides.

[0046] In one embodiment, a siNA molecule of the invention comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence of a BACE gene or a portion thereof, and the siNA further comprises a sense region comprising a nucleotide sequence substantially similar to the nucleotide sequence of the BACE gene or a portion thereof. In another embodiment, the

antisense region and the sense region each comprise about 18 to about 23 nucleotides and the antisense region comprises at least about 18 nucleotides that are complementary to nucleotides of the sense region. The BACE gene can comprise, for example, sequences referred to in Table I.

[0047] In one embodiment, a siNA molecule of the invention comprises a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by a BACE gene, or a portion thereof, and the sense region comprises a nucleotide sequence that is complementary to the antisense region. In one embodiment, the siNA molecule is assembled from two separate oligonucleotide fragments, wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. In another embodiment, the sense region is connected to the antisense region via a linker molecule. In another embodiment, the sense region is connected to the antisense region via a linker molecule, such as a nucleotide or non-nucleotide linker. The BACE gene can comprise, for example, sequences referred to in Table I.

[0048] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene comprising a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by the BACE gene or a portion thereof and the sense region comprises a nucleotide sequence that is complementary to the antisense region, and wherein the siNA molecule has one or more modified pyrimidine and/or purine nucleotides. In one embodiment, the pyrimidine nucleotides in the sense region are 2'-O-methyl pyrimidine nucleotides or 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-deoxy purine nucleotides. In another embodiment, the pyrimidine nucleotides in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-O-methyl purine nucleotides. In another embodiment, the pyrimidine nucleotides in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-deoxy purine nucleotides. In one embodiment, the pyrimidine nucleotides in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the antisense region are 2'-O-methyl or 2'-deoxy purine nucleotides. In another embodiment of any of the above-described siNA molecules, any nucleotides present in a non-complementary region of the sense strand (e.g. overhang region) are 2'-deoxy nucleotides.

[0049] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule, and wherein the fragment comprising the sense region includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the fragment. In one embodiment, the terminal cap moiety is an inverted deoxy abasic moiety or glyceryl moiety. In one embodiment, each of the two fragments of the siNA molecule comprise about 21 nucleotides.

[0050] In one embodiment, the invention features a siNA molecule comprising at least one modified nucleotide, wherein the modified nucleotide is a 2'-deoxy-2'-fluoro nucleotide. The siNA can be, for example, of length between about 12 and about 36 nucleotides. In one embodiment, all pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides. In one embodiment, the modified nucleotides in the siNA include at least one 2'-deoxy-2'-fluoro cytidine or 2'-deoxy-2'-fluoro uridine nucleotide. In another embodiment, the modified nucleotides in the siNA include at least one 2'-fluoro cytidine and at least one 2'-deoxy-2'-fluoro uridine nucleotides. In one embodiment, all uridine nucleotides present in the siNA are 2'-deoxy-2'-fluoro uridine nucleotides. In one embodiment, all cytidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro cytidine nucleotides. In one embodiment, all adenosine nucleotides present in the siNA are 2'-deoxy-2'-fluoro adenosine nucleotides. In one embodiment, all guanosine nucleotides present in the siNA are 2'-deoxy-2'-fluoro guanosine nucleotides. The siNA can further comprise at least one modified internucleotidic linkage, such as phosphorothioate linkage. In one embodiment, the 2'-deoxy-2'-fluoronucleotides are present at specifically selected locations in the siNA that are sensitive to cleavage by ribonucleases, such as locations having pyrimidine nucleotides.

[0051] In one embodiment, the invention features a method of increasing the stability of a siNA molecule against cleavage by ribonucleases comprising introducing at least one modified nucleotide into the siNA molecule, wherein the modified nucleotide is a 2'-deoxy-2'-fluoro nucleotide. In one embodiment, all pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides. In one embodiment, the modified nucleotides in the siNA include at least one 2'-deoxy-2'-fluoro cytidine or 2'-deoxy-2'-fluoro uridine nucleotide. In another embodiment, the modified nucleotides in the siNA include at least one 2'-fluoro cytidine and at least one 2'-deoxy-2'-fluoro uridine nucleotides. In one embodiment, all uridine nucleotides present in the siNA are 2'-deoxy-2'-fluoro uridine nucleotides. In one embodiment, all cytidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro cytidine nucleotides. In one embodiment, all adenosine nucleotides present in the siNA are 2'-deoxy-2'-fluoro adenosine nucleotides. In one embodiment, all guanosine nucleotides present in the siNA are 2'-deoxy-2'-fluoro guanosine nucleotides. The siNA can further comprise at least one modified internucleotidic linkage, such as phosphorothioate linkage. In one embodiment, the 2'-deoxy-2'-fluoronucleotides are present at specifically selected locations in the siNA that are sensitive to cleavage by ribonucleases, such as locations having pyrimidine nucleotides.

[0052] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene comprising a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by the BACE gene or a portion thereof and the sense region comprises a nucleotide sequence that is complementary to the antisense region, and wherein the purine nucleotides present in the antisense region comprise 2'-deoxy-purine nucleotides. In an alternative embodiment, the purine nucleotides present in the antisense region comprise 2'-O-methyl purine nucleotides. In either of the above embodiments, the

antisense region can comprise a phosphorothioate internucleotide linkage at the 3' end of the antisense region. Alternatively, in either of the above embodiments, the antisense region can comprise a glyceryl modification at the 3' end of the antisense region. In another embodiment of any of the above-described siNA molecules, any nucleotides present in a non-complementary region of the antisense strand (e.g. overhang region) are 2'-deoxy nucleotides.

[0053] In one embodiment, the antisense region of a siNA molecule of the invention comprises sequence complementary to a portion of a BACE transcript having sequence unique to a particular BACE disease related allele, such as sequence comprising a single nucleotide polymorphism (SNP) associated with the disease specific allele. As such, the antisense region of a siNA molecule of the invention can comprise sequence complementary to sequences that are unique to a particular allele to provide specificity in mediating selective RNAi against the disease, condition, or trait related allele.

[0054] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a BACE gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. In another embodiment about 19 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule and wherein at least two 3' terminal nucleotides of each fragment of the siNA molecule are not base-paired to the nucleotides of the other fragment of the siNA molecule. In one embodiment, each of the two 3' terminal nucleotides of each fragment of the siNA molecule is a 2'-deoxy-pyrimidine nucleotide, such as a 2'-deoxy-thymidine. In another embodiment, all 21 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule. In another embodiment, about 19 nucleotides of the antisense region are base-paired to the nucleotide sequence or a portion thereof of the RNA encoded by the BACE gene. In another embodiment, about 21 nucleotides of the antisense region are base-paired to the nucleotide sequence or a portion thereof of the RNA encoded by the BACE gene. In any of the above embodiments, the 5'-end of the fragment comprising said antisense region can optionally include a phosphate group.

[0055] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of a BACE RNA sequence (e.g., wherein said target RNA sequence is encoded by a BACE gene involved in the BACE pathway), wherein the siNA molecule does not contain any ribonucleotides and wherein each strand of the double-stranded siNA molecule is about 21 nucleotides long. Examples of non-ribonucleotide containing siNA constructs are combinations of stabilization chemistries shown in Table IV in any combination of Sense/Antisense chemistries, such as Stab 7/8, Stab 7/11, Stab 8/8, Stab 18/8, Stab 18/11, Stab 12/13, Stab 7/13, Stab 18/13, Stab 7/19, Stab 8/19, Stab 18/19, Stab 7/20, Stab 8/20, or Stab 18/20.

[0056] In one embodiment, the invention features a chemically synthesized double stranded RNA molecule that directs

cleavage of a BACE RNA via RNA interference, wherein each strand of said RNA molecule is about 21 to about 23 nucleotides in length; one strand of the RNA molecule comprises nucleotide sequence having sufficient complementarity to the BACE RNA for the RNA molecule to direct cleavage of the BACE RNA via RNA interference; and wherein at least one strand of the RNA molecule comprises one or more chemically modified nucleotides described herein, such as deoxynucleotides, 2'-O-methyl nucleotides, 2'-deoxy-2'-fluoro nucleotides, 2'-O-methoxyethyl nucleotides etc.

[0057] In one embodiment, the invention features a medicament comprising a siNA molecule of the invention.

[0058] In one embodiment, the invention features an active ingredient comprising a siNA molecule of the invention.

[0059] In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule to down-regulate expression of a BACE gene, wherein the siNA molecule comprises one or more chemical modifications and each strand of the double-stranded siNA is about 18 to about 28 or more (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 or more) nucleotides long.

[0060] In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of BACE RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.

[0061] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of BACE RNA or a portion thereof, wherein the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.

[0062] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of BACE RNA that encodes a protein or portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification. In one embodiment, each strand of the siNA molecule comprises about 18 to about 29 or more (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 or

more) nucleotides, wherein each strand comprises at least about 18 nucleotides that are complementary to the nucleotides of the other strand. In one embodiment, the siNA molecule is assembled from two oligonucleotide fragments, wherein one fragment comprises the nucleotide sequence of the antisense strand of the siNA molecule and a second fragment comprises nucleotide sequence of the sense region of the siNA molecule. In one embodiment, the sense strand is connected to the antisense strand via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker. In a further embodiment, the pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-deoxy purine nucleotides. In another embodiment, the pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-O-methyl purine nucleotides. In still another embodiment, the pyrimidine nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2'-deoxy purine nucleotides. In another embodiment, the antisense strand comprises one or more 2'-deoxy-2'-fluoro pyrimidine nucleotides and one or more 2'-O-methyl purine nucleotides. In another embodiment, the pyrimidine nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2'-O-methyl purine nucleotides. In a further embodiment the sense strand comprises a 3'-end and a 5'-end, wherein a terminal cap moiety (e.g., an inverted deoxy abasic moiety or inverted deoxy nucleotide moiety such as inverted thymidine) is present at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the sense strand. In another embodiment, the antisense strand comprises a phosphorothioate internucleotide linkage at the 3' end of the antisense strand. In another embodiment, the antisense strand comprises a glyceryl modification at the 3' end. In another embodiment, the 5'-end of the antisense strand optionally includes a phosphate group.

[0063] In any of the above-described embodiments of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, each of the two strands of the siNA molecule can comprise about 21 nucleotides. In one embodiment, about 21 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule. In another embodiment, about 19 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule, wherein at least two 3' terminal nucleotides of each strand of the siNA molecule are not base-paired to the nucleotides of the other strand of the siNA molecule. In another embodiment, each of the two 3' terminal nucleotides of each fragment of the siNA molecule is a 2'-deoxy-pyrimidine, such as 2'-deoxy-thymidine. In one embodiment, each strand of the siNA molecule is base-paired to the complementary nucleotides of the other strand of the siNA molecule. In one embodiment, about 19 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the BACE RNA or a portion thereof. In one embodiment,

about 21 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the BACE RNA or a portion thereof.

[0064] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of BACE RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the 5'-end of the antisense strand optionally includes a phosphate group.

[0065] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of BACE RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the nucleotide sequence or a portion thereof of the antisense strand is complementary to a nucleotide sequence of the untranslated region or a portion thereof of the BACE RNA.

[0066] In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a BACE gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of BACE RNA or a portion thereof, wherein the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the nucleotide sequence of the antisense strand is complementary to a nucleotide sequence of the BACE RNA or a portion thereof that is present in the BACE RNA.

[0067] In one embodiment, the invention features a composition comprising a siNA molecule of the invention in a pharmaceutically acceptable carrier or diluent.


[0068] In a non-limiting example, the introduction of chemically-modified nucleotides into nucleic acid molecules provides a powerful tool in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically-modified nucleic acid molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically-modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically-modified nucleic acid

molecule is reduced as compared to a native nucleic acid molecule, for example, when compared to an all-RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than that of the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siNA, chemically-modified siNA can also minimize the possibility of activating interferon activity in humans.

[0069] In any of the embodiments of siNA molecules described herein, the antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3'-end of said antisense region. In any of the embodiments of siNA molecules described herein, the antisense region can comprise about one to about five phosphorothioate internucleotide linkages at the 5'-end of said antisense region. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs of a siNA molecule of the invention can comprise ribonucleotides or deoxyribonucleotides that are chemically-modified at a nucleic acid sugar, base, or backbone. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs can comprise one or more acyclic nucleotides.

[0070] One embodiment of the invention provides an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention in a manner that allows expression of the nucleic acid molecule. Another embodiment of the invention provides a mammalian cell comprising such an expression vector. The mammalian cell can be a human cell. The siNA molecule of the expression vector can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to a RNA or DNA sequence encoding BACE and the sense region can comprise sequence complementary to the antisense region. The siNA molecule can comprise two distinct strands having complementary sense and antisense regions. The siNA molecule can comprise a single strand having complementary sense and antisense regions.

[0071] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides comprising a backbone modified internucleotide linkage having Formula I:




[0072] wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally-occurring or chemically-modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O,

S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or acetyl and wherein W, X, Y, and Z are optionally not all O. In another embodiment, a backbone modification of the invention comprises a phosphonoacetate and/or thiophosphonoacetate internucleotide linkage (see for example Sheehan et al., 2003, *Nucleic Acids Research*, 31, 4109-4118).

[0073] The chemically-modified internucleotide linkages having Formula I, for example, wherein any Z, W, X, and/or Y independently comprises a sulphur atom, can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically-modified internucleotide linkages having Formula I at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified internucleotide linkages having Formula I at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In another embodiment, a siNA molecule of the invention having internucleotide linkage(s) of Formula I also comprises a chemically-modified nucleotide or non-nucleotide having any of Formulae I-VII.

[0074] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula II:




[0075] wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkyl-

lamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

[0076] The chemically-modified nucleotide or non-nucleotide of Formula II can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula II at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 3'-end of the sense strand, the antisense strand, or both strands.

[0077] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula III:




[0078] wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be employed to be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or

any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

[0079] The chemically-modified nucleotide or non-nucleotide of Formula III can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula III at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide(s) or non-nucleotide(s) of Formula III at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide or non-nucleotide of Formula III at the 3'-end of the sense strand, the antisense strand, or both strands.

[0080] In another embodiment, a siNA molecule of the invention comprises a nucleotide having Formula II or III, wherein the nucleotide having Formula II or III is in an inverted configuration. For example, the nucleotide having Formula II or III is connected to the siNA construct in a 3'-3', 3'-2', 2'-3', or 5'-5' configuration, such as at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both siNA strands.

[0081] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system, wherein the chemical modification comprises a 5'-terminal phosphate group having Formula IV:



[0082] wherein each X and Y is independently O, S, N, alkyl, substituted alkyl, or alkylhalo; wherein each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, alkylhalo, or acetyl; and wherein W, X, Y and Z are not all O.

[0083] In one embodiment, the invention features a siNA molecule having a 5'-terminal phosphate group having Formula IV on the target-complementary strand, for example, a strand complementary to a target RNA, wherein the siNA molecule comprises an all RNA siNA molecule. In another embodiment, the invention features a siNA molecule having a 5'-terminal phosphate group having Formula IV on the target-complementary strand wherein the siNA molecule also comprises about 1 to about 3 (e.g., about 1, 2, or 3) nucleotide 3'-terminal nucleotide overhangs having about 1 to about 4 (e.g., about 1, 2, 3, or 4) deoxyribonucleotides on the 3'-end of one or both strands. In another embodiment, a 5'-terminal phosphate group having Formula IV is present on the target-complementary strand of a siNA molecule of the invention, for example a siNA molecule having chemical modifications having any of Formulae I-VII.

[0084] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more phosphorothioate internucleotide linkages. For example, in a non-limiting example, the invention features a chemically-modified short interfering nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siNA strand. In yet another embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in both siNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more phosphorothioate internucleotide linkages at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands.

[0085] In one embodiment, the invention features a siNA molecule, wherein the sense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or about one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3' and 5'-ends, being present in the same or different strand.

[0086] In another embodiment, the invention features a siNA molecule, wherein the sense strand comprises about 1 to about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate

internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5 or more, for example about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

[0087] In one embodiment, the invention features a siNA molecule, wherein the antisense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or about one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

[0088] In another embodiment, the invention features a siNA molecule, wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one

or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

[0089] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule having about 1 to about 5 or more (specifically about 1, 2, 3, 4, 5 or more) phosphorothioate internucleotide linkages in each strand of the siNA molecule.

[0090] In another embodiment, the invention features a siNA molecule comprising 2'-5' internucleotide linkages. The 2'-5' internucleotide linkage(s) can be at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of one or both siNA sequence strands. In addition, the 2'-5' internucleotide linkage(s) can be present at various other positions within one or both siNA sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siNA molecule can comprise a 2'-5' internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siNA molecule can comprise a 2'-5' internucleotide linkage.

[0091] In another embodiment, a chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified, wherein each strand is about 18 to about 27 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27) nucleotides in length, wherein the duplex has about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the chemical modification comprises a structure having any of Formulae I-VII. For example, an exemplary chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein each strand consists of about 21 nucleotides, each having a 2-nucleotide 3'-terminal nucleotide overhang, and wherein the duplex has about 19 base pairs. In another embodiment, a siNA molecule of the invention comprises a single stranded hairpin structure, wherein the siNA is about 36 to about 70 (e.g., about 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having about 19 base pairs and a 2-nucleotide 3'-terminal nucleotide overhang. In another embodiment, a linear hairpin siNA molecule of the invention

contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. For example, a linear hairpin siNA molecule of the invention is designed such that degradation of the loop portion of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides.

[0092] In another embodiment, a siNA molecule of the invention comprises a hairpin structure, wherein the siNA is about 25 to about 50 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides in length having about 3 to about 25 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) base pairs, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 25 to about 35 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) nucleotides that is chemically-modified with one or more chemical modifications having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having about 3 to about 23 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) base pairs and a 5'-terminal phosphate group that can be chemically modified as described herein (for example a 5'-terminal phosphate group having Formula IV). In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. In one embodiment, a linear hairpin siNA molecule of the invention comprises a loop portion comprising a non-nucleotide linker.


[0093] In another embodiment, a siNA molecule of the invention comprises an asymmetric hairpin structure, wherein the siNA is about 25 to about 50 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides in length having about 3 to about 20 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) base pairs, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 25 to about 35 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) nucleotides that is chemically-modified with one or more chemical modifications having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms an asymmetric hairpin structure having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) base pairs and a 5'-terminal phosphate group that can be chemically modified as described herein (for example a 5'-terminal phosphate group having Formula IV). In one embodiment, an asymmetric hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. In another embodiment, an asymmetric hairpin siNA molecule of the invention comprises a loop portion comprising a non-nucleotide linker.

[0094] In another embodiment, a siNA molecule of the invention comprises an asymmetric double stranded structure having separate polynucleotide strands comprising sense and antisense regions, wherein the antisense region is about 16 to about 25 (e.g., about 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length, wherein the sense region is about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides in length, wherein the sense region and the antisense region have at least 3 complementary nucleotides, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises an asymmetric double stranded structure having separate polynucleotide strands comprising sense and antisense regions, wherein the antisense region is about 18 to about 22 (e.g., about 18, 19, 20, 21, or 22) nucleotides in length and wherein the sense region is about 3 to about 15 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) nucleotides in length, wherein the sense region the antisense region have at least 3 complementary nucleotides, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. In another embodiment, the asymmetric double stranded siNA molecule can also have a 5'-terminal phosphate group that can be chemically modified as described herein (for example a 5'-terminal phosphate group having Formula IV).

[0095] In another embodiment, a siNA molecule of the invention comprises a circular nucleic acid molecule, wherein the siNA is about 38 to about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification, which comprises a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a circular oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the circular oligonucleotide forms a dumbbell shaped structure having about 19 base pairs and 2 loops.


[0096] In another embodiment, a circular siNA molecule of the invention contains two loop motifs, wherein one or both loop portions of the siNA molecule is biodegradable. For example, a circular siNA molecule of the invention is designed such that degradation of the loop portions of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides.

[0097] In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) basic moiety, for example a compound having Formula V:




[0098] wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH2, S=O, CHF, or CF2.

[0099] In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) inverted abasic moiety, for example a compound having Formula VI:



[0100] wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH2, S=O, CHF, or CF2, and either R2, R3, R8 or R13 serve as points of attachment to the siNA molecule of the invention.

[0101] In another embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituted polyalkyl moieties, for example a compound having Formula VII:



[0102] wherein each n is independently an integer from 1 to 12, each R1, R2 and R3 is independently H, OH, alkyl,

substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or a group having Formula I, and R1, R2 or R3 serves as points of attachment to the siNA molecule of the invention.

[0103] In another embodiment, the invention features a compound having Formula VII, wherein R1 and R2 are hydroxyl (OH) groups, n=1, and R3 comprises O and is the point of attachment to the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both strands of a double-stranded siNA molecule of the invention or to a single-stranded siNA molecule of the invention. This modification is referred to herein as "glyceryl" (for example modification 6 in FIG. 10).

[0104] In another embodiment, a chemically modified nucleoside or non-nucleoside (e.g. a moiety having any of Formula V, VI or VII) of the invention is at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of a siNA molecule of the invention. For example, chemically modified nucleoside or non-nucleoside (e.g., a moiety having Formula V, VI or VII) can be present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense strand, the sense strand, or both antisense and sense strands of the siNA molecule. In one embodiment, the chemically modified nucleoside or non-nucleoside (e.g., a moiety having Formula V, VI or VII) is present at the 5'-end and 3'-end of the sense strand and the 3'-end of the antisense strand of a double stranded siNA molecule of the invention. In one embodiment, the chemically modified nucleoside or non-nucleoside (e.g., a moiety having Formula V, VI or VII) is present at the terminal position of the 5'-end and 3'-end of the sense strand and the 3'-end of the antisense strand of a double stranded siNA molecule of the invention. In one embodiment, the chemically modified nucleoside or non-nucleoside (e.g., a moiety having Formula V, VI or VII) is present at the two terminal positions of the 5'-end and 3'-end of the sense strand and the 3'-end of the antisense strand of a double stranded siNA molecule of the invention. In one embodiment, the chemically modified nucleoside or non-nucleoside (e.g., a moiety having Formula V, VI or VII) is present at the penultimate position of the 5'-end and 3'-end of the sense strand and the 3'-end of the antisense strand of a double stranded siNA molecule of the invention. In addition, a moiety having Formula VII can be present at the 3'-end or the 5'-end of a hairpin siNA molecule as described herein.

[0105] In another embodiment, a siNA molecule of the invention comprises an abasic residue having Formula V or VI, wherein the abasic residue having Formula VI or VI is connected to the siNA construct in a 3'-3', 3'-2', 2'-3', or 5'-5' configuration, such as at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both siNA strands.

[0106] In one embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acid (LNA) nucleotides, for example, at the 5'-end, the 3'-end, both of the 5' and 3'-ends, or any combination thereof, of the siNA molecule.

[0107] In another embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6,

[0116] In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system comprising a sense region, wherein one or more

pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and one or more purine nucleotides present in the sense region are 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides), and an antisense region, wherein one or more pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides). The sense region and/or the antisense region can have a terminal cap modification, such as any modification described herein or shown in FIG. 10, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense and/or antisense sequence. The sense and/or antisense region can optionally further comprise a 3'-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxynucleotides. The overhang nucleotides can further comprise one or more (e.g., about 1, 2, 3, 4 or more) phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate internucleotide linkages. Non-limiting examples of these chemically-modified siNAs are shown in FIGS. 4 and 5 and Tables III and IV herein. In any of these described embodiments, the purine nucleotides present in the sense region are alternatively 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides) and one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides). Also, in any of these embodiments, one or more purine nucleotides present in the sense region are alternatively purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides) and any purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides). Additionally, in any of these embodiments, one or more purine nucleotides present in the sense region and/or present in the antisense region are alternatively selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides).

[0117] In another embodiment, any modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, are resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi. Non-limiting examples of nucleotides having a northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2'-O, 4'-C-methylene-(D-ribofuranosyl) nucleotides); 2'-methoxyethoxy (MOE) nucleotides; 2'-methyl-thio-ethyl, 2'-deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-chloro nucleotides, 2'-azido nucleotides, and 2'-O-methyl nucleotides.

[0118] In one embodiment, the sense strand of a double stranded siNA molecule of the invention comprises a terminal cap moiety, (see for example FIG. 10) such as an inverted deoxyabaisc moiety, at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand.

[0119] In one embodiment, the invention features a chemically-modified short interfering nucleic acid molecule (siNA) capable of mediating RNA interference (RNAi) against BACE inside a cell or reconstituted in vitro system, wherein the chemical modification comprises a conjugate covalently attached to the chemically-modified siNA molecule. Non-limiting examples of conjugates contemplated by the invention include conjugates and ligands described in Vargeese et al., U.S. Ser. No. 10/427,160, filed Apr. 30, 2003, incorporated by reference herein in its entirety, including the drawings. In another embodiment, the conjugate is covalently attached to the chemically-modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In another embodiment, the conjugate molecule is attached at the 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In yet another embodiment, the conjugate molecule is attached both the 3'-end and 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof. In one embodiment, a conjugate molecule of the invention comprises a molecule that facilitates delivery of a chemically-modified siNA molecule into a biological system, such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified siNA molecule is a polyethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can be attached to chemically-modified siNA molecules are described in Vargeese et al., U.S. Ser. No. 10/201,394, filed Jul. 22, 2002 incorporated by reference herein. The type of conjugates used and the extent of conjugation of siNA molecules of the invention can be evaluated for improved

pharmacokinetic profiles, bioavailability, and/or stability of siNA constructs while at the same time maintaining the ability of the siNA to mediate RNAi activity. As such, one skilled in the art can screen siNA constructs that are modified with various conjugates to determine whether the siNA conjugate complex possesses improved properties while maintaining the ability to mediate RNAi, for example in animal models as are generally known in the art.

[0120] In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule of the invention, wherein the siNA further comprises a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the siNA to the antisense region of the siNA. In one embodiment, a nucleotide linker of the invention can be a linker of ≥ 2 nucleotides in length, for example about 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In another embodiment, the nucleotide linker can be a nucleic acid aptamer. By "aptamer" or "nucleic acid aptamer" as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that comprises a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art. (See, for example, Gold et al., 1995, *Annu. Rev. Biochem.*, 64, 763; Brody and Gold, 2000, *J. Biotechnol.*, 74, 5; Sun, 2000, *Curr. Opin. Mol. Ther.*, 2, 100; Kusser, 2000, *J. Biotechnol.*, 74, 27; Hermann and Patel, 2000, *Science*, 287, 820; and Jayasena, 1999, *Clinical Chemistry*, 45, 1628.)

[0121] In yet another embodiment, a non-nucleotide linker of the invention comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g. polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 1987, 15:3113; Cload and Schepartz, *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma et al., *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand et al., *Nucleic Acids Res.* 1990, 18:6353; McCurdy et al., *Nucleosides & Nucleotides* 1991, 10:287; Jschke et al., *Tetrahedron Lett.* 1993, 34:301; Ono et al., *Biochemistry* 1991, 30:9914; Arnold et al., International Publication No. WO 89/02439; Usman et al., International Publication No. WO 95/06731; Dudycz et al., International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000, all hereby incorporated by reference herein. A "non-nucleotide" further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a

commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, for example at the C1 position of the sugar.

[0122] In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein one or both strands of the siNA molecule that are assembled from two separate oligonucleotides do not comprise any ribonucleotides. For example, a siNA molecule can be assembled from a single oligonucleotide where the sense and antisense regions of the siNA comprise separate oligonucleotides that do not have any ribonucleotides (e.g., nucleotides having a 2'-OH group) present in the oligonucleotides. In another example, a siNA molecule can be assembled from a single oligonucleotide where the sense and antisense regions of the siNA are linked or circularized by a nucleotide or non-nucleotide linker as described herein, wherein the oligonucleotide does not have any ribonucleotides (e.g., nucleotides having a 2'-OH group) present in the oligonucleotide. Applicant has surprisingly found that the presence of ribonucleotides (e.g., nucleotides having a 2'-hydroxyl group) within the siNA molecule is not required or essential to support RNAi activity. As such, in one embodiment, all positions within the siNA can include chemically modified nucleotides and/or non-nucleotides such as nucleotides and or non-nucleotides having Formula I, II, III, IV, V, VI, or VII or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

[0123] In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system comprising a single stranded polynucleotide having complementarity to a target nucleic acid sequence. In another embodiment, the single stranded siNA molecule of the invention comprises a 5'-terminal phosphate group. In another embodiment, the single stranded siNA molecule of the invention comprises a 5'-terminal phosphate group and a 3'-terminal phosphate group (e.g., a 2',3'-cyclic phosphate). In another embodiment, the single stranded siNA molecule of the invention comprises about 18 to about 29 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides. In yet another embodiment, the single stranded siNA molecule of the invention comprises one or more chemically modified nucleotides or non-nucleotides described herein. For example, all the positions within the siNA molecule can include chemically-modified nucleotides such as nucleotides having any of Formulae I-VII, or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

[0124] In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system comprising a single stranded polynucleotide having complementarity to a target nucleic acid sequence, wherein one or more pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a

plurality of purine nucleotides are 2'-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in FIG. 10, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence. The siNA optionally further comprises about 1 to about 4 or more (e.g., about 1, 2, 3, 4 or more) terminal 2'-deoxynucleotides at the 3'-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, 4 or more) phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5'-terminal phosphate group. In any of these embodiments, any purine nucleotides present in the antisense region are alternatively 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides). Also, in any of these embodiments, any purine nucleotides present in the siNA (i.e., purine nucleotides present in the sense and/or antisense region) can alternatively be locked nucleic acid (LNA) nucleotides (e.g., wherein all purine nucleotides are LNA nucleotides or alternately a plurality of purine nucleotides are LNA nucleotides). Also, in any of these embodiments, any purine nucleotides present in the siNA are alternatively 2'-methoxyethyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-methoxyethyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-methoxyethyl purine nucleotides). In another embodiment, any modified nucleotides present in the single stranded siNA molecules of the invention comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the single stranded siNA molecules of the invention are preferably resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi.

[0125] In one embodiment, the invention features a method for modulating the expression of a BACE gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the BACE gene in the cell.

[0126] In one embodiment, the invention features a method for modulating the expression of a BACE gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequence of the target RNA; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the BACE gene in the cell.

[0127] In another embodiment, the invention features a method for modulating the expression of more than one BACE gene within a cell comprising: (a) synthesizing siNA

molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE genes; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the BACE genes in the cell.

[0128] In another embodiment, the invention features a method for modulating the expression of two or more BACE genes within a cell comprising: (a) synthesizing one or more siNA molecules of the invention, which can be chemically-modified, wherein the siNA strands comprise sequences complementary to RNA of the BACE genes and wherein the sense strand sequences of the siNAs comprise sequences identical or substantially similar to the sequences of the target RNAs; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the BACE genes in the cell.

[0129] In another embodiment, the invention features a method for modulating the expression of more than one BACE gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequences of the target RNAs; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the BACE genes in the cell.

[0130] In one embodiment, siNA molecules of the invention are used as reagents in ex vivo applications. For example, siNA reagents are introduced into tissue or cells that are transplanted into a subject for therapeutic effect. The cells and/or tissue can be derived from an organism or subject that later receives the explant, or can be derived from another organism or subject prior to transplantation. The siNA molecules can be used to modulate the expression of one or more genes in the cells or tissue, such that the cells or tissue obtain a desired phenotype or are able to perform a function when transplanted in vivo. In one embodiment, certain target cells from a patient are extracted. These extracted cells are contacted with siNAs targeting a specific nucleotide sequence within the cells under conditions suitable for uptake of the siNAs by these cells (e.g. using delivery reagents such as cationic lipids, liposomes and the like or using techniques such as electroporation to facilitate the delivery of siNAs into cells). The cells are then reintroduced back into the same patient or other patients. In one embodiment, the invention features a method of modulating the expression of a BACE gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE gene; and (b) introducing the siNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the BACE gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the BACE gene in that organism.

[0131] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a

tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequence of the target RNA; and (b) introducing the siNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the BACE gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the BACE gene in that organism.

[0132] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in a tissue explant comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE genes; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the BACE genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the BACE genes in that organism.

[0133] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a subject or organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE gene; and (b) introducing the siNA molecule into the subject or organism under conditions suitable to modulate the expression of the BACE gene in the subject or organism. The level of BACE protein or RNA can be determined using various methods well-known in the art.

[0134] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in a subject or organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the BACE genes; and (b) introducing the siNA molecules into the subject or organism under conditions suitable to modulate the expression of the BACE genes in the subject or organism. The level of BACE protein or RNA can be determined as is known in the art.

[0135] In one embodiment, the invention features a method for modulating the expression of a BACE gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the BACE gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the BACE gene in the cell.

[0136] In another embodiment, the invention features a method for modulating the expression of more than one BACE gene within a cell comprising: (a) synthesizing siNA

molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the BACE gene; and (b) contacting the cell in vitro or in vivo with the siNA molecule under conditions suitable to modulate the expression of the BACE genes in the cell.

[0137] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the BACE gene; and (b) contacting a cell of the tissue explant derived from a particular subject or organism with the siNA molecule under conditions suitable to modulate the expression of the BACE gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the subject or organism the tissue was derived from or into another subject or organism under conditions suitable to modulate the expression of the BACE gene in that subject or organism.

[0138] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in a tissue explant comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the BACE gene; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular subject or organism under conditions suitable to modulate the expression of the BACE genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the subject or organism the tissue was derived from or into another subject or organism under conditions suitable to modulate the expression of the BACE genes in that subject or organism.

[0139] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a subject or organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the BACE gene; and (b) introducing the siNA molecule into the subject or organism under conditions suitable to modulate the expression of the BACE gene in the subject or organism.

[0140] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in a subject or organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the BACE gene; and (b) introducing the siNA molecules into the subject or organism under conditions suitable to modulate the expression of the BACE genes in the subject or organism.

[0141] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a subject or organism comprising contacting the subject or organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the BACE gene in the subject or organism.

[0142] In one embodiment, the invention features a method for treating Alzheimer's disease in a subject or

organism comprising contacting the subject or organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the BACE gene in the subject or organism.

[0143] In one embodiment, the invention features a method for treating neurodegenerative disorders or conditions, such as dementia, in a subject or organism comprising contacting the subject or organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the BACE gene in the subject or organism.

[0144] In one embodiment, the invention features a method for treating stroke/cardiovascular accident in a subject or organism comprising contacting the subject or organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the BACE gene in the subject or organism.

[0145] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in a subject or organism comprising contacting the subject or organism with one or more siNA molecules of the invention under conditions suitable to modulate the expression of the BACE genes in the subject or organism.

[0146] The siNA molecules of the invention can be designed to down regulate or inhibit target (e.g., BACE) gene expression through RNAi targeting of a variety of RNA molecules. In one embodiment, the siNA molecules of the invention are used to target various RNAs corresponding to a target gene. Non-limiting examples of such RNAs include messenger RNA (mRNA), alternate RNA splice variants of target gene(s), post-transcriptionally modified RNA of target gene(s), pre-mRNA of target gene(s), and/or RNA templates. If alternate splicing produces a family of transcripts that are distinguished by usage of appropriate exons, the instant invention can be used to inhibit gene expression through the appropriate exons to specifically inhibit or to distinguish among the functions of gene family members. For example, a protein that contains an alternatively spliced transmembrane domain can be expressed in both membrane bound and secreted forms. Use of the invention to target the exon containing the transmembrane domain can be used to determine the functional consequences of pharmaceutical targeting of membrane bound as opposed to the secreted form of the protein. Non-limiting examples of applications of the invention relating to targeting these RNA molecules include therapeutic pharmaceutical applications, pharmaceutical discovery applications, molecular diagnostic and gene function applications, and gene mapping, for example using single nucleotide polymorphism mapping with siNA molecules of the invention. Such applications can be implemented using known gene sequences or from partial sequences available from an expressed sequence tag (EST).

[0147] In another embodiment, the siNA molecules of the invention are used to target conserved sequences corresponding to a gene family or gene families such as BACE family genes. As such, siNA molecules targeting multiple BACE targets can provide increased therapeutic effect. In addition, siNA can be used to characterize pathways of gene function in a variety of applications. For example, the present invention can be used to inhibit the activity of target gene(s) in a pathway to determine the function of uncharacterized gene(s) in gene function analysis, mRNA function analysis, or translational analysis. The invention can be used

to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The invention can be used to understand pathways of gene expression involved in, for example, Alzheimer's disease and other neurodegenerative disorders or conditions, such as dementia, and stroke/cardiovascular accident.

[0148] In one embodiment, siNA molecule(s) and/or methods of the invention are used to down regulate the expression of gene(s) that encode RNA referred to by Genbank Accession, for example, BACE genes encoding RNA sequence(s) referred to herein by Genbank Accession number, for example, Genbank Accession Nos. shown in Table I.

[0149] In one embodiment, the invention features a method comprising: (a) generating a library of siNA constructs having a predetermined complexity; and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target RNA sequence. In one embodiment, the siNA molecules of (a) have strands of a fixed length, for example, about 23 nucleotides in length. In another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 18 to about 25 (e.g., about 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted in vitro siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for in vitro systems, and by cellular expression in in vivo systems.

[0150] In one embodiment, the invention features a method comprising: (a) generating a randomized library of siNA constructs having a predetermined complexity, such as of 4^N , where N represents the number of base paired nucleotides in each of the siNA construct strands (eg. for a siNA construct having 21 nucleotide sense and antisense strands with 19 base pairs, the complexity would be 4^{19}); and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target BACE RNA sequence. In another embodiment, the siNA molecules of (a) have strands of a fixed length, for example about 23 nucleotides in length. In yet another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 18 to about 25 (e.g., about 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted in vitro siNA assay as described in Example 7 herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of BACE RNA are analyzed for detectable levels of cleavage, for example, by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target BACE RNA sequence. The target BACE RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for in vitro systems, and by cellular expression in in vivo systems.

[0151] In another embodiment, the invention features a method comprising: (a) analyzing the sequence of a RNA target encoded by a target gene; (b) synthesizing one or more sets of siNA molecules having sequence complementary to one or more regions of the RNA of (a); and (c) assaying the siNA molecules of (b) under conditions suitable to determine RNAi targets within the target RNA sequence. In one embodiment, the siNA molecules of (b) have strands of a fixed length, for example about 23 nucleotides in length. In another embodiment, the siNA molecules of (b) are of differing length, for example having strands of about 18 to about 25 (e.g., about 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted in vitro siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. Fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for in vitro systems, and by expression in in vivo systems.

[0152] By "target site" is meant a sequence within a target RNA that is "targeted" for cleavage mediated by a siNA construct which contains sequences within its antisense region that are complementary to the target sequence.

[0153] By "detectable level of cleavage" is meant cleavage of target RNA (and formation of cleaved product RNAs) to an extent sufficient to discern cleavage products above the background of RNAs produced by random degradation of the target RNA. Production of cleavage products from 1-5% of the target RNA is sufficient to detect above the background for most methods of detection.

[0154] In one embodiment, the invention features a composition comprising a siNA molecule of the invention, which can be chemically-modified, in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a pharmaceutical composition comprising siNA molecules of the invention, which can be chemically-modified, targeting one or more genes in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a method for diagnosing a disease or condition in a subject comprising administering to the subject a composition of the invention under conditions suitable for the diagnosis of the disease or condition in the subject. In another embodiment, the invention features a method for treating or preventing a disease or condition in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease or condition in the subject, alone or in conjunction with one or more other therapeutic compounds. In yet another embodiment, the invention features a method for treating Alzheimer's disease and/or other neurodegenerative disorders, such as dementia and stroke/cardiovascular accident in a subject comprising administering to the subject a composition of the invention under conditions suitable for the treatment of Alzheimer's disease and/or other neurodegenerative disorders, such as dementia and stroke/cardiovascular accident in the subject.

[0155] In another embodiment, the invention features a method for validating a BACE gene target, comprising: (a)

synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence complementary to RNA of a BACE target gene; (b) introducing the siNA molecule into a cell, tissue, subject or organism under conditions suitable for modulating expression of the BACE target gene in the cell, tissue, subject, or organism; and (c) determining the function of the gene by assaying for any phenotypic change in the cell, tissue, subject, or organism.

[0156] In another embodiment, the invention features a method for validating a BACE target comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence complementary to RNA of a BACE target gene; (b) introducing the siNA molecule into a biological system under conditions suitable for modulating expression of the BACE target gene in the biological system; and (c) determining the function of the gene by assaying for any phenotypic change in the biological system.

[0157] By "biological system" is meant, material, in a purified or unpurified form, from biological sources, including but not limited to human or animal, wherein the system comprises the components required for RNAi activity. The term "biological system" includes, for example, a cell, tissue, subject, or organism, or extract thereof. The term biological system also includes reconstituted RNAi systems that can be used in an in vitro setting.

[0158] By "phenotypic change" is meant any detectable change to a cell that occurs in response to contact or treatment with a nucleic acid molecule of the invention (e.g., siNA). Such detectable changes include, but are not limited to, changes in shape, size, proliferation, motility, protein expression or RNA expression or other physical or chemical changes as can be assayed by methods known in the art. The detectable change can also include expression of reporter genes/molecules such as Green Florescent Protein (GFP) or various tags that are used to identify an expressed protein or any other cellular component that can be assayed.

[0159] In one embodiment, the invention features a kit containing a siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of a BACE target gene in a biological system, including, for example, in a cell, tissue, subject, or organism. In another embodiment, the invention features a kit containing more than one siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of more than one BACE target gene in a biological system, including, for example, in a cell, tissue, subject, or organism.

[0160] In one embodiment, the invention features a cell containing one or more siNA molecules of the invention, which can be chemically-modified. In another embodiment, the cell containing a siNA molecule of the invention is a mammalian cell. In yet another embodiment, the cell containing a siNA molecule of the invention is a human cell.

[0161] In one embodiment, the synthesis of a siNA molecule of the invention, which can be chemically-modified, comprises: (a) synthesis of two complementary strands of the siNA molecule; (b) annealing the two complementary strands together under conditions suitable to obtain a double-stranded siNA molecule. In another embodiment,

synthesis of the two complementary strands of the siNA molecule is by solid phase oligonucleotide synthesis. In yet another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase tandem oligonucleotide synthesis.

[0162] In one embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing a first oligonucleotide sequence strand of the siNA molecule, wherein the first oligonucleotide sequence strand comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of the second oligonucleotide sequence strand of the siNA; (b) synthesizing the second oligonucleotide sequence strand of siNA on the scaffold of the first oligonucleotide sequence strand, wherein the second oligonucleotide sequence strand further comprises a chemical moiety than can be used to purify the siNA duplex; (c) cleaving the linker molecule of (a) under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex; and (d) purifying the siNA duplex utilizing the chemical moiety of the second oligonucleotide sequence strand. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example, under hydrolysis conditions using an alkylamine base such as methylamine. In one embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place concomitantly. In another embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group, which can be employed in a trityl-on synthesis strategy as described herein. In yet another embodiment, the chemical moiety, such as a dimethoxytrityl group, is removed during purification, for example, using acidic conditions.

[0163] In a further embodiment, the method for siNA synthesis is a solution phase synthesis or hybrid phase synthesis wherein both strands of the siNA duplex are synthesized in tandem using a cleavable linker attached to the first sequence which acts a scaffold for synthesis of the second sequence. Cleavage of the linker under conditions suitable for hybridization of the separate siNA sequence strands results in formation of the double-stranded siNA molecule.

[0164] In another embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing one oligonucleotide sequence strand of the siNA molecule, wherein the sequence comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of another oligonucleotide sequence; (b) synthesizing a second oligonucleotide sequence having complementarity to the first sequence strand on the scaffold of (a), wherein the second sequence comprises the other strand of the double-stranded siNA molecule and wherein the second sequence further comprises a chemical moiety than can be used to isolate the attached oligonucleotide sequence; (c) purifying the product of (b) utilizing the chemical moiety of

the second oligonucleotide sequence strand under conditions suitable for isolating the full-length sequence comprising both siNA oligonucleotide strands connected by the cleavable linker and under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example, under hydrolysis conditions. In another embodiment, cleavage of the linker molecule in (c) above takes place after deprotection of the oligonucleotide. In another embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity or differing reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place either concomitantly or sequentially. In one embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group.

[0165] In another embodiment, the invention features a method for making a double-stranded siNA molecule in a single synthetic process comprising: (a) synthesizing an oligonucleotide having a first and a second sequence, wherein the first sequence is complementary to the second sequence, and the first oligonucleotide sequence is linked to the second sequence via a cleavable linker, and wherein a terminal 5'-protecting group, for example, a 5'-O-dimethoxytrityl group (5'-O-DMT) remains on the oligonucleotide having the second sequence; (b) deprotecting the oligonucleotide whereby the deprotection results in the cleavage of the linker joining the two oligonucleotide sequences; and (c) purifying the product of (b) under conditions suitable for isolating the double-stranded siNA molecule, for example using a trityl-on synthesis strategy as described herein.

[0166] In another embodiment, the method of synthesis of siNA molecules of the invention comprises the teachings of Scaringe et al., U.S. Pat. Nos. 5,889,136; 6,008,400; and 6,111,086, incorporated by reference herein in their entirety.

[0167] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications, for example, one or more chemical modifications having any of Formulae I-VII or any combination thereof that increases the nuclease resistance of the siNA construct.

[0168] In another embodiment, the invention features a method for generating siNA molecules with increased nuclease resistance comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased nuclease resistance.

[0169] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the sense and antisense strands of the siNA construct.

[0170] In another embodiment, the invention features a method for generating siNA molecules with increased bind-

ing affinity between the sense and antisense strands of the siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the sense and antisense strands of the siNA molecule.

[0171] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target RNA sequence within a cell.

[0172] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target DNA sequence within a cell.

[0173] In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence.

[0174] In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target DNA sequence comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target DNA sequence.

[0175] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications described herein that modulate the polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA construct.

[0176] In another embodiment, the invention features a method for generating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to a chemically-modified siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA molecule.

[0177] In one embodiment, the invention features chemically-modified siNA constructs that mediate RNAi against

BACE in a cell, wherein the chemical modifications do not significantly effect the interaction of siNA with a target RNA molecule, DNA molecule and/or proteins or other factors that are essential for RNAi in a manner that would decrease the efficacy of RNAi mediated by such siNA constructs.

[0178] In another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against BACE comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity.

[0179] In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against BACE target RNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target RNA.

[0180] In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against BACE target DNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target DNA.

[0181] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the cellular uptake of the siNA construct.

[0182] In another embodiment, the invention features a method for generating siNA molecules against BACE with improved cellular uptake comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved cellular uptake.

[0183] In one embodiment, the invention features siNA constructs that mediate RNAi against BACE, wherein the siNA construct comprises one or more chemical modifications described herein that increases the bioavailability of the siNA construct, for example, by attaching polymeric conjugates such as polyethyleneglycol or equivalent conjugates that improve the pharmacokinetics of the siNA construct, or by attaching conjugates that target specific tissue types or cell types in vivo. Non-limiting examples of such conjugates are described in Vargeese et al., U.S. Ser. No. 10/201,394 incorporated by reference herein.

[0184] In one embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing a conjugate into the structure of a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability. Such conjugates can include ligands for cellular receptors, such as peptides derived from naturally occurring protein ligands; protein localization sequences, including cellular ZIP code sequences; antibodies; nucleic acid aptam-

ers; vitamins and other co-factors, such as folate and N-acetylgalactosamine; polymers, such as polyethyleneglycol (PEG); phospholipids; cholesterol; polyamines, such as spermine or spermidine; and others.

[0185] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence is chemically modified in a manner that it can no longer act as a guide sequence for efficiently mediating RNA interference and/or be recognized by cellular proteins that facilitate RNAi.

[0186] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein the second sequence is designed or modified in a manner that prevents its entry into the RNAi pathway as a guide sequence or as a sequence that is complementary to a target nucleic acid (e.g., RNA) sequence. Such design or modifications are expected to enhance the activity of siNA and/or improve the specificity of siNA molecules of the invention. These modifications are also expected to minimize any off-target effects and/or associated toxicity.

[0187] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence is incapable of acting as a guide sequence for mediating RNA interference.

[0188] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence does not have a terminal 5'-hydroxyl (5'-OH) or 5'-phosphate group.

[0189] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence comprises a terminal cap moiety at the 5'-end of said second sequence. In one embodiment, the terminal cap moiety comprises an inverted abasic, inverted deoxy abasic, inverted nucleotide moiety, a group shown in FIG. 10, an alkyl or cycloalkyl group, a heterocycle, or any other group that prevents RNAi activity in which the second sequence serves as a guide sequence or template for RNAi.

[0190] In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence comprises a terminal cap moiety at the 5'-end and 3'-end of said second sequence. In one embodiment, each terminal cap moiety individually

comprises an inverted abasic, inverted deoxy abasic, inverted nucleotide moiety, a group shown in FIG. 10, an alkyl or cycloalkyl group, a heterocycle, or any other group that prevents RNAi activity in which the second sequence serves as a guide sequence or template for RNAi.

[0191] In one embodiment, the invention features a method for generating siNA molecules of the invention with improved specificity for down regulating or inhibiting the expression of a target nucleic acid (e.g., a DNA or RNA such as a gene or its corresponding RNA), comprising (a) introducing one or more chemical modifications into the structure of a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved specificity. In another embodiment, the chemical modification used to improve specificity comprises terminal cap modifications at the 5'-end, 3'-end, or both 5' and 3'-ends of the siNA molecule. The terminal cap modifications can comprise, for example, structures shown in FIG. 10 (e.g. inverted deoxyabasic moieties) or any other chemical modification that renders a portion of the siNA molecule (e.g. the sense strand) incapable of mediating RNA interference against an off target nucleic acid sequence. In a non-limiting example, a siNA molecule is designed such that only the antisense sequence of the siNA molecule can serve as a guide sequence for RISC mediated degradation of a corresponding target RNA sequence. This can be accomplished by rendering the sense sequence of the siNA inactive by introducing chemical modifications to the sense strand that preclude recognition of the sense strand as a guide sequence by RNAi machinery. In one embodiment, such chemical modifications comprise any chemical group at the 5'-end of the sense strand of the siNA, or any other group that serves to render the sense strand inactive as a guide sequence for mediating RNA interference. These modifications, for example, can result in a molecule where the 5'-end of the sense strand no longer has a free 5'-hydroxyl (5'-OH) or a free 5'-phosphate group (e.g., phosphate, diphosphate, triphosphate, cyclic phosphate etc.). Non-limiting examples of such siNA constructs are described herein, such as "Stab 9/10", "Stab 7/8", "Stab 7/19", "Stab 17/22", "Stab 23/24", and "Stab 24/25" chemistries and variants thereof (see Table IV) wherein the 5'-end and 3'-end of the sense strand of the siNA do not comprise a hydroxyl group or phosphate group.

[0192] In one embodiment, the invention features a method for generating siNA molecules of the invention with improved specificity for down regulating or inhibiting the expression of a target nucleic acid (e.g., a DNA or RNA such as a gene or its corresponding RNA), comprising introducing one or more chemical modifications into the structure of a siNA molecule that prevent a strand or portion of the siNA molecule from acting as a template or guide sequence for RNAi activity. In one embodiment, the inactive strand or sense region of the siNA molecule is the sense strand or sense region of the siNA molecule, i.e. the strand or region of the siNA that does not have complementarity to the target nucleic acid sequence. In one embodiment, such chemical modifications comprise any chemical group at the 5'-end of the sense strand or region of the siNA that does not comprise a 5'-hydroxyl (5'-OH) or 5'-phosphate group, or any other group that serves to render the sense strand or sense region inactive as a guide sequence for mediating RNA interference. Non-limiting examples of such siNA constructs are described herein, such as "Stab 9/10", "Stab 7/8", "Stab 7/19", "Stab 17/22", "Stab 23/24", and "Stab 24/25" chem-

istries and variants thereof (see Table IV) wherein the 5'-end and 3'-end of the sense strand of the siNA do not comprise a hydroxyl group or phosphate group.

[0193] In one embodiment, the invention features a method for screening siNA molecules that are active in mediating RNA interference against a target nucleic acid sequence comprising (a) generating a plurality of unmodified siNA molecules, (b) screening the siNA molecules of step (a) under conditions suitable for isolating siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence, and (c) introducing chemical modifications (e.g. chemical modifications as described herein or as otherwise known in the art) into the active siNA molecules of (b). In one embodiment, the method further comprises re-screening the chemically modified siNA molecules of step (c) under conditions suitable for isolating chemically modified siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence.

[0194] In one embodiment, the invention features a method for screening chemically modified siNA molecules that are active in mediating RNA interference against a target nucleic acid sequence comprising (a) generating a plurality of chemically modified siNA molecules (e.g. siNA molecules as described herein or as otherwise known in the art), and (b) screening the siNA molecules of step (a) under conditions suitable for isolating chemically modified siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence.

[0195] The term "ligand" refers to any compound or molecule, such as a drug, peptide, hormone, or neurotransmitter, that is capable of interacting with another compound, such as a receptor, either directly or indirectly. The receptor that interacts with a ligand can be present on the surface of a cell or can alternately be an intercellular receptor. Interaction of the ligand with the receptor can result in a biochemical reaction, or can simply be a physical interaction or association.

[0196] In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing an excipient formulation to a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability. Such excipients include polymers such as cyclodextrins, lipids, cationic lipids, polyamines, phospholipids, nanoparticles, receptors, ligands, and others.

[0197] In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing nucleotides having any of Formulae I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability.

[0198] In another embodiment, polyethylene glycol (PEG) can be covalently attached to siNA compounds of the present invention. The attached PEG can be any molecular weight, preferably from about 2,000 to about 50,000 daltons (Da).

[0199] The present invention can be used alone or as a component of a kit having at least one of the reagents

necessary to carry out the in vitro or in vivo introduction of RNA to test samples and/or subjects. For example, preferred components of the kit include a siNA molecule of the invention and a vehicle that promotes introduction of the siNA into cells of interest as described herein (e.g., using lipids and other methods of transfection known in the art, see for example Beigelman et al, U.S. Pat. No. 6,395,713). The kit can be used for target validation, such as in determining gene function and/or activity, or in drug optimization, and in drug discovery (see for example Usman et al., U.S. Ser. No. 60/402,996). Such a kit can also include instructions to allow a user of the kit to practice the invention.

[0200] The term "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or "chemically-modified short interfering nucleic acid molecule" as used herein refers to any nucleic acid molecule capable of inhibiting or down regulating gene expression or viral replication, for example by mediating RNA interference "RNAi" or gene silencing in a sequence-specific manner; see for example Zamore et al., 2000, *Cell*, 101, 25-33; Bass, 2001, *Nature*, 411, 428-429; Elbashir et al., 2001, *Nature*, 411, 494-498; and Kreutzer et al., International PCT Publication No. WO 00/44895; Zernicka-Goetz et al., International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plactinck et al., International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO 99/07409; and Li et al., International PCT Publication No. WO 00/44914; Allshire, 2002, *Science*, 297, 1818-1819; Volpe et al., 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall et al., 2002, *Science*, 297, 2232-2237; Hutvagner and Zamore, 2002, *Science*, 297, 2056-60; McManus et al., 2002, *RNA*, 8, 842-850; Reinhart et al., 2002, *Gene & Dev.*, 16, 1616-1626; and Reinhart & Bartel, 2002, *Science*, 297, 1831). Non limiting examples of siNA molecules of the invention are shown in FIGS. 4-6, and Tables II and III herein. For example the siNA can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e. each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure, for example wherein the double stranded region is about 19 base pairs); the antisense strand comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, the siNA is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA are linked by means of a nucleic acid based or non-nucleic acid-based linker(s). The siNA can be a polynucleotide with a duplex,

asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active siNA molecule capable of mediating RNAi. The siNA can also comprise a single stranded polynucleotide having nucleotide sequence complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof (for example, where such siNA molecule does not require the presence within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof), wherein the single stranded polynucleotide can further comprise a terminal phosphate group, such as a 5'-phosphate (see for example Martinez et al., 2002, *Cell*, 110, 563-574 and Schwarz et al., 2002, *Molecular Cell*, 10, 537-568), or 5',3'-diphosphate. In certain embodiments, the siNA molecule of the invention comprises separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linker molecules as is known in the art, or are alternately non-covalently linked by ionic interactions, hydrogen bonding, van der Waals interactions, hydrophobic interactions, and/or stacking interactions. In certain embodiments, the siNA molecules of the invention comprise nucleotide sequence that is complementary to nucleotide sequence of a target gene. In another embodiment, the siNA molecule of the invention interacts with nucleotide sequence of a target gene in a manner that causes inhibition of expression of the target gene. As used herein, siNA molecules need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2'-hydroxy (2'-OH) containing nucleotides. Applicant describes in certain embodiments short interfering nucleic acids that do not require the presence of nucleotides having a 2'-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e.g., nucleotides having a 2'-OH group). Such siNA molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. Optionally, siNA molecules can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. The modified short interfering nucleic acid molecules of the invention can also be referred to as short interfering modified oligonucleotides "siMON." As used herein, the term siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are

capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term RNAi is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics. For example, siNA molecules of the invention can be used to epigenetically silence genes at both the post-transcriptional level or the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siNA molecules of the invention can result from siNA mediated modification of chromatin structure or methylation pattern to alter gene expression (see, for example, Verdel et al., 2004, *Science*, 303, 672-676; Pal-Bhadra et al., 2004, *Science*, 303, 669-672; Allshire, 2002, *Science*, 297, 1818-1819; Volpe et al., 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall et al., 2002, *Science*, 297, 2232-2237).

[0201] In one embodiment, a siNA molecule of the invention is a duplex forming oligonucleotide "DFO", (see for example FIGS. 14-15 and Vaish et al., U.S. Ser. No. 10/727,780 filed Dec. 3, 2003 and International PCT Application No. US04/16390, filed May 24, 2004).

[0202] In one embodiment, a siNA molecule of the invention is a multifunctional siNA, (see for example FIGS. 16-21 and Jadhav et al., U.S. Ser. No. 60/543,480 filed Feb. 10, 2004 and International PCT Application No. US04/16390, filed May 24, 2004). The multifunctional siNA of the invention can comprise sequence targeting, for example, two regions of BACE RNA (see for example target sequences in Tables II and III).

[0203] By "asymmetric hairpin" as used herein is meant a linear siNA molecule comprising an antisense region, a loop portion that can comprise nucleotides or non-nucleotides, and a sense region that comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complementary nucleotides to base pair with the antisense region and form a duplex with loop. For example, an asymmetric hairpin siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a cell or in vitro system (e.g. about 19 to about 22, or about 19, 20, 21, or 22 nucleotides) and a loop region comprising about 4 to about 8 (e.g., about 4, 5, 6, 7, or 8) nucleotides, and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region. The asymmetric hairpin siNA molecule can also comprise a 5'-terminal phosphate group that can be chemically modified. The loop portion of the asymmetric hairpin siNA molecule can comprise nucleotides, non-nucleotides, linker molecules, or conjugate molecules as described herein.

[0204] By "asymmetric duplex" as used herein is meant a siNA molecule having two separate strands comprising a sense region and an antisense region, wherein the sense region comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complementary nucleotides to base pair with the antisense region and

form a duplex. For example, an asymmetric duplex siRNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a cell or in vitro system e.g. about 19 to about 22 (e.g. about 19, 20, 21, or 22) nucleotides and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region.

[0205] By “modulate” is meant that the expression of the gene, or level of RNA molecule or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the absence of the modulator. For example, the term “modulate” can mean “inhibit,” but the use of the word “modulate” is not limited to this definition.

[0206] By “inhibit”, “down-regulate”, or “reduce”, it is meant that the expression of the gene, or level of RNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits, is reduced below that observed in the absence of the nucleic acid molecules (e.g., siRNA) of the invention. In one embodiment, inhibition, down-regulation or reduction with an siRNA molecule is below that level observed in the presence of an inactive or attenuated molecule. In another embodiment, inhibition, down-regulation, or reduction with siRNA molecules is below that level observed in the presence of, for example, an siRNA molecule with scrambled sequence or with mismatches. In another embodiment, inhibition, down-regulation, or reduction of gene expression with a nucleic acid molecule of the instant invention is greater in the presence of the nucleic acid molecule than in its absence. In one embodiment, inhibition, down regulation, or reduction of gene expression is associated with post transcriptional silencing, such as RNAi mediated cleavage of a target nucleic acid molecule (e.g. RNA) or inhibition of translation. In one embodiment, inhibition, down regulation, or reduction of gene expression is associated with pretranscriptional silencing.

[0207] By “gene”, or “target gene”, is meant, a nucleic acid that encodes an RNA, for example, nucleic acid sequences including, but not limited to, structural genes encoding a polypeptide. A gene or target gene can also encode a functional RNA (fRNA) or non-coding RNA (ncRNA), such as small temporal RNA (stRNA), micro RNA (miRNA), small nuclear RNA (snRNA), short interfering RNA (siRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA) and precursor RNAs thereof. Such non-coding RNAs can serve as target nucleic acid molecules for siRNA mediated RNA interference in modulating the activity of fRNA or ncRNA involved in functional or regulatory cellular processes. Aberrant fRNA or ncRNA activity leading to disease can therefore be modulated by siRNA molecules of the invention. siRNA molecules targeting fRNA and ncRNA can also be used to manipulate or alter the genotype or phenotype of a subject, organism or cell, by intervening in cellular processes such as genetic imprinting, transcription, translation, or nucleic acid processing (e.g., transamination, methylation etc.). The target gene can be a gene derived from a cell, an endogenous gene, a transgene, or exogenous genes such as genes of a pathogen, for example a virus, which is present in the cell

after infection thereof. The cell containing the target gene can be derived from or contained in any organism, for example a plant, animal, protozoan, virus, bacterium, or fungus. Non-limiting examples of plants include monocots, dicots, or gymnosperms. Non-limiting examples of animals include vertebrates or invertebrates. Non-limiting examples of fungi include molds or yeasts. For a review, see for example Snyder and Gerstein, 2003, *Science*, 300, 258-260.

[0208] By “non-canonical base pair” is meant any non-Watson Crick base pair, such as mismatches and/or wobble base pairs, including flipped mismatches, single hydrogen bond mismatches, trans-type mismatches, triple base interactions, and quadruple base interactions. Non-limiting examples of such non-canonical base pairs include, but are not limited to, AC reverse Hoogsteen, AC wobble, AU reverse Hoogsteen, GU wobble, AA N7 amino, CC 2-carbonyl-amino(H1)-N-3-amino(H2), GA sheared, UC 4-carbonyl-amino, UU imino-carbonyl, AC reverse wobble, AU Hoogsteen, AU reverse Watson Crick, CG reverse Watson Crick, GC N3-amino-amino N3, AA N1-amino symmetric, AA N7-amino symmetric, GA N7-N1 amino-carbonyl, GA+ carbonyl-amino N7-N1, GG N1-carbonyl symmetric, GG N3-amino symmetric, CC carbonyl-amino symmetric, CC N3-amino symmetric, UU 2-carbonyl-imino symmetric, UU 4-carbonyl-imino symmetric, AA amino-N3, AA Ni-amino, AC amino 2-carbonyl, AC N3-amino, AC N7-amino, AU amino-4-carbonyl, AU N1-imino, AU N3-imino, AU N7-imino, CC carbonyl-amino, GA amino-N1, GA amino-N7, GA carbonyl-amino, GA N3-amino, GC amino-N3, GC carbonyl-amino, GC N3-amino, GC N7-amino, GG amino-N7, GG carbonyl-imino, GG N7-amino, GU amino-2-carbonyl, GU carbonyl-imino, GU imino-2-carbonyl, GU N7-imino, psiU imino-2-carbonyl, UC 4-carbonyl-amino, UC imino-carbonyl, UU imino-4-carbonyl, AC C2-H-N3, GA carbonyl-C2-H, UU imino-4-carbonyl 2 carbonyl-C5-H, AC amino(A) N3(C)-carbonyl, GC imino amino-carbonyl, Gpsi imino-2-carbonyl amino-2-carbonyl, and GU imino amino-2-carbonyl base pairs.

[0209] By “BACE” or “beta secretase” as used herein is meant, BACE protein, peptide, or polypeptide having beta-secretase activity, such as that involved in generating beta-amyloid, for example, sequences encoded by BACE Genbank Accession Nos. shown in Table I. The term BACE also refers to nucleic acid sequences encoding any BACE protein, peptide, or polypeptide having BACE activity. The term “BACE” is also meant to include other BACE encoding sequence, such as BACE isoforms, mutant BACE genes, splice variants of BACE genes, and BACE gene polymorphisms.

[0210] By “APP” or “amyloid precursor protein” as used herein is meant any protein, peptide, or polypeptide that is processed to generate beta-amyloid. The term APP also refers to sequences that encode APP protein, for example, Genbank Accession Nos. shown in Table I. The term APP also refers to nucleic acid sequences encoding any APP protein, peptide, or polypeptide having APP activity. The term “APP” is also meant to include other APP encoding sequence, such as APP isoforms, mutant APP genes, splice variants of APP, and APP gene polymorphisms.

[0211] By “presenillin” or “PS”, i.e., “PS-1” or “PS-2”, or “PSEN”, i.e., “PSEN1” or “PSEN2”, as used herein is meant any protein, peptide, or polypeptide having gamma-secre-

tase activity, such as that involved in generating beta-amyloid. The term PS also refers to sequences that encode presenillin protein, for example, PS-1 or PS-2, (i.e., Genbank Accession Nos. shown in Table I). The term "PS", for example, "PS-1" or "PS-2", also refers to nucleic acid sequences encoding any PS protein, peptide, or polypeptide having PS activity. The term "PS", for example, "PS-1" or "PS-2", is also meant to include other PS encoding sequence, such as PS isoforms, mutant PS genes, splice variants of PS, and PS gene polymorphisms.

[0212] By "PIN-1" as used herein is meant any protein, peptide, or polypeptide having peptidyl-prolyl cis/trans isomerase activity, such as those involved in the development of Neurofibrillary Tangles. The term PIN-1 also refers to sequences that encode PIN-1 protein, i.e., Genbank Accession Nos. shown in Table I. The term PIN-1 also refers to nucleic acid sequences encoding any PIN-1 protein, peptide, or polypeptide having PIN-1 activity. The term "PIN-1" is also meant to include other PIN-1 encoding sequence, such as PIN-1 isoforms, mutant PIN-1 genes, splice variants of PIN-1, and PIN-1 gene polymorphisms.

[0213] Furthermore, as discussed previously, all embodiments, compositions, methods, and uses described herein using BACE as an exemplary gene are equally applicable to APP, PIN-1, and PS (i.e., PS-1, and PS-2) genes.

[0214] By "homologous sequence" is meant, a nucleotide sequence that is shared by one or more polynucleotide sequences, such as genes, gene transcripts and/or non-coding polynucleotides. For example, a homologous sequence can be a nucleotide sequence that is shared by two or more genes encoding related but different proteins, such as different members of a gene family, different protein epitopes, different protein isoforms or completely divergent genes, such as a cytokine and its corresponding receptors. A homologous sequence can be a nucleotide sequence that is shared by two or more non-coding polynucleotides, such as noncoding DNA or RNA, regulatory sequences, introns, and sites of transcriptional control or regulation. Homologous sequences can also include conserved sequence regions shared by more than one polynucleotide sequence. Homology does not need to be perfect homology (e.g., 100%), as partially homologous sequences are also contemplated by the instant invention (e.g., 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc.).

[0215] By "conserved sequence region" is meant, a nucleotide sequence of one or more regions in a polynucleotide does not vary significantly between generations or from one biological system, subject, or organism to another biological system, subject, or organism. The polynucleotide can include both coding and non-coding DNA and RNA.

[0216] By "sense region" is meant a nucleotide sequence of a siNA molecule having complementarity to an antisense region of the siNA molecule. In addition, the sense region of a siNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence.

[0217] By "antisense region" is meant a nucleotide sequence of a siNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a siNA molecule can optionally comprise a nucleic acid sequence having complementarity to a sense region of the siNA molecule.

[0218] By "target nucleic acid" is meant any nucleic acid sequence whose expression or activity is to be modulated. The target nucleic acid can be DNA or RNA.

[0219] By "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, *CSH Symp. Quant. Biol.* LII pp. 123-133; Frier et al., 1986, *Proc. Nat. Acad. Sci. USA* 83:9373-9377; Turner et al., 1987, *J. Am. Chem. Soc.* 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.

[0220] In one embodiment, siNA molecules of the invention that down regulate or reduce BACE gene expression are used for treating Alzheimer's disease in a subject or organism.

[0221] In one embodiment, the siNA molecules of the invention are used to treat neurodegenerative disorders or conditions, such as dementia, and stroke/cardiovascular accident in a subject or organism.

[0222] In one embodiment of the present invention, each sequence of a siNA molecule of the invention is independently about 18 to about 24 nucleotides in length, in specific embodiments about 18, 19, 20, 21, 22, 23, or 24 nucleotides in length. In another embodiment, the siNA duplexes of the invention independently comprise about 17 to about 23 base pairs (e.g., about 17, 18, 19, 20, 21, 22, or 23). In yet another embodiment, siNA molecules of the invention comprising hairpin or circular structures are about 35 to about 55 (e.g., about 35, 40, 45, 50 or 55) nucleotides in length, or about 38 to about 44 (e.g., about 38, 39, 40, 41, 42, 43, or 44) nucleotides in length and comprising about 16 to about 22 (e.g., about 16, 17, 18, 19, 20, 21 or 22) base pairs. Exemplary siNA molecules of the invention are shown in Table II. Exemplary synthetic siNA molecules of the invention are shown in Table III and/or FIGS. 4-5.

[0223] As used herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell.

[0224] The siNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues *ex vivo*, or *in vivo* through direct dermal application, transdermal application, or injection, with or without their incorporation in biopolymers. In particular embodiments, the nucleic acid molecules of the invention comprise sequences shown in Tables II-III and/or FIGS. 4-5. Examples of such nucleic acid molecules consist essentially of sequences defined in these tables and figures. Furthermore, the chemically modified constructs described in Table IV can be applied to any siNA sequence of the invention.

[0225] In another aspect, the invention provides mammalian cells containing one or more siNA molecules of this invention. The one or more siNA molecules can independently be targeted to the same or different sites.

[0226] By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" is meant a nucleotide with a hydroxyl group at the 2' position of a β -D-ribofuranose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.

[0227] By "subject" is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. "Subject" also refers to an organism to which the nucleic acid molecules of the invention can be administered. A subject can be a mammal or mammalian cells, including a human or human cells.

[0228] The term "phosphorothioate" as used herein refers to an internucleotide linkage having Formula I, wherein Z and/or W comprise a sulfur atom. Hence, the term phosphorothioate refers to both phosphorothioate and phosphorodithioate internucleotide linkages.

[0229] The term "phosphonoacetate" as used herein refers to an internucleotide linkage having Formula I, wherein Z and/or W comprise an acetyl or protected acetyl group.

[0230] The term "thiophosphonoacetate" as used herein refers to an internucleotide linkage having Formula I, wherein Z comprises an acetyl or protected acetyl group and W comprises a sulfur atom or alternately W comprises an acetyl or protected acetyl group and Z comprises a sulfur atom.

[0231] The term "universal base" as used herein refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such

as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example Loakes, 2001, *Nucleic Acids Research*, 29, 2437-2447).

[0232] The term "acyclic nucleotide" as used herein refers to any nucleotide having an acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide.

[0233] The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to for preventing or treating Alzheimer's disease and other neurodegenerative disorders or conditions, such as dementia and stroke/cardiovascular accident in a subject or organism.

[0234] For example, the siNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

[0235] In a further embodiment, the siNA molecules can be used in combination with other known treatments to prevent or treat Alzheimer's disease and other neurodegenerative disorders or conditions, such as dementia and stroke/cardiovascular accident in a subject or organism. For example, the described molecules could be used in combination with one or more known compounds, treatments, or procedures to prevent or treat Alzheimer's disease and other neurodegenerative disorders or conditions, such as dementia and stroke/cardiovascular accident in a subject or organism as are known in the art.

[0236] In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention, in a manner which allows expression of the siNA molecule. For example, the vector can contain sequence(s) encoding both strands of a siNA molecule comprising a duplex. The vector can also contain sequence(s) encoding a single nucleic acid molecule that is self-complementary and thus forms a siNA molecule. Non-limiting examples of such expression vectors are described in Paul et al., 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee et al., 2002, *Nature Biotechnology*, 19, 500; and Novina et al., 2002, *Nature Medicine*, advance online publication doi: 10.1038/nm725.

[0237] In another embodiment, the invention features a mammalian cell, for example, a human cell, including an expression vector of the invention.

[0238] In yet another embodiment, the expression vector of the invention comprises a sequence for a siNA molecule having complementarity to a RNA molecule referred to by a Genbank Accession numbers, for example Genbank Accession Nos. shown in Table I.

[0239] In one embodiment, an expression vector of the invention comprises a nucleic acid sequence encoding two or more siNA molecules, which can be the same or different.

[0240] In another aspect of the invention, siNA molecules that interact with target RNA molecules and down-regulate gene encoding target RNA molecules (for example target RNA molecules referred to by Genbank Accession numbers herein) are expressed from transcription units inserted into

DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of siNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell.

[0241] By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

[0242] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0243] FIG. 1 shows a non-limiting example of a scheme for the synthesis of siNA molecules. The complementary siNA sequence strands, strand 1 and strand 2, are synthesized in tandem and are connected by a cleavable linkage, such as a nucleotide succinate or abasic succinate, which can be the same or different from the cleavable linker used for solid phase synthesis on a solid support. The synthesis can be either solid phase or solution phase, in the example shown, the synthesis is a solid phase synthesis. The synthesis is performed such that a protecting group, such as a dimethoxytrityl group, remains intact on the terminal nucleotide of the tandem oligonucleotide. Upon cleavage and deprotection of the oligonucleotide, the two siNA strands spontaneously hybridize to form a siNA duplex, which allows the purification of the duplex by utilizing the properties of the terminal protecting group, for example by applying a trityl on purification method wherein only duplexes/oligonucleotides with the terminal protecting group are isolated.

[0244] FIG. 2 shows a MALDI-TOF mass spectrum of a purified siNA duplex synthesized by a method of the invention. The two peaks shown correspond to the predicted mass of the separate siNA sequence strands. This result demonstrates that the siNA duplex generated from tandem synthesis can be purified as a single entity using a simple trityl-on purification methodology.

[0245] FIG. 3 shows a non-limiting proposed mechanistic representation of target RNA degradation involved in RNAi. Double-stranded RNA (dsRNA), which is generated by RNA-dependent RNA polymerase (RdRP) from foreign single-stranded RNA, for example viral, transposon, or other exogenous RNA, activates the DICER enzyme that in turn generates siNA duplexes. Alternately, synthetic or expressed siNA can be introduced directly into a cell by appropriate means. An active siNA complex forms which recognizes a target RNA, resulting in degradation of the target RNA by the RISC endonuclease complex or in the synthesis of additional RNA by RNA-dependent RNA polymerase

(RdRP), which can activate DICER and result in additional siNA molecules, thereby amplifying the RNAi response.

[0246] FIG. 4A-F shows non-limiting examples of chemically-modified siNA constructs of the present invention. In the figure, N stands for any nucleotide (adenosine, guanosine, cytosine, uridine, or optionally thymidine, for example thymidine can be substituted in the overhanging regions designated by parenthesis (N N). Various modifications are shown for the sense and antisense strands of the siNA constructs.

[0247] FIG. 4A: The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all nucleotides present are ribonucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all nucleotides present are ribonucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s", optionally connects the (N N) nucleotides in the antisense strand.

[0248] FIG. 4B: The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s", optionally connects the (N N) nucleotides in the sense and antisense strand.

[0249] FIG. 4C: The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl or 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N)

nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s", optionally connects the (N N) nucleotides in the antisense strand.

[0250] FIG. 4D: The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein all purine nucleotides that may be present are 2'-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s", optionally connects the (N N) nucleotides in the antisense strand.

[0251] FIG. 4E: The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s", optionally connects the (N N) nucleotides in the antisense strand.

[0252] FIG. 4F: The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein all purine nucleotides that may be present are 2'-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothio-

ate internucleotide linkage and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-deoxy nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s", optionally connects the (N N) nucleotides in the antisense strand. The antisense strand of constructs A-F comprise sequence complementary to any target nucleic acid sequence of the invention. Furthermore, when a glyceryl moiety (L) is present at the 3'-end of the antisense strand for any construct shown in FIG. 4A-F, the modified internucleotide linkage is optional.

[0253] FIG. 5A-F shows non-limiting examples of specific chemically-modified siNA sequences of the invention. A-F applies the chemical modifications described in FIG. 4A-F to a BACE siNA sequence. Such chemical modifications can be applied to any BACE sequence and/or BACE polymorphism sequence.

[0254] FIG. 6 shows non-limiting examples of different siNA constructs of the invention. The examples shown (constructs 1, 2, and 3) have 19 representative base pairs; however, different embodiments of the invention include any number of base pairs described herein. Bracketed regions represent nucleotide overhangs, for example, comprising about 1, 2, 3, or 4 nucleotides in length, preferably about 2 nucleotides. Constructs 1 and 2 can be used independently for RNAi activity. Construct 2 can comprise a polynucleotide or non-nucleotide linker, which can optionally be designed as a biodegradable linker. In one embodiment, the loop structure shown in construct 2 can comprise a biodegradable linker that results in the formation of construct 1 in vivo and/or in vitro. In another example, construct 3 can be used to generate construct 2 under the same principle wherein a linker is used to generate the active siNA construct 2 in vivo and/or in vitro, which can optionally utilize another biodegradable linker to generate the active siNA construct 1 in vivo and/or in vitro. As such, the stability and/or activity of the siNA constructs can be modulated based on the design of the siNA construct for use in vivo or in vitro and/or in vitro.

[0255] FIG. 7A-C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate siNA hairpin constructs.

[0256] FIG. 7A: A DNA oligomer is synthesized with a 5'-restriction site (R1) sequence followed by a region having sequence identical (sense region of siNA) to a predetermined BACE target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, which is followed by a loop sequence of defined sequence (X), comprising, for example, about 3 to about 10 nucleotides.

[0257] FIG. 7B: The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence that will result in a siNA transcript having specificity for a BACE target sequence and having self-complementary sense and antisense regions.

[0258] FIG. 7C: The construct is heated (for example to about 95° C.) to linearize the sequence, thus allowing

extension of a complementary second DNA strand using a primer to the 3'-restriction sequence of the first strand. The double-stranded DNA is then inserted into an appropriate vector for expression in cells. The construct can be designed such that a 3'-terminal nucleotide overhang results from the transcription, for example, by engineering restriction sites and/or utilizing a poly-U termination region as described in Paul et al., 2002, *Nature Biotechnology*, 29, 505-508.

[0259] FIG. 8A-C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate double-stranded siNA constructs.

[0260] FIG. 8A: A DNA oligomer is synthesized with a 5'-restriction (R1) site sequence followed by a region having sequence identical (sense region of siNA) to a predetermined BACE target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, and which is followed by a 3'-restriction site (R2) which is adjacent to a loop sequence of defined sequence (X).

[0261] FIG. 8B: The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence.

[0262] FIG. 8C: The construct is processed by restriction enzymes specific to R1 and R2 to generate a double-stranded DNA which is then inserted into an appropriate vector for expression in cells. The transcription cassette is designed such that a U6 promoter region flanks each side of the dsDNA which generates the separate sense and antisense strands of the siNA. Poly T termination sequences can be added to the constructs to generate U overhangs in the resulting transcript.

[0263] FIG. 9A-E is a diagrammatic representation of a method used to determine target sites for siNA mediated RNAi within a particular target nucleic acid sequence, such as messenger RNA.

[0264] FIG. 9A: A pool of siNA oligonucleotides are synthesized wherein the antisense region of the siNA constructs has complementarity to target sites across the target nucleic acid sequence, and wherein the sense region comprises sequence complementary to the antisense region of the siNA.

[0265] FIGS. 9B&C: (FIG. 9B) The sequences are pooled and are inserted into vectors such that (FIG. 9C) transfection of a vector into cells results in the expression of the siNA.

[0266] FIG. 9D: Cells are sorted based on phenotypic change that is associated with modulation of the target nucleic acid sequence.

[0267] FIG. 9E: The siNA is isolated from the sorted cells and is sequenced to identify efficacious target sites within the target nucleic acid sequence.

[0268] FIG. 10 shows non-limiting examples of different stabilization chemistries (1-10) that can be used, for example, to stabilize the 3'-end of siNA sequences of the invention, including (1) [3'-3']-inverted deoxyribose; (2) deoxyribonucleotide; (3) [5'-3']-3'-deoxyribonucleotide; (4) [5'-3']-ribonucleotide; (5) [5'-3']-3'-O-methyl ribonucleotide; (6) 3'-glyceryl; (7) [3'-5']-3'-deoxyribonucleotide; (8) [3'-3']-deoxyribonucleotide; (9) [5'-2']-deoxyribonucleotide;

and (10) [5'-3']-dideoxyribonucleotide. In addition to modified and unmodified backbone chemistries indicated in the figure, these chemistries can be combined with different backbone modifications as described herein, for example, backbone modifications having Formula I. In addition, the 2'-deoxy nucleotide shown 5' to the terminal modifications shown can be another modified or unmodified nucleotide or non-nucleotide described herein, for example modifications having any of Formulae I-VII or any combination thereof.

[0269] FIG. 11 shows a non-limiting example of a strategy used to identify chemically modified siNA constructs of the invention that are nuclease resistance while preserving the ability to mediate RNAi activity. Chemical modifications are introduced into the siNA construct based on educated design parameters (e.g. introducing 2'-modifications, base modifications, backbone modifications, terminal cap modifications etc). The modified construct is tested in an appropriate system (e.g. human serum for nuclease resistance, shown, or an animal model for PK/delivery parameters). In parallel, the siNA construct is tested for RNAi activity, for example in a cell culture system such as a luciferase reporter assay). Lead siNA constructs are then identified which possess a particular characteristic while maintaining RNAi activity, and can be further modified and assayed once again. This same approach can be used to identify siNA-conjugate molecules with improved pharmacokinetic profiles, delivery, and RNAi activity.

[0270] FIG. 12 shows non-limiting examples of phosphorylated siNA molecules of the invention, including linear and duplex constructs and asymmetric derivatives thereof.

[0271] FIG. 13 shows non-limiting examples of chemically modified terminal phosphate groups of the invention.

[0272] FIG. 14A shows a non-limiting example of methodology used to design self complementary DFO constructs utilizing palindrome and/or repeat nucleic acid sequences that are identified in a target nucleic acid sequence. (i) A palindrome or repeat sequence is identified in a nucleic acid target sequence. (ii) A sequence is designed that is complementary to the target nucleic acid sequence and the palindrome sequence. (iii) An inverse repeat sequence of the non-palindrome/repeat portion of the complementary sequence is appended to the 3'-end of the complementary sequence to generate a self complementary DFO molecule comprising sequence complementary to the nucleic acid target. (iv) The DFO molecule can self-assemble to form a double stranded oligonucleotide. FIG. 14B shows a non-limiting representative example of a duplex forming oligonucleotide sequence. FIG. 14C shows a non-limiting example of the self assembly schematic of a representative duplex forming oligonucleotide sequence. FIG. 14D shows a non-limiting example of the self assembly schematic of a representative duplex forming oligonucleotide sequence followed by interaction with a target nucleic acid sequence resulting in modulation of gene expression.

[0273] FIG. 15 shows a non-limiting example of the design of self complementary DFO constructs utilizing palindrome and/or repeat nucleic acid sequences that are incorporated into the DFO constructs that have sequence complementary to any target nucleic acid sequence of interest. Incorporation of these palindrome/repeat sequences allow the design of DFO constructs that form duplexes in which each strand is capable of mediating modulation of

target gene expression, for example by RNAi. First, the target sequence is identified. A complementary sequence is then generated in which nucleotide or non-nucleotide modifications (shown as X or Y) are introduced into the complementary sequence that generate an artificial palindrome (shown as XYXYXY in the Figure). An inverse repeat of the non-palindrome/repeat complementary sequence is appended to the 3'-end of the complementary sequence to generate a self complementary DFO comprising sequence complementary to the nucleic acid target. The DFO can self-assemble to form a double stranded oligonucleotide.

[0274] FIG. 16 shows non-limiting examples of multifunctional siNA molecules of the invention comprising two separate polynucleotide sequences that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences. FIG. 16A shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 3'-ends of each polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. FIG. 16B shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 5'-ends of each polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.

[0275] FIG. 17 shows non-limiting examples of multifunctional siNA molecules of the invention comprising a single polynucleotide sequence comprising distinct regions that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences. FIG. 17A shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the second complementary region is situated at the 3'-end of the polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. FIG. 17B shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first complementary region is situated at the 5'-end of the polynucleotide sequence in the multifunctional siNA. The dashed portions

of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. In one embodiment, these multifunctional siNA constructs are processed in vivo or in vitro to generate multifunctional siNA constructs as shown in FIG. 16.

[0276] FIG. 18 shows non-limiting examples of multifunctional siNA molecules of the invention comprising two separate polynucleotide sequences that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences and wherein the multifunctional siNA construct further comprises a self complementary, palindrome, or repeat region, thus enabling shorter bifunctional siNA constructs that can mediate RNA interference against differing target nucleic acid sequences. FIG. 18A shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 3'-ends of each polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. FIG. 18B shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 5'-ends of each polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.

[0277] FIG. 19 shows non-limiting examples of multifunctional siNA molecules of the invention comprising a single polynucleotide sequence comprising distinct regions that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences and wherein the multifunctional siNA construct further comprises a self complementary, palindrome, or repeat region, thus enabling shorter bifunctional siNA constructs that can mediate RNA interference against differing target nucleic acid sequences. FIG. 19A shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the second complementary region is situated at the 3'-end of the polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA

construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. FIG. 19B shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first complementary region is situated at the 5'-end of the polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. In one embodiment, these multifunctional siNA constructs are processed in vivo or in vitro to generate multifunctional siNA constructs as shown in FIG. 18.

[0278] FIG. 20 shows a non-limiting example of how multifunctional siNA molecules of the invention can target two separate target nucleic acid molecules, such as separate RNA molecules encoding differing proteins, for example, a cytokine and its corresponding receptor, differing viral strains, a virus and a cellular protein involved in viral infection or replication, or differing proteins involved in a common or divergent biologic pathway that is implicated in the maintenance of progression of disease. Each strand of the multifunctional siNA construct comprises a region having complementarity to separate target nucleic acid molecules. The multifunctional siNA molecule is designed such that each strand of the siNA can be utilized by the RISC complex to initiate RNA interference mediated cleavage of its corresponding target. These design parameters can include destabilization of each end of the siNA construct (see for example Schwarz et al., 2003, *Cell*, 115, 199-208). Such destabilization can be accomplished for example by using guanosine-cytidine base pairs, alternate base pairs (e.g., wobbles), or destabilizing chemically modified nucleotides at terminal nucleotide positions as is known in the art.

[0279] FIG. 21 shows a non-limiting example of how multifunctional siNA molecules of the invention can target two separate target nucleic acid sequences within the same target nucleic acid molecule, such as alternate coding regions of a RNA, coding and non-coding regions of a RNA, or alternate splice variant regions of a RNA. Each strand of the multifunctional siNA construct comprises a region having complementarity to the separate regions of the target nucleic acid molecule. The multifunctional siNA molecule is designed such that each strand of the siNA can be utilized by the RISC complex to initiate RNA interference mediated cleavage of its corresponding target region. These design parameters can include destabilization of each end of the siNA construct (see for example Schwarz et al., 2003, *Cell*, 115, 199-208). Such destabilization can be accomplished for example by using guanosine-cytidine base pairs, alternate base pairs (e.g., wobbles), or destabilizing chemically modified nucleotides at terminal nucleotide positions as is known in the art.

[0280] FIG. 22 shows a non-limiting example of reduction of BACE mRNA levels in A549 cells after treatment with siNA molecules targeting BACE mRNA. A549 cells

were transfected with 0.25 ug/well of lipid complexed with 25 nM siNA. A screen of siNA constructs comprising ribonucleotides and 3'-terminal dithymidine caps was compared to untreated cells, scrambled siNA control constructs (Scram 1 and Scram 2), and the cells transfected with lipid alone (transfection control). As shown in the Figure, all of the siNA constructs show significant reduction of BACE RNA expression.

[0281] FIG. 23 shows a non-limiting example of reduction of BACE mRNA levels in A549 cells (5,000 cells/well) 24 hours after treatment with siNA molecules targeting BACE mRNA. A549 cells were transfected with 0.25 ug/well of lipid complexed with 25 nM siNA. A lead siNA construct (31007/31083) chosen from the screen described in FIG. 22 was further modified using chemical modifications described in Table IV herein. Chemically modified constructs having Stab 4/5 chemistry (31378/31381) and Stab 7/11 chemistry (31384/31387) (solid bars; see Tables III and IV) were tested for efficacy compared to matched chemistry inverted controls (open bars; sequences shown in Table III). The original lead siNA construct (31007/31083) and the Stab 4/5 and Stab 7/11 constructs were compared to untreated cells, scrambled siNA control constructs (Scram1 and Scram2), and cells transfected with lipid alone (transfection control). As shown in the figure, the original lead construct and the Stab 4/5 and Stab 7/11 modified siNA constructs all show significant reduction of BACE RNA expression.

[0282] FIG. 24 shows a non-limiting example of reduction of APP mRNA in SK-N-SH cells mediated by chemically modified siNAs that target APP mRNA. SK-N-SH cells were transfected with 0.25 ug/well of lipid complexed with 25 nM siNA. Active siNA constructs comprising various stabilization chemistries (solid bars; see Tables III and IV) were compared to untreated cells, matched chemistry irrelevant siNA control constructs (IC1), and cells transfected with lipid alone (transfection control). As shown in the figure, the siNA constructs significantly reduce APP RNA expression.

[0283] FIG. 25 shows a non-limiting example of reduction of PSEN1 mRNA in SK-N-SH cells mediated by chemically modified siNAs that target PSEN1 mRNA. SK-N-SH cells were transfected with 0.25 ug/well of lipid complexed with 25 nM siNA. Active siNA constructs comprising various stabilization chemistries (solid bars; see Tables III and IV) were compared to untreated cells, matched chemistry irrelevant siNA control constructs (IC1), and cells transfected with lipid alone (transfection control). As shown in the figure, the siNA constructs significantly reduce PSEN1 RNA expression.

[0284] FIG. 26 shows a non-limiting example of reduction of PSEN2 mRNA in SK-N-SH cells mediated by chemically modified siNAs that target PSEN2 mRNA. SK-N-SH cells were transfected with 0.25 ug/well of lipid complexed with 25 nM siNA. Active siNA constructs comprising various stabilization chemistries (solid bars; see Tables III and IV) were compared to untreated cells, matched chemistry irrelevant siNA control constructs (IC1), and cells transfected with lipid alone (transfection control). As shown in the figure, the siNA constructs significantly reduce PSEN2 RNA expression.

DETAILED DESCRIPTION OF THE INVENTION

[0285] Mechanism of Action of Nucleic Acid Molecules of the Invention

[0286] The discussion that follows discusses the proposed mechanism of RNA interference mediated by short interfering RNA as is presently known, and is not meant to be limiting and is not an admission of prior art. Applicant demonstrates herein that chemically-modified short interfering nucleic acids possess similar or improved capacity to mediate RNAi as do siRNA molecules and are expected to possess improved stability and activity in vivo; therefore, this discussion is not meant to be limiting only to siRNA and can be applied to siNA as a whole. By "improved capacity to mediate RNAi" or "improved RNAi activity" is meant to include RNAi activity measured in vitro and/or in vivo where the RNAi activity is a reflection of both the ability of the siNA to mediate RNAi and the stability of the siNAs of the invention. In this invention, the product of these activities can be increased in vitro and/or in vivo compared to an all RNA siRNA or a siNA containing a plurality of ribonucleotides. In some cases, the activity or stability of the siNA molecule can be decreased (i.e., less than ten-fold), but the overall activity of the siNA molecule is enhanced in vitro and/or in vivo.

[0287] RNA interference refers to the process of sequence specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire et al., 1998, *Nature*, 391, 806). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes which is commonly shared by diverse flora and phyla (Fire et al., 1999, *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

[0288] The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as Dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Berstein et al., 2001, *Nature*, 409, 363). Short interfering RNAs derived from Dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (siRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which

mediates cleavage of single-stranded RNA having sequence homologous to the siRNA. Cleavage of the target RNA takes place in the middle of the region complementary to the guide sequence of the siRNA duplex (Elbashir et al., 2001, *Genes Dev.*, 15, 188). In addition, RNA interference can also involve small RNA (e.g., micro-RNA or miRNA) mediated gene silencing, presumably through cellular mechanisms that regulate chromatin structure and thereby prevent transcription of target gene sequences (see for example Allshire, 2002, *Science*, 297, 1818-1819; Volpe et al., 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall et al., 2002, *Science*, 297, 2232-2237). As such, siNA molecules of the invention can be used to mediate gene silencing via interaction with RNA transcripts or alternately by interaction with particular gene sequences, wherein such interaction results in gene silencing either at the transcriptional level or post-transcriptional level.

[0289] RNAi has been studied in a variety of systems. Fire et al., 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. elegans*. Wianny and Goez, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond et al., 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir et al., 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two 2-nucleotide 3'-terminal nucleotide overhangs. Furthermore, substitution of one or both siRNA strands with 2'-deoxy or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of 3'-terminal siRNA nucleotides with deoxy nucleotides was shown to be tolerated. Mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end (Elbashir et al., 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen et al., 2001, *Cell*, 107, 309); however, siRNA molecules lacking a 5'-phosphate are active when introduced exogenously, suggesting that 5'-phosphorylation of siRNA constructs may occur in vivo.

[0290] Synthesis of Nucleic Acid Molecules

[0291] Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small" refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., individual siNA oligonucleotide sequences or siNA sequences synthesized in tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure. Exemplary mol-

ecules of the instant invention are chemically synthesized, and others can similarly be synthesized.

[0292] Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers et al., 1992, *Methods in Enzymology* 211, 3-19, Thompson et al., International PCT Publication No. WO 99/54459, Wincott et al., 1995, *Nucleic Acids Res.* 23, 2677-2684, Wincott et al., 1997, *Methods Mol. Bio.*, 74, 59, Brennan et al., 1998, *Biotechnol Bioeng.*, 61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μ mol scale protocol with a 2.5 min coupling step for 2'-O-methylated nucleotides and a 45 second coupling step for 2'-deoxy nucleotides or 2'-deoxy-2'-fluoro nucleotides. Table V outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μ mol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μ L of 0.11 M=6.6 μ mol) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μ L of 0.25 M=15 μ mol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40 μ L of 0.11 M=4.4 μ mol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μ L of 0.25 M=10 μ mol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by calorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM I₂, 49 mM pyridine, 9% water in THF (PerSeptive Biosystems, Inc.). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

[0293] Deprotection of the DNA-based oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aqueous methylamine (1 mL) at 65° C. for 10 minutes. After cooling to -20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.

[0294] The method of synthesis used for RNA including certain siNA molecules of the invention follows the proce-

dures as described in Usman et al., 1987, *J. Am. Chem. Soc.*, 109, 7845; Scaringe et al., 1990, *Nucleic Acids Res.*, 18, 5433; and Wincott et al., 1995, *Nucleic Acids Res.* 23, 2677-2684 Wincott et al., 1997, *Methods Mol. Bio.*, 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μ mol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-O-methylated nucleotides. Table V outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μ mol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μ L of 0.11 M=6.6 μ mol) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μ L of 0.25 M=15 μ mol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 66-fold excess (120 μ L of 0.11 M=13.2 μ mol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μ L of 0.25 M=30 μ mol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM I₂, 49 mM pyridine, 9% water in THF (PerSeptive Biosystems, Inc.). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

[0295] Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to -20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μ L of a solution of 1.5 mL N-methylpyrrolidinone, 750 μ L TEA and 1 mL TEA:3HF to provide a 1.4 M HF concentration) and heated to 65° C. After 1.5 h, the oligomer is quenched with 1.5 M NH₄HCO₃.

[0296] Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65° C. for 15 minutes. The vial is brought to room temperature TEA:3HF

(0.1 mL) is added and the vial is heated at 65° C. for 15 minutes. The sample is cooled at -20° C. and then quenched with 1.5 M NH_4HCO_3 .

[0297] For purification of the trityl-on oligomers, the quenched NH_4HCO_3 solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 minutes. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.

[0298] The average stepwise coupling yields are typically >98% (Wincott et al., 1995 *Nucleic Acids Res.* 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96-well format.

[0299] Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al., 1992, *Science* 256, 9923; Draper et al., International PCT publication No. WO 93/23569; Shabarova et al., 1991, *Nucleic Acids Research* 19, 4247; Bellon et al., 1997, *Nucleosides & Nucleotides*, 16, 951; Bellon et al., 1997, *Bioconjugate Chem.* 8, 204), or by hybridization following synthesis and/or deprotection.

[0300] The siNA molecules of the invention can also be synthesized via a tandem synthesis methodology as described in Example 1 herein, wherein both siNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a cleavable linker which is subsequently cleaved to provide separate siNA fragments or strands that hybridize and permit purification of the siNA duplex. The linker can be a polynucleotide linker or a non-nucleotide linker. The tandem synthesis of siNA as described herein can be readily adapted to both multiwell/multiplate synthesis platforms such as 96 well or similarly larger multi-well platforms. The tandem synthesis of siNA as described herein can also be readily adapted to large scale synthesis platforms employing batch reactors, synthesis columns and the like.

[0301] A siNA molecule can also be assembled from two distinct nucleic acid strands or fragments wherein one fragment includes the sense region and the second fragment includes the antisense region of the RNA molecule.

[0302] The nucleic acid molecules of the present invention can be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman et al., 1994, *Nucleic Acids Symp. Ser.* 31, 163). siNA constructs can be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra, the totality of which is hereby incorporated herein by reference) and re-suspended in water.

[0303] In another aspect of the invention, siNA molecules of the invention are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral

vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules.

[0304] Optimizing Activity of the Nucleic Acid Molecule of the Invention.

[0305] Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their potency (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990 *Nature* 344, 565; Pieken et al., 1991, *Science* 253, 314; Usman and Cedergren, 1992, *Trends in Biochem. Sci.* 17, 334; Usman et al., International Publication No. WO 93/15187; and Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold et al., U.S. Pat. No. 6,300, 074; and Burgin et al., supra; all of which are incorporated by reference herein). All of the above references describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. Modifications that enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.

[0306] There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-O-allyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman et al., 1994, *Nucleic Acids Symp. Ser.* 31, 163; Burgin et al., 1996, *Biochemistry*, 35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al. *Nature*, 1990, 344, 565-568; Pieken et al. *Science*, 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.*, 1992, 17, 334-339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995, *J. Biol. Chem.*, 270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824; Usman et al., U.S. Pat. No. 5,627,053; Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., U.S. Ser. No. 60/082, 404 which was filed on Apr. 20, 1998; Karpeisky et al., 1998, *Tetrahedron Lett.*, 39, 1131; Eamshaw and Gait, 1998, *Biopolymers (Nucleic Acid Sciences)*, 48, 39-55; Verma and Eckstein, 1998, *Annu. Rev. Biochem.*, 67, 99-134; and Burlina et al., 1997, *Bioorg. Med Chem.*, 5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the siNA nucleic acid molecules of the instant

invention so long as the ability of siNA to promote RNAi in cells is not significantly inhibited.

[0307] While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorodithioate, and/or 5'-methylphosphonate linkages improves stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting in increased efficacy and higher specificity of these molecules.

[0308] Short interfering nucleic acid (siNA) molecules having chemical modifications that maintain or enhance activity are provided. Such a nucleic acid is also generally more resistant to nucleases than an unmodified nucleic acid. Accordingly, the in vitro and/or in vivo activity should not be significantly lowered. In cases in which modulation is the goal, therapeutic nucleic acid molecules delivered exogenously should optimally be stable within cells until translation of the target RNA has been modulated long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Improvements in the chemical synthesis of RNA and DNA (Wincott et al., 1995, *Nucleic Acids Res.* 23, 2677; Caruthers et al., 1992, *Methods in Enzymology* 211, 3-19 (incorporated by reference herein)) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability, as described above.

[0309] In one embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J. Am. Chem. Soc.*, 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands. In another embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) LNA "locked nucleic acid" nucleotides such as a 2',4'-C methylene bicyclo nucleotide (see for example Wengel et al., International PCT Publication No. WO 00/66604 and WO 99/14226).

[0310] In another embodiment, the invention features conjugates and/or complexes of siNA molecules of the invention. Such conjugates and/or complexes can be used to facilitate delivery of siNA molecules into a biological system, such as a cell. The conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including, but not limited to, small molecules, lipids, cholesterol, phospholipids, nucleosides, nucleotides, nucleic

acids, antibodies, toxins, negatively charged polymers and other polymers, for example proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either individually or as part of a multi-component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, in the presence or absence of serum (see Sullenger and Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules described herein can be attached to biologically active molecules via linkers that are biodegradable, such as biodegradable nucleic acid linker molecules.

[0311] The term "biodegradable linker" as used herein, refers to a nucleic acid or non-nucleic acid linker molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule to a siNA molecule of the invention or the sense and antisense strands of a siNA molecule of the invention. The biodegradable linker is designed such that its stability can be modulated for a particular purpose, such as delivery to a particular tissue or cell type. The stability of a nucleic acid-based biodegradable linker molecule can be modulated by using various chemistries, for example combinations of ribonucleotides, deoxyribonucleotides, and chemically-modified nucleotides, such as 2'-O-methyl, 2'-fluoro, 2'-amino, 2'-O-amino, 2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.

[0312] The term "biodegradable" as used herein, refers to degradation in a biological system, for example, enzymatic degradation or chemical degradation.

[0313] The term "biologically active molecule" as used herein refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active siNA molecules either alone or in combination with other molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.

[0314] The term "phospholipid" as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phos-

phorus-containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.

[0315] Therapeutic nucleic acid molecules (e.g., siNA molecules) delivered exogenously optimally are stable within cells until reverse transcription of the RNA has been modulated long enough to reduce the levels of the RNA transcript. The nucleic acid molecules are resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

[0316] In yet another embodiment, siNA molecules having chemical modifications that maintain or enhance enzymatic activity of proteins involved in RNAi are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acids. Thus, in vitro and/or in vivo the activity should not be significantly lowered.

[0317] Use of the nucleic acid-based molecules of the invention will lead to better treatments by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes; nucleic acid molecules coupled with known small molecule modulators; or intermittent treatment with combinations of molecules, including different motifs and/or other chemical or biological molecules). The treatment of subjects with siNA molecules can also include combinations of different types of nucleic acid molecules, such as enzymatic nucleic acid molecules (ribozymes), allozymes, antisense, 2,5-A oligoadenylate, decoys, and aptamers.

[0318] In another aspect a siNA molecule of the invention comprises one or more 5' and/or a 3'-cap structure, for example, on only the sense siNA strand, the antisense siNA strand, or both siNA strands.

[0319] By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic et al., U.S. Pat. No. 5,998,203, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'-terminal (3'-cap) or may be present on both termini. In non-limiting examples, the 5'-cap includes, but is not limited to, glyceryl, inverted deoxy abasic residue (moiety); 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide; 4'-thio nucleotide; carbocyclic nucleotide; 1,5-anhydroxitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide; 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety.

[0320] Non-limiting examples of the 3'-cap include, but are not limited to, glyceryl, inverted deoxy abasic residue

(moiety), 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydroxitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Iyer, 1993, *Tetrahedron* 49, 1925; incorporated by reference herein).

[0321] By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1'-position.

[0322] An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino, or SH. The term also includes alkenyl groups that are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably, it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, N(CH₃)₂, amino, or SH. The term "alkyl" also includes alkynyl groups that have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably, it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino or SH.

[0323] Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group that has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups

wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an —C(O)—NH—R , where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an —C(O)—OR' , where R is either alkyl, aryl, alkylaryl or hydrogen.

[0324] By "nucleotide" as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, *supra*; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman & Peyman, *supra*, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin et al., 1996, *Biochemistry*, 35, 14090; Uhlman & Peyman, *supra*). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents.

[0325] In one embodiment, the invention features modified siNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995, *Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods*, VCH, 331-417, and Mesmaeker et al., 1994, *Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research*, ACS, 24-39.

[0326] By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, see for example Adamic et al., U.S. Pat. No. 5,998,203.

[0327] By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, or uracil joined to the 1' carbon of β -D-ribo-furanose.

[0328] By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure

of an unmodified nucleotide base, sugar and/or phosphate. Non-limiting examples of modified nucleotides are shown by Formulae I-VII and/or other modifications described herein.

[0329] In connection with 2'-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH₂ or 2'-O—NH₂, which can be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., U.S. Pat. No. 6,248,878, which are both incorporated by reference in their entireties.

[0330] Various modifications to nucleic acid siNA structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

[0331] Administration of Nucleic Acid Molecules

[0332] A siNA molecule of the invention can be adapted for use to prevent or treat a variety of neurodegenerative diseases, including Alzheimer's disease, dementia, stroke (CVA), or any other trait, disease or condition that is related to or will respond to the levels of BACE in a cell or tissue, alone or in combination with other therapies.

[0333] For example, a siNA molecule can comprise a delivery vehicle, including liposomes, for administration to a subject, carriers and diluents and their salts, and/or can be present in pharmaceutically acceptable formulations. Methods for the delivery of nucleic acid molecules are described in Akhtar et al., 1992, *Trends Cell Bio.*, 2, 139; *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995, Maurer et al., 1999, *Mol. Membr. Biol.*, 16, 129-140; Hofland and Huang, 1999, *Handb. Exp. Pharmacol.*, 137, 165-192; and Lee et al., 2000, *ACS Symp. Ser.*, 752, 184-192, all of which are incorporated herein by reference. Beigelman et al., U.S. Pat. No. 6,395,713 and Sullivan et al., PCT WO 94/02595 further describe the general methods for delivery of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as biodegradable polymers, hydrogels, cyclodextrins (see for example Gonzalez et al., 1999, *Bioconjugate Chem.*, 10, 1068-1074; Wang et al., International PCT publication Nos. WO 03/47518 and WO 03/46185), poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see for example U.S. Pat. No. 6,447,796 and U.S. Patent Application Publication No. U.S. 2002130430), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication No. WO 00/53722). In another embodiment, the nucleic acid molecules of the invention can also be formulated or complexed with polyethyleneimine and derivatives thereof, such as polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine (PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL) derivatives.

[0334] In one embodiment, a siNA molecule of the invention is complexed with membrane disruptive agents such as

those described in U.S. Patent Application Publication No. 20010007666, incorporated by reference herein in its entirety including the drawings. In another embodiment, the membrane disruptive agent or agents and the siNA molecule are also complexed with a cationic lipid or helper lipid molecule, such as those lipids described in U.S. Pat. No. 6,235,310, incorporated by reference herein in its entirety including the drawings.

[0335] In one embodiment, a siNA molecule of the invention is complexed with delivery systems as described in U.S. Patent Application Publication No. 2003077829 and International PCT Publication Nos. WO 00/03683 and WO 02/087541, all incorporated by reference herein in their entirety including the drawings.

[0336] In one embodiment, siNA molecules of the invention are formulated or complexed with polyethylenimine (e.g., linear or branched PEI) and/or polyethylenimine derivatives, including for example grafted PEIs such as galactose PEI, cholesterol PEI, antibody derivatized PEI, and polyethylene glycol PEI (PEG-PEI) derivatives thereof (see for example Ogris et al., 2001, *AAPA PharmSci*, 3, 1-11; Furgeson et al., 2003, *Bioconjugate Chem.*, 14, 840-847; Kunath et al., 2002, *Pharmaceutical Research*, 19, 810-817; Choi et al., 2001, *Bull. Korean Chem. Soc.*, 22, 46-52; Bettinger et al., 1999, *Bioconjugate Chem.*, 10, 558-561; Peterson et al., 2002, *Bioconjugate Chem.*, 13, 845-854; Erbacher et al., 1999, *Journal of Gene Medicine Preprint*, 1, 1-18; Godbey et al., 1999, *PNAS USA*, 96, 5177-5181; Godbey et al., 1999, *Journal of Controlled Release*, 60, 149-160; Diebold et al., 1999, *Journal of Biological Chemistry*, 274, 19087-19094; Thomas and Klibanov, 2002, *PNAS USA*, 99, 14640-14645; and Sagara, U.S. Pat. No. 6,586,524, incorporated by reference herein.

[0337] In one embodiment, a siNA molecule of the invention comprises a bioconjugate, for example a nucleic acid conjugate as described in Vargeese et al., U.S. Ser. No. 10/427,160, filed Apr. 30, 2003; U.S. Pat. No. 6,528,631; U.S. Pat. No. 6,335,434; U.S. Pat. No. 6,235,886; U.S. Pat. No. 6,153,737; U.S. Pat. No. 5,214,136; U.S. Pat. No. 5,138,045, all incorporated by reference herein.

[0338] Thus, the invention features a pharmaceutical composition comprising one or more nucleic acid(s) of the invention in an acceptable carrier, such as a stabilizer, buffer, and the like. The polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced to a subject by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention can also be formulated and used as creams, gels, sprays, oils and other suitable compositions for topical, dermal, or transdermal administration as is known in the art.

[0339] The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.

[0340] A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic or local administration, into a

cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged nucleic acid is desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.

[0341] In one embodiment, the invention features the use of methods to deliver the nucleic acid molecules of the instant invention to the central nervous system and/or peripheral nervous system. Experiments have demonstrated the efficient in vivo uptake of nucleic acids by neurons. As an example of local administration of nucleic acids to nerve cells, Sommer et al., 1998, *Antisense Nuc. Acid Drug Dev.*, 8, 75, describe a study in which a 15mer phosphorothioate antisense nucleic acid molecule to c-fos is administered to rats via microinjection into the brain. Antisense molecules labeled with tetramethylrhodamine-isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) were taken up by exclusively by neurons thirty minutes post-injection. A diffuse cytoplasmic staining and nuclear staining was observed in these cells. As an example of systemic administration of nucleic acid to nerve cells, Epa et al., 2000, *Antisense Nuc. Acid Drug Dev.*, 10, 469, describe an in vivo mouse study in which beta-cyclodextrin-adamantane-oligonucleotide conjugates were used to target the p75 neurotrophin receptor in neuronally differentiated PC12 cells. Following a two week course of IP administration, pronounced uptake of p75 neurotrophin receptor antisense was observed in dorsal root ganglion (DRG) cells. In addition, a marked and consistent down-regulation of p75 was observed in DRG neurons. Additional approaches to the targeting of nucleic acid to neurons are described in Broadbudd et al., 1998, *J. Neurosurg.*, 88(4), 734; Karle et al., 1997, *Eur. J. Pharmacol.*, 340(2/3), 153; Bannai et al., 1998, *Brain Research*, 784(1,2), 304; Rajakumar et al., 1997, *Synapse*, 26(3), 199; Wu-pong et al., 1999, *BioPharm*, 12(1), 32; Bannai et al., 1998, *Brain Res. Protoc.*, 3(1), 83; Simantov et al., 1996, *Neuroscience*, 74(1), 39. Nucleic acid molecules of the invention are therefore amenable to delivery to and uptake by cells that express repeat expansion allelic variants for modulation of RE gene expression. The delivery of nucleic acid molecules of the invention, targeting RE is provided by a variety of different strategies. Traditional approaches to CNS delivery that can be used include, but are not limited to, intrathecal and intracerebroventricular administration, implantation of catheters and pumps, direct injection or perfusion at the site of injury or lesion, injection into the brain arterial system, or by chemical or osmotic opening of the blood-brain barrier. Other approaches can include the use of various transport and carrier systems, for example though the use of conjugates and biodegradable polymers. Furthermore, gene therapy approaches, for example as described in Kaplitt et al., U.S. Pat. No. 6,180,613 and Davidson, WO 04/013280, can be used to express nucleic acid molecules in the CNS.

[0342] In one embodiment, nucleic acid molecules of the invention are administered to the central nervous system (CNS) or peripheral nervous system (PNS). Experiments have demonstrated the efficient in vivo uptake of nucleic

acids by neurons. As an example of local administration of nucleic acids to nerve cells, Sommer et al., 1998, *Antisense Nuc. Acid Drug Dev.*, 8, 75, describe a study in which a 15mer phosphorothioate antisense nucleic acid molecule to c-fos is administered to rats via microinjection into the brain. Antisense molecules labeled with tetramethylrhodamine-isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) were taken up by exclusively by neurons thirty minutes post-injection. A diffuse cytoplasmic staining and nuclear staining was observed in these cells. As an example of systemic administration of nucleic acid to nerve cells, Epa et al., 2000, *Antisense Nuc. Acid Drug Dev.*, 10, 469, describe an in vivo mouse study in which beta-cyclodextrin-adamantane-oligonucleotide conjugates were used to target the p75 neurotrophin receptor in neuronally differentiated PC12 cells. Following a two week course of IP administration, pronounced uptake of p75 neurotrophin receptor antisense was observed in dorsal root ganglion (DRG) cells. In addition, a marked and consistent down-regulation of p75 was observed in DRG neurons. Additional approaches to the targeting of nucleic acid to neurons are described in Broadus et al., 1998, *J. Neurosurg.*, 88(4), 734; Karle et al., 1997, *Eur. J. Pharmacol.*, 340(2/3), 153; Bannai et al., 1998, *Brain Research*, 784(1,2), 304; Rajakumar et al., 1997, *Synapse*, 26(3), 199; Wu-pong et al., 1999, *BioPharm*, 12(1), 32; Bannai et al., 1998, *Brain Res. Protoc.*, 3(1), 83; Simantov et al., 1996, *Neuroscience*, 74(1), 39. Nucleic acid molecules of the invention are therefore amenable to delivery to and uptake by cells in the CNS and/or PNS.

[0343] The delivery of nucleic acid molecules of the invention to the CNS is provided by a variety of different strategies. Traditional approaches to CNS delivery that can be used include, but are not limited to, intrathecal and intracerebroventricular administration, implantation of catheters and pumps, direct injection or perfusion at the site of injury or lesion, injection into the brain arterial system, or by chemical or osmotic opening of the blood-brain barrier. Other approaches can include the use of various transport and carrier systems, for example though the use of conjugates and biodegradable polymers. Furthermore, gene therapy approaches, for example as described in Kaplitt et al., U.S. Pat. No. 6,180,613 and Davidson, WO 04/013280, can be used to express nucleic acid molecules in the CNS.

[0344] In one embodiment, dermal delivery systems of the invention include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer. Examples of liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,N,N,N-tetramethyl-N,N,N,N-tetrapalmit-y-spermine and dioleoyl phosphatidylethanolamine (DOPE) (GIBCO BRL); (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N-[1-(2,3-dioleoyloxy)-N,N,N-tri-methyl-ammonium-methylsulfate] (Boehringer Mannheim); and (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO BRL).

[0345] In one embodiment, siNA molecules of the invention are administered to a subject by systemic administration in a pharmaceutically acceptable composition or formulation. By "systemic administration" is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the siNA molecules of the invention to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells.

[0346] In one embodiment, siNA molecules of the invention are formulated or complexed with polyethylenimine (e.g., linear or branched PEI) and/or polyethylenimine derivatives, including for example grafted PEIs such as galactose PEI, cholesterol PEI, antibody derivatized PEI, and polyethylene glycol PEI (PEG-PEI) derivatives thereof (see for example Ogris et al., 2001, *AAFA PharmSci*, 3, 1-11; Furgeson et al., 2003, *Bioconjugate Chem.*, 14, 840-847; Kunath et al., 2002, *Pharmaceutical Research*, 19, 810-817; Choi et al., 2001, *Bull. Korean Chem. Soc.*, 22, 46-52; Bettinger et al., 1999, *Bioconjugate Chem.*, 10, 558-561; Peterson et al., 2002, *Bioconjugate Chem.*, 13, 845-854; Erbacher et al., 1999, *Journal of Gene Medicine Preprint*, 1, 1-18; Godbey et al., 1999, *PNAS USA*, 96, 5177-5181; Godbey et al., 1999, *Journal of Controlled Release*, 60, 149-160; Diebold et al., 1999, *Journal of Biological Chemistry*, 274, 19087-19094; Thomas and Klibanov, 2002, *PNAS USA*, 99, 14640-14645; and Sagara, U.S. Pat. No. 6,586,524, incorporated by reference herein.

[0347] By "pharmaceutically acceptable formulation" or "pharmaceutically acceptable composition" is meant a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery (Emerich, D F et al, 1999, *Cell Transplant*, 8, 47-58); and loaded nanoparticles, such as those made of polybutylcyanoacrylate. Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado et al., 1998, *J. Pharm. Sci.*, 87, 1308-1315; Tyler et al., 1999, *FEBS Lett.*, 421, 280-284; Pardridge et al., 1995, *PNAS USA*, 92, 5592-5596; Boado, 1995, *Adv. Drug Delivery Rev.*, 15, 73-107; Aldrian-Herrada et al., 1998, *Nucleic Acids Res.*, 26, 4910-4916; and Tyler et al., 1999, *PNAS USA*, 96, 7053-7058.

[0348] The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. *Chem. Rev.* 1995, 95, 2601-2627; Ishiwata et al., *Chem. Pharm. Bull.* 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., *Science* 1995, 267, 1275-1276; Oku et al., 1995, *Biochim. Biophys. Acta*, 1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., *J. Biol. Chem.* 1995, 42, 24864-24870; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

[0349] The present invention also includes compositions prepared for storage or administration that include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A. R. Gennaro edit. 1985), hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used.

[0350] A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate) a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

[0351] The nucleic acid molecules of the invention and formulations thereof can be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier. One or more nucleic

acid molecules of the invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

[0352] Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.

[0353] Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

[0354] Aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0355] Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a

thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0356] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.

[0357] Pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents.

[0358] Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butandiol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0359] The nucleic acid molecules of the invention can also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.

[0360] Nucleic acid molecules of the invention can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

[0361] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per subject per day). The amount

of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient.

[0362] It is understood that the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

[0363] For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.

[0364] The nucleic acid molecules of the present invention can also be administered to a subject in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.

[0365] Alternatively, certain siNA molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, *Science*, 229, 345; McGarry and Lindquist, 1986, *Proc. Natl. Acad. Sci. USA* 83, 399; Scanlon et al., 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet et al., 1992, *Antisense Res. Dev.*, 2, 3-15; Dropulic et al., 1992, *J. Virol.*, 66, 1432-41; Weerasinghe et al., 1991, *J. Virol.*, 65, 5531-4; Ojwang et al., 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen et al., 1992, *Nucleic Acids Res.*, 20, 4581-9; Sarver et al., 1990 *Science*, 247, 1222-1225; Thompson et al., 1995, *Nucleic Acids Res.*, 23, 2259; Good et al., 1997, *Gene Therapy*, 4, 45. Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992, *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira et al., 1991, *Nucleic Acids Res.*, 19, 5125-30; Ventura et al., 1993, *Nucleic Acids Res.*, 21, 3249-55; Chowrira et al., 1994, *J. Biol. Chem.*, 269, 25856.

[0366] In another aspect of the invention, RNA molecules of the present invention can be expressed from transcription units (see for example Couture et al., 1996, *TIG.*, 12, 510) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. In another embodiment, pol III based constructs are used to express nucleic acid molecules of the invention (see for example Thompson, U.S. Pats. Nos. 5,902,880 and 6,146,886). The recombinant vectors capable of expressing the siNA molecules can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid mol-

ecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecule interacts with the target mRNA and generates an RNAi response. Delivery of siNA molecule expressing vectors can be systemic, such as by intravenous or intra-muscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., 1996, *TIG*, 12, 510).

[0367] In one aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the instant invention. The expression vector can encode one or both strands of a siNA duplex, or a single self-complementary strand that self hybridizes into a siNA duplex. The nucleic acid sequences encoding the siNA molecules of the instant invention can be operably linked in a manner that allows expression of the siNA molecule (see for example Paul et al., 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee et al., 2002, *Nature Biotechnology*, 19, 500; and Novina et al., 2002, *Nature Medicine*, advance online publication doi:10.1038/nm725).

[0368] In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); and c) a nucleic acid sequence encoding at least one of the siNA molecules of the instant invention, wherein said sequence is operably linked to said initiation region and said termination region in a manner that allows expression and/or delivery of the siNA molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the siNA of the invention; and/or an intron (intervening sequences).

[0369] Transcription of the siNA molecule sequences can be driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, *Proc. Natl. Acad. Sci. USA*, 87, 6743-7; Gao and Huang 1993, *Nucleic Acids Res.*, 21, 2867-72; Lieber et al., 1993, *Methods Enzymol.*, 217, 47-66; Zhou et al., 1990, *Mol. Cell. Biol.*, 10, 4529-37). Several investigators have demonstrated that nucleic acid molecules expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992, *Antisense Res. Dev.*, 2, 3-15; Ojwang et al., 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen et al., 1992, *Nucleic Acids Res.*, 20, 4581-9; Yu et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90, 6340-4; L'Huillier et al., 1992, *EMBO J*, 11, 4411-8; Lisiewicz et al., 1993, *Proc. Natl. Acad. Sci. U S A*, 90, 8000-4; Thompson et al., 1995, *Nucleic Acids Res.*, 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high

concentrations of desired RNA molecules such as siNA in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997, *Gene Ther.*, 4, 45; Beigelman et al., International PCT Publication No. WO 96/18736. The above siNA transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, supra).

[0370] In another aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the siNA molecules of the invention in a manner that allows expression of that siNA molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; and c) a nucleic acid sequence encoding at least one strand of the siNA molecule, wherein the sequence is operably linked to the initiation region and the termination region in a manner that allows expression and/or delivery of the siNA molecule.

[0371] In another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; and d) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the open reading frame and the termination region in a manner that allows expression and/or delivery of the siNA molecule. In yet another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; and d) a nucleic acid sequence encoding at least one siNA molecule, wherein the sequence is operably linked to the initiation region, the intron and the termination region in a manner which allows expression and/or delivery of the nucleic acid molecule.

[0372] In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; and e) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the intron, the open reading frame and the termination region in a manner which allows expression and/or delivery of the siNA molecule.

[0373] BACE, APP, PIN-1 and PS Biology and Biochemistry

[0374] Alzheimer's disease is characterized by the progressive formation of insoluble plaques and vascular deposits in the brain consisting of the 4 kD amyloid β peptide ($A\beta$). These plaques are characterized by dystrophic neurites that show profound synaptic loss, neurofibrillary tangle formation, and gliosis. $A\beta$ arises from the proteolytic cleavage of the large type I transmembrane protein, β -amyloid precursor protein (APP) (Kang et al., 1987, *Nature*, 325, 733). Processing of APP to generate $A\beta$ requires two sites of cleavage by a β -secretase and a γ -secretase. β -secretase cleavage of APP results in the cytoplasmic release of a 100 kD soluble amino-terminal fragment, APPs β , leaving behind

a 12 kD transmembrane carboxy-terminal fragment, C99. Alternately, APP can be cleaved by a α -secretase to generate cytoplasmic APP α and transmembrane C83 fragments. Both remaining transmembrane fragments, C99 and C83, can be further cleaved by a γ -secretase, leading to the release and secretion of Alzheimer's related A β and a non-pathogenic peptide, p3, respectively (Vassar et al., 1999, *Science*, 286, 735-741). Early onset familial Alzheimer's disease is characterized by mutant APP protein with a Met to Leu substitution at position P1, characterized as the "Swedish" familial mutation (Mullan et al., 1992, *Nature Genet.*, 1, 345). This APP mutation is characterized by a dramatic enhancement in β -secretase cleavage (Citron et al., 1992, *Nature*, 360, 672).

[0375] The identification of β -secretase and γ -secretase constituents involved in the release of β -amyloid protein is of primary importance in the development of treatment strategies for Alzheimer's disease. Characterization of α -secretase is also important in this regard since α -secretase cleavage may compete with β -secretase cleavage resulting in changes in the relative amounts of non-pathogenic and pathogenic protein production. Involvement of the two metalloproteases, ADAM 10 and TACE, has been demonstrated in α -cleavage of AAP (Buxbaum et al., 1999, *J. Biol. Chem.*, 273, 27765, and Lammich et al., 1999, *Proc. Natl. Acad. Sci. U.S.A.*, 96, 3922). Studies of γ -secretase activity have demonstrated presenilin dependence (De Strooper et al., 1998, *Nature*, 391, 387, and De Strooper et al., 1999, *Nature*, 398, 518), and as such, presenilins have been proposed as γ -secretase even though presenilin does not present proteolytic activity (Wolfe et al., 1999, *Nature*, 398, 513).

[0376] Studies have shown β -secretase cleavage of AAP by the transmembrane aspartic protease beta site APP cleaving enzyme, BACE (Vassar et al., supra). While other potential candidates for β -secretase have been proposed (for review see Evin et al., 1999, *Proc. Natl. Acad. Sci. U.S.A.*, 96, 3922), none have demonstrated the full range of characteristics expected from this enzyme. Studies have shown that BACE expression and localization are as expected for β -secretase, that BACE overexpression in cells results in increased β -secretase cleavage of APP and Swedish APP, that isolated BACE demonstrates site specific proteolytic activity on APP derived peptide substrates, and that antisense mediated endogenous BACE inhibition results in dramatically reduced β -secretase activity (Vassar et al., supra).

[0377] Current treatment strategies for Alzheimer's disease rely on either the prevention or the alleviation of symptoms and/or the slowing down of disease progression. Two drugs approved in the treatment of Alzheimer's, donepezil (Aricept®) and tacrine (Cognex®), both cholinomimetics, attempt to slow the loss of cognitive ability by increasing the amount of acetylcholine available to the brain. Antioxidant therapy through the use of antioxidant compounds such as alpha-tocopherol (vitamin E), melatonin, and selegiline (Eldepryl®) attempt to slow disease progression by minimizing free radical damage. Estrogen replacement therapy is thought to incur a possible preventative benefit in the development of Alzheimer's disease based on limited data. The use of anti-inflammatory drugs may be associated with a reduced risk of Alzheimer's as well. Calcium channel blockers such as Nimodipine® are considered to have a potential benefit in treating Alzheimer's

disease due to protection of nerve cells from calcium overload, thereby prolonging nerve cell survival. Nootropic compounds, such as acetyl-L-carnitine (Alcar®) and insulin, have been proposed to have some benefit in treating Alzheimer's due to enhancement of cognitive and memory function based on cellular metabolism.

[0378] Whereby the above treatment strategies can all improve quality of life in Alzheimer's patients, there exists an unmet need in the comprehensive treatment and prevention of this disease. As such, there exists the need for therapeutics effective in reversing the physiological changes associated with Alzheimer's disease, specifically, therapeutics that can eliminate and/or reverse the deposition of amyloid β peptide. The use of compounds, such as small nucleic acid molecules (e.g., short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi)), to modulate the expression of proteases that are instrumental in the release of amyloid β peptide, namely β -secretase (BACE), γ -secretase (presenilin), and the amyloid precursor protein (APP), is of therapeutic significance.

EXAMPLES

[0379] The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.

Example 1

Tandem Synthesis of siNA Constructs

[0380] Exemplary siNA molecules of the invention are synthesized in tandem using a cleavable linker, for example, a succinyl-based linker. Tandem synthesis as described herein is followed by a one-step purification process that provides RNAi molecules in high yield. This approach is highly amenable to siNA synthesis in support of high throughput RNAi screening, and can be readily adapted to multi-column or multi-well synthesis platforms.

[0381] After completing a tandem synthesis of a siNA oligo and its complement in which the 5'-terminal dimethoxytrityl (5'-O-DMT) group remains intact (trityl on synthesis), the oligonucleotides are deprotected as described above. Following deprotection, the siNA sequence strands are allowed to spontaneously hybridize. This hybridization yields a duplex in which one strand has retained the 5'-O-DMT group while the complementary strand comprises a terminal 5'-hydroxyl. The newly formed duplex behaves as a single molecule during routine solid-phase extraction purification (Trityl-On purification) even though only one molecule has a dimethoxytrityl group. Because the strands form a stable duplex, this dimethoxytrityl group (or an equivalent group, such as other trityl groups or other hydrophobic moieties) is all that is required to purify the pair of oligos, for example, by using a C18 cartridge.

[0382] Standard phosphoramidite synthesis chemistry is used up to the point of introducing a tandem linker, such as an inverted deoxy abasic succinate or glyceryl succinate linker (see FIG. 1) or an equivalent cleavable linker. A non-limiting example of linker coupling conditions that can be used includes a hindered base such as diisopropylethy-

lamine (DIPA) and/or DMAP in the presence of an activator reagent such as Bromotripyrrolidinophosphoniumhexafluorophosphate (PyBrOP). After the linker is coupled, standard synthesis chemistry is utilized to complete synthesis of the second sequence leaving the terminal the 5'-O-DMT intact. Following synthesis, the resulting oligonucleotide is deprotected according to the procedures described herein and quenched with a suitable buffer, for example with 50 mM NaOAc or 1.5M $\text{NH}_4\text{H}_2\text{CO}_3$.

[0383] Purification of the siNA duplex can be readily accomplished using solid phase extraction, for example, using a Waters C18 SepPak 1 g cartridge conditioned with 1 column volume (CV) of acetonitrile, 2 CV H_2O , and 2 CV 50 mM NaOAc. The sample is loaded and then washed with 1 CV H_2O or 50 mM NaOAc. Failure sequences are eluted with 1 CV 14% ACN (Aqueous with 50 mM NaOAc and 50 mM NaCl). The column is then washed, for example with 1 CV H_2O followed by on-column detritylation, for example by passing 1 CV of 1% aqueous trifluoroacetic acid (TFA) over the column, then adding a second CV of 1% aqueous TFA to the column and allowing to stand for approximately 10 minutes. The remaining TFA solution is removed and the column washed with H_2O followed by 1 CV 1M NaCl and additional H_2O . The siNA duplex product is then eluted, for example, using 1 CV 20% aqueous CAN.

[0384] FIG. 2 provides an example of MALDI-TOF mass spectrometry analysis of a purified siNA construct in which each peak corresponds to the calculated mass of an individual siNA strand of the siNA duplex. The same purified siNA provides three peaks when analyzed by capillary gel electrophoresis (CGE), one peak presumably corresponding to the duplex siNA, and two peaks presumably corresponding to the separate siNA sequence strands. Ion exchange HPLC analysis of the same siNA construct only shows a single peak. Testing of the purified siNA construct using a luciferase reporter assay described below demonstrated the same RNAi activity compared to siNA constructs generated from separately synthesized oligonucleotide sequence strands.

Example 2

Identification of Potential siNA Target Sites in Any RNA Sequence

[0385] The sequence of an RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siNA targets having complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art. Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or deletions, can be used to design siNA molecules targeting those sites. Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology

between various regions of the target sequence, or the relative position of the target sequence within the RNA transcript. Based on these determinations, any number of target sites within the RNA transcript can be chosen to screen siNA molecules for efficacy, for example by using *in vitro* RNA cleavage assays, cell culture, or animal models. In a non-limiting example, anywhere from 1 to 1000 target sites are chosen within the transcript based on the size of the siNA construct to be used. High throughput screening assays can be developed for screening siNA molecules using methods known in the art, such as with multi-well or multi-plate assays to determine efficient reduction in target gene expression.

Example 3

Selection of siNA Molecule Target Sites in a RNA

[0386] The following non-limiting steps can be used to carry out the selection of siNAs targeting a given gene sequence or transcript.

[0387] 1. The target sequence is parsed *in silico* into a list of all fragments or subsequences of a particular length, for example 23 nucleotide fragments, contained within the target sequence. This step is typically carried out using a custom Perl script, but commercial sequence analysis programs such as Oligo, MacVector, or the GCG Wisconsin Package can be employed as well.

[0388] 2. In some instances the siNAs correspond to more than one target sequence; such would be the case for example in targeting different transcripts of the same gene, targeting different transcripts of more than one gene, or for targeting both the human gene and an animal homolog. In this case, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find matching sequences in each list. The subsequences are then ranked according to the number of target sequences that contain the given subsequence; the goal is to find subsequences that are present in most or all of the target sequences. Alternately, the ranking can identify subsequences that are unique to a target sequence, such as a mutant target sequence. Such an approach would enable the use of siNA to target specifically the mutant sequence and not effect the expression of the normal sequence.

[0389] 3. In some instances the siNA subsequences are absent in one or more sequences while present in the desired target sequence; such would be the case if the siNA targets a gene with a paralogous family member that is to remain untargeted. As in case 2 above, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find sequences that are present in the target gene but are absent in the untargeted paralog.

[0390] 4. The ranked siNA subsequences can be further analyzed and ranked according to GC content. A preference can be given to sites containing 30-70% GC, with a further preference to sites containing 40-60% GC.

[0391] 5. The ranked siNA subsequences can be further analyzed and ranked according to self-folding and internal hairpins. Weaker internal folds are preferred; strong hairpin structures are to be avoided.

[0392] 6. The ranked siNA subsequences can be further analyzed and ranked according to whether they have runs of

GGG or CCC in the sequence. GGG (or even more Gs) in either strand can make oligonucleotide synthesis problematic and can potentially interfere with RNAi activity, so it is avoided whenever better sequences are available. CCC is searched in the target strand because that will place GGG in the antisense strand.

[0393] 7. The ranked siNA subsequences can be further analyzed and ranked according to whether they have the dinucleotide UU (uridine dinucleotide) on the 3'-end of the sequence, and/or AA on the 5'-end of the sequence (to yield 3' UU on the antisense sequence). These sequences allow one to design siNA molecules with terminal TT thymidine dinucleotides.

[0394] 8. Four or five target sites are chosen from the ranked list of subsequences as described above. For example, in subsequences having 23 nucleotides, the right 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the upper (sense) strand of the siNA duplex, while the reverse complement of the left 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the lower (antisense) strand of the siNA duplex (see Tables II and III). If terminal TT residues are desired for the sequence (as described in paragraph 7), then the two 3' terminal nucleotides of both the sense and antisense strands are replaced by TT prior to synthesizing the oligos.

[0395] 9. The siNA molecules are screened in an in vitro, cell culture or animal model system to identify the most active siNA molecule or the most preferred target site within the target RNA sequence.

[0396] 10. Other design considerations can be used when selecting target nucleic acid sequences, see, for example, Reynolds et al., 2004, *Nature Biotechnology Advanced Online Publication*, 1 Feb. 2004, doi:10.1038/nbt936 and Ui-Tei et al., 2004, *Nucleic Acids Research*, 32, doi:10.1093/nar/gkh247.

[0397] In an alternate approach, a pool of siNA constructs specific to a BACE target sequence is used to screen for target sites in cells expressing BACE RNA, such as cultured A549 cells, 7PA2 cells, Chinese hamster ovary (CHO) cells, or APPsw (Swedish type amyloid precursor protein expressing) cells. The general strategy used in this approach is shown in FIG. 9. A non-limiting example of such is a pool comprising sequences having any of SEQ ID NOS 1-1900. Cells expressing BACE (e.g., A549 cells) are transfected with the pool of siNA constructs and cells that demonstrate a phenotype associated with BACE inhibition are sorted. The pool of siNA constructs can be expressed from transcription cassettes inserted into appropriate vectors (see for example FIG. 7 and FIG. 8). The siNA from cells demonstrating a positive phenotypic change (e.g., decreased proliferation, decreased BACE mRNA levels or decreased BACE protein expression), are sequenced to determine the most suitable target site(s) within the target BACE RNA sequence.

Example 4

BACE Targeted siNA Design

[0398] siNA target sites were chosen by analyzing sequences of the BACE RNA target and optionally priori-

tizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siNA accessibility to the target), by using a library of siNA molecules as described in Example 3, or alternately by using an in vitro siNA system as described in Example 6 herein. siNA molecules were designed that could bind each target and are optionally individually analyzed by computer folding to assess whether the siNA molecule can interact with the target sequence. Varying the length of the siNA molecules can be chosen to optimize activity. Generally, a sufficient number of complementary nucleotide bases are chosen to bind to, or otherwise interact with, the target RNA, but the degree of complementarity can be modulated to accommodate siNA duplexes or varying length or base composition. By using such methodologies, siNA molecules can be designed to target sites within any known RNA sequence, for example those RNA sequences corresponding to the any gene transcript.

[0399] Chemically modified siNA constructs are designed to provide nuclease stability for systemic administration in vivo and/or improved pharmacokinetic, localization, and delivery properties while preserving the ability to mediate RNAi activity. Chemical modifications as described herein are introduced synthetically using synthetic methods described herein and those generally known in the art. The synthetic siNA constructs are then assayed for nuclease stability in serum and/or cellular/tissue extracts (e.g. liver extracts). The synthetic siNA constructs are also tested in parallel for RNAi activity using an appropriate assay, such as a luciferase reporter assay as described herein or another suitable assay that can quantify RNAi activity. Synthetic siNA constructs that possess both nuclease stability and RNAi activity can be further modified and re-evaluated in stability and activity assays. The chemical modifications of the stabilized active siNA constructs can then be applied to any siNA sequence targeting any chosen RNA and used, for example, in target screening assays to pick lead siNA compounds for therapeutic development (see for example FIG. 11).

Example 5

Chemical Synthesis and Purification of siNA

[0400] siNA molecules can be designed to interact with various sites in the RNA message, for example, target sequences within the RNA sequences described herein. The sequence of one strand of the siNA molecule(s) is complementary to the target site sequences described above. The siNA molecules can be chemically synthesized using methods described herein. Inactive siNA molecules that are used as control sequences can be synthesized by scrambling the sequence of the siNA molecules such that it is not complementary to the target sequence. Generally, siNA constructs can be synthesized using solid phase oligonucleotide synthesis methods as described herein (see for example Usman et al., U.S. Pat. Nos. 5,804,683; 5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117; 6,469,158; Scaringe et al., U.S. Pat. Nos. 6,111,086; 6,008,400; 6,111,086 all incorporated by reference herein in their entirety).

[0401] In a non-limiting example, RNA oligonucleotides are synthesized in a stepwise fashion using the phosphoramidite chemistry as is known in the art. Standard phosphoramidite chemistry involves the use of nucleosides comprising any of 5'-O-dimethoxytrityl, 2'-O-tert-butyldimethylsilyl,

3'-O-2-Cyanoethyl N,N-diisopropylphosphoramidite groups, and exocyclic amine protecting groups (e.g. N6-benzoyl adenosine, N4 acetyl cytidine, and N2-isobutyl guanosine). Alternately, 2'-O-Silyl Ethers can be used in conjunction with acid-labile 2'-O-orthoester protecting groups in the synthesis of RNA as described by Scaringe supra. Differing 2' chemistries can require different protecting groups, for example 2'-deoxy-2'-amino nucleosides can utilize N-phthaloyl protection as described by Usman et al., U.S. Pat. No. 5,631,360, incorporated by reference herein in its entirety).

[0402] During solid phase synthesis, each nucleotide is added sequentially (3'- to 5'-direction) to the solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support (e.g., controlled pore glass or polystyrene) using various linkers. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are combined resulting in the coupling of the second nucleoside phosphoramidite onto the 5'-end of the first nucleoside. The support is then washed and any unreacted 5'-hydroxyl groups are capped with a capping reagent such as acetic anhydride to yield inactive 5'-acetyl moieties. The trivalent phosphorus linkage is then oxidized to a more stable phosphate linkage. At the end of the nucleotide addition cycle, the 5'-O-protecting group is cleaved under suitable conditions (e.g., acidic conditions for trityl-based groups and Fluoride for silyl-based groups). The cycle is repeated for each subsequent nucleotide.

[0403] Modification of synthesis conditions can be used to optimize coupling efficiency, for example by using differing coupling times, differing reagent/phosphoramidite concentrations, differing contact times, differing solid supports and solid support linker chemistries depending on the particular chemical composition of the siNA to be synthesized. Deprotection and purification of the siNA can be performed as is generally described in Deprotection and purification of the siNA can be performed as is generally described in Usman et al., U.S. Pat. No. 5,831,071, U.S. Pat. No. 6,353,098, U.S. Pat. No. 6,437,117, and Bellon et al., U.S. Pat. No. 6,054,576, U.S. Pat. No. 6,162,909, U.S. Pat. No. 6,303,773, or Scaringe supra, incorporated by reference herein in their entirety. Additionally, deprotection conditions can be modified to provide the best possible yield and purity of siNA constructs. For example, applicant has observed that oligonucleotides comprising 2'-deoxy-2'-fluoro nucleotides can degrade under inappropriate deprotection conditions. Such oligonucleotides are deprotected using aqueous methylamine at about 35° C. for 30 minutes. If the 2'-deoxy-2'-fluoro containing oligonucleotide also comprises ribonucleotides, after deprotection with aqueous methylamine at about 35° C. for 30 minutes, TEA-HF is added and the reaction maintained at about 65° C. for an additional 15 minutes.

Example 6

RNAi in Vitro Assay to Assess siNA Activity

[0404] An in vitro assay that recapitulates RNAi in a cell-free system is used to evaluate siNA constructs targeting BACE RNA targets. The assay comprises the system described by Tuschl et al., 1999, *Genes and Development*, 13, 3191-3197 and Zamore et al., 2000, *Cell*, 101, 25-33 adapted for use with BACE target RNA. A *Drosophila*

extract derived from syncytial blastoderm is used to reconstitute RNAi activity in vitro. Target RNA is generated via in vitro transcription from an appropriate BACE expressing plasmid using T7 RNA polymerase or via chemical synthesis as described herein. Sense and antisense siNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 minute at 90° C. followed by 1 hour at 37° C., then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and stained with ethidium bromide. The *Drosophila* lysate is prepared using zero to two-hour-old embryos from Oregon R flies collected on yeast molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer containing siNA (10 nM final concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 ug/ml creatine phosphokinase, 100 uM GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C. for 10 minutes before adding RNA, then incubated at 25° C. for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25xPassive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR analysis or other methods known in the art and are compared to control reactions in which siNA is omitted from the reaction.

[0405] Alternately, internally-labeled target RNA for the assay is prepared by in vitro transcription in the presence of [α - 32 P] CTP, passed over a G50 Sephadex column by spin chromatography and used as target RNA without further purification. Optionally, target RNA is 5'- 32 P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage products generated by RNAi are visualized on an autoradiograph of a gel. The percentage of cleavage is determined by PHOSPHOR IMAGER® (autoradiography) quantitation of bands representing intact control RNA or RNA from control reactions without siNA and the cleavage products generated by the assay.

[0406] In one embodiment, this assay is used to determine target sites in the BACE RNA target for siNA mediated RNAi cleavage, wherein a plurality of siNA constructs are screened for RNAi mediated cleavage of the BACE RNA target, for example, by analyzing the assay reaction by electrophoresis of labeled target RNA, or by northern blotting, as well as by other methodology well known in the art.

Example 7

Nucleic Acid Inhibition of BACE Target RNA

[0407] siNA molecules targeted to the human BACE RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity in vivo, for example, using the following procedure. The target sequences and the nucleotide location within the BACE RNA are given in Tables II and III.

[0408] Two formats are used to test the efficacy of siNAs targeting BACE. First, the reagents are tested in cell culture

using, for example, cultured A549 cells, 7PA2 cells, Chinese hamster ovary (CHO) cells, APPsw (Swedish type amyloid precursor protein expressing) cells, or SK-N-SH cells, to determine the extent of RNA and protein inhibition. siNA reagents (e.g.; see Tables II and III) are selected against the BACE target as described herein. RNA inhibition is measured after delivery of these reagents by a suitable transfection agent to, for example, A549 cells, 7PA2 cells, CHO cells, APPsw cells, or SK-N-SH cells. Relative amounts of target RNA are measured versus actin using real-time PCR monitoring of amplification (e.g., ABI 7700 TAQMAN®). A comparison is made to a mixture of oligonucleotide sequences made to unrelated targets or to a randomized siNA control with the same overall length and chemistry, but randomly substituted at each position. Primary and secondary lead reagents are chosen for the target and optimization performed. After an optimal transfection agent concentration is chosen, a RNA time-course of inhibition is performed with the lead siNA molecule. In addition, a cell-plating format can be used to determine RNA inhibition.

[0409] Delivery of siNA to Cells

[0410] Cells (e.g., A549 cells, 7PA2 cells, CHO cells, APPsw cells, or SK-N-SH cells) are seeded, for example, at 1×10^5 cells per well of a six-well dish in EGM-2 (BioWhittaker) the day before transfection. siNA (final concentration, for example 20 nM) and cationic lipid (e.g., final concentration 2 $\mu\text{g}/\text{ml}$) are complexed in EGM basal media (BioWhittaker) at 37° C. for 30 minutes in polystyrene tubes. Following vortexing, the complexed siNA is added to each well and incubated for the times indicated. For initial optimization experiments, cells are seeded, for example, at 1×10^5 in 96 well plates and siNA complex added as described. Efficiency of delivery of siNA to cells is determined using a fluorescent siNA complexed with lipid. Cells in 6-well dishes are incubated with siNA for 24 hours, rinsed with PBS and fixed in 2% paraformaldehyde for 15 minutes at room temperature. Uptake of siNA is visualized using a fluorescent microscope.

[0411] TAQMAN® (Real-Time PCR Monitoring of Amplification) and Lightcycler Quantification of mRNA

[0412] Total RNA is prepared from cells following siNA delivery, for example, using Qiagen RNA purification kits for 6-well or Rneasy extraction kits for 96-well assays. For TAQMAN® analysis (real-time PCR monitoring of amplification), dual-labeled probes are synthesized with the reporter dye, FAM or JOE, covalently linked at the 5'-end and the quencher dye TAMRA conjugated to the 3'-end. One-step RT-PCR amplifications are performed on, for example, an ABI PRISM 7700 Sequence Detector using 50 μl reactions consisting of 10 μl total RNA, 100 nM forward primer, 900 nM reverse primer, 100 nM probe, 1 \times TaqMan PCR reaction buffer (PE-Applied Biosystems), 5.5 mM MgCl_2 , 300 μM each dATP, dCTP, dGTP, and dTTP, 10U RNase Inhibitor (Promega), 1.25U AMPLITAQ GOLD® (DNA polymerase) (PE-Applied Biosystems) and 10U M-MLV Reverse Transcriptase (Promega). The thermal cycling conditions can consist of 30 minutes at 48° C., 10 minutes at 95° C., followed by 40 cycles of 15 seconds at 95° C. and 1 minute at 60° C. Quantitation of mRNA levels is determined relative to standards generated from serially diluted total cellular RNA (300, 100, 33, 11 ng/rxn) and normalizing to β -actin or GAPDH mRNA in parallel TAQ-

MAN® reactions (real-time PCR monitoring of amplification). For each gene of interest an upper and lower primer and a fluorescently labeled probe are designed. Real time incorporation of SYBR Green I dye into a specific PCR product can be measured in glass capillary tubes using a lightcycler. A standard curve is generated for each primer pair using control cRNA. Values are represented as relative expression to GAPDH in each sample.

[0413] Western Blotting

[0414] Nuclear extracts can be prepared using a standard micro preparation technique (see for example Andrews and Faller, 1991, *Nucleic Acids Research*, 19, 2499). Protein extracts from supernatants are prepared, for example using TCA precipitation. An equal volume of 20% TCA is added to the cell supernatant, incubated on ice for 1 hour and pelleted by centrifugation for 5 minutes. Pellets are washed in acetone, dried and resuspended in water. Cellular protein extracts are run on a 10% Bis-Tris NuPage (nuclear extracts) or 4-12% Tris-Glycine (supernatant extracts) polyacrylamide gel and transferred onto nitro-cellulose membranes. Non-specific binding can be blocked by incubation, for example, with 5% non-fat milk for 1 hour followed by primary antibody for 16 hour at 4° C. Following washes, the secondary antibody is applied, for example (1:10,000 dilution) for 1 hour at room temperature and the signal detected with SuperSignal reagent (Pierce).

Example 8

Models Useful to Evaluate the Down-Regulation of BACE Gene Expression

[0415] Cell Culture

[0416] Vassar et al., 1999, *Science*, 286, 735-741, describe a cell culture model for studying BACE inhibition. Specific antisense nucleic acid molecules targeting BACE mRNA were used for inhibition studies of endogenous BACE expression in 101 cells and APPsw (Swedish type amyloid precursor protein expressing) cells via lipid mediated transfection. Antisense treatment resulted in dramatic reduction of both BACE mRNA by Northern blot analysis, and APPs β sw ("Swedish" type β -secretase cleavage product) by ELISA, with maximum inhibition of both parameters at 75-80%. This model was also used to study the effect of BACE inhibition on amyloid β -peptide production in APPsw cells. Similarly, such a model can be used to screen siRNA molecules of the instant invention for efficacy and potency.

[0417] In several cell culture systems, cationic lipids have been shown to enhance the bioavailability of oligonucleotides to cells in culture (Bennet, et al., 1992, *Mol. Pharmacology*, 41, 1023-1033). In one embodiment, siNA molecules of the invention are complexed with cationic lipids for cell culture experiments. siNA and cationic lipid mixtures are prepared in serum-free DMEM immediately prior to addition to the cells. DMEM plus additives are warmed to room temperature (about 20-25° C.) and cationic lipid is added to the final desired concentration and the solution is vortexed briefly. siNA molecules are added to the final desired concentration and the solution is again vortexed briefly and incubated for 10 minutes at room temperature. In dose response experiments, the RNA/lipid complex is serially diluted into DMEM following the 10 minute incubation.

[0418] Animal Models

[0419] Evaluating the efficacy of anti-BACE agents in animal models is an important prerequisite to human clinical trials. Games et al., 1995, *Nature*, 373, 523-527, describe a transgenic mouse model in which mutant human familial type APP (Phe 717 instead of Val) is overexpressed. This model results in mice that progressively develop many of the pathological hallmarks of Alzheimer's disease, and as such, provides a model for testing therapeutic drugs, including siNA constructs of the instant invention.

Example 9**RNAi Mediated Inhibition of BACE, APP, PS1 or PS2 Expression in Cell Culture**

[0420] Inhibition of BACE, APP, PS1, or PS2 RNA Expression Using siNA Targeting BACE, APP, PS1, or PS2 RNA

[0421] siNA constructs (Table III) are tested for efficacy in reducing BACE, APP, PS1 or PS2 RNA Expression in A549 or SK-N-SH cells. Cells are plated approximately 24 hours before transfection in 96-well plates at 5,000-7,500 cells/well, 100 μ l/well, such that at the time of transfection cells are 70-90% confluent. For transfection, annealed siNAs are mixed with the transfection reagent (Lipofectamine 2000, Invitrogen) in a volume of 50 μ l/well and incubated for 20 minutes at room temperature. The siNA transfection mixtures are added to cells to give a final siNA concentration of 25 nM in a volume of 150 μ l. Each siNA transfection mixture is added to 3 wells for triplicate siNA treatments. Cells are incubated at 37° for 24 hours in the continued presence of the siNA transfection mixture. At 24 hours, RNA is prepared from each well of treated cells. The supernatants with the transfection mixtures are first removed and discarded, then the cells are lysed and RNA prepared from each well. Target gene expression following treatment is evaluated by RT-PCR for the target gene and for a control gene (36B4, an RNA polymerase subunit) for normalization. The triplicate data is averaged and the standard deviations determined for each treatment. Normalized data are graphed and the percent reduction of target mRNA by active siNAs in comparison to their respective inverted control siNAs is determined.

[0422] In a non-limiting example, using the method described above, siNA constructs were screened for activity (see FIG. 22) and compared to untreated cells, scrambled siNA control constructs (Scram1 and Scram2), and cells transfected with lipid alone (transfection control). As shown in FIG. 22, the siNA constructs show significant reduction of BACE RNA expression. Leads generated from such a screen are then further assayed. In a non-limiting example, siNA constructs comprising ribonucleotides and 3'-terminal dithymidine caps are assayed along with a chemically modified siNA construct comprising 2'-deoxy-2'-fluoro pyrimidine nucleotides and purine ribonucleotides, in which the sense strand of the siNA is further modified with 5' and 3'-terminal inverted deoxybasic caps and the antisense strand comprises a 3'-terminal phosphorothioate internucleotide linkage. Additional stabilization chemistries as described in Table IV are similarly assayed for activity. These siNA constructs are compared to appropriate matched chemistry inverted controls. In addition, the siNA constructs

are also compared to untreated cells, cells transfected with lipid and scrambled siNA constructs, and cells transfected with lipid alone (transfection control).

[0423] Using the method described above, a lead siNA construct (31007/31083) chosen from the screen described in FIG. 22 above was further modified using chemical modifications described in Table IV herein. Results are shown in FIG. 23. A549 cells were transfected with 0.25 μ g/well of lipid complexed with 25 nM siNA. Chemically modified constructs having Stab 4/5 chemistry (31378/31381) and Stab 7/11 chemistry (31384/31387) (solid bars; see Table IV) were tested for efficacy compared to matched chemistry inverted controls (open bars; sequences of the siNA constructs shown in Table III). The original lead siNA construct (31007/31083) and the Stab 4/5 and Stab 7/11 constructs were compared to untreated cells, scrambled siNA control constructs (Scram1 and Scram2), and cells transfected with lipid alone (transfection control). As shown in FIG. 23, the original lead construct and the Stab 4/5 and Stab 7/11 modified siNA constructs all show significant reduction of BACE RNA expression.

[0424] FIG. 24 shows a non-limiting example of the reduction of APP mRNA in SK-N-SH cells mediated by siNAs that target APP mRNA. SK-N-SH cells were transfected with 0.25 μ g/well of lipid complexed with 25 nM siNA. Active chemically modified siNA constructs (solid bars; see Tables III and IV) were compared to untreated cells, matched chemistry irrelevant siNA control constructs (IC-1), and cells transfected with lipid alone (transfection control). As shown in FIG. 24, the siNA constructs significantly reduce APP RNA expression compared with irrelevant siNA control and transfection control constructs.

[0425] FIG. 25 shows a non-limiting example of the reduction of PSEN1 mRNA in SK-N-SH cells mediated by siNAs that target PSEN1 mRNA. SK-N-SH cells were transfected with 0.25 μ g/well of lipid complexed with 25 nM siNA. Active chemically modified siNA constructs (solid bars; see Tables III and IV) were compared to untreated cells, matched chemistry irrelevant siNA control constructs (IC-1), and cells transfected with lipid alone (transfection control). As shown in FIG. 25, the siNA constructs significantly reduce PSEN1 RNA expression compared with irrelevant siNA control and transfection control constructs.

[0426] FIG. 26 shows a non-limiting example of the reduction of PSEN2 mRNA in SK-N-SH cells mediated by siNAs that target PSEN2 mRNA. SK-N-SH cells were transfected with 0.25 μ g/well of lipid complexed with 25 nM siNA. Active chemically modified siNA constructs (solid bars; see Tables III and IV) were compared to untreated cells, matched chemistry irrelevant siNA control constructs (IC-1), and cells transfected with lipid alone (transfection control). As shown in FIG. 26, the siNA constructs significantly reduce PSEN2 RNA expression compared with irrelevant siNA control and transfection control constructs.

Example 10**Indications**

[0427] Particular degenerative and disease states that can be associated with BACE, APP, PIN-1, PS-1 and/or PS-2 expression modulation include but are not limited to: Alzheimer's disease, dementia, stroke (CVA) and any other dis-

eases or conditions that are related to the levels of BACE, APP, PIN-1, PS-1 and/or PS-2 in a cell or tissue, alone or in combination with other therapies. The reduction of BACE, APP, PIN-1, PS-1 and/or PS-2 expression (specifically BACE, APP, PIN-1, PS-1 and/or PS-2 RNA levels) and thus reduction in the level of the respective protein relieves, to some extent, the symptoms of the disease or condition.

[0428] Those skilled in the art will recognize that other drug compounds and therapies may be readily combined with or used in conjunction with the nucleic acid molecules of the instant invention (e.g., siNA molecules) are hence within the scope of the instant invention.

Example 11

Diagnostic Uses

[0429] The siNA molecules of the invention can be used in a variety of diagnostic applications, such as in the identification of molecular targets (e.g., RNA) in a variety of applications, for example, in clinical, industrial, environmental, agricultural and/or research settings. Such diagnostic use of siNA molecules involves utilizing reconstituted RNAi systems, for example, using cellular lysates or partially purified cellular lysates. siNA molecules of this invention can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of endogenous or exogenous, for example viral, RNA in a cell. The close relationship between siNA activity and the structure of the target RNA allows the detection of mutations in any region of the molecule, which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple siNA molecules described in this invention, one can map nucleotide changes, which are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with siNA molecules can be used to inhibit gene expression and define the role of specified gene products in the progression of disease or infection. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes, siNA molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations siNA molecules and/or other chemical or biological molecules). Other in vitro uses of siNA molecules of this invention are well known in the art, and include detection of the presence of mRNAs associated with a disease, infection, or related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a siNA using standard methodologies, for example, fluorescence resonance emission transfer (FRET).

[0430] In a specific example, siNA molecules that cleave only wild-type or mutant forms of the target RNA are used for the assay. The first siNA molecules (i.e., those that cleave only wild-type forms of target RNA) are used to identify wild-type RNA present in the sample and the second siNA molecules (i.e., those that cleave only mutant forms of target RNA) are used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA are cleaved by both siNA molecules to demonstrate the relative siNA efficiencies in the reactions and the absence of cleavage of the "non-targeted" RNA species. The

cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus, each analysis requires two siNA molecules, two substrates and one unknown sample, which is combined into six reactions. The presence of cleavage products is determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., disease related or infection related) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels is adequate and decreases the cost of the initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

[0431] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

[0432] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

[0433] It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The present invention teaches one skilled in the art to test various combinations and/or substitutions of chemical modifications described herein toward generating nucleic acid constructs with improved activity for mediating RNAi activity. Such improved activity can comprise improved stability, improved bioavailability, and/or improved activation of cellular responses mediating RNAi. Therefore, the specific embodiments described herein are not limiting and one skilled in the art can readily appreciate that specific combinations of the modifications described herein can be tested without undue experimentation toward identifying siNA molecules with improved RNAi activity.

[0434] The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of", and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such

terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

[0435] In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

TABLE I

Accession Numbers
NM_012104 <i>Homo sapiens</i> beta-site APP-cleaving enzyme (BACE), transcript variant a, mRNA gi 21040369 ref NM_012104.2 21040369 NM_006222 <i>Homo sapiens</i> protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1-like (PIN1L), mRNA gi 5453899 ref NM_006222.1 5453899 L76517 <i>Homo sapiens</i> (clone cc44) senilin 1 (PS1; S182) mRNA, complete cds gi 1479973 gb L76517.1 HUMPS1.MRNA[1479973] L43964 <i>Homo sapiens</i> (clone F-T03796) STM-2 mRNA, complete cds gi 951202 gb L43964.1 HUMSTM2R[951202] NM_138973 <i>Homo sapiens</i> beta-site APP-cleaving enzyme (BACE), transcript variant d, mRNA gi 21040367 ref NM_138973.1 21040367 NM_138972 <i>Homo sapiens</i> beta-site APP-cleaving enzyme (BACE), transcript variant b, mRNA gi 21040365 ref NM_138972.1 21040365 NM_138971 <i>Homo sapiens</i> beta-site APP-cleaving enzyme (BACE), transcript variant c, mRNA gi 21040363 ref NM_138971.1 21040363 <i>Homo sapiens</i> cDNA FLJ90568 fis, clone OVARC1001570, highly similar to <i>Homo sapiens</i> beta-site APP cleaving enzyme (BACE) mRNA gi 22760888 dbj AK075049.1 22760888 AF527782 <i>Homo sapiens</i> beta-site APP-cleaving enzyme (BACE) mRNA, partial cds, alternatively spliced gi 22094870 gb AF527782.1 22094870 AF324837 <i>Homo sapiens</i> beta-site APP cleaving enzyme mRNA, partial cds, alternatively spliced gi 21449275 gb AF324837.1 21449275 AF338817 <i>Homo sapiens</i> beta-site APP cleaving enzyme type C mRNA, complete cds gi 13699247 gb AF338817.1 13699247 AF338816 <i>Homo sapiens</i> beta-site APP cleaving enzyme type B mRNA, complete cds gi 13699245 gb AF338816.1 13699245 AB050438 <i>Homo sapiens</i> BACE mRNA for beta-site APP cleaving enzyme 1-432, complete cds

TABLE I-continued

Accession Numbers
gi 13568410 dbj AB050438.1 13568410 AB050437 <i>Homo sapiens</i> BACE mRNA for beta-site APP cleaving enzyme 1-457, complete cds gi 13568408 dbj AB050437.1 13568408 AB050436 <i>Homo sapiens</i> BACE mRNA for beta-site APP cleaving enzyme 1-476, complete cds gi 13568406 dbj AB050436.1 13568406 AF190725 <i>Homo sapiens</i> beta-site APP cleaving enzyme (BACE) mRNA, complete cds gi 6118538 gb AF190725.1 AF190725[6118538] NM_007319 <i>Homo sapiens</i> presenilin 1 (Alzheimer disease 3) (PSEN1), transcript variant 1-374., mRNA gi 7549814 ref NM_007319.1 7549814 NM_138992 <i>Homo sapiens</i> beta-site APP-cleaving enzyme 2 (BACE2), transcript variant b, mRNA gi 21040361 ref NM_138992.1 21040361 NM_138991 <i>Homo sapiens</i> beta-site APP-cleaving enzyme 2 (BACE2), transcript variant c, mRNA gi 21040359 ref NM_138991.1 21040359 NM_012105 <i>Homo sapiens</i> beta-site APP-cleaving enzyme 2 (BACE2), transcript variant a, mRNA gi 21040358 ref NM_012105.3 21040358 AB066441 <i>Homo sapiens</i> APP mRNA for amyloid precursor protein, partial cds, D678N mutant gi 16904654 dbj AB066441.1 16904654 AB050438 <i>Homo sapiens</i> BACE mRNA for beta-site APP cleaving enzyme 1-432, complete cds gi 13568410 dbj AB050438.1 13568410 AB050437 <i>Homo sapiens</i> BACE mRNA for beta-site APP cleaving enzyme 1-457, complete cds gi 13568408 dbj AB050437.1 13568408 AB050436 <i>Homo sapiens</i> BACE mRNA for beta-site APP cleaving enzyme 1-476, complete cds gi 13568406 dbj AB050436.1 13568406 NM_012486 <i>Homo sapiens</i> presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mRNA gi 7108359 ref NM_012486.1 7108359 NM_000447 <i>Homo sapiens</i> presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1, mRNA gi 4506164 ref NM_000447.1 4506164 AF188277 <i>Homo sapiens</i> aspartyl protease (BACE2) mRNA, complete cds, alternatively spliced gi 7025334 gb AF188277.1 AF188277[7025334] AF188276 <i>Homo sapiens</i> aspartyl protease (BACE2) mRNA, complete cds, alternatively spliced gi 7025332 gb AF188276.1 AF188276[7025332] AF178532 <i>Homo sapiens</i> aspartyl protease (BACE2) mRNA, complete cds gi 6851265 gb AF178532.1 AF178532[6851265] D87675 <i>Homo sapiens</i> DNA for amyloid precursor protein, complete cds gi 2429080 dbj D87675.1 2429080 AF201468 <i>Homo sapiens</i> APP beta-secretase mRNA, complete cds gi 6601444 gb AF201468.1 AF201468[6601444]

TABLE I-continued

Accession Numbers
AF190725 <i>Homo sapiens</i> beta-site APP cleaving enzyme (BACE) mRNA, complete cds gi 6118538 gb AF190725.1 AF190725[6118538] E14707 DNA encoding a mutated amyloid precursor protein gi 5709390 dbj E14707.11 pat JP1998001499 1[5709390] AF168956 <i>Homo sapiens</i> amyloid precursor protein homolog HSD-2 mRNA, complete cds gi 5702387 gb AF168956.1 AF168956[5702387] S60099 APPH - amyloid precursor protein homolog [human, placenta, mRNA, 3727 nt] gi 300168 bbm 300685 bbs 131198 gb S60099.1 S60099[300168] U50939 Human amyloid precursor protein-binding protein 1 mRNA, complete cds gi 1314559 gb U50939.1 HSU50939[1314559] NM_000484 <i>Homo sapiens</i> amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) (APP), transcript variant 1, mRNA gi 41406053 ref NM_000484.2 [41406053] BC018937 <i>Homo sapiens</i> amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease), mRNA (cDNA clone IMAGE: 4126584) gi 39645179 gb BC018937.2 [39645179]

TABLE I-continued

Accession Numbers
NM_201413 <i>Homo sapiens</i> amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) (APP), transcript variant 2, mRNA gi 41406054 ref NM_201413.1 [41406054] NM_201414 <i>Homo sapiens</i> amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) (APP), transcript variant 3, mRNA gi 41406056 ref NM_201414.1 [41406056] BC065529 <i>Homo sapiens</i> amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease), transcript variant 2, mRNA (cDNA clone MGC: 75167 IMAGE: 6152423), complete cds gi 41350938 gb BC065529.1 [41350938] Y00264 Human mRNA for amyloid A4 precursor of Alzheimer's disease gi 28525 emb Y00264.1 HSAFPA4[28525] AF282245 <i>Homo sapiens</i> amyloid precursor protein 639 (APP639) mRNA, complete cds gi 33339673 gb AF282245.1 [33339673] X06989 <i>Homo sapiens</i> mRNA for amyloid A4 protein (APP gene) gi 28720 emb X06989.1 HSAFPA4R[28720]

[0436]

TABLE II

APP, BACE, PSEN1, PSEN2 s1na AND TARGET SEQUENCES								
APP NM_000484								
Pos	Seq	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID
3	UUUCCUCGGCAGCGGUAGG	1	3	UUUCCUCGGCAGCGGUAGG	1	21	CCUACCGCUGCCGAGGAAA	200
21	GCGAGAGCACGCGGAGGAG	2	21	GCGAGAGCACGCGGAGGAG	2	39	CUCCUCCGCGUGCUCUCGC	201
39	GCGUGCGCGGGGGCCCCGG	3	39	GCGUGCGCGGGGGCCCCGG	3	57	CCGGGGCCCCCGCGCACGC	202
57	GGAGACGGCGGCGGUGGCG	4	57	GGAGACGGCGGCGGUGGCG	4	75	CGCCACCGCCGCCGUCUCC	203
75	GGCGCGGGCAGAGCAAGGA	5	75	GGCGCGGGCAGAGCAAGGA	5	93	UCCUUGCUCUGCCCGCGCC	204
93	ACGCGGCGGAUCCACUCG	6	93	ACGCGGCGGAUCCACUCG	6	111	CGAGUGGGAUCCGCGCGU	205
111	GCACAGCAGCGCACUCGGU	7	111	GCACAGCAGCGCACUCGGU	7	129	ACCGAGUGCGCUGCUGUC	206
129	UGCCCCGCGCAGGGUCGCG	8	129	UGCCCCGCGCAGGGUCGCG	8	147	CGCGACCCUGCGCGGGGCA	207
147	GAUGCUGCCCGGUUUGGCA	9	147	GAUGCUGCCCGGUUUGGCA	9	165	UGCCAAACCGGGCAGCAUC	208
165	ACUGCUCUUGCUGGCCGCC	10	165	ACUGCUCUUGCUGGCCGCC	10	183	GGCGGCCAGCAGGAGCAGU	209
183	CUGGACGGCUCGGCGCUG	11	183	CUGGACGGCUCGGCGCUG	11	201	CAGCGCCCGAGCCGUCCAG	210
201	GGAGGUACCCACUGAUGGU	12	201	GGAGGUACCCACUGAUGGU	12	219	ACCAUCAGUGGGUACCUCC	211
219	UAAUGCUGGCCUGCUGGCU	13	219	UAAUGCUGGCCUGCUGGCU	13	237	AGCCAGCAGGCCAGCAUUA	212
237	UGAACCCAGAUUGCCAUG	14	237	UGAACCCAGAUUGCCAUG	14	255	CAUGGCAUUGGGGUUCA	213
255	GUUCUGUGGCAGACUGAAC	15	255	GUUCUGUGGCAGACUGAAC	15	273	GUUCAGUCUGCCACAGAAC	214

TABLE II-continued

APP, BACE, PSEN1, PSEN2 sRNA AND TARGET SEQUENCES											
273	CAUGCACAUGAAUGUCCAG	16	273	CAUGCACAUGAAUGUCCAG	16	291	CUGGACAUAUCAUGUGCAUG	215			
291	GAAUGGGAAGUGGGAUUA	17	291	GAAUGGGAAGUGGGAUUA	17	309	UGAAUCCACUCCCCAUUC	216			
309	AGAUCCAUCAGGGACCAAA	18	309	AGAUCCAUCAGGGACCAAA	18	327	UUUGGUCCCUGAUGGAUCU	217			
327	AACCUCAUUGAUACCAAG	19	327	AACCUCAUUGAUACCAAG	19	345	CUUGGUUAUCAAUGCAGGUU	218			
345	GGAAGGCAUCCUGCAGUAU	20	345	GGAAGGCAUCCUGCAGUAU	20	363	AUACUGCAGGAUGCCUUC	219			
363	UUGCCAAGAAGUCUACCCU	21	363	UUGCCAAGAAGUCUACCCU	21	381	AGGGUAGACUUCUUGGCAA	220			
381	UGAACUGCAGAUACCAAU	22	381	UGAACUGCAGAUACCAAU	22	399	AUUGGUGAUCUGCAGUUA	221			
399	UGUGGUAGAAGCCAACCAA	23	399	UGUGGUAGAAGCCAACCAA	23	417	UUGGUUGGCUUCUACCACA	222			
417	ACCAGUGACCAUCCAGAAC	24	417	ACCAGUGACCAUCCAGAAC	24	435	GUUCUGGAGUGGUCACUGGU	223			
435	CUGGUGCAAGCGGGCCGC	25	435	CUGGUGCAAGCGGGCCGC	25	453	GCGGCCCCGCUUGCACCAG	224			
453	CAAGCAGUGCAAGACCAU	26	453	CAAGCAGUGCAAGACCAU	26	471	AUGGGUCUUGCACUGCUUG	225			
471	UCCCCACUUUGUGAUUCCC	27	471	UCCCCACUUUGUGAUUCCC	27	489	GGGAAUCACAAAGUGGGGA	226			
489	CUACCGCUGCUUAGUUGGU	28	489	CUACCGCUGCUUAGUUGGU	28	507	ACCAACUAAGCAGCGGUAG	227			
507	UGAGUUUGUAAGUGAUGCC	29	507	UGAGUUUGUAAGUGAUGCC	29	525	GGCAUCACUUACAAACUCA	228			
525	CCUUCUCGUUCCUGACAAG	30	525	CCUUCUCGUUCCUGACAAG	30	543	CUUGUCAGGAACGAGAAGG	229			
543	GUGCAAAUUCUUACACCAG	31	543	GUGCAAAUUCUUACACCAG	31	561	CUGGUGUAAGAAUUUGCAC	230			
561	GGAGAGGAUGGAUGUUUGC	32	561	GGAGAGGAUGGAUGUUUGC	32	579	GCAAACAUCCAUCUCCUCC	231			
579	CGAAACUCAUCUACACUGG	33	579	CGAAACUCAUCUACACUGG	33	597	CCAGUGAAGAUGAGUUUCG	232			
597	GCACACCGUCGCCAAAGAG	34	597	GCACACCGUCGCCAAAGAG	34	615	CUCUUUGGCGACGGUGUC	233			
615	GACAUGCAGUGAGAAGAGU	35	615	GACAUGCAGUGAGAAGAGU	35	633	ACUCUUCUCACUGCAUGUC	234			
633	UACCAACUUGCAUGACUAC	36	633	UACCAACUUGCAUGACUAC	36	651	GUAGUCAUGCAAGUUUGUA	235			
651	CGGCAUGUUGCUGCCCUGC	37	651	CGGCAUGUUGCUGCCCUGC	37	669	GCAGGGCAGCAACAUCCCG	236			
669	CGGAAUUGACAAGUCCGA	38	669	CGGAAUUGACAAGUCCGA	38	687	UCGGAACUUGUCAAUUCCG	237			
687	AGGGGUAGAGUUUGUGUGU	39	687	AGGGGUAGAGUUUGUGUGU	39	705	ACACACAAACUCUACCCCU	238			
705	UUGCCCACUGGCUGAAGAA	40	705	UUGCCCACUGGCUGAAGAA	40	723	UUCUUCAGCCAGUGGGCAA	239			
723	AAGUGACAAUGUGGAUUCU	41	723	AAGUGACAAUGUGGAUUCU	41	741	AGAAUCCACAUUGUCACUU	240			
741	UGCUGAUGCGGAGGAGGAU	42	741	UGCUGAUGCGGAGGAGGAU	42	759	AUCCUCCUCCGCAUCAGCA	241			
759	UGACUCGGAUGUCUGGUGG	43	759	UGACUCGGAUGUCUGGUGG	43	777	CCACCAGACAUCGAGUCA	242			
777	GGCGGAGCAGACACAGAC	44	777	GGCGGAGCAGACACAGAC	44	795	GUCUGUGUCUGUCCGCC	243			
795	CUAUGCAGAUGGAGUGAA	45	795	CUAUGCAGAUGGAGUGAA	45	813	UUCACUCCCAUCUGCAUAG	244			
813	AGACAAAGUAGUAGAAGUA	46	813	AGACAAAGUAGUAGAAGUA	46	831	UACUUCUACUACUUUGUCU	245			
831	AGCAGAGGAGGAAGAAGUG	47	831	AGCAGAGGAGGAAGAAGUG	47	849	CACUUCUUCUCCUCUGUCU	246			
849	GGCUGAGGUGGAAGAAGAA	48	849	GGCUGAGGUGGAAGAAGAA	48	867	UUCUUCUUCACCUCAGCC	247			
867	AGAAGCCGAUGAUGACGAG	49	867	AGAAGCCGAUGAUGACGAG	49	885	CUCGUCAUCAUCGGCUUCU	248			
885	GGACGAUGAGGAUGGUGAU	50	885	GGACGAUGAGGAUGGUGAU	50	903	AUCACCAUCCUCAUCGUCC	249			
903	UGAGGUAGAGGAAGAGGCU	51	903	UGAGGUAGAGGAAGAGGCU	51	921	AGCCUCUUCUCCUACCUCA	250			
921	UGAGGAACCCUACGAAGAA	52	921	UGAGGAACCCUACGAAGAA	52	939	UUCUUCGUAGGGUUCUCA	251			

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES									
939	AGCCACAGAGAGAACCACC	53	939	AGCCACAGAGAGAACCACC	53	957	GGUGGUUCUCUCUGUGGCU	252	
957	CAGCAUUGCCACCACCACC	54	957	CAGCAUUGCCACCACCACC	54	975	GGUGGUGGUGGCAUUGCUG	253	
975	CACCACCACCACAGAGUCU	55	975	CACCACCACCACAGAGUCU	55	993	AGACUCUGUGUGUGUGUG	254	
993	UGUGGAAGAGGUGGUUCGA	56	993	UGUGGAAGAGGUGGUUCGA	56	1011	UCGAACCACCUCUCCACA	255	
1011	AGAGGUGUGCUCUGAACAA	57	1011	AGAGGUGUGCUCUGAACAA	57	1029	UUGUUCAGAGCACACCUCU	256	
1029	AGCCGAGACGGGCCGUGC	58	1029	AGCCGAGACGGGCCGUGC	58	1047	GCACGGCCCCGUCUGGCU	257	
1047	CCGAGCAAUGAUCUCCCGC	59	1047	CCGAGCAAUGAUCUCCCGC	59	1065	GCGGAGAUCAUUGCUCGG	258	
1065	CUGGUACUUUGAUGUGACU	60	1065	CUGGUACUUUGAUGUGACU	60	1083	AGUCACAUCAAAGUACCAG	259	
1083	UGAAGGGAAGUGUGCCCCA	61	1083	UGAAGGGAAGUGUGCCCCA	61	1101	UGGGGCACACUUCCCUUCA	260	
1101	AUUCUUUACGGCGGAUGU	62	1101	AUUCUUUACGGCGGAUGU	62	1119	ACAUCGCGGUAAGAAAU	261	
1119	UGGCGGCAACCGGAACAAC	63	1119	UGGCGGCAACCGGAACAAC	63	1137	GUUGUCCGGUUGCCGCCA	262	
1137	CUUUGACACAGAAGAGUAC	64	1137	CUUUGACACAGAAGAGUAC	64	1155	GUACUCUUCUGUGCAAAG	263	
1155	CUGCAUGGCCUGUGUGGC	65	1155	CUGCAUGGCCUGUGUGGC	65	1173	GCCACACACGGCCAUGCAG	264	
1173	CAGCGCCAUGUCCCAAAGU	66	1173	CAGCGCCAUGUCCCAAAGU	66	1191	ACUUUGGGACAUUGGCGUG	265	
1191	UUUACUCAAGACUACCCAG	67	1191	UUUACUCAAGACUACCCAG	67	1209	CUGGGUAGUCUUGAGUAAA	266	
1209	GGAACCUCUUGCCCGAGAU	68	1209	GGAACCUCUUGCCCGAGAU	68	1227	AUCUCGGGCAAGAGGUUCC	267	
1227	UCCUGUUAAACUCCUACA	69	1227	UCCUGUUAAACUCCUACA	69	1245	UGUAGGAAGUUUACAGGA	268	
1245	AACAGCAGCCAGUACCCCU	70	1245	AACAGCAGCCAGUACCCCU	70	1263	AGGGGUACUGGUGUGUUU	269	
1263	UGAUGCCGUUGACAAGUAU	71	1263	UGAUGCCGUUGACAAGUAU	71	1281	AUACUUGUCAACGGCAUCA	270	
1281	UCUCGAGACACCGGGGAU	72	1281	UCUCGAGACACCGGGGAU	72	1299	AUCCCCAGGUGUCUGAGA	271	
1299	UGAGAAUGAACUGCCCAU	73	1299	UGAGAAUGAACUGCCCAU	73	1317	AUGGGCAUGUUCUUCUCA	272	
1317	UUUCCAGAAAGCCAAAGAG	74	1317	UUUCCAGAAAGCCAAAGAG	74	1335	CUCUUUGGCUUUCUGGAAA	273	
1335	GAGGCUUGAGGCCAAGCAC	75	1335	GAGGCUUGAGGCCAAGCAC	75	1353	GUGCUUGGCCUCAAGCCUC	274	
1353	CCGAGAGAGAAUGUCCAG	76	1353	CCGAGAGAGAAUGUCCAG	76	1371	CUGGGACAUUCUCUCUGG	275	
1371	GGUCAUGAGAGAAUGGGAA	77	1371	GGUCAUGAGAGAAUGGGAA	77	1389	UUCCAUUCUCUCAUGACC	276	
1389	AGAGGCAGAACGUAAGCA	78	1389	AGAGGCAGAACGUAAGCA	78	1407	UGCUGACGUUCUGCCUCU	277	
1407	AAAGAACUUGCCUAAAGCU	79	1407	AAAGAACUUGCCUAAAGCU	79	1425	AGCUUUAGGCAAGUUCUUU	278	
1425	UGAUAGAAGGCAGUUAUC	80	1425	UGAUAGAAGGCAGUUAUC	80	1443	GAUAACUGCCUUCUUAUCA	279	
1443	CCAGCAUUUCCAGAGAAA	81	1443	CCAGCAUUUCCAGAGAAA	81	1461	UUUCUCCUGGAAUUGCUGG	280	
1461	AGUGGAAUCUUUGGAACAG	82	1461	AGUGGAAUCUUUGGAACAG	82	1479	CUGUCCCAAAGAUUCCACU	281	
1479	GGAAGCAGCCAACGAGAGA	83	1479	GGAAGCAGCCAACGAGAGA	83	1497	UCUCUGGUUGGUGCUUCC	282	
1497	ACAGCAGCUGGUGGAGACA	84	1497	ACAGCAGCUGGUGGAGACA	84	1515	UGUCUCCACCAGCUGCUGU	283	
1515	ACACAUGGCCAGAGUGGAA	85	1515	ACACAUGGCCAGAGUGGAA	85	1533	UUCCACUCUGGCCAUGUGU	284	
1533	AGCCAUGCUCUAAUGACCGC	86	1533	AGCCAUGCUCUAAUGACCGC	86	1551	GCGGUCAUUGAGCAUGGCU	285	
1551	CCGCCGCCUGGCCUUGGAG	87	1551	CCGCCGCCUGGCCUUGGAG	87	1569	CUCCAGGGCCAGCGGCGG	286	
1569	GAACUACAUCACCGCUCUG	88	1569	GAACUACAUCACCGCUCUG	88	1587	CAGAGCGGUGAUGUAGUUC	287	
1587	GCAGGCUUUCUCCUCGG	89	1587	GCAGGCUUUCUCCUCGG	89	1605	CCGAGGAGGAACAGCCUGC	288	

TABLE II-continued

APP, BACE, PSEN1, PSEN2 s1NA AND TARGET SEQUENCES					
1605 GCCUCGUCACGUGUCAAU	90	1605 GCCUCGUCACGUGUCAAU	90	1623 AUUGAACACGUGACGAGGC	289
1623 UAUGC UAAAGAAGUAUGUC	91	1623 UAUGC UAAAGAAGUAUGUC	91	1641 GACAUAUCUUCUUAGCAUA	290
1641 CCGCGCAGAACAGAGGAC	92	1641 CCGCGCAGAACAGAGGAC	92	1659 GUCCUUCUGUUCUGCGCG	291
1659 CAGACAGCACACCCUAAAG	93	1659 CAGACAGCACACCCUAAAG	93	1677 CUUUAGGGUGUGUGUCUG	292
1677 GCAUUUCGAGCAUGUGCGC	94	1677 GCAUUUCGAGCAUGUGCGC	94	1695 GCGCACAUUCUGAAUAGC	293
1695 CAUGGUGGAUCCCAAGAAA	95	1695 CAUGGUGGAUCCCAAGAAA	95	1713 UUUCUUGGGAUCCACCAUG	294
1713 AGCCGCU CAGAUCCG GUCC	96	1713 AGCCGCU CAGAUCCG GUCC	96	1731 GGACCGGAUCUGAGCGGCU	295
1731 CCAGGUUAUGACACACCUC	97	1731 CCAGGUUAUGACACACCUC	97	1749 GAGGUGUGUCAUAACCVGG	296
1749 CCGUGUGAUUUUAUGAGCGC	98	1749 CCGUGUGAUUUUAUGAGCGC	98	1767 GCGCUCAUAAAUACACAGG	297
1767 CAUGAAUCAGUCUCUCUCC	99	1767 CAUGAAUCAGUCUCUCUCC	99	1785 GGAGAGAGACUGAUUCAUG	298
1785 CCUGCUCUACAACGUGCCU	100	1785 CCUGCUCUACAACGUGCCU	100	1803 AGGCACGUUGUAGAGCAGG	299
1803 UGCAGUGGCCGAGGAGAUU	101	1803 UGCAGUGGCCGAGGAGAUU	101	1821 AAUCCUCUGGCCACUGCA	300
1821 UCAGGAUGAAGUUGAUGAG	102	1821 UCAGGAUGAAGUUGAUGAG	102	1839 CUCAUCAACUUAUCCUGA	301
1839 GCUGCUUCAGAAAGAGCAA	103	1839 GCUGCUUCAGAAAGAGCAA	103	1857 UUGCUCUUUCUGAAGCAGC	302
1857 AAACUAUUCAGAUACGUC	104	1857 AAACUAUUCAGAUACGUC	104	1875 GACGUCAUCUGAAUAGUUU	303
1875 CUUGGCCAACAUUAUAGU	105	1875 CUUGGCCAACAUUAUAGU	105	1893 ACUAAUCAUGUUGGCCAAG	304
1893 UGAACCAAGGAUCAGUUAAC	106	1893 UGAACCAAGGAUCAGUUAAC	106	1911 GUAACUGAUCCUUGGUUCA	305
1911 CGGAAACGAUGCUCUCAUG	107	1911 CGGAAACGAUGCUCUCAUG	107	1929 CAUGAGAGCAUCGUUUCCG	306
1929 GCCAUCUUUGACCGAAACG	108	1929 GCCAUCUUUGACCGAAACG	108	1947 CGUUUCGGUCAAAAGAUUGC	307
1947 GAAAACCACCGUGGAGCUC	109	1947 GAAAACCACCGUGGAGCUC	109	1965 GAGCUCCACGGUGGUUUUC	308
1965 CCUUCGCCUGAAUGGAGAG	110	1965 CCUUCGCCUGAAUGGAGAG	110	1983 CUCUCCAUCACGGGAAGG	309
1983 GUUCAGCCUGGACGAUCUC	111	1983 GUUCAGCCUGGACGAUCUC	111	2001 GAGAUCGUCCAGGCUGAAC	310
2001 CCAGCCGUGGCAUUCUUUU	112	2001 CCAGCCGUGGCAUUCUUUU	112	2019 AAAAGAAUGCCACGGCUGG	311
2019 UGGGGCUGACUCUGUGCCA	113	2019 UGGGGCUGACUCUGUGCCA	113	2037 UGGCACAGAGUCAGCCCCA	312
2037 AGCCAACACAGAAAACGAA	114	2037 AGCCAACACAGAAAACGAA	114	2055 UUCGUUUUCUGUGUUGGCU	313
2055 AGUUGAGCCUGUUGAUGCC	115	2055 AGUUGAGCCUGUUGAUGCC	115	2073 GGCAUCAACAGGCUCAACU	314
2073 CCGCCCGUCUGCCGACCGA	116	2073 CCGCCCGUCUGCCGACCGA	116	2091 UCGGUCGGCAGCAGGGCGG	315
2091 AGGACUGACCACUCGACCA	117	2091 AGGACUGACCACUCGACCA	117	2109 UGGUCGAGUGGUCAGUCCU	316
2109 AGGUUCUGGGUUGACAAAU	118	2109 AGGUUCUGGGUUGACAAAU	118	2127 AUUUGUCAACCCAGAACCU	317
2127 UAUCAAGACGGAGGAGAUC	119	2127 UAUCAAGACGGAGGAGAUC	119	2145 GAUCCUCCGUCUUGAUA	318
2145 CUCUGAAGUGAAGAUGGAU	120	2145 CUCUGAAGUGAAGAUGGAU	120	2163 AUCCAUCUUCACUUCAGAG	319
2163 UGCAGAAUUCGACAUAGAC	121	2163 UGCAGAAUUCGACAUAGAC	121	2181 GUCAUGUCGGAAUUCUGCA	320
2181 CUCAGGAUAUGAAGUUAU	122	2181 CUCAGGAUAUGAAGUUAU	122	2199 AUGAACUUCAUAUCCUGAG	321
2199 UCAUCAAAAAUUGGUGUUC	123	2199 UCAUCAAAAAUUGGUGUUC	123	2217 GAACACCAAUUUUUGAUGA	322
2217 CUUUGCAGAAGAUUGGGU	124	2217 CUUUGCAGAAGAUUGGGU	124	2235 ACCCACAUUCUUGCAAAG	323
2235 UUCAACAAAGGUGCAAUC	125	2235 UUCAACAAAGGUGCAAUC	125	2253 GAUUGCACCUUUGUUUGAA	324
2253 CAUUGGACUCAUGGUGGGC	126	2253 CAUUGGACUCAUGGUGGGC	126	2271 GCCCACCAUGAGUCCAAUG	325

TABLE II-continued

APP, BACE, PSEN1, PSEN2 sRNA AND TARGET SEQUENCES					
2271 CGGUGUUGUCAUAGCGACA	127	2271 CGGUGUUGUCAUAGCGACA	127	2289 UGUCGCUAUGACAACACCG	326
2289 AGUGAUCGUCAUACCCUUG	128	2289 AGUGAUCGUCAUACCCUUG	128	2307 CAAGGUGAUGACGAUCACU	327
2307 GGUGAUGCUGAAGAAGAAA	129	2307 GGUGAUGCUGAAGAAGAAA	129	2325 UUUCUUCUUCAGCAUACCC	328
2325 ACAGUACACAUCCAUAU	130	2325 ACAGUACACAUCCAUAU	130	2343 AUGAUGGAUGUGUACUGU	329
2343 UCAUGGUGUGGAGAGGUU	131	2343 UCAUGGUGUGGAGAGGUU	131	2361 AACCUCCACCACCAUGA	330
2361 UGACGCCGUGUCACCCCA	132	2361 UGACGCCGUGUCACCCCA	132	2379 UGGGUGACACGGCGUCA	331
2379 AGAGGAGCGCCACCUGUCC	133	2379 AGAGGAGCGCCACCUGUCC	133	2397 GGACAGGUGGCGUCCUCU	332
2397 CAAGAUGCAGCAGAACGGC	134	2397 CAAGAUGCAGCAGAACGGC	134	2415 GCCGUUCUGCUGCAUCUUG	333
2415 CUACGAAAAUCCAACCUAC	135	2415 CUACGAAAAUCCAACCUAC	135	2433 GUAGGUUGGAUUUUCGUAG	334
2433 CAAGUUCUUUGAGCAGAUG	136	2433 CAAGUUCUUUGAGCAGAUG	136	2451 CAUCUGCUCAAAGAACUUG	335
2451 GCAGAACUAGACCCCGCC	137	2451 GCAGAACUAGACCCCGCC	137	2469 GCGGGGGUCUAGUUCUGC	336
2469 CACAGCAGCCUCUGAAGUU	138	2469 CACAGCAGCCUCUGAAGUU	138	2487 AACUUCAGAGGCUGCUGUG	337
2487 UGGACAGCAAAACCAUUGC	139	2487 UGGACAGCAAAACCAUUGC	139	2505 GCAAUGGUUUUGCUGUCCA	338
2505 CUUCACUACCCAUCCGUGU	140	2505 CUUCACUACCCAUCCGUGU	140	2523 ACACCGAUGGGUAGUGAAG	339
2523 UCCAUUUAUAGAAUAAUGU	141	2523 UCCAUUUAUAGAAUAAUGU	141	2541 ACAUUUAUUCUAAAUGGA	340
2541 UGGGAAGAAACAAACCCGU	142	2541 UGGGAAGAAACAAACCCGU	142	2559 ACGGGUUUGUUUCUCCCA	341
2559 UUUUAUGAUUUACUCAUUA	143	2559 UUUUAUGAUUUACUCAUUA	143	2577 UAAUGAGUAAAUCAUAAAA	342
2577 AUCGCCUUUUGACAGCUGU	144	2577 AUCGCCUUUUGACAGCUGU	144	2595 ACAGCUGUCAAAAGGCGAU	343
2595 UGCUGUAACACAAGUAGAU	145	2595 UGCUGUAACACAAGUAGAU	145	2613 AUCUACUUGUGUACAGCA	344
2613 UGCCUGAACUUGAAUUAU	146	2613 UGCCUGAACUUGAAUUAU	146	2631 AUUAAUUCAGUUCAGGCA	345
2631 UCCACACAUCAGUAAUGUA	147	2631 UCCACACAUCAGUAAUGUA	147	2649 UACAUUACUGAUGUGUGGA	346
2649 AUUCUACUCUCUUUACAU	148	2649 AUUCUACUCUCUUUACAU	148	2667 AUGUAAAGAGAGAUAGAAU	347
2667 UUUUGGUCUCUUAUACACA	149	2667 UUUUGGUCUCUUAUACACA	149	2685 UGUAGUAUAGAGACCAAAA	348
2685 AUUAUUAAUGGGUUUGUG	150	2685 AUUAUUAAUGGGUUUGUG	150	2703 CACAAAACCCAUUAUUAU	349
2703 GUACUGUAAAGAAUUAGC	151	2703 GUACUGUAAAGAAUUAGC	151	2721 GCUAAAUUCUUACAGUAC	350
2721 CUGUAUCAAACUAGUGCAU	152	2721 CUGUAUCAAACUAGUGCAU	152	2739 AUGCACUAGUUUGAUACAG	351
2739 UGAAUAGAUUCUCUCCUGA	153	2739 UGAAUAGAUUCUCUCCUGA	153	2757 UCAGGAGAGAAUCUAUUA	352
2757 AUUAUUUAUCACAUAGCCC	154	2757 AUUAUUUAUCACAUAGCCC	154	2775 GGGCUAUGUGAUAAAUAU	353
2775 CCUUAAGCCAGUUGUAUUAU	155	2775 CCUUAAGCCAGUUGUAUUAU	155	2793 AAUAUACAACUGGCUAAGG	354
2793 UAUUCUUGUGGUUUGUGAC	156	2793 UAUUCUUGUGGUUUGUGAC	156	2811 GUCACAAACCACAAGAAUA	355
2811 CCCAAUUAAGUCCUACUUU	157	2811 CCCAAUUAAGUCCUACUUU	157	2829 AAAGUAGGACUUAUUUGGG	356
2829 UACAUUAGCUUUUAGAAUC	158	2829 UACAUUAGCUUUUAGAAUC	158	2847 GAUUCUUAAAGCAUUAUGUA	357
2847 CGAUGGGGAUGCUUCAUG	159	2847 CGAUGGGGAUGCUUCAUG	159	2865 CAUGAAGCAUCCCCAUCG	358
2865 GUGAACGUGGAGUUCAGC	160	2865 GUGAACGUGGAGUUCAGC	160	2883 CGCUAACUCCACGUUCAC	359
2883 CUGCUUCUCUUGCCUAAGU	161	2883 CUGCUUCUCUUGCCUAAGU	161	2901 ACUUAGGCAAGAGAAGCAG	360
2901 UAUUCCUUUCCUGAUCACU	162	2901 UAUUCCUUUCCUGAUCACU	162	2919 AGUGAUCAGGAAAGGAAUA	361
2919 UAUUGCAUUUAAAGUAAA	163	2919 UAUUGCAUUUAAAGUAAA	163	2937 UUUAAUUAUUAAUGCAUA	362

TABLE II-continued

APP, BACE, PSEN1, PSEN2 s1NA AND TARGET SEQUENCES					
2937	ACAUUUUUAAAGUAUUUCAG	164	2937	ACAUUUUUAAAGUAUUUCAG	164
2955	GAUGC UUAGAGAGAUUUU	165	2955	GAUGC UUAGAGAGAUUUU	165
2973	UUUUUCCAUGACUGCAUUU	166	2973	UUUUUCCAUGACUGCAUUU	166
2991	UUACUGUACAGAUUGCUGC	167	2991	UUACUGUACAGAUUGCUGC	167
3009	CUUCUGCUAAUUAUUGUGAU	168	3009	CUUCUGCUAAUUAUUGUGAU	168
3027	UAUAGGAAUUUAGAGGAUA	169	3027	UAUAGGAAUUUAGAGGAUA	169
3045	ACACACGUUUUGUUUCUUCG	170	3045	ACACACGUUUUGUUUCUUCG	170
3063	GUGCCUGUUUUUUGUGCAC	171	3063	GUGCCUGUUUUUUGUGCAC	171
3081	CACAUUAGGCAUUGAGACU	172	3081	CACAUUAGGCAUUGAGACU	172
3099	UUC AAGCUUUUCUUUUUUU	173	3099	UUC AAGCUUUUCUUUUUUU	173
3117	UGUCCACGUAUCUUUGGGU	174	3117	UGUCCACGUAUCUUUGGGU	174
3135	UCUUUGAUAAAGAAAAGAA	175	3135	UCUUUGAUAAAGAAAAGAA	175
3153	AUCCUGUUC AUUGUAAGC	176	3153	AUCCUGUUC AUUGUAAGC	176
3171	CACUUUUACGGGGCGGGUG	177	3171	CACUUUUACGGGGCGGGUG	177
3189	GGGGAGGGGUGCUCUGCUG	178	3189	GGGGAGGGGUGCUCUGCUG	178
3207	GGUCUCAAUUAACCAAGAA	179	3207	GGUCUCAAUUAACCAAGAA	179
3225	AUUCUCCAAAACAAUUUUC	180	3225	AUUCUCCAAAACAAUUUUC	180
3243	CUGCAGGAUGAUUGUACAG	181	3243	CUGCAGGAUGAUUGUACAG	181
3261	GAAUCAUUGC UUAUGACAU	182	3261	GAAUCAUUGC UUAUGACAU	182
3279	UGAUCGCUUUCUACACUGU	183	3279	UGAUCGCUUUCUACACUGU	183
3297	UAUUAACAUAUUAUUAUA	184	3297	UAUUAACAUAUUAUUAUA	184
3315	AAUAAAAUAACCCCGGGCA	185	3315	AAUAAAAUAACCCCGGGCA	185
3333	AAGACUUUUCUUUGAAGGA	186	3333	AAGACUUUUCUUUGAAGGA	186
3351	AUGACUACAGACAUUAAAU	187	3351	AUGACUACAGACAUUAAAU	187
3369	UAAUCGAAGUAUUUUGGG	188	3369	UAAUCGAAGUAUUUUGGG	188
3387	GUGGGGAGAAGAGGCAGAU	189	3387	GUGGGGAGAAGAGGCAGAU	189
3405	UUCAAUUUUCUUUUAACCAG	190	3405	UUCAAUUUUCUUUUAACCAG	190
3423	GUCUGAAGUUUCAUUUAUG	191	3423	GUCUGAAGUUUCAUUUAUG	191
3441	GAUACAAAAGAAGAUAAA	192	3441	GAUACAAAAGAAGAUAAA	192
3459	AAUGGAAGUGGCAAUUAUA	193	3459	AAUGGAAGUGGCAAUUAUA	193
3477	AGGGGAUGAGGAAGGCAUG	194	3477	AGGGGAUGAGGAAGGCAUG	194
3495	GCCUGGACAAACCCUUCUU	195	3495	GCCUGGACAAACCCUUCUU	195
3513	UUUAAGAUGUGUCUCAAU	196	3513	UUUAAGAUGUGUCUCAAU	196
3531	UUUGUAUAAAUGGUGUUU	197	3531	UUUGUAUAAAUGGUGUUU	197
3549	UUC AUGUAAAUAUUAUACAU	198	3549	UUC AUGUAAAUAUUAUACAU	198
3559	UAAAUACAUCUUGGAGGA	199	3559	UAAAUACAUCUUGGAGGA	199
2955	CUGAAAUAUCUAAAAAUGU	363	2973	AAAUCUCUCUAAAGCAUC	364
2991	AAUAGCAGUCAUGGAAAAA	365	3009	GCAGCAAUCUGUACAGUAA	366
3027	AUCACAAUAUAGCAGAAG	367	3045	UAUCCUCUUAUUAUCCUAUA	368
3063	CGAAGAAACAAACGUGUGU	369	3081	GUGCACAUAAAACAGGCAC	370
3099	AGUCUCAUUGCCUAAUGUG	371	3117	AAAAAAGAAAAGCUUGAA	372
3135	ACCCAAGAUACGUGGACA	373	3153	UUCUUUUCUUUAUCAAGA	374
3171	GCUUACAUAUGAACAGGGAU	375	3189	CACCCGCCCCGUAAAAGUG	376
3207	CAGCAGAGCACCCUCCCC	377	3225	UUCUUGGUAAUUGAAGACC	378
3243	GAAAAUUGUUUUGGAGAAU	379	3261	CUGUACAAUUAUCCUGCAG	380
3279	AUGUCAUAAGCAAUGAUUC	381	3297	ACAGUGUAGAAAGCGAUCA	382
3315	UUAUUUAUUUAUGUAAUA	383	3333	UGCCCCGGGUUUUUUAUU	384
3351	UCCUUCAAAAGAAAAGUCUU	385	3369	AUUUAAUGUCUGUAGUCAU	386
3387	CCCAAAAUUACUUCGAUUA	387	3405	AUCUGCCUCUUCUCCCCAC	388
3423	CUGGUUAAAGAAAAUUGAA	389	3441	CAUAAAUGAAACUUCAGAC	390
3459	UUUAUCUUCUUUUGUAUC	391	3477	UUUAUUGCCACUCCAUU	392
3495	CAUGCCUUCUUAUCCCCU	393	3513	AAGAAGGGUUUGUCCAGGC	394
3531	AUUGAAGACACAUCUAAAA	395	3549	AAACACCAUUUUUAUACAAA	396
3567	AUGUAUUUAUUUAUUGAA	397	3577	UCCUCCAAGAAUGUAUUUA	398

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES						
BACE NM_012104						
Pos	Seq	Seq ID	UPos Upper seq	Seq ID	LPos Lower seq	Seq ID
1	CGCACUCGUCCCCAGCCCG	399	1 CGCACUCGUCCCCAGCCCG	399	19 CGGGCUGGGGACGAGUGCG	724
19	GCCCGGGAGCUGCGAGCCG	400	19 GCCCGGGAGCUGCGAGCCG	400	37 CGGCUCGCAGCUCCCGGGC	725
37	GCGAGCUGGAUUAUGGUGG	401	37 GCGAGCUGGAUUAUGGUGG	401	55 CCACCAUAAUCCAGCUCGC	726
55	GCCUGAGCAGCCAACGCAG	402	55 GCCUGAGCAGCCAACGCAG	402	73 CUGCGUUGGCUGCUCAGGC	727
73	GCCGCAGGAGCCCGGAGCC	403	73 GCCGCAGGAGCCCGGAGCC	403	91 GGCUCGCGGCUCUGCGGC	728
91	CCUUGCCCCUGCCCGGCC	404	91 CCUUGCCCCUGCCCGGCC	404	109 GCGCGGGCAGGGGCAAGG	729
109	CGCCGCCCGCCGGGGGAC	405	109 CGCCGCCCGCCGGGGGAC	405	127 GUCCCCCGCGGGCGCGC	730
127	CCAGGGAAGCCGCCACCGG	406	127 CCAGGGAAGCCGCCACCGG	406	145 CCGGUGCGCGCUUCCUGG	731
145	GCCCCGCAUGCCCGCCCU	407	145 GCCCCGCAUGCCCGCCCU	407	163 AGGGGCGGGCAUGGCGGC	732
163	UCCAGCCCCGCCGGGAGC	408	163 UCCAGCCCCGCCGGGAGC	408	181 GCUCCCGCGGGGUGGGA	733
181	CCCGCGCCCGCUGCCAGG	409	181 CCCGCGCCCGCUGCCAGG	409	199 CCUGGGCAGCGGGCGCGG	734
199	GCUGGCCGCCGCCUGCCG	410	199 GCUGGCCGCCGCCUGCCG	410	217 CGGCACGGCGCGGCCAGC	735
217	GAUGUAGCGGCUCCGGAU	411	217 GAUGUAGCGGCUCCGGAU	411	235 AUCCGGAGCCCGCUACAUC	736
235	UCCAGCCUCUCCCCUGCU	412	235 UCCAGCCUCUCCCCUGCU	412	253 AGCAGGGGAGAGGCUGGGA	737
253	UCCCGUGCUCUGCGGAUCU	413	253 UCCCGUGCUCUGCGGAUCU	413	271 AGAUCCGCAGAGCACGGGA	738
271	UCCCCUGACCGCUCUCCAC	414	271 UCCCCUGACCGCUCUCCAC	414	289 GUGGAGAGCGGUCAGGGGA	739
289	CAGCCCGGACCCGGGGGCU	415	289 CAGCCCGGACCCGGGGGCU	415	307 AGCCCCCGGUCCGGGCGUG	740
307	UGGCCAGGGCCCUAGG	416	307 UGGCCAGGGCCCUAGG	416	325 CCUGCAGGGCCUUGGGCCA	741
325	GCCUGGGCUGCUGAUGCC	417	325 GCCUGGGCUGCUGAUGCC	417	343 GGCAUCAGGACGCCAGGGC	742
343	CCCCAAGCUCUCCUCCUG	418	343 CCCCCAAGCUCUCCUCCUG	418	361 CAGGAGAGGGAGCUUGGGG	743
361	GAGAAGCCACCAGACCAC	419	361 GAGAAGCCACCAGACCAC	419	379 GUGGUGCUGGUGGCUUCUC	744
379	CCCAGACUUGGGGCGAGG	420	379 CCCAGACUUGGGGCGAGG	420	397 GCCUGCCCCAAGUCUGGG	745
397	CGCCAGGGACGGACGUGGG	421	397 CGCCAGGGACGGACGUGGG	421	415 CCCACGUCCGUCCUGGCG	746
415	GCCAGUGCGAGCCAGAGG	422	415 GCCAGUGCGAGCCAGAGG	422	433 CCUCUGGGCUCGCACUGGC	747
433	GGCCCCAAGGCCGGGGCCC	423	433 GGCCCCAAGGCCGGGGCCC	423	451 GGGCCCCGGCCUUCGGGCC	748
451	CACCAUGGCCAAGCCUG	424	451 CACCAUGGCCAAGCCUG	424	469 CAGGGCUUGGGCAUGGUG	749
469	GCCUGGGCUCUGUGUGG	425	469 GCCUGGGCUCUGUGUGG	425	487 CCACAGCAGGAGCCAGGGC	750
487	GAUGGGCGCGGAGUGCUG	426	487 GAUGGGCGCGGAGUGCUG	426	505 CAGCACUCCCGGCCCAUC	751
505	GCCUGCCACGGCACCCAG	427	505 GCCUGCCACGGCACCCAG	427	523 CUGGGUGCCGUGGGCAGGC	752
523	GCACGGCAUCCGGCUGCCC	428	523 GCACGGCAUCCGGCUGCCC	428	541 GGGCAGCCGGAUGCCGUGC	753
541	CCUGCGCAGCGGCCUGGGG	429	541 CCUGCGCAGCGGCCUGGGG	429	559 CCCCAGGCCGUGCGCAGG	754
559	GGGCGCCCCCUGGGGCGUG	430	559 GGGCGCCCCCUGGGGCGUG	430	577 CAGCCCCAGGGGGGCGCCC	755
577	GCGGUGCCCCGGGAGACC	431	577 GCGGUGCCCCGGGAGACC	431	595 GGUCUCCCGGGGAGCCGC	756
595	CGACGAAGAGCCCGAGGAG	432	595 CGACGAAGAGCCCGAGGAG	432	613 CUCCUGGGCUCUUCGUCG	757

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siNA AND TARGET SEQUENCES					
613 GCCCGGCCGAGGGGCAGC	433	613 GCCCGGCCGAGGGGCAGC	433	631 GCUGCCCCUCCGGCCGGGC	758
631 CUUUGUGGAGAUGGUGGAC	434	631 CUUUGUGGAGAUGGUGGAC	434	649 GUCCACCAUCUCCACAAAG	759
649 CAACCUGAGGGGCAAGUCG	435	649 CAACCUGAGGGGCAAGUCG	435	667 CGACUUGCCCCUCAGGUUG	760
667 GGGGCAGGGCUACUACGUG	436	667 GGGGCAGGGCUACUACGUG	436	685 CACGUAGUAGCCUGCCCC	761
685 GGAGAUGACCGUGGGCAGC	437	685 GGAGAUGACCGUGGGCAGC	437	703 GCUGCCCACGGUCAUCUCC	762
703 CCCCCCGCAGACGCUCAAC	438	703 CCCCCCGCAGACGCUCAAC	438	721 GUUGAGCGUCUGCGGGGG	763
721 CAUCCUGGUGAUACAGGC	439	721 CAUCCUGGUGAUACAGGC	439	739 GCCUGUAUCCACCAGGAUG	764
739 CAGCAGUAACUUUGCAGUG	440	739 CAGCAGUAACUUUGCAGUG	440	757 CACUGCAAAGUUACUGCUG	765
757 GGGUGUCGCCCCCACC	441	757 GGGUGUCGCCCCCACC	441	775 GGGUGGGGGGCAGCACC	766
775 CUUCCUGCAUCGCUACUAC	442	775 CUUCCUGCAUCGCUACUAC	442	793 GUAGUAGCGAUGCAGGAAG	767
793 CCAGAGGCAGCUGUCCAGC	443	793 CCAGAGGCAGCUGUCCAGC	443	811 GCUGGACAGCUGCCUCUG	768
811 CACAUACCGGGACCUCGG	444	811 CACAUACCGGGACCUCGG	444	829 CCGGAGGUCCCGUAUGUG	769
829 GAAGGGUGUGUAUGUGCC	445	829 GAAGGGUGUGUAUGUGCC	445	847 GGGCACAUACACCCUUC	770
847 CUACACCCAGGGCAAGUGG	446	847 CUACACCCAGGGCAAGUGG	446	865 CCACUUGCCCUGGGUGUAG	771
865 GGAAGGGGAGCUGGGCACC	447	865 GGAAGGGGAGCUGGGCACC	447	883 GGUGCCCAGCUCUCCUUC	772
883 CGACCGUGUAAGCAUCCCC	448	883 CGACCGUGUAAGCAUCCCC	448	901 GGGGAUGCUUACCAGGUCG	773
901 CCAUGGCCCCAACGUCACU	449	901 CCAUGGCCCCAACGUCACU	449	919 AGUGACGUUGGGGCCAUG	774
919 UGUGCGUGCCAACAUAUGCU	450	919 UGUGCGUGCCAACAUAUGCU	450	937 AGCAAUGUUGGCACGCACA	775
937 UGCCAUCACUGAAUCAGAC	451	937 UGCCAUCACUGAAUCAGAC	451	955 GUCUGAUUCAGUGAUGGCA	776
955 CAAGUUCUUCAUCAACGGC	452	955 CAAGUUCUUCAUCAACGGC	452	973 GCCGUUGAUGAAGAACUUG	777
973 CUCCAACUGGGAAGGCAUC	453	973 CUCCAACUGGGAAGGCAUC	453	991 GAUGCCUCCCCAGUUGGAG	778
991 CCUGGGGUGGCCUAUGCU	454	991 CCUGGGGUGGCCUAUGCU	454	1009 AGCAUAGGCCAGCCCCAGG	779
1009 UGAGAUUGCCAGGCCUGAC	455	1009 UGAGAUUGCCAGGCCUGAC	455	1027 GUCAGGCCUGGCAAUUCA	780
1027 CGACUCCUGGAGCCUUC	456	1027 CGACUCCUGGAGCCUUC	456	1045 GAAAGGCUCCAGGGAGUCG	781
1045 CUUUGACUCUCUGGUAAG	457	1045 CUUUGACUCUCUGGUAAG	457	1063 CUUUAACAGAGAGUCAAG	782
1063 GCAGACCCACGUUCCCAAC	458	1063 GCAGACCCACGUUCCCAAC	458	1081 GUUGGGAACGUGGGUCUGC	783
1081 CCUCUUCUCCUGCAGCUU	459	1081 CCUCUUCUCCUGCAGCUU	459	1099 AAGCUGCAGGGAGAAGAGG	784
1099 UUGUGGUGCUGGCUUCCCC	460	1099 UUGUGGUGCUGGCUUCCCC	460	1117 GGGGAAGCCAGCACCACAA	785
1117 CCUCAACCAGUCUGAAGUG	461	1117 CCUCAACCAGUCUGAAGUG	461	1135 CACUUCAGACUGGUUGAGG	786
1135 GCUGGCCUCUGCGGAGGG	462	1135 GCUGGCCUCUGCGGAGGG	462	1153 CCCUCCGACAGAGGCCAGC	787
1153 GAGCAUGAUCAUUGGAGGU	463	1153 GAGCAUGAUCAUUGGAGGU	463	1171 ACCUCCAUGAUCAUGCUC	788
1171 UAUCGACCACUCGUGUAC	464	1171 UAUCGACCACUCGUGUAC	464	1189 GUACAGCGAGUGGUGGAUA	789
1189 CACAGGCAGUCUCUGUAU	465	1189 CACAGGCAGUCUCUGUAU	465	1207 AUACCAGAGACUGCCUGUG	790
1207 UACACCCAUCGCGGGGAG	466	1207 UACACCCAUCGCGGGGAG	466	1225 CUCCCGCCGAUGGGUGUA	791
1225 GUGGUAUUAUGAGGUCAUC	467	1225 GUGGUAUUAUGAGGUCAUC	467	1243 GAUGACCUCAUAUAUCCAC	792
1243 CAUUGUGCGGGUGGAGAUC	468	1243 CAUUGUGCGGGUGGAGAUC	468	1261 GAUCCACCCCGCACAAUG	793
1261 CAAUGGACAGGAUCUGAAA	469	1261 CAAUGGACAGGAUCUGAAA	469	1279 UUUCAGAUCCUGUCCAUUG	794

TABLE II-continued

APP, BACE, PSEN1, PSEN2 s1NA AND TARGET SEQUENCES					
1279 AAUGGACUGCAAGGAGUAC	470	1279 AAUGGACUGCAAGGAGUAC	470	1297 GUACUCCUUGCAGUCCAUU	795
1297 CAACUAUGACAAGAGCAUU	471	1297 CAACUAUGACAAGAGCAUU	471	1315 AAUGCUCUUGUCAUAGUUG	796
1315 UGUGGACAGUGGCACCACC	472	1315 UGUGGACAGUGGCACCACC	472	1333 GGUGGUGCCACUGUCCACA	797
1333 CAACCUUCGUUUGCCCAAG	473	1333 CAACCUUCGUUUGCCCAAG	473	1351 CUUGGGCAAACGAAGGUUG	798
1351 GAAAGUGUUUGAAGCUGCA	474	1351 GAAAGUGUUUGAAGCUGCA	474	1369 UGCAGCUUCAAACACUUUC	799
1369 AGUCAAAUCCAUAAGGCA	475	1369 AGUCAAAUCCAUAAGGCA	475	1387 UGCCUUGAUGGAUUUGACU	800
1387 AGCCUCCUCCACGGAGAAG	476	1387 AGCCUCCUCCACGGAGAAG	476	1405 CUUCUCCUGGAGGAGGCU	801
1405 GUUCCUGAUGGUUUCUGG	477	1405 GUUCCUGAUGGUUUCUGG	477	1423 CCAGAAACCAUCAGGGAAC	802
1423 GCUAGGAGAGCAGCUGGUG	478	1423 GCUAGGAGAGCAGCUGGUG	478	1441 CACCAGCUGCUCUCCUAGC	803
1441 GUGCUGGCAAGCAGGCACC	479	1441 GUGCUGGCAAGCAGGCACC	479	1459 GGUGCCUGCUUGCCAGCAC	804
1459 CACCCUUGGAACAUUUUC	480	1459 CACCCUUGGAACAUUUUC	480	1477 GAAAUGUCCAAGGGGUG	805
1477 CCCAGUCAUCUCACUCUAC	481	1477 CCCAGUCAUCUCACUCUAC	481	1495 GUAGAGUGAGAUACUGGG	806
1495 CCUAAUGGGUGAGGUUACC	482	1495 CCUAAUGGGUGAGGUUACC	482	1513 GGUAACCUCACCCAUAUAGG	807
1513 CAACAGUCCUUCGCAUC	483	1513 CAACAGUCCUUCGCAUC	483	1531 GAUGCGGAAGGACUGGUUG	808
1531 CACCAUCCUUCGCGAGCAA	484	1531 CACCAUCCUUCGCGAGCAA	484	1549 UUGCUGCGGAAGGAUGGUG	809
1549 AUACCUGCGGCCAGUGGAA	485	1549 AUACCUGCGGCCAGUGGAA	485	1567 UUCCACUGGCCGAGGUAU	810
1567 AGAUGUGGCCACGUCCAA	486	1567 AGAUGUGGCCACGUCCAA	486	1585 UUGGGACUGUGGCCACAUCU	811
1585 AGACGACUGUUAACAGUUU	487	1585 AGACGACUGUUAACAGUUU	487	1603 AAACUUGUAACAGUCGUCU	812
1603 UGCCAUCUCACAGUCAUCC	488	1603 UGCCAUCUCACAGUCAUCC	488	1621 GGAGACUGUGAGAUGGCA	813
1621 CACGGGCACUGUUAUGGGA	489	1621 CACGGGCACUGUUAUGGGA	489	1639 UCCCAUAACAGUGCCCGUG	814
1639 AGCUGUUAUCAUGGAGGGC	490	1639 AGCUGUUAUCAUGGAGGGC	490	1657 GCCCUCCAUGAUAACAGCU	815
1657 CUUCUACGUUGUCUUUGAU	491	1657 CUUCUACGUUGUCUUUGAU	491	1675 AUCAAAGACAACGUAGAAG	816
1675 UCGGGCCCGAAAACGAAUU	492	1675 UCGGGCCCGAAAACGAAUU	492	1693 AAUUCGUUUUCGGGCCCCGA	817
1693 UGGCUUUGCUGUCAGCGCU	493	1693 UGGCUUUGCUGUCAGCGCU	493	1711 AGCGCUGACAGCAAAGCCA	818
1711 UUGCCAUGUGCAGCAUGAG	494	1711 UUGCCAUGUGCAGCAUGAG	494	1729 CUCAUCGUGCACAUGGCAA	819
1729 GUUCAGGACGGCAGCGGUG	495	1729 GUUCAGGACGGCAGCGGUG	495	1747 CACCGCUGCCGUCCUGAAC	820
1747 GGAAGGCCCUUUUGUCACC	496	1747 GGAAGGCCCUUUUGUCACC	496	1765 GGUGACAAAAGGGCCUUC	821
1765 CUUGGACAUGGAAGACUGU	497	1765 CUUGGACAUGGAAGACUGU	497	1783 ACAGUCUCCAUUGUCCAAG	822
1783 UGGCUACAACAUUCCACAG	498	1783 UGGCUACAACAUUCCACAG	498	1801 CUGUGGAAUGUUGUAGCCA	823
1801 GACAGAUGAGUCAACCCUC	499	1801 GACAGAUGAGUCAACCCUC	499	1819 GAGGUUGACUCAUCUGUC	824
1819 CAUGACCAUAGCCUAUGUC	500	1819 CAUGACCAUAGCCUAUGUC	500	1837 GACAUAGGCUAUGGUCAUG	825
1837 CAUGGCUGCCAUCUGCGCC	501	1837 CAUGGCUGCCAUCUGCGCC	501	1855 GGCGCAGAUUGCAGCCAUG	826
1855 CCUCUUAUGCUGCCACUC	502	1855 CCUCUUAUGCUGCCACUC	502	1873 GAGUGGCAGCAUGAAGAGG	827
1873 CUGCCUUAUGGUGUGUCAG	503	1873 CUGCCUUAUGGUGUGUCAG	503	1891 CUGACACACCAUGAGGCAG	828
1891 GUGGCGCUGCCUCCGUGC	504	1891 GUGGCGCUGCCUCCGUGC	504	1909 GCAGCGGAGGCAGCGCCAC	829
1909 CCUGCGCCAGCAGCAUGAU	505	1909 CCUGCGCCAGCAGCAUGAU	505	1927 AUCAUGCUGCUGGCGCAGG	830
1927 UGACUUUGCUGAUGACAUC	506	1927 UGACUUUGCUGAUGACAUC	506	1945 GAUGUCAUCAGCAAAGUCA	831

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siNA AND TARGET SEQUENCES					
1945 CUCCCCUGCUGAAGUGAGGA	507	1945 CUCCCCUGCUGAAGUGAGGA	507	1963 UCCUCACUUCAGCAGGGAG	832
1963 AGGCCCAUGGGCAGAAGAU	508	1963 AGGCCCAUGGGCAGAAGAU	508	1981 AUCUUCUGCCCAUGGGCCU	833
1981 UAGAGAUUCCCCUGGACCA	509	1981 UAGAGAUUCCCCUGGACCA	509	1999 UGGUCCAGGGGAUUCUCUA	834
1999 ACACCUCCUGGUUUCACUU	510	1999 ACACCUCCUGGUUUCACUU	510	2017 AAGUGAACACGGAGGUGU	835
2017 UUGGUACAAGUAGGAGAC	511	2017 UUGGUACAAGUAGGAGAC	511	2035 GUCUCCUACUUGUGACCA	836
2035 CACAGAUGGCACCUUGUGC	512	2035 CACAGAUGGCACCUUGUGC	512	2053 GCCACAGUGCCAUCUGUG	837
2053 CCAGAGCACCUCAGGACCC	513	2053 CCAGAGCACCUCAGGACCC	513	2071 GGGUCCUGAGGUGUCUGG	838
2071 CUCCCCACCCACCAAUGC	514	2071 CUCCCCACCCACCAAUGC	514	2089 GCAUUUGGUGGGUGGGAG	839
2089 CCUCUGCCUUGAUGGAGAA	515	2089 CCUCUGCCUUGAUGGAGAA	515	2107 UUCUCCAUCAAGGCAGAGG	840
2107 AGGAAAAGGCUGGCAAGGU	516	2107 AGGAAAAGGCUGGCAAGGU	516	2125 ACCUUGCCAGCCUUUCCU	841
2125 UGGGUUCCAGGGACUGUAC	517	2125 UGGGUUCCAGGGACUGUAC	517	2143 GUACAGUCCUGGAACCCA	842
2143 CCUGUAGGAAACAGAAAAG	518	2143 CCUGUAGGAAACAGAAAAG	518	2161 CUUUUCUGUUUCCUACAGG	843
2161 GAGAAGAAAGAAGCACUCU	519	2161 GAGAAGAAAGAAGCACUCU	519	2179 AGAGUGCUUCUUUCUUCUC	844
2179 UGCUGGCGGGAAUACUCUU	520	2179 UGCUGGCGGGAAUACUCUU	520	2197 AAGAGUAUCCCCGCCAGCA	845
2197 UGGUCACCUCAAAUUUAAG	521	2197 UGGUCACCUCAAAUUUAAG	521	2215 CUUAAAUUUGAGGUGACCA	846
2215 GUCGGGAAAUUCUGUGCU	522	2215 GUCGGGAAAUUCUGUGCU	522	2233 AGCAGCAGAAUUUCCCGAC	847
2233 UUGAAACUUCAGCCCUGAA	523	2233 UUGAAACUUCAGCCCUGAA	523	2251 UUCAGGGCUGAAGUUUCAA	848
2251 ACCUUUGUCCACCAUCCU	524	2251 ACCUUUGUCCACCAUCCU	524	2269 AGGAAUGGUGGACAAAGGU	849
2269 UUUAAAUUCUCCAAACCAA	525	2269 UUUAAAUUCUCCAAACCAA	525	2287 UUGGGUUGGAGAAUUUAAA	850
2287 AAGUAUUCUUCUUUCUUA	526	2287 AAGUAUUCUUCUUUCUUA	526	2305 UAAGAAAAGAAGAAUACUU	851
2305 AGUUUCAGAGUACUGGCA	527	2305 AGUUUCAGAGUACUGGCA	527	2323 UGCCAGUACUUCUGAAACU	852
2323 AUCACACGCAGGUUACCU	528	2323 AUCACACGCAGGUUACCU	528	2341 AAGGUAACCGUGUGAU	853
2341 UGGCGUGUGUCCUGUGGU	529	2341 UGGCGUGUGUCCUGUGGU	529	2359 ACCACAGGGACACAGCCA	854
2359 UACCCUGGCAGAGAAGAGA	530	2359 UACCCUGGCAGAGAAGAGA	530	2377 UCUCUUCUCUGCCAGGGUA	855
2377 ACCAAGCUUGUUUCCUGC	531	2377 ACCAAGCUUGUUUCCUGC	531	2395 GCAGGGAAACAAGCUUGGU	856
2395 CUGGCCAAAGUCAGUAGGA	532	2395 CUGGCCAAAGUCAGUAGGA	532	2413 UCCUACUGACUUUGGCCAG	857
2413 AGAGGAUGCAGAUUUGCU	533	2413 AGAGGAUGCAGAUUUGCU	533	2431 AGCAAACUGUGCAUCCUCU	858
2431 UAUUUGCUUUAGAGACAGG	534	2431 UAUUUGCUUUAGAGACAGG	534	2449 CCUGUCUCUAAAGCAAAUA	859
2449 GGACUGUAUAAACAAGCCU	535	2449 GGACUGUAUAAACAAGCCU	535	2467 AGGCUUGUUUAUACAGUCC	860
2467 UAACAUUGGUGCAAAGAUU	536	2467 UAACAUUGGUGCAAAGAUU	536	2485 AAUCUUUGCACCAUUGUUA	861
2485 UGCCUCUUGAAUUAAAAA	537	2485 UGCCUCUUGAAUUAAAAA	537	2503 UUUUUUAAUUAAGAGGCA	862
2503 AAAAAACUAGAUUGACUUA	538	2503 AAAAAACUAGAUUGACUUA	538	2521 AUAGUCAAUUCUAGUUUUU	863
2521 UUUUAUACAAUUGGGGCGG	539	2521 UUUUAUACAAUUGGGGCGG	539	2539 CCGCCCCAUUUGUAUAAA	864
2539 GCUGGAAAGAGGAGAAGGA	540	2539 GCUGGAAAGAGGAGAAGGA	540	2557 UCCUUCUCCUUCUCCAGC	865
2557 AGAGGGAGUACAAAGACAG	541	2557 AGAGGGAGUACAAAGACAG	541	2575 CUGUCUUUGUACUCCUCU	866
2575 GGGAAUAGUGGGAUCAAG	542	2575 GGGAAUAGUGGGAUCAAG	542	2593 CUUUGAUCCCAUAUCCCC	867
2593 GCUAGGAAAGGCAGAAACA	543	2593 GCUAGGAAAGGCAGAAACA	543	2611 UGUUUCUGCCUUUCCUAGC	868

TABLE II-continued

APP, BACE, PSEN1, PSEN2 s1NA AND TARGET SEQUENCES					
2611 ACAACCACUCACCAGUCCU	544	2611 ACAACCACUCACCAGUCCU	544	2629 AGGACUGGUGAGUGGUUGU	869
2629 UAGUUUUAGACCUCAUCUC	545	2629 UAGUUUUAGACCUCAUCUC	545	2647 GAGAUGAGGUCUAAAACUA	870
2647 CCAAGAUAGCAUCCCAUCU	546	2647 CCAAGAUAGCAUCCCAUCU	546	2665 AGAUGGGAUGCUAUCUUGG	871
2665 UCAGAAGAUGGGUGUUGUU	547	2665 UCAGAAGAUGGGUGUUGUU	547	2683 AACAAACCCAUUCUCUGA	872
2683 UUUCAAUGUUUUUCUUUCU	548	2683 UUUCAAUGUUUUUCUUUCU	548	2701 AGAAAAGAAAACAUUGAAA	873
2701 UGUGGUUGCAGCCUGACCA	549	2701 UGUGGUUGCAGCCUGACCA	549	2719 UGGUCAGGCUGCAACCACA	874
2719 AAAAGUGAGAUGGGAAGGG	550	2719 AAAAGUGAGAUGGGAAGGG	550	2737 CCCUCCCAUCUCACUUUU	875
2737 GCUUAUCUAGCCAAAGAGC	551	2737 GCUUAUCUAGCCAAAGAGC	551	2755 GCUCUUUGGCUAGAUAAGC	876
2755 CUCUUUUUAGCUCUCUUA	552	2755 CUCUUUUUAGCUCUCUUA	552	2773 UAAGAGAGCUAAAAAGAG	877
2773 AAUGAAGUGCCACUAAG	553	2773 AAUGAAGUGCCACUAAG	553	2791 CUUAGUGGGCACUUCUUUU	878
2791 GAAGUCCACUUAACACAU	554	2791 GAAGUCCACUUAACACAU	554	2809 AUGUGUUAAGUGGAACUUC	879
2809 UGAAUUCUGCCAUUAUUA	555	2809 UGAAUUCUGCCAUUAUUA	555	2827 UUAUAUGGCAGAAUUA	880
2827 AUUUCAUUGUCUCUAUCUG	556	2827 AUUUCAUUGUCUCUAUCUG	556	2845 CAGAUAGAGACAAUGAAU	881
2845 GAACCACCCUUUAUUCUAC	557	2845 GAACCACCCUUUAUUCUAC	557	2863 GUAGAAUAAAGGUGGUUC	882
2863 CAUAUGAUAGGCAGCACUG	558	2863 CAUAUGAUAGGCAGCACUG	558	2881 CAGUGCUGCCUAUCAUAUG	883
2881 GAAAUUCCUAACCCCUA	559	2881 GAAAUUCCUAACCCCUA	559	2899 UAGGGGUUAGGAUAUUUC	884
2899 AAGCUCCAGGUGCCUCUG	560	2899 AAGCUCCAGGUGCCUCUG	560	2917 CACAGGGCACCUGGAGCUU	885
2917 GGGAGAGCAACUGGACUUA	561	2917 GGGAGAGCAACUGGACUUA	561	2935 AUAGUCCAGUUGCUCUCCC	886
2935 UAGCAGGGCUGGGCUCUGU	562	2935 UAGCAGGGCUGGGCUCUGU	562	2953 ACAGAGCCAGCCUCUGUA	887
2953 UCUUCCUGGUCAUAGGCUC	563	2953 UCUUCCUGGUCAUAGGCUC	563	2971 GAGCCUAUGACCAGGAAGA	888
2971 CACUCUUUCCCCCAAUCU	564	2971 CACUCUUUCCCCCAAUCU	564	2989 AGAUUUGGGGAAAGAGUG	889
2989 UUCCUCUGGAGCUUUGCAG	565	2989 UUCCUCUGGAGCUUUGCAG	565	3007 CUGCAAAGCUCCAGAGGAA	890
3007 GCCAAGGUGCUAAAAGGAA	566	3007 GCCAAGGUGCUAAAAGGAA	566	3025 UUCCUUUAGCACCUUGGC	891
3025 AUAGGUAGGAGACCUCUUC	567	3025 AUAGGUAGGAGACCUCUUC	567	3043 GAAGAGGUCUCCUACCUAU	892
3043 CUUUCUAAUCCUAAAAGC	568	3043 CUUUCUAAUCCUAAAAGC	568	3061 GCUUUUAAGGAUUAAGAUAG	893
3061 CAUAAUGUUGAACAUUCAU	569	3061 CAUAAUGUUGAACAUUCAU	569	3079 AUGAAUGUUAACAUAUUG	894
3079 UUCAACAGCUGAUGCCCUA	570	3079 UUCAACAGCUGAUGCCCUA	570	3097 UAGGGCAUCAGCUGUUGAA	895
3097 AUAACCCUGCCUGGAUUU	571	3097 AUAACCCUGCCUGGAUUU	571	3115 AAUCCAGGCAGGGUUUAU	896
3115 UCUUCCUAUUAGGCUAUA	572	3115 UCUUCCUAUUAGGCUAUA	572	3133 UUAUAGCCUAAUAGGAAGA	897
3133 AGAAGUAGCAAGAUUUUA	573	3133 AGAAGUAGCAAGAUUUUA	573	3151 UAAAGAUUUGCUCUUCU	898
3151 ACAUAAUUCAGAGUGGUUU	574	3151 ACAUAAUUCAGAGUGGUUU	574	3169 AAACCACUCUGAAUUAUGU	899
3169 UCAUUGCCUCCUACCCUC	575	3169 UCAUUGCCUCCUACCCUC	575	3187 GAGGGUAGGAAGGCAUGA	900
3187 CUCUAAUGGCCCCUCCAUU	576	3187 CUCUAAUGGCCCCUCCAUU	576	3205 AAUGGAGGGGCCAUUAGAG	901
3205 UUAUUUGACUAAAGCAUCA	577	3205 UUAUUUGACUAAAGCAUCA	577	3223 UGAUGC UUAGUCAAAUUA	902
3223 ACACAGUGGCACUAGCAUU	578	3223 ACACAGUGGCACUAGCAUU	578	3241 AAUGCUGUGCCACUGUGU	903
3241 UAUACCAAGAGUAUGAGAA	579	3241 UAUACCAAGAGUAUGAGAA	579	3259 UUCUCAUACUCUUGGUUAU	904
3259 AAUACAGUGCUUUAUGGCU	580	3259 AAUACAGUGCUUUAUGGCU	580	3277 AGCCAUAAAGCACUGUAUU	905

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES					
3277 UCUAACAUAUCUGCCUUA	581	3277 UCUAACAUAUCUGCCUUA	581	3295 UGAAGGCAGUAAUGUUAGA	906
3295 AGUAUCAAGGCUGCCUGGA	582	3295 AGUAUCAAGGCUGCCUGGA	582	3313 UCCAGGCAGCCUUGAUACU	907
3313 AGAAAGGAUGGCAGCCUCA	583	3313 AGAAAGGAUGGCAGCCUCA	583	3331 UGAGGCUGCCAUCCUUUCU	908
3331 AGGGCUUCCUUAUGUCCUC	584	3331 AGGGCUUCCUUAUGUCCUC	584	3349 GAGGACAUAAAGGAAGCCCU	909
3349 CCACCACAAGAGCUCCUUG	585	3349 CCACCACAAGAGCUCCUUG	585	3367 CAAGGAGCUCUUGUGGUGG	910
3367 GAUGAAGGUCAUCUUUUUC	586	3367 GAUGAAGGUCAUCUUUUUC	586	3385 GAAAAGAUAGACCUUAUC	911
3385 CCCCUAUCUGUUCUUCCC	587	3385 CCCCUAUCUGUUCUUCCC	587	3403 GGGAAAGAACAGAUAGGGG	912
3403 CCUCCCCGCUCCUAAUGGU	588	3403 CCUCCCCGCUCCUAAUGGU	588	3421 ACCAUUAGGAGCGGGGAGG	913
3421 UACGUGGUUACCCAGGCUG	589	3421 UACGUGGUUACCCAGGCUG	589	3439 CAGCCUGGGUACCCACGUA	914
3439 GGUUCUUGGGCUAGGUAGU	590	3439 GGUUCUUGGGCUAGGUAGU	590	3457 ACUACCUAGCCCAAGAACC	915
3457 UGGGGACCAAGUUAUUAAC	591	3457 UGGGGACCAAGUUAUUAAC	591	3475 GUAAUGAACUUGGUCCCCA	916
3475 CCUCCCUAUCAGUUCUAGC	592	3475 CCUCCCUAUCAGUUCUAGC	592	3493 GCUAGAACUGAUAGGGAGG	917
3493 CAUAGUAAACUACGGUACC	593	3493 CAUAGUAAACUACGGUACC	593	3511 GGUACCGUAGUUUACUAUG	918
3511 CAGUGUUGUGGGAGAGGC	594	3511 CAGUGUUGUGGGAGAGGC	594	3529 GCUCUCCCCACUAACACUG	919
3529 CUGGGUUUUCUAGUAUAC	595	3529 CUGGGUUUUCUAGUAUAC	595	3547 GUUACUAGGAAAACCCAG	920
3547 CCCACUGCAUCCUACUCCU	596	3547 CCCACUGCAUCCUACUCCU	596	3565 AGGAGUAGGAUGCAGUGGG	921
3565 UACCUGGUCAACCCGCGUC	597	3565 UACCUGGUCAACCCGCGUC	597	3583 GCAGCGGGUUGACCAGGUA	922
3583 CUUCCAGGUUUGGACCUG	598	3583 CUUCCAGGUUUGGACCUG	598	3601 CAGGUCCCAUACCUGGAAG	923
3601 GCUAAGUGUGGAAUUAACU	599	3601 GCUAAGUGUGGAAUUAACU	599	3619 AGGUAAUCCACACUUAAC	924
3619 UGAUAAGGGAGAGGGAAAU	600	3619 UGAUAAGGGAGAGGGAAAU	600	3637 AUUUCUCCUCCUUAUCA	925
3637 UACAAGGAGGGCCUCUGGU	601	3637 UACAAGGAGGGCCUCUGGU	601	3655 ACCAGAGGCCUCCUUGUA	926
3655 UGUUCCUGGCCUCAGCCAG	602	3655 UGUUCCUGGCCUCAGCCAG	602	3673 CUGGCUAGGCCAGGAACA	927
3673 GCUGCCCACAAGCCAUAUA	603	3673 GCUGCCCACAAGCCAUAUA	603	3691 UUAUUGGCUUGUGGGCAGC	928
3691 ACCAAUAAAACAAGAAUAC	604	3691 ACCAAUAAAACAAGAAUAC	604	3709 GUUUCUUGUUUAUUGGU	929
3709 CUGAGUCAGUUUUUAUCU	605	3709 CUGAGUCAGUUUUUAUCU	605	3727 AGAUAAAAACUGACUCAG	930
3727 UGGGUUCUCUUAUUCUCA	606	3727 UGGGUUCUCUUAUUCUCA	606	3745 UGGGAUAGAGAAACCCA	931
3745 ACUGCACUUGGUGCUGCUU	607	3745 ACUGCACUUGGUGCUGCUU	607	3763 AAGCAGCACCAAGUCAGU	932
3763 UUGGCUAGCUGGGAACACC	608	3763 UUGGCUAGCUGGGAACACC	608	3781 GGUGUUCUCCAGUCAGCCAA	933
3781 CCCAUAAUACAGAGUCUG	609	3781 CCCAUAAUACAGAGUCUG	609	3799 CAGACUCUGUAGUUAUGGG	934
3799 GACAGGAAGACUGGAGACU	610	3799 GACAGGAAGACUGGAGACU	610	3817 AGUCUCCAGUCUCCUGUC	935
3817 UGUCCACUUCUAGCUCGGA	611	3817 UGUCCACUUCUAGCUCGGA	611	3835 UCCGAGCUAGAAGUGGACA	936
3835 AACUUACUGUGUAAAUAAA	612	3835 AACUUACUGUGUAAAUAAA	612	3853 UUUUUUACACAGUAAGUU	937
3853 ACUUUCAGAACUGCUACCA	613	3853 ACUUUCAGAACUGCUACCA	613	3871 UGGUAGCAGUUCUGAAAGU	938
3871 AUGAAGUGAAAAUGCCACA	614	3871 AUGAAGUGAAAAUGCCACA	614	3889 UGUGGCAUUUUCACUUAU	939
3889 AUUUUGCUUUUAUUUUUCU	615	3889 AUUUUGCUUUUAUUUUUCU	615	3907 AGAAAUUAUAAAGCAAAAU	940
3907 UACCAUGUUGGGAUAAAC	616	3907 UACCAUGUUGGGAUAAAC	616	3925 GUUUUUCCCAACAUGGGUA	941
3925 CUGGCUUUUUCCAGCCCU	617	3925 CUGGCUUUUUCCAGCCCU	617	3943 AGGGCUGGGAAAAAGCCAG	942

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES									
3943	UUUCCAGGGCAUAAACUC	618	3943	UUUCCAGGGCAUAAACUC	618	3961	GAGUUUUAUGCCUGGAAA	943	
3961	CAACCCUUCGAUAGCAAG	619	3961	CAACCCUUCGAUAGCAAG	619	3979	CUUGCUAUCGAAGGGUUG	944	
3979	GUCCCAUCAGCCUAUUUU	620	3979	GUCCCAUCAGCCUAUUUU	620	3997	AAUAAUAGGCUAUGGGAC	945	
3997	UUUUUAAAGAAACUUGC	621	3997	UUUUUAAAGAAACUUGC	621	4015	GCAAGUUUCUUUAAAAA	946	
4015	CACUUGUUUUUUUUUAC	622	4015	CACUUGUUUUUUUUUAC	622	4033	GUAAAAAGAAAAACAGUG	947	
4033	CAGUUAUCUCCUCCUGCC	623	4033	CAGUUAUCUCCUCCUGCC	623	4051	GGCAGGAAGGAAGUAACUG	948	
4051	CCCAAAUUAUAAACUCUA	624	4051	CCCAAAUUAUAAACUCUA	624	4069	UAGAGUUUAUUUUUGGG	949	
4069	AAGUGUAAAAAAGUCUU	625	4069	AAGUGUAAAAAAGUCUU	625	4087	AAGACUUUUUUUACACUU	950	
4087	UAACAACAGCUUCUGCUU	626	4087	UAACAACAGCUUCUGCUU	626	4105	AAGCAAGAACGUGUUGUUA	951	
4105	UGUAAAAUAUGUAUUUA	627	4105	UGUAAAAUAUGUAUUUA	627	4123	UAUAAUACAUAUUUUACA	952	
4123	ACAUCUGUAUUUUAAAUU	628	4123	ACAUCUGUAUUUUAAAUU	628	4141	AAUUUAAAAUACAGAUUG	953	
4141	UCUGCUCUGAAAAAUGAC	629	4141	UCUGCUCUGAAAAAUGAC	629	4159	GUCAUUUUUCAGGAGCAGA	954	
4159	CUGUCCCAUUCUCCACUA	630	4159	CUGUCCCAUUCUCCACUA	630	4177	UGAGUGGAGAAUGGGACAG	955	
4177	ACUGCAUUGGGGCCUUUC	631	4177	ACUGCAUUGGGGCCUUUC	631	4195	GAAGGGCCCCAAUUGCAGU	956	
4195	CCCAUUGGUCUGCAUGUCU	632	4195	CCCAUUGGUCUGCAUGUCU	632	4213	AGACAUGCAGACCAUUGGG	957	
4213	UUUUUAUCAUUGCAGGCCAG	633	4213	UUUUUAUCAUUGCAGGCCAG	633	4231	CUGGCCUGCAAUGAUAAAA	958	
4231	GUGGACAGAGGGAGAAGGG	634	4231	GUGGACAGAGGGAGAAGGG	634	4249	CCCUUCUCCUUCUGUCCAC	959	
4249	GAGAACAGGGGUCGCCAAC	635	4249	GAGAACAGGGGUCGCCAAC	635	4267	GUUGGCGACCCUGUUCUC	960	
4267	CACUUGUGUUGCUUUCUGA	636	4267	CACUUGUGUUGCUUUCUGA	636	4285	UCAGAAAGCAACACAAGUG	961	
4285	ACUGAUCCUGAACAAAGAA	637	4285	ACUGAUCCUGAACAAAGAA	637	4303	UUUCUUGUUCAGGAUCAGU	962	
4303	AGAGUAACACUGAGGCGCU	638	4303	AGAGUAACACUGAGGCGCU	638	4321	AGCGCCUCAGUGUUACUCU	963	
4321	UCGCUCCCAUGCACAACUC	639	4321	UCGCUCCCAUGCACAACUC	639	4339	GAGUUGUGCAUGGGAGCGA	964	
4339	CUCCAAACACUUAUCCUC	640	4339	CUCCAAACACUUAUCCUC	640	4357	GAGGAUAAGUGUUUUGGAG	965	
4357	CCUGCAAGAGUGGGCUUUC	641	4357	CCUGCAAGAGUGGGCUUUC	641	4375	GAAGCCCACUCUUGCAGG	966	
4375	CCAGGGUCUUUACUGGGAA	642	4375	CCAGGGUCUUUACUGGGAA	642	4393	UUCCAGUAAAGACCCUGG	967	
4393	AGCAGUUAAGCCCCUCCU	643	4393	AGCAGUUAAGCCCCUCCU	643	4411	AGGAGGGGGCUUACUGCU	968	
4411	UCACCCUUCUUUUUUUCU	644	4411	UCACCCUUCUUUUUUUCU	644	4429	AGAAAAAGGAAGGGGUGA	969	
4429	UUUCUUUACUCCUUUGGCU	645	4429	UUUCUUUACUCCUUUGGCU	645	4447	AGCCAAAGGAGUAAAGAAA	970	
4447	UUCAAAGGAUUUUGGAAA	646	4447	UUCAAAGGAUUUUGGAAA	646	4465	UUUCCAAAAUCCUUUGAA	971	
4465	AGAAACAUAUGCUUUACA	647	4465	AGAAACAUAUGCUUUACA	647	4483	UGUAAAGCAUAUUGUUUCU	972	
4483	ACUCAUUUCAAUUUCUAA	648	4483	ACUCAUUUCAAUUUCUAA	648	4501	UUAGAAAUUGAAAAUGAGU	973	
4501	AAUUUGCAGGGGAUACUGA	649	4501	AAUUUGCAGGGGAUACUGA	649	4519	UCAGUAUCCUCCUGCAAAU	974	
4519	AAAAUACGGCAGGUGGCC	650	4519	AAAAUACGGCAGGUGGCC	650	4537	GGCCACCUGCCGUUUUUU	975	
4537	CUAAGGCUGCUGUAAAGUU	651	4537	CUAAGGCUGCUGUAAAGUU	651	4555	AACUUUACAGCAGCCUUAG	976	
4555	UGAGGGGAGAGGAAUUCU	652	4555	UGAGGGGAGAGGAAUUCU	652	4573	AAGAUUCCUCUCCCUCA	977	
4573	UAAGAUUACAAGAUAAAA	653	4573	UAAGAUUACAAGAUAAAA	653	4591	UUUUUAUCUUGUAAUUA	978	
4591	AACGAUCCCUAAACAAA	654	4591	AACGAUCCCUAAACAAA	654	4609	UUUGUUAGGGGAUUCGUU	979	

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES					
4609 AAAGAACAUAAGAACUGGU	655	4609 AAAGAACAUAAGAACUGGU	658627	ACCAGUUCUAUUGUUCUUU	980
4627 UCUUCCAUAUUGCCACCUU	656	4627 UCUUCCAUAUUGCCACCUU	658645	AAGGUGGCAAAAUGGAAGA	981
4645 UUCCUGUUAUGACAGCUA	657	4645 UUCCUGUUAUGACAGCUA	658663	UAGCUGUCAUGAACAGGAA	982
4663 ACUAACCUUGGAGACAGUAA	658	4663 ACUAACCUUGGAGACAGUAA	658681	UUACUGUCUCCAGGUUAGU	983
4681 ACAUUUCAUUAACCAAAGA	659	4681 ACAUUUCAUUAACCAAAGA	6594699	UCUUUGGUUAAUGAAAUUGU	984
4699 AAAGUGGUCACCUAGACCU	660	4699 AAAGUGGUCACCUAGACCU	660717	AGGUCAGGUGACCCACUUU	985
4717 UCUGAAGAGCUGAGUACUC	661	4717 UCUGAAGAGCUGAGUACUC	661735	GAGUACUCAGCUCUUCAGA	986
4735 CAGGCCACUCCAAUCACCC	662	4735 CAGGCCACUCCAAUCACCC	662753	GGGUGAUUGGAGUGGCCUG	987
4753 CUACAAGAUGCCAAGGAGG	663	4753 CUACAAGAUGCCAAGGAGG	662771	CCUCCUUGGCAUCUUGUAG	988
4771 GUCCCAGGAAGUCCAGCUC	664	4771 GUCCCAGGAAGUCCAGCUC	664789	GAGCUGGACUCCUGGGAC	989
4789 CCUUAACUGACGCUAGUC	665	4789 CCUUAACUGACGCUAGUC	665807	GACUAGCGUCAGUUUAAGG	990
4807 CAAUAAACCUGGGCAAGUG	666	4807 CAAUAAACCUGGGCAAGUG	666825	CACUUGCCCAGGUUUAUUG	991
4825 GAGGCAAGAGAAUAGAGGA	667	4825 GAGGCAAGAGAAUAGAGGA	667843	UCCUCAUUUCUUGCCUC	992
4843 AAGAAUCCAUCUGUGAGGU	668	4843 AAGAAUCCAUCUGUGAGGU	668861	ACCUCACAGAUGGAUUCUU	993
4861 UGACAGGCAAGGAUGAAAG	669	4861 UGACAGGCAAGGAUGAAAG	668879	CUUUCAUCCUUGCCUGUCA	994
4879 GACAAAGAAGGAAAAGAGU	670	4879 GACAAAGAAGGAAAAGAGU	670897	ACUCUUUCCUUCUUUGUC	995
4897 UAUCAXAGGCAGAAAGGAG	671	4897 UAUCAXAGGCAGAAAGGAG	671915	CUCCUUUCUGCCUUUGAUA	996
4915 GAUCAUUUAGUUGGUCUG	672	4915 GAUCAUUUAGUUGGUCUG	672933	CAGACCCAACUAAAUGAUC	997
4933 GAAAGGAAAAGUCUUUGCU	673	4933 GAAAGGAAAAGUCUUUGCU	673951	AGCAAAGACUUUUCUUUC	998
4951 UAUCCGACAUGUACUGCUA	674	4951 UAUCCGACAUGUACUGCUA	674969	UAGCAGUACAUGUCGGAUA	999
4969 AGUACCUGUAAGCAUUUUA	675	4969 AGUACCUGUAAGCAUUUUA	675987	UAAAAGUCUUACAGGUACU	1000
4987 AGGUCCAGAAUGGAAAAA	676	4987 AGGUCCAGAAUGGAAAAA	676005	UUUUUCCAUCUGGGACCU	1001
5005 AAAAUACAGCUAUUGGUAA	677	5005 AAAAUACAGCUAUUGGUAA	677023	UUACCAUAGCUGAUUUUU	1002
5023 AUUAUAAUAGUCCUUUCC	678	5023 AUUAUAAUAGUCCUUUCC	678041	GGAAAGGACAUUAUUAUUA	1003
5041 CCUGGAGUCAGUUUUUUUA	679	5041 CCUGGAGUCAGUUUUUUUA	679059	UAAAAAACUGACUCCAGG	1004
5059 AAAAGUUAACUCUUAGUU	680	5059 AAAAGUUAACUCUUAGUU	680077	AACUAAGAGUUAACUUUUU	1005
5077 UUUUACUUGUUAAUUCUA	681	5077 UUUUACUUGUUAAUUCUA	681095	UAGAAUUAACAAGUAAAA	1006
5095 AAAAGAGAAGGGAGCUGAG	682	5095 AAAAGAGAAGGGAGCUGAG	682113	CUCAGCUCUUUCUCUUUU	1007
5113 GGCCAUUCUCCUGUAGGAGU	683	5113 GGCCAUUCUCCUGUAGGAGU	683131	ACUCCUACAGGGAUUGGCC	1008
5131 UAAAGAUAAAAGGAUAGGA	684	5131 UAAAGAUAAAAGGAUAGGA	684149	UCCUAUCCUUUAUCUUUA	1009
5149 AAAAGAUCAAAGCUCUAA	685	5149 AAAAGAUCAAAGCUCUAA	685167	UUAGAGCUUUGAAUCUUUU	1010
5167 AUAGAGUCACAGCUUUCCC	686	5167 AUAGAGUCACAGCUUUCCC	686185	GGGAAAGCUGUGACUCUAU	1011
5185 CAGGUUAUAAAACCUAAAAU	687	5185 CAGGUUAUAAAACCUAAAAU	687203	AUUUUAGGUUUUAUACCUU	1012
5203 UUAAGAAGUACAUAAGCA	688	5203 UUAAGAAGUACAUAAGCA	688221	UGCUUUUGUACUUCUUAA	1013
5221 AGAGGUGGAAAUGAUCUA	689	5221 AGAGGUGGAAAUGAUCUA	689239	UAGAUCUUUUCCACCUCU	1014
5239 AGUCCUGAUAGCUACCCA	690	5239 AGUCCUGAUAGCUACCCA	690257	UGGUAGCUAUCAGGAACU	1015
5257 ACAGAGCAAGUGAUUUUAU	691	5257 ACAGAGCAAGUGAUUUUAU	691275	UAUAAAACACUUGCUCUGU	1016

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siNA AND TARGET SEQUENCES									
5275	AAAUUUGAAAUCCAAACUA	692	5275	AAAUUUGAAAUCCAAACUA	692	5293	UAGUUUGGAUUUCAAUUU	1017	
5293	ACUUUCUUAUAUCACUUU	693	5293	ACUUUCUUAUAUCACUUU	693	5311	AAAGUGAUUUAAGAAAGU	1018	
5311	UGGUCUCCAUUUUUCCAG	694	5311	UGGUCUCCAUUUUUCCAG	694	5329	CUGGGAAAAAUGGAGACCA	1019	
5329	GGACAGGAAUAUGUCCCC	695	5329	GGACAGGAAUAUGUCCCC	695	5347	GGGACAUUUUCCUGUCC	1020	
5347	CCCCUAACUUUCUUGCUUC	696	5347	CCCCUAACUUUCUUGCUUC	696	5365	GAAGCAAGAAAGUUAGGGG	1021	
5365	CAAAAAUAAAAUCCAGCA	697	5365	CAAAAAUAAAAUCCAGCA	697	5383	UGCUGGAUUUAAUUUUUG	1022	
5383	AUCCCAAGAUAUUCUACA	698	5383	AUCCCAAGAUAUUCUACA	698	5401	UGUAGAAUGAUCUUGGGAU	1023	
5401	AAGUAAUUUUGCACAGACA	699	5401	AAGUAAUUUUGCACAGACA	699	5419	UGUCUGUGCAAAAUUACUU	1024	
5419	AUCUCCUACCCCAGUGCC	700	5419	AUCUCCUACCCCAGUGCC	700	5437	GGCACUGGGUGAGGAGAU	1025	
5437	CUGUCUGGAGCUCACCCAA	701	5437	CUGUCUGGAGCUCACCCAA	701	5455	UUGGGUGAGCUCAGACAG	1026	
5455	AGGUCACCAACAACUUGG	702	5455	AGGUCACCAACAACUUGG	702	5473	CCAAGUUGUUUGGUGACCU	1027	
5473	GUUGUGAACCAACUGCCUU	703	5473	GUUGUGAACCAACUGCCUU	703	5491	AAGGCAGUUGGUUACAAC	1028	
5491	UAACCUUCUGGGGAGGGG	704	5491	UAACCUUCUGGGGAGGGG	704	5509	CCCCUCCCCAGAAAGGUUA	1029	
5509	GAUUUAGCUAGACUAGGAG	705	5509	GAUUUAGCUAGACUAGGAG	705	5527	CUCCUAGUCUAGCUAAUCC	1030	
5527	GACCAGAAGUGAAUGGGAA	706	5527	GACCAGAAGUGAAUGGGAA	706	5545	UUCCCAUUCACUUCUGGUC	1031	
5545	AAGGGUGAGGACUUCACAA	707	5545	AAGGGUGAGGACUUCACAA	707	5563	UUGUGAAGUCCUACCCUU	1032	
5563	AUGUUGGCCUGUCAGAGCU	708	5563	AUGUUGGCCUGUCAGAGCU	708	5581	AGCUCUGACAGGCCAACAU	1033	
5581	UUGAUUAGAAGCCAAGACA	709	5581	UUGAUUAGAAGCCAAGACA	709	5599	UGUCUUGGCUUCUAAUCAA	1034	
5599	AGUGGCAGCAAAGGAAGAC	710	5599	AGUGGCAGCAAAGGAAGAC	710	5617	GUCUUCUUUGCUGCCACU	1035	
5617	CUUGGCCAGGAAAAACCU	711	5617	CUUGGCCAGGAAAAACCU	711	5635	AGGUUUUCCUGGGCCAAG	1036	
5635	UGUGGGUUGUGCUAAUUUC	712	5635	UGUGGGUUGUGCUAAUUUC	712	5653	GAAAUUAGCACAAACCACA	1037	
5653	CUGUCCAGAAAAUAGGGUG	713	5653	CUGUCCAGAAAAUAGGGUG	713	5671	CACCCUAAUUUCUGGACAG	1038	
5671	GGACAGAAGCUUGUGGGU	714	5671	GGACAGAAGCUUGUGGGU	714	5689	ACCCCAAGCUUCUGUCC	1039	
5689	UGCAUGGAGGAAUUGGGAC	715	5689	UGCAUGGAGGAAUUGGGAC	715	5707	GUCCCAAUUCUCCAUUGCA	1040	
5707	CCUGGUUAUGUGUUAUUC	716	5707	CCUGGUUAUGUGUUAUUC	716	5725	GAAUACAACAUAACCAGG	1041	
5725	CUCGGACUGUGAAUUUUGG	717	5725	CUCGGACUGUGAAUUUUGG	717	5743	CCAAAAUUCACAGUCCGAG	1042	
5743	GUGAUGUAAAACAGAAUUAU	718	5743	GUGAUGUAAAACAGAAUUAU	718	5761	AUAUUCUGUUUACAUCAC	1043	
5761	UUCUGUAAACCUAAUGUCU	719	5761	UUCUGUAAACCUAAUGUCU	719	5779	AGACAUUAGGUUUACAGAA	1044	
5779	UGUAUAAAUUAGAGCGUU	720	5779	UGUAUAAAUUAGAGCGUU	720	5797	AACGCUCAUUUUUAUACA	1045	
5797	UAACACAGUAAAAUUAUCA	721	5797	UAACACAGUAAAAUUAUCA	721	5815	UGAAUAAUUUACUGUGUUA	1046	
5815	AAUAAGAAGUCAAAAAAAA	722	5815	AAUAAGAAGUCAAAAAAAA	722	5833	UUUUUUUUGACUUCUUAUU	1047	
5821	AAGUCAAAAAAAAAAAAAA	723	5821	AAGUCAAAAAAAAAAAAAA	723	5839	UUUUUUUUUUUUUGACUU	1048	

PSEN1 NM_007319

Pos	Seq	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID
3	GACAGAGUUACCUGCACCG	1049	3	GACAGAGUUACCUGCACCG	1049	21	CGGUGCAGGUACUCUGUC	1132
21	GUUGUCCUACUCCAGAAU	1050	21	GUUGUCCUACUCCAGAAU	1050	39	AUUCUGGAAGUAGGACAAC	1133
39	UGCACAGAUUCUGAGGAC	1051	39	UGCACAGAUUCUGAGGAC	1051	57	GUCCUCAGACAUCUGUGCA	1134

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES											
57	CAACCACCUGAGCAAUACU	1052	57	CAACCACCUGAGCAAUACU	1052	75	AGUAUUGCUCAGGUGGUUG	1135			
75	UAAUGACAAUAGAGAACGG	1053	75	UAAUGACAAUAGAGAACGG	1053	93	CCGUUCUCUAUUGUCAUUA	1136			
93	GCAGGAGCACAAACGACAGA	1054	93	GCAGGAGCACAAACGACAGA	1054	111	UCUGUCGUUGUGCUCCUGC	1137			
111	ACGGAGCCUUGGCCACCCU	1055	111	ACGGAGCCUUGGCCACCCU	1055	129	AGGGUGGCCAAGGCUCCGU	1138			
129	UGAGCCAUUAUCUAAUGGA	1056	129	UGAGCCAUUAUCUAAUGGA	1056	147	UCCAUUAGAUAAUGGCUCA	1139			
147	ACGACCCCAGGGUACUCC	1057	147	ACGACCCCAGGGUACUCC	1057	165	GGAGUUACCCUGGGGUCGU	1140			
165	CCGGCAGGUGGUGGAGCAA	1058	165	CCGGCAGGUGGUGGAGCAA	1058	183	UUGCUCACCACCUGCCGG	1141			
183	AGAUGAGGAAGAAGAUAG	1059	183	AGAUGAGGAAGAAGAUAG	1059	201	CUCAUCUUCUCCUCAUCU	1142			
201	GGAGCUGACAUUGAAUAU	1060	201	GGAGCUGACAUUGAAUAU	1060	219	AUAUUCAAUGUCAGCUCC	1143			
219	UGGCGCCAAGCAUGUGAUC	1061	219	UGGCGCCAAGCAUGUGAUC	1061	237	GAUCACAUGCUGGGGCCA	1144			
237	CAUGCUCUUUGUCCUGUG	1062	237	CAUGCUCUUUGUCCUGUG	1062	255	CACAGGACAAAGAGCAUG	1145			
255	GACUCUCUGCAUGGUGGUG	1063	255	GACUCUCUGCAUGGUGGUG	1063	273	CACCACCAUGCAGAGAGUC	1146			
273	GGUCGUGGCUACCAUUAAG	1064	273	GGUCGUGGCUACCAUUAAG	1064	291	CUUAAUGGUAGCCACGACC	1147			
291	GUCAGUCAGCUUUUAUACC	1065	291	GUCAGUCAGCUUUUAUACC	1065	309	GGUAUAAAAGCUGACUGAC	1148			
309	CCGGAAGGAUGGGCAGCUA	1066	309	CCGGAAGGAUGGGCAGCUA	1066	327	UAGCUGCCAUCCUUCGG	1149			
327	AAUCUAUACCCCAUUCACA	1067	327	AAUCUAUACCCCAUUCACA	1067	345	UGUGAAUGGGGUUAGAUAU	1150			
345	AGAAGAUACCGAGACUGUG	1068	345	AGAAGAUACCGAGACUGUG	1068	363	CACAGUCUCGGUAUCUUCU	1151			
363	GGGCCAGAGACCCUGCAC	1069	363	GGGCCAGAGACCCUGCAC	1069	381	GUGCAGGGCUCUCUGGCC	1152			
381	CUCAAUUCUGAAUGCUGCC	1070	381	CUCAAUUCUGAAUGCUGCC	1070	399	GGCAGCAUUCAGAAUUGAG	1153			
399	CAUCAUGAUCAGUGUCAUU	1071	399	CAUCAUGAUCAGUGUCAUU	1071	417	AAUGACACUGAUGAUGAUG	1154			
417	UGUUGUCAUGACUAUCCUC	1072	417	UGUUGUCAUGACUAUCCUC	1072	435	GAGGAUAGUCAUGACAACA	1155			
435	CCUGGUGGUUCUGUAUAAA	1073	435	CCUGGUGGUUCUGUAUAAA	1073	453	UUUAUACAGAACCCACAG	1156			
453	AUACAGGUGCUAUAAGGUC	1074	453	AUACAGGUGCUAUAAGGUC	1074	471	GACCUUAUAGCACCUGUAU	1157			
471	CAUCCAUGCCUGGCUUAUU	1075	471	CAUCCAUGCCUGGCUUAUU	1075	489	AAUAAGCCAGGCAUGGAUG	1158			
489	UAUAUCAUCUCUAUUGUUG	1076	489	UAUAUCAUCUCUAUUGUUG	1076	507	CAACAAUAGAGAUGAUUA	1159			
507	GCUGUUCUUUUUUAUUC	1077	507	GCUGUUCUUUUUUAUUC	1077	525	GAAUGAAAAAAGAACAGC	1160			
525	CAUUUACUUGGGGAAGUG	1078	525	CAUUUACUUGGGGAAGUG	1078	543	CACUCCCCCAAGUAAAUG	1161			
543	GUUUAAAACCUAAACGUU	1079	543	GUUUAAAACCUAAACGUU	1079	561	AACGUUAUAGGUUUUAAAC	1162			
561	UGCUGGACUACAUUACU	1080	561	UGCUGGACUACAUUACU	1080	579	AGUAAUGUAGUCCACAGCA	1163			
579	UGUUGCACUCCUGAUCUGG	1081	579	UGUUGCACUCCUGAUCUGG	1081	597	CCAGAUCAAGGAGUGCAACA	1164			
597	GAAUUUUGGUGUGGUGGA	1082	597	GAAUUUUGGUGUGGUGGA	1082	615	UCCCACCACACCAAAAUUC	1165			
615	AAUGAUUUCCAUCACUGG	1083	615	AAUGAUUUCCAUCACUGG	1083	633	CCAGUGAAUGGAAAUCAUU	1166			
633	GAAAGGUCCACUUCGACUC	1084	633	GAAAGGUCCACUUCGACUC	1084	651	GAGUCGAAGUGACCUUUC	1167			
651	CCAGCAGGCAUAUCUCAUU	1085	651	CCAGCAGGCAUAUCUCAUU	1085	669	AAUGAGAUUAGCCUGCUGG	1168			
669	UAUGAUUAGUGCCUCAUG	1086	669	UAUGAUUAGUGCCUCAUG	1086	687	CAUGAGGGCACUAUUAUA	1169			
687	GGCCUUGGUGUUUAUCAAG	1087	687	GGCCUUGGUGUUUAUCAAG	1087	705	CUUGAUAAACACCAGGGCC	1170			
705	GUACCUCCUGAAGGACU	1088	705	GUACCUCCUGAAGGACU	1088	723	AGUCCAUUCAGGGAGGUAC	1171			

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES											
723	UGCUGGGCUCAUCUUGGCU	1089	723	UGCUGGGCUCAUCUUGGCU	1089	741	AGCCAAGAUGAGCCACGCA	1172			
741	UGUGAUUUCGGUAUAUGAU	1090	741	UGUGAUUUCGGUAUAUGAU	1090	759	AUCAUAUACCGAAAUCACA	1173			
759	UUUAGUGGCUGUUUUGUGU	1091	759	UUUAGUGGCUGUUUUGUGU	1091	777	ACACAAAACAGCCACUAAA	1174			
777	UCCGAAAGGUCCACUUCGU	1092	777	UCCGAAAGGUCCACUUCGU	1092	795	ACGAAGUGGACCUUUCGGA	1175			
795	UAUGCUGGUUGAAACAGCU	1093	795	UAUGCUGGUUGAAACAGCU	1093	813	AGCUGUUUCAACCAGCAUA	1176			
813	UCAGGAGAGAAAUGAAACG	1094	813	UCAGGAGAGAAAUGAAACG	1094	831	CGUUUCAUUUCUCCUGA	1177			
831	GCUUUUUCCAGCUCUCAU	1095	831	GCUUUUUCCAGCUCUCAU	1095	849	AAUGAGAGCUGGAAAAAGC	1178			
849	UUACUCCUCAACAAUGGUG	1096	849	UUACUCCUCAACAAUGGUG	1096	867	CACCAUUGUUGAGGAGUAA	1179			
867	GUGGUUGGUGAAUAUGGCA	1097	867	GUGGUUGGUGAAUAUGGCA	1097	885	UGCCAUAUUCACCAACCAC	1180			
885	AGAAGGAGACCCGGAAGCU	1098	885	AGAAGGAGACCCGGAAGCU	1098	903	AGCUUCCGGGUCUCCUUCU	1181			
903	UCAAAGGAGAGUAUCCAAA	1099	903	UCAAAGGAGAGUAUCCAAA	1099	921	UUUGGAUACUCUCCUUUGA	1182			
921	AAAUUCCAAGUAUAUGCA	1100	921	AAAUUCCAAGUAUAUGCA	1100	939	UGCAUUAUACUUGGAAUUU	1183			
939	AGAAAGAGCCUGUCUGCCU	1101	939	AGAAAGAGCCUGUCUGCCU	1101	957	AGGCAGACAGGCUCUUUCU	1184			
957	UCCUGCUGCCAUAACCCUG	1102	957	UCCUGCUGCCAUAACCCUG	1102	975	CAGGUUGAUGGCAGCAGGA	1185			
975	GCUGUCUAUAGCUCUCCAU	1103	975	GCUGUCUAUAGCUCUCCAU	1103	993	CAUGGGAGCUAUAAGACAGC	1186			
993	GGCACCCAGGCUGUUAUG	1104	993	GGCACCCAGGCUGUUAUG	1104	1011	CAUGAACAGCCUGGGUGCC	1187			
1011	GCCAAAGGGUGCCUGCAGG	1105	1011	GCCAAAGGGUGCCUGCAGG	1105	1029	CCUGCAGGCACCCUUUGGC	1188			
1029	GCCACGGCACAGAAAGGG	1106	1029	GCCACGGCACAGAAAGGG	1106	1047	CCCUUUCUGUGCCGUGGGC	1189			
1047	GAGUCACAAGACACUGUUG	1107	1047	GAGUCACAAGACACUGUUG	1107	1065	CAACAGUGUCUUGUGACUC	1190			
1065	GCAGAGAAUGAUGAUGGCG	1108	1065	GCAGAGAAUGAUGAUGGCG	1108	1083	CGCCAUCAUAUUCUCUGC	1191			
1083	GGGUUCAGUGAGGAAUGGG	1109	1083	GGGUUCAGUGAGGAAUGGG	1109	1101	CCCAUUCUCCACUGAACCC	1192			
1101	GAAGCCAGAGGGACAGUC	1110	1101	GAAGCCAGAGGGACAGUC	1110	1119	GACUGUCCUCCUGGGCUUC	1193			
1119	CAUCUAGGGCCUACUCGU	1111	1119	CAUCUAGGGCCUACUCGU	1111	1137	AGCGAUGAGGCCCUAGAU	1194			
1137	UCUACACUGAGUCACGAG	1112	1137	UCUACACUGAGUCACGAG	1112	1155	CUGGUGACUCAGGUGUAGA	1195			
1155	GCUGCUGUCCAGGAACUUU	1113	1155	GCUGCUGUCCAGGAACUUU	1113	1173	AAAGUCCUGGACAGCAGC	1196			
1173	UCCAGCAGUAUCCUCGUG	1114	1173	UCCAGCAGUAUCCUCGUG	1114	1191	CAGCGAGGAUACUGCUGGA	1197			
1191	GGUGAAGACCCAGAGGAAA	1115	1191	GGUGAAGACCCAGAGGAAA	1115	1209	UUUCCUCUGGGUCUUCACC	1198			
1209	AGGGGAGUAAAACUUGGAU	1116	1209	AGGGGAGUAAAACUUGGAU	1116	1227	AUCCAAGUUUACUCCCCU	1199			
1227	UUGGGAGAUUUAUUUUCU	1117	1227	UUGGGAGAUUUAUUUUCU	1117	1245	AGAAAUGAAAUCUCCAA	1200			
1245	UACAGUGUUCUGGUUGGUA	1118	1245	UACAGUGUUCUGGUUGGUA	1118	1263	UACCAACAGAACACUGUA	1201			
1263	AAAGCCUCAGCAACAGCCA	1119	1263	AAAGCCUCAGCAACAGCCA	1119	1281	UGGCUGUUGCUGAGGCUUU	1202			
1281	AGUGGAGACUGGAACACAA	1120	1281	AGUGGAGACUGGAACACAA	1120	1299	UUGUGUCCAGUCUCCACU	1203			
1299	ACCAUAGCCUGUUCGUAG	1121	1299	ACCAUAGCCUGUUCGUAG	1121	1317	CUACGAAACAGGCUAUGGU	1204			
1317	GCCAUUAUAAUUGGUUUGU	1122	1317	GCCAUUAUAAUUGGUUUGU	1122	1335	ACAAACCAUUAUAAUUGGC	1205			
1335	UGCCUUAUUAUUAUACUCC	1123	1335	UGCCUUAUUAUUAUACUCC	1123	1353	GGAGUAAUAAUGUAAGGCA	1206			
1353	CUUGCCAUUUUAAGAAAG	1124	1353	CUUGCCAUUUUAAGAAAG	1124	1371	CUUUUUGAAAAUGGCAAG	1207			
1371	GCAUUGCCAGCUCUCCAA	1125	1371	GCAUUGCCAGCUCUCCAA	1125	1389	UUGGAAGAGCUGGCAUUGC	1208			

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siNA AND TARGET SEQUENCES									
1389	AUCUCCAUCACCUUUUGGC	1126	1389	AUCUCCAUCACCUUUUGGC	1126	1407	GCCCAAAGGUGAUGGAGAU	1209	
1407	CUUGUUUUUCUACUUUGCCA	1127	1407	CUUGUUUUUCUACUUUGCCA	1127	1425	UGGCAAAGUAGAAAACAAG	1210	
1425	ACAGAUUAUCUUGUACAGC	1128	1425	ACAGAUUAUCUUGUACAGC	1128	1443	GCUGUACAAGAUAAUCUGU	1211	
1443	CCUUUUUUGGACCAAUUAG	1129	1443	CCUUUUUUGGACCAAUUAG	1129	1461	CUAAUUGGUCCAUAAGG	1212	
1461	GCAUCCAUCACAAUUUUUAUA	1130	1461	GCAUCCAUCACAAUUUUUAUA	1130	1479	UAUAAAAUUGAUGGAAUGC	1213	
1464	UCCAUCACAAUUUUUAUAUCU	1131	1464	UCCAUCACAAUUUUUAUAUCU	1131	1482	AGAUUAAAAUUGAUGGAA	1214	
PSEN2 NM_000447									
Pos	Seq	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
3	AGCGGGCGGCGGAGCAGGCA	1215	3	AGCGGGCGGCGGAGCAGGCA	1215	21	UGCCUGUCUCCGCCGCCGCU	1339	
21	AUUUCCAGCAGUGAGGAGA	1216	21	AUUUCCAGCAGUGAGGAGA	1216	39	UCUCCUCACUGCUGGAAAU	1340	
39	ACAGCCAGAAGCAAGCUAU	1217	39	ACAGCCAGAAGCAAGCUAU	1217	57	AUAGCUUGCUCUGGCUGU	1341	
57	UUGGAGCUGAAGGAACCUG	1218	57	UUGGAGCUGAAGGAACCUG	1218	75	CAGGUUCCUUCAGCUCCAA	1342	
75	GAGACAGAAGCUAGUCCCC	1219	75	GAGACAGAAGCUAGUCCCC	1219	93	GGGGACUAGCUUCUGUCUC	1343	
93	CCCUCUGAAUUUUACUGAU	1220	93	CCCUCUGAAUUUUACUGAU	1220	111	AUCAGUAAAAUUCAGAGGG	1344	
111	UGAAGAAACUGAGGCCACA	1221	111	UGAAGAAACUGAGGCCACA	1221	129	UGUGGCCUCAGUUUCUUA	1345	
129	AGAGCUAAAGUGACUUUUC	1222	129	AGAGCUAAAGUGACUUUUC	1222	147	GAAAGUCACUUUAGCUCU	1346	
147	CCCAAGGUCGCCAGCGAG	1223	147	CCCAAGGUCGCCAGCGAG	1223	165	CUCGUGGGGCGACCUUGGG	1347	
165	GGACGUGGGACUUCUCAGA	1224	165	GGACGUGGGACUUCUCAGA	1224	183	UCUGAGAAGUCCACGUCC	1348	
183	ACGUCAGGAGAGUGAUGUG	1225	183	ACGUCAGGAGAGUGAUGUG	1225	201	CACAUCACUCUCCUGACGU	1349	
201	GAGGGAGCUGUGUGACCAU	1226	201	GAGGGAGCUGUGUGACCAU	1226	219	AUGGUCACACAGCUCCUC	1350	
219	UAGAAAGUGACGUGUAAA	1227	219	UAGAAAGUGACGUGUAAA	1227	237	UUUAACACGUCACUUUCUA	1351	
237	AAACCAGCGUGCCUCUU	1228	237	AAACCAGCGUGCCUCUU	1228	255	AAGAGGCGAGCGUGGUUU	1352	
255	UUGAAAGCCAGGGAGCAUC	1229	255	UUGAAAGCCAGGGAGCAUC	1229	273	GAUGCUCCUGGCUUUCAA	1353	
273	CAUUCAUUUAGCCUGCUGA	1230	273	CAUUCAUUUAGCCUGCUGA	1230	291	UCAGCAGGCUAAAUGAAUG	1354	
291	AGAAGAAGAAACCAAGUGU	1231	291	AGAAGAAGAAACCAAGUGU	1231	309	ACACUUGGUUUCUUCUUCU	1355	
309	UCCGGGAUUCAGACCUCUC	1232	309	UCCGGGAUUCAGACCUCUC	1232	327	GAGAGGUCUGAAUCCCGGA	1356	
327	CUGCGGCCCAAGUGUUCG	1233	327	CUGCGGCCCAAGUGUUCG	1233	345	CGAACACUUGGGGCCGAG	1357	
345	GUGGUGCUUCCAGAGGCAG	1234	345	GUGGUGCUUCCAGAGGCAG	1234	363	CUGCCUCUGGAAGCACCCAC	1358	
363	GGGCUAUGCUCACAUUCAU	1235	363	GGGCUAUGCUCACAUUCAU	1235	381	AUGAAUGUGAGCAUAGCCC	1359	
381	UGGCCUCUGACAGCGAGGA	1236	381	UGGCCUCUGACAGCGAGGA	1236	399	UCCUCGCGUCAGAGGCCA	1360	
399	AAGAAGUGUGUGAUGAGCG	1237	399	AAGAAGUGUGUGAUGAGCG	1237	417	CGCUCAUCACACAUUCUU	1361	
417	GGACGUCCUAAUGUCGGC	1238	417	GGACGUCCUAAUGUCGGC	1238	435	GCCGACAUUAGGGACGUCC	1362	
435	CCGAGAGCCCCACGCCGCG	1239	435	CCGAGAGCCCCACGCCGCG	1239	453	CGCGGCGUGGGGCUUCGG	1363	
453	GCUCCUGGCCAGGAGGGCAG	1240	453	GCUCCUGGCCAGGAGGGCAG	1240	471	CUGCCUCCUGGCAGGAGC	1364	
471	GGCAGGGCCCAGAGGAUGG	1241	471	GGCAGGGCCCAGAGGAUGG	1241	489	CCAUCCUUGGGCCUGCC	1365	
489	GAGAGAACACUGCCCAGUG	1242	489	GAGAGAACACUGCCCAGUG	1242	507	CACUGGGCAGUGUUCUCUC	1366	

TABLE II-continued

APP, BACE, PSEN1, PSEN2 s1NA AND TARGET SEQUENCES											
507	GGAGAAGCCAGGAGAACGA	1243	507	GGAGAAGCCAGGAGAACGA	1243	525	UCGUUCUCCUGGCUUCUCC	1367			
525	AGGAGGACGGUGAGGAGGA	1244	525	AGGAGGACGGUGAGGAGGA	1244	543	UCCUCCUACCGUCCUCCU	1368			
543	ACCCUGACCGCUAUGUCUG	1245	543	ACCCUGACCGCUAUGUCUG	1245	561	CAGACAUAGCGGUCAGGGU	1369			
561	GUAGUGGGGUUCCGGGCG	1246	561	GUAGUGGGGUUCCGGGCG	1246	579	CGCCGGGAACCCACUAC	1370			
579	GGCCGCCAGGCCUGGAGGA	1247	579	GGCCGCCAGGCCUGGAGGA	1247	597	UCCUCCAGGCCUGGCGGCC	1371			
597	AAGAGCUGACCCUCAAUA	1248	597	AAGAGCUGACCCUCAAUA	1248	615	UAUUUGAGGGUCAGCUUU	1372			
615	ACGGAGCGAAGCAGGUGAU	1249	615	ACGGAGCGAAGCAGGUGAU	1249	633	AUCACGUGCUUCGCUCCGU	1373			
633	UCAUGCUGUUUGGCCUGU	1250	633	UCAUGCUGUUUGGCCUGU	1250	651	ACAGGCACAAACAGCAUGA	1374			
651	UCACUCUGUGCAUGAUCGU	1251	651	UCACUCUGUGCAUGAUCGU	1251	669	ACGAUCAUGCACAGAGUGA	1375			
669	UGGUGGUAGCCACCAUCAA	1252	669	UGGUGGUAGCCACCAUCAA	1252	687	UUGAUGGUGGCUACCACCA	1376			
687	AGUCUGUGCGCUUCUACAC	1253	687	AGUCUGUGCGCUUCUACAC	1253	705	GUGUAGAAGCGCACAGACU	1377			
705	CAGAGAAGAAUGGACAGCU	1254	705	CAGAGAAGAAUGGACAGCU	1254	723	AGCUGUCCAUCUUCUCUG	1378			
723	UCAUCUACACGACAUUCAC	1255	723	UCAUCUACACGACAUUCAC	1255	741	GUGAAUGUCGUGUAGAUGA	1379			
741	CUGAGGACACACCCUCGGU	1256	741	CUGAGGACACACCCUCGGU	1256	759	ACCGAGGGUGUGUCCUCAG	1380			
759	UGGGCCACGCGCCUCCUCAA	1257	759	UGGGCCACGCGCCUCCUCAA	1257	777	UUGAGGAGGCGCUGGCCCA	1381			
777	ACUCCGUGCUGAACACCCU	1258	777	ACUCCGUGCUGAACACCCU	1258	795	AGGGUGUUCAGCACGGAGU	1382			
795	UCAUCAUGAUCAGCGUCAU	1259	795	UCAUCAUGAUCAGCGUCAU	1259	813	AUGACGCUGAUGAUGAUGA	1383			
813	UCGUGGUUAUGACCAUCUU	1260	813	UCGUGGUUAUGACCAUCUU	1260	831	AAGAUGGUCAUAACCACGA	1384			
831	UCUUGGUGGUGCUCUACAA	1261	831	UCUUGGUGGUGCUCUACAA	1261	849	UUGUAGAGCACCACCAAGA	1385			
849	AGUACCGCUGCUACAAGUU	1262	849	AGUACCGCUGCUACAAGUU	1262	867	AACUUGUAGCAGCGGUACU	1386			
867	UCAUCCAUGGCGUGGUUGAU	1263	867	UCAUCCAUGGCGUGGUUGAU	1263	885	AUCAACCAGCCAUGGAUGA	1387			
885	UCAUGUCUUCACUGAUGCU	1264	885	UCAUGUCUUCACUGAUGCU	1264	903	AGCAUCAGUGAAGACAUGA	1388			
903	UGCUGUCCUUCUACCUA	1265	903	UGCUGUCCUUCUACCUA	1265	921	UAGGUGAAGAGGAACAGCA	1389			
921	AUAUCUACCUUGGGGAAGU	1266	921	AUAUCUACCUUGGGGAAGU	1266	939	ACUCCCCAAGGUAGAUAU	1390			
939	UGCUCAAGACCUACAAGU	1267	939	UGCUCAAGACCUACAAGU	1267	957	ACAUUGUAGGUCUUGAGCA	1391			
957	UGGCCAUGGACUACCCAC	1268	957	UGGCCAUGGACUACCCAC	1268	975	GUGGGGUAGUCCAUGGCCA	1392			
975	CCCUCUUGCUGACUGUCUG	1269	975	CCCUCUUGCUGACUGUCUG	1269	993	CAGACAGUCAGCAAGAGGG	1393			
993	GGAACUUCGGGGCAGUGGG	1270	993	GGAACUUCGGGGCAGUGGG	1270	1011	CCCACUGCCCCGAAGUCC	1394			
1011	GCAUGGUGUGCAUCCACUG	1271	1011	GCAUGGUGUGCAUCCACUG	1271	1029	CAGUGGAUGCACACCAUGC	1395			
1029	GGAAGGGCCUCUGGUGCU	1272	1029	GGAAGGGCCUCUGGUGCU	1272	1047	AGCACCAGAGGGCCUUC	1396			
1047	UGCAGCAGGCCUACCUCAU	1273	1047	UGCAGCAGGCCUACCUCAU	1273	1065	AUGAGGUAGGCCUGCUGCA	1397			
1065	UCAUGAUCAGUGCGUCAU	1274	1065	UCAUGAUCAGUGCGUCAU	1274	1083	AUGAGCGCACUGAUGAUGA	1398			
1083	UGGCCCUAGUGUUAUCAA	1275	1083	UGGCCCUAGUGUUAUCAA	1275	1101	UGAUGAACACUAGGCCCA	1399			
1101	AGUACCUCCAGAGUGGUC	1276	1101	AGUACCUCCAGAGUGGUC	1276	1119	GACCACUCUGGGAGGUACU	1400			
1119	CCGCGUGGGUCAUCCUGGG	1277	1119	CCGCGUGGGUCAUCCUGGG	1277	1137	CCCAGGAUGACCCACGCGG	1401			
1137	GCGCCAUCUCUGUGUAUGA	1278	1137	GCGCCAUCUCUGUGUAUGA	1278	1155	UCAUACACAGAGAUGGCGC	1402			
1155	AUCUCGUGGCUGUGCUGUG	1279	1155	AUCUCGUGGCUGUGCUGUG	1279	1173	CACAGCACAGCCACGAGAU	1403			

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siRNA AND TARGET SEQUENCES									
1173 GUCCCAAAGGGCCUCUGAG	1280	1173 GUCCCAAAGGGCCUCUGAG	1280	1191 CUCAGAGGCCCUUUGGGAC	1404				
1191 GAAUGCUGGUAGAAACUGC	1281	1191 GAAUGCUGGUAGAAACUGC	1281	1209 GCAGUUUCUACCAGCAUUC	1405				
1209 CCCAGGAGAGAAAUGAGCC	1282	1209 CCCAGGAGAGAAAUGAGCC	1282	1227 GGCUCAUUUCUCCUGGG	1406				
1227 CCAUAUCCCCUGCCUGAU	1283	1227 CCAUAUCCCCUGCCUGAU	1283	1245 AUCAGGGCAGGGAUAUUG	1407				
1245 UAUACUCAUCUGCCAUGGU	1284	1245 UAUACUCAUCUGCCAUGGU	1284	1263 ACCAUGGCAGAUAGAUUA	1408				
1263 UGUGGACGGUUGGCAUGGC	1285	1263 UGUGGACGGUUGGCAUGGC	1285	1281 GCCAUGCCAACCGUCCACA	1409				
1281 CGAAGCUGGACCCUCCUC	1286	1281 CGAAGCUGGACCCUCCUC	1286	1299 GAGGAGGGGUCCAGCUUCG	1410				
1299 CUCAGGGUGCCCUCAGCU	1287	1299 CUCAGGGUGCCCUCAGCU	1287	1317 AGCUGGAGGGCACCCUGAG	1411				
1317 UCCCCUACGACCCGGAGAU	1288	1317 UCCCCUACGACCCGGAGAU	1288	1335 AUCUCCGGGUCGUAGGGGA	1412				
1335 UGGAAGAAGACUCCUAUGA	1289	1335 UGGAAGAAGACUCCUAUGA	1289	1353 UCAUAGGAGUCUUCUCCA	1413				
1353 ACAGUUUUGGGGAGCCUUC	1290	1353 ACAGUUUUGGGGAGCCUUC	1290	1371 GAAGGCUCCCCAAAACUGU	1414				
1371 CAUACCCCGAAGUCUUUGA	1291	1371 CAUACCCCGAAGUCUUUGA	1291	1389 UCAAAGACUUCGGGGUAUG	1415				
1389 AGCCUCCCUUGACUGGCUA	1292	1389 AGCCUCCCUUGACUGGCUA	1292	1407 UAGCCAGUCAAGGGAGGCU	1416				
1407 ACCCAGGGGAGGAGCUGGA	1293	1407 ACCCAGGGGAGGAGCUGGA	1293	1425 UCCAGCUCCUCCUUGGGU	1417				
1425 AGGAAGAGGAGGAAAGGGG	1294	1425 AGGAAGAGGAGGAAAGGGG	1294	1443 CCCCUIUCCUCCUUCUCCU	1418				
1443 GCGUGAAGCUUGGCCUCGG	1295	1443 GCGUGAAGCUUGGCCUCGG	1295	1461 CCGAGGCCAAGCUUCACGC	1419				
1461 GGGACUUCACUUCUACAG	1296	1461 GGGACUUCACUUCUACAG	1296	1479 CUGUAGAAGAUGAAGUCCC	1420				
1479 GUGUGCUGGUGGGCAAGGC	1297	1479 GUGUGCUGGUGGGCAAGGC	1297	1497 GCCUUGCCCACCAGCACAC	1421				
1497 CGGCUGCCACGGGCAGCGG	1298	1497 CGGCUGCCACGGGCAGCGG	1298	1515 CCGCUGCCCUGGCGAGCCG	1422				
1515 GGGACUGGAAUACCACGCU	1299	1515 GGGACUGGAAUACCACGCU	1299	1533 AGCGUGGUUUUCCAGUCCC	1423				
1533 UGGCCUGCUUCGUGGCCAU	1300	1533 UGGCCUGCUUCGUGGCCAU	1300	1551 AUGGCCACGAAGCAGGCCA	1424				
1551 UCCUCAUUGGCUUGUGUCU	1301	1551 UCCUCAUUGGCUUGUGUCU	1301	1569 AGACACAAGCCAAUGAGGA	1425				
1569 UGACCCUCCUGCUGCUUGC	1302	1569 UGACCCUCCUGCUGCUUGC	1302	1587 GCAAGCAGCAGGAGGGUCA	1426				
1587 CUGUGUUCAGAAGGCGCU	1303	1587 CUGUGUUCAGAAGGCGCU	1303	1605 AGCGCCUUCUUGAACACAG	1427				
1605 UGCCCCGCCUCCCCAUCUC	1304	1605 UGCCCCGCCUCCCCAUCUC	1304	1623 GAGUUGGGGAGGGCGGGCA	1428				
1623 CCAUCACGUUCGGGCUCAU	1305	1623 CCAUCACGUUCGGGCUCAU	1305	1641 AUGAGCCCGAACGUGAUGG	1429				
1641 UCUIUUUACUUCACCGGA	1306	1641 UCUIUUUACUUCACCGGA	1306	1659 UCCGUGGAGAAGUAAAAGA	1430				
1659 ACAACCUUGUGCGGCCGUU	1307	1659 ACAACCUUGUGCGGCCGUU	1307	1677 AACGGCCGCACCAGGUUGU	1431				
1677 UCAUGGACACCCUGGCCUC	1308	1677 UCAUGGACACCCUGGCCUC	1308	1695 GAGGCCAGGGUGUCCAUGA	1432				
1695 CCCAUCAGCUCUACAUCUG	1309	1695 CCCAUCAGCUCUACAUCUG	1309	1713 CAGAUGUAGAGCUGAUGGG	1433				
1713 GAGGGACAUGGUGGCCAC	1310	1713 GAGGGACAUGGUGGCCAC	1310	1731 GUGGCACACCAUGUCCCUC	1434				
1731 CAGGCUGCAAGCUGCAGGG	1311	1731 CAGGCUGCAAGCUGCAGGG	1311	1749 CCUGCAGCUUGCAGCCUG	1435				
1749 GAAUUUUAUUGGAUGCAG	1312	1749 GAAUUUUAUUGGAUGCAG	1312	1767 CUGCAUCCAAUGAAAUUC	1436				
1767 GUUGUAUAGUUUACACUC	1313	1767 GUUGUAUAGUUUACACUC	1313	1785 GAGUGUAAAACUAUACAAC	1437				
1785 CUAGUGCCAUUAUUUUUA	1314	1785 CUAGUGCCAUUAUUUUUA	1314	1803 UAAAAUAUUGGCACUAG	1438				
1803 AAGACUUUUUCCUUAA	1315	1803 AAGACUUUUUCCUUAA	1315	1821 UUAAGGAAAGAAAAGUCUU	1439				
1821 AAAAAUAAAGUACGUGUUU	1316	1821 AAAAAUAAAGUACGUGUUU	1316	1839 AAACACGUACUUUUUUU	1440				

TABLE II-continued

APP, BACE, PSEN1, PSEN2 siNA AND TARGET SEQUENCES								
1839	UACUUGGUGAGGAGGAGGC	1317	1839	UACUUGGUGAGGAGGAGGC	1317	1857	GCCUCCUCCUACCAAGUA	1441
1857	CAGAACCAGCUCUUUGGUG	1318	1857	CAGAACCAGCUCUUUGGUG	1318	1875	CACCAAAGAGCUGGUUCUG	1442
1875	GCCAGCUGUUUCAUCACCA	1319	1875	GCCAGCUGUUUCAUCACCA	1319	1893	UGGUGAUGAAACAGCUGGC	1443
1893	AGACUUUGGCUCGCCGUUU	1320	1893	AGACUUUGGCUCGCCGUUU	1320	1911	AAAGCGGGAGCCAAGUCU	1444
1911	UGGGGAGCGCCUCGCUUA	1321	1911	UGGGGAGCGCCUCGCUUA	1321	1929	UGAAGCGAGGCGCUCCCA	1445
1929	ACGGACAGGAAGCACAGCA	1322	1929	ACGGACAGGAAGCACAGCA	1322	1947	UGCUGUGCUUCCUGUCCGU	1446
1947	AGGUUUUAUCCAGAUGAACU	1323	1947	AGGUUUUAUCCAGAUGAACU	1323	1965	AGUUCAUCUGGAUAAACCU	1447
1965	UGAGAAGGUCAGAUUAGGG	1324	1965	UGAGAAGGUCAGAUUAGGG	1324	1983	CCCUAAUCUGACCUUCUCA	1448
1983	GCGGGGAGAAGAGCAUCCG	1325	1983	GCGGGGAGAAGAGCAUCCG	1325	2001	CGGAUGCUCUUCUCCCCG	1449
2001	GGCAUGAGGGCUGAGAUGC	1326	2001	GGCAUGAGGGCUGAGAUGC	1326	2019	GCAUCUCAGCCUCAUGCC	1450
2019	CGCAAAGAGUGUGCUCGGG	1327	2019	CGCAAAGAGUGUGCUCGGG	1327	2037	CCCGAGCACACUCUUUGCG	1451
2037	GAGUGGCCCCUGGCACCUG	1328	2037	GAGUGGCCCCUGGCACCUG	1328	2055	CAGGUGCCAGGGGCCACUC	1452
2055	GGGUGCUCUGGCUGGAGAG	1329	2055	GGGUGCUCUGGCUGGAGAG	1329	2073	CUCUCCAGCCAGAGCACCC	1453
2073	GGAAGAGCCAGUUCCCUAC	1330	2073	GGAAGAGCCAGUUCCCUAC	1330	2091	GUAGGGAAUCGGCUUUUCC	1454
2091	CGAGGAGUGUUCCCAAUGC	1331	2091	CGAGGAGUGUUCCCAAUGC	1331	2109	GCAUUGGGAACACUCCUCG	1455
2109	CUUUGUCCAUGAUGUCCUU	1332	2109	CUUUGUCCAUGAUGUCCUU	1332	2127	AAGGACAUCAUGGACAAAG	1456
2127	UGUUUUUUUAUUGCCUUUA	1333	2127	UGUUUUUUUAUUGCCUUUA	1333	2145	UAAAGGCAUAAAAUAACA	1457
2145	AGAAACUGAGUCCUGUUCU	1334	2145	AGAAACUGAGUCCUGUUCU	1334	2163	AGAACAGGACUCAGUUUCU	1458
2163	UUGUUACGGCAGUCACACU	1335	2163	UUGUUACGGCAGUCACACU	1335	2181	AGUGUGACUGCCGUAACAA	1459
2181	UGCUGGGAAGUGGCUUAAU	1336	2181	UGCUGGGAAGUGGCUUAAU	1336	2199	AUUAAAGCCACUUCCAGCA	1460
2199	UAGUAAUAUCAUAAAUAG	1337	2199	UAGUAAUAUCAUAAAUAG	1337	2217	CUAUUUUAUUGAUUUACUA	1461
2216	AGAUGAGUCCUGUUAGAAA	1338	2216	AGAUGAGUCCUGUUAGAAA	1338	2234	UUUCUACAGGACUCAUCU	1462

[0437] The 3'-ends of the Upper sequence and the Lower sequence of the siNA construct can include an overhang sequence, for example about 1, 2, 3, or 4 nucleotides in length, preferably 2 nucleotides in length, wherein the overhanging sequence of the lower sequence is optionally

complementary to a portion of the target sequence. The upper sequence is also referred to as the sense strand, whereas the lower sequence is also referred to as the antisense strand. The upper and lower sequences in the Table can further comprise a chemical modification having Formulae I-VII or any combination thereof.

TABLE III

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
Tar- get Pos	Target	APP			Sequence	Seq ID
		Seq ID	Cmpd #	Aliases		
791	CAGACUAUGCAGAUUGGGAGUGAA	1463		APP:793U21 sense siNA	GACUAUGCAGAUUGGGAGUGTT	1495
829	GUAGCAGAGGAGGAAGAAGUGGC	1464		APP:831U21 sense siNA	AGCAGAGGAGGAAGAAGUGTT	1496
851	CUGAGGUGGAAGAAGAAGGCC	1465		APP:853U21 sense siNA	GAGGUGGAAGAAGAAGTT	1497
1356	AGAGAGAAUGUCCAGGUCAUGA	1466		APP:1358U21 sense siNA	AGAGAAUGUCCAGGUCAUTT	1498

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1570U21 sense siNA	AACUACAUCACCGCUCUGCTT	1499	
2012 AUUCUUUUGGGCUGACUCUGUG	1468	APP:2014U21 sense siNA	UCUUUUGGGCUGACUCUGTT	1500	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2483U21 sense siNA	AAGUUGGACAGCAAAACCATT	1501	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2484U21 sense siNA	AGUUGGACAGCAAAACCAUTT	1502	
791 CAGACUAUGCAGAUGGGAGUGAA	1463	APP:811L21 antisense siNA (793C)	CACUCCCAUCUGCAUAGUCTT	1503	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:849L21 antisense siNA (831C)	CACUUCUUCUCCUCUGCUTT	1504	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	APP:871L21 antisense siNA (853C)	CUUCUUCUUCUCCACCUCTT	1505	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1376L21 antisense siNA (1358C)	AUGACCUGGGACAUCUCUTT	1506	
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1588L21 antisense siNA (157CC)	GCAGAGCGGUGAUGUAGUUTT	1507	
2012 AUUCUUUUGGGCUGACUCUGUG	1468	APP:2032L21 antisense siNA (2014C)	CAGAGUCAGCCCCAAAAGATT	1508	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2501L21 antisense siNA (2483C)	UGGUUUUUGCUGUCCAACUUTT	1509	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2502L21 antisense siNA (2484C)	AUGGUUUUUGCUGUCCAACUTT	1510	
791 CAGACUAUGCAGAUGGGAGUGAA	1463	APP:793U21 sense siNA stab04	B GAcuAuGcAGAuGGGAGuGTT B	1511	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:831U21 sense siNA stab04	B AGcAGAGGAGGAAGAAGuGTT B	1512	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	APP:853U21 sense siNA stab04	B GAGGuGGAAGAAGAAGAGTT B	1513	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1358U21 sense siNA stab04	B AGAGAAuGuCCcAGGucAuTT B	1514	
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1570U21 sense siNA stab04	B AAcuAcAucAccGcucuGcTT B	1515	
2012 AUUCUUUUGGGCUGACUCUGUG	1468	APP:2014U21 sense siNA stab04	B ucuuuuGGGGuGAcucuGTT B	1516	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2483U21 sense siNA stab04	B AAGuuGGAcAGcAAAaccATT B	1517	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2484U21 sense siNA stab04	B AGuuGGAcAGcAAAaccAuTT B	1518	
791 CAGACUAUGCAGAUGGGAGUGAA	1463	APP:811L21 antisense siNA (793C) stab05	cAcucccAucuGcAuAGucTsT	1519	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:849L21 antisense siNA (831C) stab05	cAcuucuuccuccucuGcuTsT	1520	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	APP:871L21 antisense siNA (853C) stab05	cuucuucuuccuuccAccucTsT	1521	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1376L21 antisense siNA (1358C) stab05	AuGAccuGGGAcAuucucuTsT	1522	
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1588L21 antisense siNA (1570C) stab05	GcAGAGcGGuGAuGuAGuuTsT	1523	
2012 AUUCUUUUGGGCUGACUCUGUG	1468	APP:2032L21 antisense siNA (2014C) stab05	cAGAGucAGccccAAAAGATsT	1524	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2501L21 antisense siNA (2483C) stab05	uGGuuuuGcuGuccAAcuuTsT	1525	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2502L21 antisense siNA (2484C) stab05	AuGGuuuuGcuGuccAAcuTsT	1526	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
791 CAGACUAUGCAGAU GGG GAGUGAA	1463	APP:793U21 sense siNA stab07	B G AcuAu G cAGAu GGG GAGuGTT B	1527	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:831U21 sense siNA stab07	B AGCAGAGGAGGAAGAAGuGTT B	1528	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	APP:853U21 sense siNA stab07	B GAGGuGGAAGAAGAAGATT B	1529	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1358U21 sense siNA stab07	B AGAGAAuGu ccc AGGuAuTT B	1530	
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1570U21 sense siNA stab07	B AACuAcAucAccGcucuGcTT B	1531	
2012 AUUCUUUUGGGGUGACUCUGUG	1468	APP:2014U21 sense siNA stab07	B ucuuuuGGGGuGAcucuGTT B	1532	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2483U21 sense siNA stab07	B AAGuuGGAcAGcAAAaccATT B	1533	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2484U21 sense siNA stab07	B AGuuGGAcAGcAAAaccAuTT B	1534	
791 CAGACUAUGCAGAU GGG GAGUGAA	1463	APP:811L21 antisense siNA (793C) stab11	cAcucccAucuGcAuAGucTsT	1535	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:849L21 antisense siNA (831C) stab11	cA <u>cu</u> cuu <u>ccu</u> ccucuGcuTsT	1536	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	APP:871L21 antisense siNA (853C) stab11	cu <u>cu</u> cuu <u>ccu</u> ccu <u>cc</u> AccucTsT	1537	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1376L21 antisense siNA (1358C) stab11	AuG <u>accu</u> GGGAcAuucucuTsT	1538	
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1588L21 antisense siNA (1570C) stab11	GcAGAGcGGuGAuGuAGuuTsT	1539	
2012 AUUCUUUUGGGGUGACUCUGUG	1468	APP:2032L21 antisense siNA (2014C) stab11	cAGAGucAG <u>cccc</u> AAAAGATsT	1540	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2501L21 antisense siNA (2483C) stab11	uGGuuuuGcuGuccAAcuTsT	1541	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2502L21 antisense siNA (2484C) stab11	AuGGuuuuGcuGuccAAcuTsT	1542	
791 CAGACUAUGCAGAU GGG GAGUGAA	1463	APP:793U21 sense siNA stab18	B G AcuAu G cAGAu GGG GAGuGTT B	1543	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:831U21 sense siNA stab18	B AG cAGAGGAGGAAGAAGuGTT B	1544	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	APP:853U21 sense siNA stab18	B GAGGuGGAAGAAGAAGATT B	1545	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1358U21 sense siNA stab18	B AGAGAAuGu ccc AGGuAuTT B	1546	
1568 AGAACUACAUCACCGCUCUGCAG	1467	APP:1570U21 sense siNA stab18	B A acu A cAuc A ccGcucuGcTT B	1547	
2012 AUUCUUUUGGGGUGACUCUGUG	1468	APP:2014U21 sense siNA stab18	B ucuuuuGGGGuGAcucuGTT B	1548	
2481 UGAAGUUGGACAGCAAAACCAUU	1469	APP:2483U21 sense siNA stab18	B AAGuuGGAcAGcAAAaccATT B	1549	
2482 GAAGUUGGACAGCAAAACCAUUG	1470	APP:2484U21 sense siNA stab18	B AGuuGGAcAGcAAAaccAuTT B	1550	
791 CAGACUAUGCAGAU GGG GAGUGAA	1463	33885 APP:811L21 antisense siNA (793C) stab08	cAcucccAucuGcAuAGucTsT	1551	
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	33886 APP:849L21 antisense siNA (831C) stab08	cA <u>cu</u> cuu <u>ccu</u> ccucuGcuTsT	1552	
851 CUGAGGUGGAAGAAGAAGAGCC	1465	33887 APP:871L21 antisense siNA (853C) stab08	cu <u>cu</u> cuu <u>ccu</u> ccu <u>cc</u> AccucTsT	1553	
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	33888 APP:1376L21 antisense siNA (1358C) stab08	AuG <u>accu</u> GGGAcAuucucuTsT	1554	
1568 AGAACUACAUCACCGCUCUGCAG	1467	33889 APP:1588L21 antisense siNA (1570C) stab08	GcAGAGcGGuGAuGuAGuuTsT	1555	
2012 AUUCUUUUGGGGUGACUCUGUG	1468	33890 APP:2032L21 antisense siNA (2014C) stab08	cAGAGucAG <u>cccc</u> AAAAGATsT	1556	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
2481 UGAAGUUGGACAGCAAAACCAUU	1469	33891	APP:2501L21 antisense siNA (2483C) stab08	uGGuuuuGcuGuccAAcuuTsT	1557
2482 GAAGUUGGACAGCAAAACCAUUG	1470	33892	APP:2502L21 antisense siNA (2484C) stab08	AuGGuuuuGcuGuccAAcuTsT	1558
791 CAGACUAUGCAGAUGGGAGUGAA	1463	33869	APP:793U21 sense siNA stab09	B GACUAUGCAGAUGGGAGUGTT B	1559
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	33870	APP:831U21 sense siNA stab09	B AGCAGAGGAGGAAGAAGUGTT B	1560
851 CUGAGGUGGAAGAAGAAGGCC	1465	33871	APP:853U21 sense siNA stab09	B GAGGUGGAAGAAGAAGTT B	1561
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	33872	APP:1358U21 sense siNA stab09	B AGAGAAUGUCCAGGUCAUTT B	1562
1568 AGAACUACAUCACCGCUCUGCAG	1467	33873	APP:1570U21 sense siNA stab09	B AACUACAUCACCGCUCUGTT B	1563
2012 AUUCUUUUGGGCUGACUCUGUG	1468	33874	APP:2014U21 sense siNA stab09	B UCUUUUGGGCUGACUCUGTT B	1564
2481 UGAAGUUGGACAGCAAAACCAUU	1469	33875	APP:2483U21 sense siNA stab09	B AAGUUGGACAGCAAAACCAT B	1565
2482 GAAGUUGGACAGCAAAACCAUUG	1470	33876	APP:2484U21 sense siNA stab09	B AGUUGGACAGCAAAACCAUTT B	1566
791 CAGACUAUGCAGAUGGGAGUGAA	1463	33877	APP:811L21 antisense siNA (793C) stab10	CACUCCCAUCUGCAUAGUCTsT	1567
829 GUAGCAGAGGAGGAAGAAGUGGC	1464	33878	APP:849L21 antisense siNA (831C) stab10	CACUUCUUCUCCUCUGCUTsT	1568
851 CUGAGGUGGAAGAAGAAGGCC	1465	33879	APP:871L21 antisense siNA (853C) stab10	CUUCUUCUUCUCCACCUCTsT	1569
1356 AGAGAGAAUGUCCAGGUCAUGA	1466	33880	APP:1376L21 antisense siNA (1358C) stab10	AUGACCUGGGACAUCUCUTsT	1570
1568 AGAACUACAUCACCGCUCUGCAG	1467	33881	APP:1588L21 antisense siNA (1570C) stab10	GCAGAGCGGUGAUGUAGUUTsT	1571
2012 AUUCUUUUGGGCUGACUCUGUG	1468	33882	APP:2032L21 antisense siNA (2014C) stab10	CAGAGUCAGCCCCAAAAGATsT	1572
2481 UGAAGUUGGACAGCAAAACCAUU	1469	33883	APP:2501L21 antisense siNA (2483C) stab10	UGGUUUUGCUGUCCAACUUTsT	1573
2482 GAAGUUGGACAGCAAAACCAUUG	1470	33884	APP:2502L21 antisense siNA (2484C) stab10	AUGGUUUUGCUGUCCAACUTsT	1574
791 CAGACUAUGCAGAUGGGAGUGAA	1463		APP:811L21 antisense siNA (793C) stab19	cAcucccAucuGcAuAGucTT B	1575
829 GUAGCAGAGGAGGAAGAAGUGGC	1464		APP:849L21 antisense siNA (831C) stab19	cAcuucuuuccuucucuGcuTT B	1576
851 CUGAGGUGGAAGAAGAAGGCC	1465		APP:871L21 antisense siNA (853C) stab19	cuucuuuuuuccAccucTT B	1577
1356 AGAGAGAAUGUCCAGGUCAUGA	1466		APP:1376L21 antisense siNA (1358C) stab19	AuGAccuGGGAcAuucucuTT B	1578
1568 AGAACUACAUCACCGCUCUGCAG	1467		APP:1588L21 antisense siNA (1570C) stab19	GcAGAGcGGuGAuGuAGuuTT B	1579
2012 AUUCUUUUGGGCUGACUCUGUG	1468		APP:2032L21 antisense siNA (2014C) stab19	cAGAGucAGccccAAAAGATT B	1580
2481 UGAAGUUGGACAGCAAAACCAUU	1469		APP:2501L21 antisense siNA (2483C) stab19	uGGuuuuGcuGuccAAcuTT B	1581
2482 GAAGUUGGACAGCAAAACCAUUG	1470		APP:2502L21 antisense siNA (2484C) stab19	AuGGuuuuGcuGuccAAcuTT B	1582
791 CAGACUAUGCAGAUGGGAGUGAA	1463		APP:811L21 antisense siNA (793C) stab22	CACUCCCAUCUGCAUAGUCTT B	1583

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
829	GUAGCAGAGGAGGAAGAAGUGGC	1464	APP:849L21 antisense siNA (831C) stab22	CACUUCUCCUCCUCUGCUTT B	1584
851	CUGAGGUGGAAGAAGAAGACC	1465	APP:871L21 antisense siNA (853C) stab22	CUUCUUCUUCUCCACCUCTT B	1585
1356	AGAGAGAAUGUCCAGGUCAUGA	1466	APP:1376L21 antisense siNA (1358C) stab22	AUGACCUGGGACAUUCUCUTT B	1586
1568	AGAACUACAUCACCGCUCUGCAG	1467	APP:1588L21 antisense siNA (1570C) stab22	GCAGAGCGGUGAUGUAGUUTT B	1587
2012	AUUCUUUUGGGGUGACUCUGUG	1468	APP:2032L21 antisense siNA (2014C) stab22	CAGAGUCAGCCCCAAAAGATT B	1588
2481	UGAAGUUGGACAGCAAAACCAUU	1469	APP:2501L21 antisense siNA (2483C) stab22	UGGUUUUGCUGUCCAACUUTT B	1589
2482	GAAGUUGGACAGCAAAACCAUUG	1470	APP:2502L21 antisense siNA (2484C) stab22	AUGGUUUUGCUGUCCAACUTT B	1590

		BACE						
Tar- get Pos	Target	Seq ID	Cmpd #	Aliases	Sequence	Seq ID		
1025	CCUGGAGCCUUUCUUUGACUCUC	1471		BACE:1027U21 sense siNA	UGGAGCCUUUCUUUGACUCTT	1591		
1028	GGAGCCUUUCUUUGACUCUCUGG	1472		BACE:1030U21 sense siNA	AGCCUUUCUUUGACUCUCUTT	1592		
1393	AGAAGUUCCUGAUGGUUUCUGG	1473		BACE:1395U21 sense siNA	AAGUUCCUGAUGGUUUCUTT	1593		
1490	AAUGGGUGAGGUUACCAACCAGU	1474	31005	BACE:1492U21 sense siNA	UGGGUGAGGUUACCAACCATT	1594		
1753	UCACCUUGGACAUGGAAGACUGU	1475	31006	BACE:1755U21 sense siNA	ACCUUGGACAUGGAAGACUTT	1595		
1803	UCAACCCUCAUGACCAUAGCCUA	1476		BACE:1805U21 sense siNA	AACCCUCAUGACCAUAGCCTT	1596		
2457	CCUAAACAUUGGUGCAAAGAUUGC	1477	31007	BACE:2459U21 sense siNA	UAACAUUGGUGCAAAGAUUTT	1597		
3583	UAUGGGACCUGCUAAGUGUGGAA	1478	31008	BACE:3585U21 sense siNA	UGGGACCUGCUAAGUGUGGTT	1598		
1025	CCUGGAGCCUUUCUUUGACUCUC	1471		BACE:1045L21 antisense siNA (1027C)	GAGUCAAGAAAGGCUCATT	1599		
1028	GGAGCCUUUCUUUGACUCUCUGG	1472		BACE:1048L21 antisense siNA (1030C)	AGAGAGUCAAGAAAGGCUTT	1600		
1393	AGAAGUUCCUGAUGGUUUCUGG	1473		BACE:1413L21 antisense siNA (1395C)	AGAAACCAUCAGGGAACUUTT	1601		
1490	AAUGGGUGAGGUUACCAACCAGU	1474	31081	BACE:1510L21 antisense siNA (1492C)	UGGUUGGUAACCUACCCATT	1602		
1753	UCACCUUGGACAUGGAAGACUGU	1475	31082	BACE:1773L21 antisense siNA (1755C)	AGUCUCCAUUGUCCAAGGUTT	1603		
1803	UCAACCCUCAUGACCAUAGCCUA	1476		BACE:1823L21 antisense siNA (1805C)	GGCUAUGGUCAUGAGGGUUTT	1604		
2457	CCUAAACAUUGGUGCAAAGAUUGC	1477	31083	BACE:2477L21 antisense siNA (2459C)	AAUCUUUGCACCAUGUUATT	1605		
3583	UAUGGGACCUGCUAAGUGUGGAA	1478	31084	BACE:3603L21 antisense siNA (3585C)	CCACACUUAGCAGGUCCATT	1606		
1025	CCUGGAGCCUUUCUUUGACUCUC	1471		BACE:1027U21 sense siNA stab04	B uGGAGccuuuuuuGAcucTT B	1607		
1028	GGAGCCUUUCUUUGACUCUCUGG	1472		BACE:1030U21 sense siNA stab04	B AGccuuuuuuGAcucucuTT B	1608		

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
1393 AGAAGUCCCCUGAUGGUUUCUGG	1473		BACE:1395U21 sense siNA stab04	B AAGuucccuGAuGGuuucuTT B	1609	
1490 AAUGGGUGAGGUUACCAACCAGU	1474	30729	BACE:1492U21 sense siNA stab04	B uGGGuGAGGuuAccAAccATT B	1610	
1753 UCACCUUGGACAUGGAAGACUGU	1475	30730	BACE:1755U21 sense siNA stab04	B AccuuGGAcAuGGAAGAcuTT B	1611	
1803 UCAACCCUCAUGACCAUAGCCUA	1476		BACE:1805U21 sense siNA stab04	B AAccucAuGAccAuAGccTT B	1612	
2457 CCUAACAUUGGUGCAAAGAUUGC	1477	31378	BACE:2459U21 sense siNA stab04	B uAAcAuuGGuGcAAAGAuTT B	1613	
3583 UAUGGGACCUGCUAAGUGUGGAA	1478	30732	BACE:3585U21 sense siNA stab04	B uGGGAccuGcuAAGuGuGGTT B	1614	
1025 CCUGGAGCCUUUCUUUGACUCUC	1471		BACE:1045L21 antisense siNA (1027C) stab05	GAGuCAAAGAAAGGuccATsT	1615	
1028 GGAGCCUUUCUUUGACUCUCUGG	1472		BACE:1048L21 antisense siNA (1030C) stab05	AGAGAGuCAAAGAAAGGcuTsT	1616	
1393 AGAAGUCCCCUGAUGGUUUCUGG	1473		BACE:1413L21 antisense siNA (1395C) stab05	AGAAAccAucAGGGAacuuTsT	1617	
1490 AAUGGGUGAGGUUACCAACCAGU	1474	30733	BACE:1510L21 antisense siNA (1492C) stab05	uGGuuGGuAAccucAcccATsT	1618	
1753 UCACCUUGGACAUGGAAGACUGU	1475	30734	BACE:1773L21 antisense siNA (1755C) stab05	AGucuuccAuGuccAAGGuTsT	1619	
1803 UCAACCCUCAUGACCAUAGCCUA	1476		BACE:1823L21 antisense siNA (1805C) stab05	GGcuAuGGucAuGAGGGuuTsT	1620	
2457 CCUAACAUUGGUGCAAAGAUUGC	1477	31381	BACE:2477L21 antisense siNA (2459C) stab05	AAucuuuGcAccAAuGuuATsT	1621	
3583 UAUGGGACCUGCUAAGUGUGGAA	1478	30736	BACE:3603L21 antisense siNA (3585C) stab05	ccAcAcuuAGcAGGucccATsT	1622	
1025 CCUGGAGCCUUUCUUUGACUCUC	1471		BACE:1027U21 sense siNA stab07	B uGGAGccuuucuuuGAcucTT B	1623	
1028 GGAGCCUUUCUUUGACUCUCUGG	1472		BACE:1030U21 sense siNA stab07	B AGccuuucuuuGAcucucTT B	1624	
1393 AGAAGUCCCCUGAUGGUUUCUGG	1473		BACE:1395U21 sense siNA stab07	B AAGuucccuGAuGGuuucuTT B	1625	
1490 AAUGGGUGAGGUUACCAACCAGU	1474		BACE:1492U21 sense siNA stab07	B uGGGuGAGGuuAccAAccATT B	1626	
1753 UCACCUUGGACAUGGAAGACUGU	1475		BACE:1755U21 sense siNA stab07	B AccuuGGAcAuGGAAGAcuTT B	1627	
1803 UCAACCCUCAUGACCAUAGCCUA	1476		BACE:1805U21 sense siNA stab07	B AAccucAuGAccAuAGccTT B	1628	
2457 CCUAACAUUGGUGCAAAGAUUGC	1477	31384	BACE:2459U21 sense siNA stab07	B uAAcAuuGGuGcAAAGAuTT B	1629	
3583 UAUGGGACCUGCUAAGUGUGGAA	1478		BACE:3585U21 sense siNA stab07	B uGGGAccuGcuAAGuGuGGTT B	1630	
1025 CCUGGAGCCUUUCUUUGACUCUC	1471		BACE:1045L21 antisense siNA (1027C) stab11	GAGuCAAAGAAAGGuccATsT	1631	
1028 GGAGCCUUUCUUUGACUCUCUGG	1472		BACE:1048L21 antisense siNA (103CC) stab11	AGAGAGuCAAAGAAAGGcuTsT	1632	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
1393	AGAAGUUCCUGAUGGUUUCUGG	1473	BACE:1413L21 antisense siNA (1395C) stab11	AGAAAccAucAGGGAACuuTsT	1633
1490	AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1510L21 antisense siNA (1492C) stab11	GGuuGGuAAccucAcccATsT	1634
1753	UCACCUUGGACAUGGAAGACUGU	1475 (1755C) stab11	BACE:1773L21 antisense siNA	GucuuccAuGuccAAGGuTsT	1635
1803	UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1823L21 antisense siNA (1805C) stab11	GcuAuGGucAuGAGGGuuTsT	1636
2457	CCUAAAUUGGUGCAAAGAUGC	1477	31387BACE:2477L21 antisense siNA (2459C) stab11	AucuuuGcAccAAuGuuATsT	1637
3583	UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3603L21 antisense siNA (3585C) stab11	ccAcAuuuAGcAGGucccATsT	1638
1025	CCUGGAGCCUUUUCUUGACUCUC	1471	BACE:1027U21 sense siNA stab18	B uGGAGccuuucuuuGAcucTT B	1639
1028	GGAGCCUUUUCUUGACUCUCUGG	1472	BACE:1030U21 sense siNA stab18	B AGccuuucuuuGAcucucTT B	1640
1393	AGAAGUUCCUGAUGGUUUCUGG	1473	BACE:1395U21 sense siNA stab18	B AAGuucccuGAuGGuuucTT B	1641
1490	AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1492U21 sense siNA stab18	B uGGGuGAGGuuAccAACcATT B	1642
1753	UCACCUUGGACAUGGAAGACUGU	1475	BACE:1755U21 sense siNA stab18	B AccuuGGAcAuGGAAGACuTT B	1643
1803	UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1805U21 sense siNA stab18	B AAcccucAuGAccAuAGccTT B	1644
2457	CCUAAAUUGGUGCAAAGAUGC	1477	BACE:2459U21 sense siNA stab18	B uAAcAuuGGuGcAAAGAuTT B	1645
3583	UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3585U21 sense siNA stab18	B uGGGAccuGcuAAGuGuGGTT B	1646
1025	CCUGGAGCCUUUUCUUGACUCUC	1471	BACE:1045L21 antisense siNA (1027C) stab08	GAGucAAAGAAAGGcuccATsT	1647
1028	GGAGCCUUUUCUUGACUCUCUGG	1472	BACE:1048L21 antisense siNA (1030C) stab08	AGAGAGucAAAGAAAGGcuTsT	1648
1393	AGAAGUUCCUGAUGGUUUCUGG	1473	BACE:1413L21 antisense siNA (1395C) stab08	AGAAAccAucAGGGAACuuTsT	1649
1490	AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1510L21 antisense siNA (1492C) stab08	uGGuuGGuAAccucAcccATsT	1650
1753	UCACCUUGGACAUGGAAGACUGU	1475	BACE:1773L21 antisense siNA (1755C) stab08	AGucuuccAuGuccAAGGuTsT	1651
1803	UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1823L21 antisense siNA (1805C) stab08	GGcuAuGGucAuGAGGGuuTsT	1652
2457	CCUAAAUUGGUGCAAAGAUGC	1477	BACE:2477L21 antisense siNA (2459C) stab08	AAucuuuGcAccAAuGuuATsT	1653
3583	UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3603L21 antisense siNA (3585C) stab08	ccAcAuuuAGcAGGucccATsT	1654
1025	CCUGGAGCCUUUUCUUGACUCUC	1471	BACE:1027U21 sense siNA stab09	B UGGAGCCUUUUCUUGACUCTT B	1655
1028	GGAGCCUUUUCUUGACUCUCUGG	1472	BACE:1030U21 sense siNA stab09	B AGCCUUUUCUUGACUCUCUTT B	1656

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
1393 AGAAGUCCUGAUGGUUUCUGG	1473	BACE:1395U21 sense siNA stab09	B AAGUCCUGAUGGUUUCUTT B	1657	
1490 AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1492U21 sense siNA stab09	B UGGGUGAGGUUACCAACCATT B	1658	
1753 UCACCUUGGACAUGGAAGACUGU	1475	BACE:1755U21 sense siNA stab09	B ACCUUGGACAUGGAAGACUTT B	1659	
1803 UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1805U21 sense siNA stab09	B AACCCUCAUGACCAUAGCCTT B	1660	
2457 CCUAACAUGGUGCAAAGAUGC	1477	BACE:2459U21 sense siNA stab09	B UAACAUGGUGCAAAGAUAUTT B	1661	
3583 UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3585U21 sense siNA stab09	B UGGGACCUGCUAAGUGUGGTT B	1662	
1025 CCUGGAGCCUUUCUUGACUCUC	1471	BACE:1045L21 antisense siNA (1027C) stab10	GAGUCAAGAAAGGUCCATT B	1663	
1028 GGAGCCUUUCUUGACUCUCUGG	1472	BACE:1048L21 antisense siNA (1030C) stab10	AGAGAGUCAAGAAAGGCUATT B	1664	
1393 AGAAGUCCUGAUGGUUUCUGG	1473	BACE:1413L21 antisense siNA (1395C) stab10	AGAAACCAUCAGGGAACUATT B	1665	
1490 AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1510L21 antisense siNA (1492C) stab10	UGGUUGGUAACCUACCCATT B	1666	
1753 UCACCUUGGACAUGGAAGACUGU	1475	BACE:1773L21 antisense siNA (1755C) stab10	AGUCUCCAUGUCCAAGGUT B	1667	
1803 UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1823L21 antisense siNA (1805C) stab10	GGCUAUGGUCAUGAGGUUATT B	1668	
2457 CCUAACAUGGUGCAAAGAUGC	1477	BACE:2477L21 antisense siNA (2459C) stab10	AAUCUUUGCACCAAGUUATT B	1669	
3583 UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3603L21 antisense siNA (3585C) stab10	CCACACUUAGCAGGUCCATT B	1670	
1025 CCUGGAGCCUUUCUUGACUCUC	1471	BACE:1045L21 antisense siNA (1027C) stab19	GAGucAAAGAAAGGuccATT B	1671	
1028 GGAGCCUUUCUUGACUCUCUGG	1472	BACE:1048L21 antisense siNA (1030C) stab19	AGAGAGucAAAGAAAGGcuTT B	1672	
1393 AGAAGUCCUGAUGGUUUCUGG	1473	BACE:1413L21 antisense siNA (1395C) stab19	AGAAaccAucAGGGAAcuuTT B	1673	
1490 AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1510L21 antisense siNA (1492C) stab19	uGGuuGGuAAaccucAcccATT B	1674	
1753 UCACCUUGGACAUGGAAGACUGU	1475	BACE:1773L21 antisense siNA (1755C) stab19	AGucuuccAuGuccAAGGuTT B	1675	
1803 UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1823L21 antisense siNA (1805C) stab19	GGcuAuGGucAuGAGGGuuTT B	1676	
2457 CCUAACAUGGUGCAAAGAUGC	1477	BACE:2477L21 antisense siNA (2459C) stab19	AAucuuuGcAccAAuGuuATT B	1677	
3583 UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3603L21 antisense siNA (3585C) stab19	ccAcAcuuAGcAGGucccATT B	1678	
1025 CCUGGAGCCUUUCUUGACUCUC	1471	BACE:1045L21 antisense siNA (1027C) stab22	GAGUCAAGAAAGGUCCATT B	1679	
1028 GGAGCCUUUCUUGACUCUCUGG	1472	BACE:1048L21 antisense siNA (1030C) stab22	AGAGAGUCAAGAAAGGCUATT B	1680	
1393 AGAAGUCCUGAUGGUUUCUGG	1473	BACE:1413L21 antisense siNA (1395C) stab22	AGAAACCAUCAGGGAACUATT B	1681	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
1490	AAUGGGUGAGGUUACCAACCAGU	1474	BACE:1510L21 antisense siNA (1492C) stab22	UGGUUGGUAACCUCACCCATT B	1682	
1753	UCACCUUGGACAUGGAAGACUGU	1475	BACE:1773L21 antisense siNA (1755C) stab22	AGUCUCCAUGUCCAAGGUTT B	1683	
1803	UCAACCCUCAUGACCAUAGCCUA	1476	BACE:1823L21 antisense siNA (1805C) stab22	GGCUAUGGUCAUGAGGGUUTT B	1684	
2457	CCUAACAUGGUGCAAAGAUGUC	1477	BACE:2477L21 antisense siNA (2459C) stab22	AAUCUUUGCACCAAUGUUATT B	1685	
3583	UAUGGGACCUGCUAAGUGUGGAA	1478	BACE:3603L21 antisense siNA (3585C) stab22	CCACACUUAGCAGGUCCATT B	1686	
2457	CCUAACAUGGUGCAAAGAUGUC	657 31390	BACE:2459U21 sense siNA inv stab04	B uuAGAAAcGuGGuuAcAAuTT B	1687	
2457	CCUAACAUGGUGCAAAGAUGUC	657 31393	BACE:2477L21 antisense siNA (2459C) inv stab05	AuuGuAAccAcGuuucuAATsT	1688	
2457	CCUAACAUGGUGCAAAGAUGUC	657 31396	BACE:2459U21 sense siNA inv stab07	B uuAGAAAcGuGGuuAcAAuTT B	1689	
2457	CCUAACAUGGUGCAAAGAUGUC	657 31399	BACE:2477L21 antisense siNA (2459C) inv stab11	AuuGuAAccAcGuuucuAATsT	1690	
PSEN1						
Tar- get Pos	Target	Seq ID	Cmpd # Aliases	Sequence	Seq ID	
693	CUAUGGACGACCCAGGGUAAAC	1479	PSEN1:695U21 sense siNA	AAUGGACGACCCAGGGUATT	1691	
1131	CUGUUGCACUCCUGAUCUGGAAU	1480	PSEN1:1133U21 sense siNA	GUUGCACUCCUGAUCUGGATT	1692	
1493	GAAAGCACAGAAAGGGAGUCACA	1481	PSEN1:1495U21 sense siNA	AAGCACAGAAAGGGAGUCATT	1693	
1505	AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1507U21 sense siNA	GGAGUCACAAGACACUGUUTT	1694	
1748	GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1750U21 sense siNA	CUGGAACACAACCAUAGCCTT	1695	
1751	UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1753U21 sense siNA	GAACACAACCAUAGCCUGUTT	1696	
2184	CUACCAGAUUUGAGGGACGAGGU	1485	PSEN1:2186U21 sense siNA	ACCAGAUUUGAGGGACGAGTT	1697	
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486	PSEN1:3009U21 sense siNA	UAUGCCCAAAGCGGUAGAATT	1698	
693	CUAUGGACGACCCAGGGUAAAC	1479	PSEN1:713L21 antisense siNA (695C)	UACCCUGGGUCGUCCAUUTT	1699	
1131	CUGUUGCACUCCUGAUCUGGAAU	1480	PSEN1:1151L21 antisense siNA (1133C)	UCCAGAUCCAGGAGUGCAACTT	1700	
1493	GAAAGCACAGAAAGGGAGUCACA	1481	PSEN1:1513L21 antisense siNA (1495C)	UGACUCCCUUUCUGUGCUUTT	1701	
1505	AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1525L21 antisense siNA (1507C)	AACAGUGUCUUGUGACUCCTT	1702	
1748	GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1768L21 antisense siNA (1750C)	GGCUAUGGUUGUGUUCAGTT	1703	
1751	UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1771L21 antisense siNA (1753C)	ACAGGCUAUGGUUGUGUUCTT	1704	
2184	CUACCAGAUUUGAGGGACGAGGU	1485	PSEN1:2204L21 antisense siNA (2186C)	CUCGUCCCUCAAUCUGGUTT	1705	
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486	PSEN1:3027L21 antisense siNA (3009C)	UUCUACCGCUUUGGGCAUATT	1706	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
693 CUAUUGGACGACCCAGGGUAAC	1479	PSEN1:695U21 sense siNA stab04	B AAUGGACGACccAGGGuATT B	1707	
1131 CUGUUGCACUCCUGAUCUGGAU	1480	PSEN1:1133U21 sense siNA stab04	B GuuGcAcuccuGAucUGGATT B	1708	
1493 GAAAGCACAGAAAGGGAGUCACA	1481	PSEN1:1495U21 sense siNA stab04	B AAGcAcAGAAAGGGAGucATT B	1709	
1505 AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1507U21 sense siNA stab04	B GGAGucAcAAGAcAcuGuuTT B	1710	
1748 GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1750U21 sense siNA stab04	B cuGGAACAcAAccAuAGccTT B	1711	
1751 UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1753U21 sense siNA stab04	B GAAcAcAAccAuAGccuGuTT B	1712	
2184 CUACCAGAUUUGAGGGACGAGGU	1485	PSEN1:2186U21 sense siNA stab04	B AccAGAUuuGAGGGAcGAGTT B	1713	
3007 UGU AUGCCCAAAGCGGUAGAAU	1486	PSEN1:3009U21 sense siNA stab04	B uAuGcccAAAGcGGuAGAATT B	1714	
693 CUAUUGGACGACCCAGGGUAAC	1479	PSEN1:713L21 antisense siNA (695C) stab05	uAcccuGGGGucGuccAuTsT	1715	
1131 CUGUUGCACUCCUGAUCUGGAU	1480	PSEN1:1151L21 antisense siNA (1133C) stab05	uccAGAUcAGGAGuGcAAcTsT	1716	
1493 GAAAGCACAGAAAGGGAGUCACA	1481	PSEN1:1513L21 antisense siNA (1495C) stab05	uGAcuccuuucuGuGcuTsT	1717	
1505 AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1525L21 antisense siNA (1507C) stab05	AAcAGuGucuuGuGAcuccTsT	1718	
1748 GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1768L21 antisense siNA (1750C) stab05	GGcuAuGGuuGuGuuccAGTsT	1719	
1751 UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1771L21 antisense siNA (1753C) stab05	AcAGGcuAuGGuuGuGuucTsT	1720	
2184 CUACCAGAUUUGAGGGACGAGGU	1485	PSEN1:2204L21 antisense siNA (2186C) stab05	cucGucccucAAAucUGGuTsT	1721	
3007 UGU AUGCCCAAAGCGGUAGAAU	1486	PSEN1:3027L21 antisense siNA (3009C) stab05	uuuAccGcuuuGGGcAuATsT	1722	
693 CUAUUGGACGACCCAGGGUAAC	1479	PSEN1:695U21 sense siNA stab07	B AAUGGACGACccAGGGuATT B	1723	
1131 CUGUUGCACUCCUGAUCUGGAU	1480	PSEN1:1133U21 sense siNA stab07	B GuuGcAcuccuGAucUGGATT B	1724	
1493 GAAAGCACAGAAAGGGAGUCACA	1481	PSEN1:1495U21 sense siNA stab07	B AAGcAcAGAAAGGGAGucATT B	1725	
1505 AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1507U21 sense siNA stab07	B GGAGucAcAAGAcAcuGuuTT B	1726	
1748 GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1750U21 sense siNA stab07	B cuGGAACAcAAccAuAGccTT B	1727	
1751 UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1753U21 sense siNA stab07	B GAAcAcAAccAuAGccuGuTT B	1728	
2184 CUACCAGAUUUGAGGGACGAGGU	1485	PSEN1:2186U21 sense siNA stab07	B AccAGAUuuGAGGGAcGAGTT B	1729	
3007 UGU AUGCCCAAAGCGGUAGAAU	1486	PSEN1:3009U21 sense siNA stab07	B uAuGcccAAAGcGGuAGAATT B	1730	
693 CUAUUGGACGACCCAGGGUAAC	1479	PSEN1:713L21 antisense siNA (695C) stab11	uAcccuGGGGucGuccAuTsT	1731	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
1131	CUGUUGCACUCCUGAUCUGAAU	1480	PSEN1:1151L21 antisense siNA (1133C) stab11	uccAGAUcAGGAGuGcAAcTsT	1732
1493	GAAAGCACAGAAAGGAGUCACA	1481	PSEN1:1513L21 antisense siNA (1495C) stab11	uGAcucccuuuGuGcuuTsT	1733
1505	AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1525L21 antisense siNA (1507C) stab11	AAcAGuGucuuGuGAcuccTsT	1734
1748	GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1768L21 antisense siNA (1750C) stab11	GGcuAuGGuuGuGuuccAGTsT	1735
1751	UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1771L21 antisense siNA (1753C) stab11	AcAGGcuAuGGuuGuGuucTsT	1736
2184	CUACCAGAUUUUGAGGACGAGGU	1485	PSEN1:2204L21 antisense siNA (2186C) stab11	cucGuuccucAAAuGuGuTsT	1737
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486	PSEN1:3027L21 antisense siNA (3009C) stab11	uuuAccGcuuuGGGcAuATsT	1738
693	CUA AUGGACGACCCAGGGUAAC	1479	PSEN1:695U21 sense siNA stab18	B AAUGGAcGAcccccAGGGuATT B	1739
1131	CUGUUGCACUCCUGAUCUGAAU	1480	PSEN1:1133U21 sense siNA stab18	B GuuGcAcuccuGAucUGATT B	1740
1493	GAAAGCACAGAAAGGAGUCACA	1481	PSEN1:1495U21 sense siNA stab18	B AAGcAcAGAAAGGAGucATT B	1741
1505	AGGGAGUCACAAGACACUGUUGC	1482	PSEN1:1507U21 sense siNA stab18	B GGAGucAcAAGAcAcuGuuTT B	1742
1748	GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1750U21 sense siNA stab18	B cuGGAAcAcAAccAuAGccTT B	1743
1751	UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1753U21 sense siNA stab18	B GAAcAcAAccAuAGccuGuTT B	1744
2184	CUACCAGAUUUUGAGGACGAGGU	1485	PSEN1:2186U21 sense siNA stab18	B AccAGAuuuGAGGAcGAGTT B	1745
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486	PSEN1:3009U21 sense siNA stab18	B uAuGcccAAAGcGGuAGAATT B	1746
693	CUA AUGGACGACCCAGGGUAAC	1479 33933	PSEN1:713L21 antisense siNA (695C) stab08	uAcccuGGGGuGuccAuTsT	1747
1131	CUGUUGGACUCCUGAUCUGAAU	1480 33934	PSEN1:1151L21 antisense siNA (1133C) stab08	uccAGAUcAGGAGuGcAAcTsT	1748
1493	GAAAGCACAGAAAGGAGUCACA	1481 33935	PSEN1:1513L21 antisense siNA (1495C) stab08	uGAcucccuuuGuGcuuTsT	1749
1505	AGGGAGUCACAAGACACUGUUGC	1482 33936	PSEN1:1525L21 antisense siNA (1507C) stab08	AAcAGuGucuuGuGAcuccTsT	1750
1748	GACUGGAACACAACCAUAGCCUG	1483 33937	PSEN1:1768L21 antisense siNA (17500) stab08	GGcuAuGGuuGuGuuccAGTsT	1751
1751	UGGAACACAACCAUAGCCUGUUU	1484 33938	PSEN1:1771L21 antisense siNA (1753C) stab08	AcAGGcuAuGGuuGuGuucTsT	1752
2184	CUACCAGAUUUUGAGGACGAGGU	1485 33939	PSEN1:2204L21 antisense siNA (2186C) stab08	cucGuuccucAAAuGuGuTsT	1753
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486 33940	PSEN1:3027L21 antisense siNA (3009C) stab08	uuuAccGcuuuGGGcAuATsT	1754
693	CUA AUGGACGACCCAGGGUAAC	1479 33917	PSEN1:695U21 sense siNA stab09	B AAUGGACGACCCAGGGUATT B	1755

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
1131	CUGUUGCACUCCUGAUCUGGAAU	1480	33918	PSEN1:1133U21 sense siNA stab09	B GUUGCACUCCUGAUCUGGATT B	1756
1493	GAAAGCACAGAAAGGGAGUCACA	1481	33919	PSEN1:1495U21 sense siNA stab09	B AAGCACAGAAAGGGAGUCATT B	1757
1505	AGGGAGUCACAAGACACUGUUGC	1482	33920	PSEN1:1507U21 sense siNA stab09	B GGAGUCACAAGACACUGUUTT B	1758
1748	GACUGGAACACAACCAUAGCCUG	1483	33921	PSEN1:1750U21 sense siNA stab09	B CUGGAACACAACCAUAGCCTT B	1759
1751	UGGAACACAACCAUAGCCUGUUU	1484	33922	PSEN1:1753U21 sense siNA stab09	B GAACACAACCAUAGCCUGUTT B	1760
2184	CUACCAGAUUUGAGGGACGAGGU	1485	33923	PSEN1:2186U21 sense siNA stab09	B ACCAGAUUUGAGGGACGAGTT B	1761
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486	33924	PSEN1:3009U21 sense siNA stab09	B UAUGCCCAAAGCGGUAGAATT B	1762
693	CUA AUGGACGACCCAGGGUAAC	1479	33925	PSEN1:713L21 antisense siNA (695C) stab10	UACCCUGGGGUCGUCCAUTtT	1763
1131	CUGUUGCACUCCUGAUCUGGAAU	1480	33926	PSEN1:1151L21 antisense siNA (1133C) stab10	UCCAGAUCAAGGAGUGCAACTtT	1764
1493	GAAAGCACAGAAAGGGAGUCACA	1481	33927	PSEN1:1513L21 antisense siNA (1495C) stab10	UGACUCCCUUUCUGUCUUTtT	1765
1505	AGGGAGUCACAAGACACUGUUGC	1482	33928	PSEN1:1525L21 antisense siNA (1507C) stab10	AACAGUGUCUUGUGACUCCTtT	1766
1748	GACUGGAACACAACCAUAGCCUG	1483	33929	PSEN1:1768L21 antisense siNA (1750C) stab10	GGCUAUGGUUGUGUCCAGTtT	1767
1751	UGGAACACAACCAUAGCCUGUUU	1484	33930	PSEN1:1771L21 antisense siNA (1753C) stab10	ACAGGCUAUGGUUGUGUUCTtT	1768
2184	CUACCAGAUUUGAGGGACGAGGU	1485	33931	PSEN1:2204L21 antisense siNA (2186C) stab10	CUCGUCCCUCAAUUGGUTtT	1769
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486	33932	PSEN1:3027L21 antisense siNA (3009C) stab10	UUCUACCGCUUUGGGCAUATtT	1770
693	CUA AUGGACGACCCAGGGUAAC	1479		PSEN1:713L21 antisense siNA (695C) stab19	uA <u>cccuGGG</u> GucGuccAuuTT B	1771
1131	CUGUUGCACUCCUGAUCUGGAAU	1480		PSEN1:1151L21 antisense siNA (1133C) stab19	ucc <u>AGA</u> uc <u>AGG</u> AguGcAAcTT B	1772
1493	GAAAGCACAGAAAGGGAGUCACA	1481		PSEN1:1513L21 antisense siNA (1495C) stab19	uG <u>A</u> cuccccuuucuG <u>uG</u> c <u>uu</u> TT B	1773
1505	AGGGAGUCACAAGACACUGUUGC	1482		PSEN1:1525L21 antisense siNA (1507C) stab19	<u>AA</u> cAGuGucuuGuG <u>A</u> cuccTT B	1774
1748	GACUGGAACACAACCAUAGCCUG	1483		PSEN1:1768L21 antisense siNA (1750C) stab19	<u>GG</u> cuA <u>uGG</u> uuGuG <u>uucc</u> AGTT B	1775
1751	UGGAACACAACCAUAGCCUGUUU	1484		PSEN1:1771L21 antisense siNA (1753C) stab19	<u>A</u> cAGGcuA <u>uGG</u> uuGuG <u>uuc</u> TT B	1776
2184	CUACCAGAUUUGAGGGACGAGGU	1485		PSEN1:2204L21 antisense siNA (2186C) stab19	cucGucccuc <u>AAA</u> ucG <u>G</u> uTT B	1777
3007	UGUAUGCCCAAAGCGGUAGAAUU	1486		PSEN1:3027L21 antisense siNA (3009C) stab19	uuuA <u>ccG</u> uuu <u>GGG</u> cA <u>u</u> TT B	1778
693	CUA AUGGACGACCCAGGGUAAC	1479		PSEN1:713L21 antisense siNA (695C) stab22	UACCCUGGGGUCGUCCAUUTT B	1779

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
1131	CUGUUGCACUCCUGAUCUGGAAU	1480	PSEN1:1151L21 antisense siNA (1133C) stab22	UCCAGAUCAAGGAGUGCAACTT B	1780	
1493	GAAAGCACAGAAAGGAGUCACA	1481	PSEN1:1513L21 antisense siNA (1495C) stab22	UGACUCCCUUUCUGUCUUTT B	1781	
1505	AGGAGUCACAAGACACUGUUGC	1482	PSEN1:1525L21 antisense siNA (1507C) stab22	AACAGUGUCUUGUGACUCCTT B	1782	
1748	GACUGGAACACAACCAUAGCCUG	1483	PSEN1:1768L21 antisense siNA (1750C) stab22	GGCUAUGGUUGUGUCCAGTT B	1783	
1751	UGGAACACAACCAUAGCCUGUUU	1484	PSEN1:1771L21 antisense siNA (1753C) stab22	ACAGGCUAUGGUUGUGUUCTT B	1784	
2184	CUACCAGAUUUGAGGGACGAGGU	1485	PSEN1:2204L21 antisense siNA (2186C) stab22	CUCGUCCCUCAAAUCUGGUTT B	1785	
3007	UGUAUGCCCAAGCGGUGAGAAU	1486	PSEN1:3027L21 antisense siNA (3009C) stab22	UUCUACCGCUUUGGGCAUATT B	1786	
PSEN2						
Tar- get Pos	Target	Seq ID	Cmpd # Aliases	Sequence	Seq ID	
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:106U21 sense siNA	ACUGAUGAAGAAACUGAGGTT	1787	
260	AGCCAGGGAGCAUCAUUAUUUA	1488	PSEN2:262U21 sense siNA	CCAGGGAGCAUCAUUAUUTT	1788	
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	PSEN2:551U21 sense siNA	CGCUAUGUCUGUAGUGGGTT	1789	
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:599U21 sense siNA	GAGCUGACCCUCAAUACGTT	1790	
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:732U21 sense siNA	CGACAUUCACUGAGGACTT	1791	
938	GUGCUAAGACCUACAAUGUGGC	1492	PSEN2:940U21 sense siNA	GCUCAAGACCUACAAUGGTT	1792	
947	ACCUACAAUGUGGCCAUGGACUA	1493	PSEN2:949U21 sense siNA	CUACAAUGUGGCCAUGGACTT	1793	
2095	GAGUGUCCCAAUGCUUUGUCCA	1494	PSEN2:2097U21 sense siNA	GUGUCCCAAUGCUUUGUCTT	1794	
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:124L21 antisense siNA (106C)	CCUCAGUUUCUUAUCAGUTT	1795	
260	AGCCAGGGAGCAUCAUUAUUUA	1488	PSEN2:280L21 antisense siNA (262C)	AAUGAAUGAUGUCCUGGTT	1796	
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	PSEN2:569L21 antisense siNA (551C)	CCCCACUACAGACAUGCGTT	1797	
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:617L21 antisense siNA (599C)	CGUAUUUGAGGGUCAGUCTT	1798	
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:750L21 antisense siNA (732C)	GUGUCCUACAGUAAUGUCGTT	1799	
938	GUGCUAAGACCUACAAUGUGGC	1492	PSEN2:958L21 antisense siNA (940C)	CACAUUGUAGGUCUUGAGCTT	1800	
947	ACCUACAAUGUGGCCAUGGACUA	1493	PSEN2:967L21 antisense siNA (949C)	GUCCAUGGCCACAUGUAGTT	1801	
2095	GAGUGUCCCAAUGCUUUGUCCA	1494	PSEN2:2115L21 antisense siNA (2097C)	GACAAAGCAUUGGGAACACTT	1802	
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:106U21 sense siNA stab04	B AcuGauGAAGAAAcuGAGGTT B	1803	
260	AGCCAGGGAGCAUCAUUAUUUA	1488	PSEN2:262U21 sense siNA stab04	B ccAGGGAGcAucAuucAuuTT B	1804	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	PSEN2:551U21 sense siNA stab04	B cGcuAuGucuGuAGUGGGGTT B	1805	
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:599U21 sense siNA stab04	B GAGcuGAcccucAAAuAcGTT B	1806	
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:732U21 sense siNA stab04	B cGAcAuucAcuGAGGAcAcTT B	1807	
938	GUGCUCAAGACCUACAAGUGGC	1492	PSEN2:940U21 sense siNA stab04	B GcucAAGAccuAcAAuGuGTT B	1808	
947	ACCUACAAGUGGCCAUGGACUA	1493	PSEN2:949U21 sense siNA stab04	B cuAcAAuGuGGccAuGGAcTT B	1809	
2095	GAGUGUUCCTAAUGCUUUGUCCA	1494	PSEN2:2097U21 sense siNA stab04	B GuGuucccAAuGcuuuGucTT B	1810	
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:124L21 antisense siNA (106C) stab05	ccucAGuuucucAucAGuTsT	1811	
260	AGCCAGGGAGCAUCAUUAUUA	1488	PSEN2:280L21 antisense siNA (262C) stab05	AAuGAAuGAuGcucccGGTsT	1812	
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	PSEN2:569L21 antisense siNA (551C) stab05	ccccAcuAcAGAcAuAGcGTsT	1813	
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:617L21 antisense siNA (5990) stab05	cGuAuuuGAGGucAGcucTsT	1814	
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:750L21 antisense siNA (7320) stab05	GuGucccAGuGAAuGucGTsT	1815	
938	GUGCUCAAGACCUACAAGUGGC	1492	PSEN2:958L21 antisense siNA (940C) stab05	cAcAuGuAGGucuuGAGcTsT	1816	
947	ACCUACAAGUGGCCAUGGACUA	1493	PSEN2:967L21 antisense siNA (949C) stab05	GuccAuGGccAcAuGuAGTsT	1817	
2095	GAGUGUUCCTAAUGCUUUGUCCA	1494	PSEN2:2115L21 antisense siNA (20970) stab05	GACAAAGcAuGGGAACAcTsT	1818	
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:106U21 sense siNA stab07	B AcuGAuGAAGAAAcuGAGGTT B	1819	
260	AGCCAGGGAGCAUCAUUAUUA	1488	PSEN2:262U21 sense siNA stab07	B ccAGGGAGcAucAuucAuTT B	1820	
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	PSEN2:551U21 sense siNA stab07	B cGcuAuGucuGuAGUGGGGTT B	1821	
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:599U21 sense siNA stab07	B GAGcuGAcccucAAAuAcGTT B	1822	
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:732U21 sense siNA stab07	B cGAcAuucAcuGAGGAcAcTT B	1823	
938	GUGCUCAAGACCUACAAGUGGC	1492	PSEN2:940U21 sense siNA stab07	B GcucAAGAccuAcAAuGuGTT B	1824	
947	ACCUACAAGUGGCCAUGGACUA	1493	PSEN2:949U21 sense siNA stab07	B cuAcAAuGuGGccAuGGAcTT B	1825	
2095	GAGUGUUCCTAAUGCUUUGUCCA	1494	PSEN2:2097U21 sense siNA stab07	B GuGuucccAAuGcuuuGucTT B	1826	
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:124L21 antisense siNA (1060) stab11	cucAGuuucucAucAGuTsT	1827	
260	AGCCAGGGAGCAUCAUUAUUA	1488	PSEN2:280L21 antisense siNA (2620) stab11	AuGAAuGAuGcucccGGTsT	1828	
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	PSEN2:569L21 antisense siNA (5510) stab11	cccAcuAcAGAcAuAGcGTsT	1829	

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:617L21 antisense siNA (599C) stab11	cGuAuuuGAGGGucAGcucTsT	1830
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:750L21 antisense siNA (732C) stab11	GuGuccucAGuGAAuGucGTsT	1831
938	GUGCUCAGACCUACAAUGUGGC	1492	PSEN2:958L21 antisense siNA (940C) stab11	cAcAuuGuAGGucuuGAGcTsT	1832
947	ACCUACAAUGUGCCAUGGACUA	1493	PSEN2:967L21 antisense siNA (949C) stab11	GuccAuGGccAcAuuGuAGTsT	1833
2095	GAGUGUCCCAAUGCUUUGUCCA	1494	PSEN2:2115L21 antisense siNA (2097C) stab11	GACAAAGcAuuGGGAAcAcTsT	1834
104	UUACUGAUGAAGAAACUGAGGCC	1487	PSEN2:106U21 sense siNA stab18	B <u>AcuGAuGAAGAAAcuGAGGTT</u> B	1835
260	AGCCAGGGAGCAUCAUUAUUUA	1488	PSEN2:262U21 sense siNA stab18	B cc <u>AGGGAGcAucAuucAuTT</u> B	1836
549	ACCGCUAUGUCUGUAGUGGGUU	1489	PSEN2:551U21 sense siNA stab18	B cGcu <u>AuGucGuAGuGGGTT</u> B	1837
597	AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:599U21 sense siNA stab18	B <u>GAGcuGAGccucAAAuAcGTT</u> B	1838
730	CACGACAUUCACUGAGGACACAC	1491	PSEN2:732U21 sense siNA stab18	B cGAc <u>AuucAcuGAGGAcAcTT</u> B	1839
938	GUGCUCAGACCUACAAUGUGGC	1492	PSEN2:940U21 sense siNA stab18	B Gcuc <u>AGAc</u> ccuAc <u>AAuGuGTT</u> B	1840
947	ACCUACAAUGUGCCAUGGACUA	1493	PSEN2:949U21 sense siNA stab18	B cuAc <u>AAuGuGGccAuGGA</u> cTT B	1841
2095	GAGUGUCCCAAUGCUUUGUCCA	1494	PSEN2:2097U21 sense siNA stab18	B GuGuuccc <u>AAuGcuuuGucTT</u> B	1842
104	UUACUGAUGAAGAAACUGAGGCC	1487 33957	PSEN2:124L21 antisense siNA (106C) stab08	ccucAGuuuc <u>uucAucAGuTsT</u>	1843
260	AGCCAGGGAGCAUCAUUAUUUA	1488 33958	PSEN2:280L21 antisense siNA (262C) stab08	<u>AAuGAAuGAuGcucccGGTsT</u>	1844
549	ACCGCUAUGUCUGUAGUGGGUU	1489 33959	PSEN2:569L21 antisense siNA (551C) stab08	ccccA <u>cuAcAGAcAuAGc</u> GTsT	1845
597	AAGAGCUGACCCUCAAUACGGA	1490 33960	PSEN2:617L21 antisense siNA (599C) stab08	cGuAuuuGAGGGucAGcucTsT	1846
730	CACGACAUUCACUGAGGACACAC	1491 33961	PSEN2:750L21 antisense siNA (732C) stab08	GuGuccucAGuGAAuGucGTsT	1847
938	GUGCUCAGACCUACAAUGUGGC	1492 33962	PSEN2:958L21 antisense siNA (940C) stab08	cAcAuuGuAGGucuuGAGcTsT	1848
947	ACCUACAAUGUGCCAUGGACUA	1493 33963	PSEN2:967L21 antisense siNA (949C) stab08	GuccAuGGccAcAuuGuAGTsT	1849
2095	GAGUGUCCCAAUGCUUUGUCCA	1494 33964	PSEN2:2115L21 antisense siNA (2097C) stab08	GACAAAGcAuuGGGAAcAcTsT	1850
104	UUACUGAUGAAGAXACUGAGGCC	1487 33941	PSEN2:106U21 sense siNA stab09	B ACUGAUGAAGAAACUGAGGTT B	1851
260	AGCCAGGGAGCAUCAUUAUUUA	1488 33942	PSEN2:262U21 sense siNA stab09	B CCAGGGAGCAUCAUUAUUTT B	1852
549	ACCGCUAUGUCUGUAGUGGGUU	1489 33943	PSEN2:551U21 sense siNA stab09	B CGCUAUGUCUGUAGUGGGTT B	1853

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS						
597	AAGAGCUGACCCUCAAAUACGGA	1490	33944	PSEN2:599U21 sense siNA stab09	B GAGCUGACCCUCAAAUACGTT B	1854
730	CACGACAUUCACUGAGGACACAC	1491	33945	PSEN2:732U21 sense siNA stab09	B CGACAUUCACUGAGGACACTT B	1855
938	GUGCUCAAGACCUACAAUGUGGC	1492	33946	PSEN2:940U21 sense siNA stab09	B GCUCAAGACCUACAAUGUGTT B	1856
947	ACCUACAAUGUGGCCAUGGACUA	1493	33947	PSEN2:949U21 sense siNA stab09	B CUACAAUGUGGCCAUGGACTT B	1857
2095	GAGUGUCCCCAAGUCUUUGUCCA	1494	33948	PSEN2:2097U21 sense siNA stab09	B GUGUCCCCAAGUCUUUGUCTT B	1858
104	UUACUGAUGAAGAAACUGAGGCC	1487	33949	PSEN2:124L21 antisense siNA (106C) stab10	CCUCAGUUUCUUCAGUTsT	1859
260	AGCCAGGGAGCAUCAUUAUUUA	1488	33950	PSEN2:280L21 antisense siNA (262C) stab10	AAUGAAUGAUGCUCUCCUGTsT	1860
549	ACCGCUAUGUCUGUAGUGGGGUU	1489	33951	PSEN2:569L21 antisense siNA (551C) stab10	CCCCACUACAGACAUAGCGTsT	1861
597	AAGAGCUGACCCUCAAAUACGGA	1490	33952	PSEN2:617L21 antisense siNA (599C) stab10	CGUAUUUGAGGGUCAGUCTsT	1862
730	CACGACAUUCACUGAGGACACAC	1491	33953	PSEN2:750L21 antisense siNA (732C) stab10	GUGUCCUCAGUGAAUGUCGTsT	1863
938	GUGCUCAAGACCUACAAUGUGGC	1492	33954	PSEN2:958L21 antisense siNA (940C) stab10	CACAUUGUAGGUCUUGAGCTsT	1864
947	ACCUACAAUGUGGCCAUGGACUA	1493	33955	PSEN2:967L21 antisense siNA (949C) stab10	GUCCAUGGCCACAUUGUAGTsT	1865
2095	GAGUGUCCCCAAGUCUUUGUCCA	1494	33956	PSEN2:2115L21 antisense siNA (2097C) stab10	GACAAAGCAUUGGGAACACTsT	1866
104	UUACUGAUGAAGAAACUGAGGCC	1487		PSEN2:124L21 antisense siNA (106C) stab19	ccucAGuuucuuucAucAGuTT B	1867
260	AGCCAGGGAGCAUCAUUAUUUA	1488		PSEN2:280L21 antisense siNA (262C) stab19	AAuGAAuGAuGcucccuGGTT B	1868
549	ACCGCUAUGUCUGUAGUGGGGUU	1489		PSEN2:569L21 antisense siNA (551C) stab19	ccccAcuAcAGAcAuAGcGTT B	1869
597	AAGAGCUGACCCUCAAAUACGGA	1490		PSEN2:617L21 antisense siNA (599C) stab19	cGuAuuuGAGGGucAGcucTT B	1870
730	CACGACAUUCACUGAGGACACAC	1491		PSEN2:750L21 antisense siNA (732C) stab19	GuGuccucAGuGAAuGucGTT B	1871
938	GUGCUCAAGACCUACAAUGUGGC	1492		PSEN2:958L21 antisense siNA (940C) stab19	cAcAuuGuAGGucuuGAGcTT B	1872
947	ACCUACAAUGUGGCCAUGGACUA	1493		PSEN2:967L21 antisense siNA (949C) stab19	GuccAuGGccAcAuuGuAGTT B	1873
2095	GAGUGUCCCCAAGUCUUUGUCCA	1494		PSEN2:2115L21 antisense siNA (2097C) stab19	GAcAAAGcAuuGGGAAcAcTT B	1874
104	UUACUGAUGAAGAAACUGAGGCC	1487		PSEN2:124L21 antisense siNA (106C) stab22	CCUCAGUUUCUUCUUCAGUTT B	1875
260	AGCCAGGGAGCAUCAUUAUUUA	1488		PSEN2:280L21 antisense siNA (262C) stab22	AAUGAAUGAUGCUCUCCUGGTT B	1876
549	ACCGCUAUGUCUGUAGUGGGGUU	1489		PSEN2:569L21 antisense siNA (551C) stab22	CCCCACUACAGACAUAGCGTT B	1877

TABLE III-continued

APP, BACE, PSEN1, PSEN2, SYNTHETIC MODIFIED siNA CONSTRUCTS					
597 AAGAGCUGACCCUCAAUACGGA	1490	PSEN2:617L21 antisense siNA (599C) stab22	CGUAUUUGAGGGUCAGCUCTT B	1878	
730 CACGACAUCACUGAGGACACAC	1491	PSEN2:750L21 antisense siNA (732C) stab22	GUGUCCUCAGUGAUGUCGTT B	1879	
938 GUGCUCAAGACCUACAUGUGGC	1492	PSEN2:958L21 antisense siNA (940C) stab22	CACAUUGUAGGUCUUGAGCTT B	1880	
947 ACCUACAAGUGGCCAUGGACUA	1493	PSEN2:967L21 antisense siNA (949C) stab22	GUCCAUGGCCACAUGUAGTT B	1881	
2095 GAGUGUCCCCAUGCUUUGUCCA	1494	PSEN2:2115L21 antisense siNA (2097C) stab22	GACAAAGCAUUGGGAACACTT B	1882	

Uppercase = ribonucleotide

u,c = 2'-deoxy-2'-fluoro U,C

T = thymidine

B = inverted deoxy abasic

s = phosphorothioate linkage

A = deoxy Adenosine

G = deoxy Guanosine

G = 2'-O-methyl Guanosine

A = 2'-O-methyl Adenosine

[0438]

TABLE IV

Non-limiting examples of Stabilization Chemistries for chemically modified siNA constructs					
Chemistry	pyrimidine	Purine	cap	p = S	Strand
"Stab 00"	Ribo	Ribo	TT at 3'-ends		S/AS
"Stab 1"	Ribo	Ribo	—	5 at 5'-end 1 at 3'-end	S/AS
"Stab 2"	Ribo	Ribo	—	All linkages	Usually AS
"Stab 3"	2'-fluoro	Ribo	—	4 at 5'-end 4 at 3'-end	Usually S
"Stab 4"	2'-fluoro	Ribo	5' and 3'-ends	—	Usually S
"Stab 5"	2'-fluoro	Ribo	—	1 at 3'-end	Usually AS
"Stab 6"	2'-O-Methyl	Ribo	5' and 3'-ends	—	Usually S
"Stab 7"	2'-fluoro	2'-deoxy	5' and 3'-ends	—	Usually S
"Stab 8"	2'-fluoro	2'-O-Methyl	—	1 at 3'-end	Usually AS
"Stab 9"	Ribo	Ribo	5' and 3'-ends	—	Usually S
"Stab 10"	Ribo	Ribo	—	1 at 3'-end	Usually AS
"Stab 11"	2'-fluoro	2'-deoxy	—	1 at 3'-end	Usually AS
"Stab 12"	2'-fluoro	LNA	5' and 3'-ends		Usually S
"Stab 13"	2'-fluoro	LNA		1 at 3'-end	Usually AS
"Stab 14"	2'-fluoro	2'-deoxy		2 at 5'-end 1 at 3'-end	Usually AS
"Stab 15"	2'-deoxy	2'-deoxy		2 at 5'-end 1 at 3'-end	Usually AS
"Stab 16"	Ribo	2'-O-Methyl	5' and 3'-ends		Usually S
"Stab 17"	2'-O-Methyl	2'-O-Methyl	5' and 3'-ends		Usually S
"Stab 18"	2'-fluoro	2'-O-Methyl	5' and 3'-ends		Usually S
"Stab 19"	2'-fluoro	2'-O-Methyl	3'-end		Usually AS

TABLE IV-continued

Non-limiting examples of Stabilization Chemistries for chemically modified siNA constructs					
Chemistry	pyrimidine	Purine	cap	p = S	Strand
"Stab 20"	2'-fluoro	2'-deoxy	3'-end		Usually AS
"Stab 21"	2'-fluoro	Ribo	3'-end		Usually AS
"Stab 22"	Ribo	Ribo	3'-end		Usually AS
"Stab 23"	2'-fluoro*	2'-deoxy*	5' and 3'-ends		Usually S
"Stab 24"	2'-fluoro*	2'-O-Methyl*	—	1 at 3'-end	Usually AS
"Stab 25"	2'-fluoro*	2'-O-Methyl*	—	1 at 3'-end	Usually AS

CAP = any terminal cap, see for example FIG. 10.

All Stab 00-25 chemistries can comprise 3'-terminal thymidine (TT) residues

All Stab 00-25 chemistries typically comprise about 21 nucleotides, but can vary as described herein.

S = sense strand

AS = antisense strand

*Stab 23 has single ribonucleotide adjacent to 3'-CAP

*Stab 24 has single ribonucleotide at 5'-terminus

*Stab 25 has three ribonucleotides at 5'-terminus

[0439]

TABLE V

Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
A. 2.5 μ mol Synthesis Cycle ABI 394 Instrument					
Phosphoramidites	6.5	163 μ L	45 sec	2.5 min	7.5 min
S-Ethyl Tetrazole	23.8	238 μ L	45 sec	2.5 min	7.5 min
Acetic Anhydride	100	233 μ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	186	233 μ L	5 sec	5 sec	5 sec
TCA	176	2.3 mL	21 sec	21 sec	21 sec
Iodine	11.2	1.7 mL	45 sec	45 sec	45 sec
Beaucage	12.9	645 μ L	100 sec	300 sec	300 sec
Acetonitrile	NA	6.67 mL	NA	NA	NA
B. 0.2 μ mol Synthesis Cycle ABI 394 Instrument					
Phosphoramidites	15	31 μ L	45 sec	233 sec	465 sec
S-Ethyl Tetrazole	38.7	31 μ L	45 sec	233 min	465 sec
Acetic Anhydride	655	124 μ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	1245	124 μ L	5 sec	5 sec	5 sec
TCA	700	732 μ L	10 sec	10 sec	10 sec
Iodine	20.6	244 μ L	15 sec	15 sec	15 sec
Beaucage	7.7	232 μ L	100 sec	300 sec	300 sec
Acetonitrile	NA	2.64 mL	NA	NA	NA
Reagent	Equivalents: DNA/2'-O-methyl/Ribo	Amount: DNA/2'-O-methyl/Ribo	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time* Ribo
C. 0.2 μ mol Synthesis Cycle 96 well Instrument					
Phosphoramidites	22/33/66	40/60/120 μ L	60 sec	180 sec	360 sec
S-Ethyl Tetrazole	70/105/210	40/60/120 μ L	60 sec	180 min	360 sec
Acetic Anhydride	265/265/265	50/50/50 μ L	10 sec	10 sec	10 sec
N-Methyl Imidazole	502/502/502	50/50/50 μ L	10 sec	10 sec	10 sec
TCA	238/475/475	250/500/500 μ L	15 sec	15 sec	15 sec
Iodine	6.8/6.8/6.8	80/80/80 μ L	30 sec	30 sec	30 sec
Beaucage	34/51/51	80/120/120	100 sec	200 sec	200 sec
Acetonitrile	NA	1150/1150/1150 μ L	NA	NA	NA

*Wait time does not include contact time during delivery.

*Tandem synthesis utilizes double coupling of linker molecule

[0440]

SEQUENCE LISTING

The patent application contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/sequence.html?DocID=20050209179>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What we claim is:

1. A chemically synthesized double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of an amyloid precursor protein (APP) RNA via RNA interference (RNAi), wherein:

a. each strand of said siNA molecule is about 18 to about 23 nucleotides in length; and

b. one strand of said siNA molecule comprises nucleotide sequence having sufficient complementarity to said APP RNA for the siNA molecule to direct cleavage of the APP RNA via RNA interference.

2. The siNA molecule of claim 1, wherein said siNA molecule comprises no ribonucleotides.

3. The siNA molecule of claim 1, wherein said siNA molecule comprises one or more ribonucleotides.

4. The siNA molecule of claim 1, wherein one strand of said double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a APP gene or a portion thereof, and wherein a second strand of said double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of said APP RNA.

5. The siNA molecule of claim 4, wherein each strand of the siNA molecule comprises about 18 to about 23 nucleotides, and wherein each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand.

6. The siNA molecule of claim 1, wherein said siNA molecule comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence of a APP gene or a portion thereof, and wherein said siNA further comprises a sense region, wherein said sense region comprises a nucleotide sequence substantially similar to the nucleotide sequence of said APP gene or a portion thereof.

7. The siNA molecule of claim 6, wherein said antisense region and said sense region comprise about 18 to about 23 nucleotides, and wherein said antisense region comprises at least about 18 nucleotides that are complementary to nucleotides of the sense region.

8. The siNA molecule of claim 1, wherein said siNA molecule comprises a sense region and an antisense region, and wherein said antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by a APP gene, or a portion thereof, and said sense region comprises a nucleotide sequence that is complementary to said antisense region.

9. The siNA molecule of claim 6, wherein said siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and a second fragment comprises the antisense region of said siNA molecule.

10. The siNA molecule of claim 6, wherein said sense region is connected to the antisense region via a linker molecule.

11. The siNA molecule of claim 10, wherein said linker molecule is a polynucleotide linker.

12. The siNA molecule of claim 10, wherein said linker molecule is a non-nucleotide linker.

13. The siNA molecule of claim 6, wherein pyrimidine nucleotides in the sense region are 2'-O-methylpyrimidine nucleotides.

14. The siNA molecule of claim 6, wherein purine nucleotides in the sense region are 2'-deoxy purine nucleotides.

15. The siNA molecule of claim 6, wherein pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides.

16. The siNA molecule of claim 9, wherein the fragment comprising said sense region includes a terminal cap moiety at a 5'-end, a 3'-end, or both of the 5' and 3' ends of the fragment comprising said sense region.

17. The siNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.

18. The siNA molecule of claim 6, wherein pyrimidine nucleotides of said antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides.

19. The siNA molecule of claim 6, wherein purine nucleotides of said antisense region are 2'-O-methyl purine nucleotides.

20. The siNA molecule of claim 6, wherein purine nucleotides present in said antisense region comprise 2'-deoxy-purine nucleotides.

21. The siNA molecule of claim 18, wherein said antisense region comprises a phosphorothioate internucleotide linkage at the 3' end of said antisense region.

22. The siNA molecule of claim 6, wherein said antisense region comprises a glyceryl modification at a 3' end of said antisense region.

23. The siNA molecule of claim 9, wherein each of the two fragments of said siNA molecule comprise about 21 nucleotides.

24. The siNA molecule of claim 23, wherein about 19 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule and wherein at least two 3'

terminal nucleotides of each fragment of the siNA molecule are not base-paired to the nucleotides of the other fragment of the siNA molecule.

25. The siNA molecule of claim 24, wherein each of the two 3' terminal nucleotides of each fragment of the siNA molecule are 2'-deoxy-pyrimidines.

26. The siNA molecule of claim 25, wherein said 2'-deoxy-pyrimidine is 2'-deoxy-thymidine.

27. The siNA molecule of claim 23, wherein all of the about 21 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule.

28. The siNA molecule of claim 23, wherein about 19 nucleotides of the antisense region are base-paired to the nucleotide sequence of the RNA encoded by a APP gene or a portion thereof.

29. The siNA molecule of claim 23, wherein about 21 nucleotides of the antisense region are base-paired to the nucleotide sequence of the RNA encoded by a APP gene or a portion thereof.

30. The siNA molecule of claim 9, wherein a 5'-end of the fragment comprising said antisense region optionally includes a phosphate group.

31. A composition comprising the siNA molecule of claim 1 in an pharmaceutically acceptable carrier or diluent.

32. A siNA according to claim 1 wherein the APP RNA comprises Genbank Accession No. NM_000484.

33. A siNA according to claim 1 wherein said siNA comprises any of SEQ ID NOs. 1-199, 200-398, 1463-1470, and 1495-1590.

34. A composition comprising the siNA of claim 32 together with a pharmaceutically acceptable carrier or diluent.

35. A composition comprising the siNA of claim 33 together with a pharmaceutically acceptable carrier or diluent.

* * * * *